<SEC-DOCUMENT>0001558370-25-007063.txt : 20250509
<SEC-HEADER>0001558370-25-007063.hdr.sgml : 20250509
<ACCEPTANCE-DATETIME>20250509070404
ACCESSION NUMBER:		0001558370-25-007063
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		55
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250509
DATE AS OF CHANGE:		20250509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		25928332

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20250331x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.10.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 5/8/2025 5:26:41 PM -->
<!-- iXBRL Library version: 1.0.9179.3415 -->
<!-- iXBRL Service Job ID: cc4504bf-ae8e-4046-a133-5def3dd66d85 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:plx="http://www.protalix.com/20250331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>PROTALIX BIOTHERAPEUTICS,&#160;INC._March 31, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" xs:nil="true" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_kXUOmRnMF02g3IyaxSwPaw"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" xs:nil="true" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" name="us-gaap:CommitmentsAndContingencies" id="Hidden_y4BLMcGH-Eq_mG7qitP-Ug"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityCentralIndexKey" id="Tc_EOoZn2yox0qPdi7ano0h_A_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:CurrentFiscalYearEndDate" id="Tc_i-mbnwOuikCCoMKpd06nsg_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentFiscalYearFocus" id="Tc_drruE08GmkeoNkNkB__yJg_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentFiscalPeriodFocus" id="Tc_-O580WD-90ekHFLu0xXy3A_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:AmendmentFlag" id="Tc_jEyg01ZU8kmrkQqHK5_QKw_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_8DshOwwsq0-xcl9XB1lxCA" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_cSxaNzcnK0mLWtm562rZ5w">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ghu49akz20uatgeBd2X7xQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WKF5iW7GJEWP-U2zSvqbMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m6Piq_wnjEaeFfGE5kdjsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_prBuP7Wn10WQWwJPcpXf0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ds3ukx2XekWVsDH9lI71mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lxOjswxMb0m6s5VE-STvCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4HrirPbHHkGUdsaYl6N3qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_BmLMKInirk-W2LzHEG8PAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lSnbdXconU6DulGwTT8MFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_90621vYqvEa1pn7bmcTY_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4ybsI5_mqUqIV1P-uoYRHA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_7lP2AsW-rUWHh6Iroj0Xlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_F8q1dlZWwEuLw9hXrYpvwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZEZl7VBCOkKOl7NTRveViw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_oXa9IlN4NEi0krV8osIOWA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_Vzwfwx4x6UqY4cHH7H5agQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F4FQvuyunUGq_SflJl8NoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eW1ZtmVb80KFn9rh2Sehpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_jLrTiAYktE2BXNkVgYPROg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Lwwrp-grPUmPH5Z8rNY9-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_75AYESP9RUK-GveVvLuOfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_nmHBOM5hwEqT3t2gduL9Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7Tgj53JZECcqAlPLWNniA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OiVYUMJ14ka7WcB5y23CLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_y6-CsnHhbUiWoMezhWCoiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_Y_QC7Pagx0qp-Num1NGb4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_1_2025_AUlgaLjEa0WUZCpYvk3KDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_8DshOwwsq0-xcl9XB1lxCA"><xbrli:measure>plx:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_YtLlGAbz7060zZ-cwF33Pg_18_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rmq72pKmPkelc_kfVf5utA_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_cLY55batqEe12Eox0KmcKQ_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Xbxl8-joqECHr07q_Wk7jA_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_D3oA6QxgOk6teZp4KIJaIA_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:9.2pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2f33002e_569d_4be2_bf1c_ea397217565a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentType" id="Narr_kjVEEPh2HUe4hZOMM69Qfw"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentQuarterlyReport" id="Narr_wZTt4ejim0CLEVa4hDdO6w"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentPeriodEndDate" id="Narr_0kC4NtG1TE6xbH520_w_ng"><b style="font-size:8pt;font-weight:bold;">March 31, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:DocumentTransitionReport" id="Narr_k3Wy6JpS50u76jHYfnTpXw"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityFileNumber" id="Narr_swxYyikyvkGfsy7bL9EuSQ"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityRegistrantName" id="Narr_CImdXA9cdEGPUPAvP3WQVQ"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_4orEdeDrd0y4H9CT5YtF5g_1_1"></a><a id="Tc_6WdP2pf_gESt6IOnh9vzIA_2_0"></a><a id="Tc_7dWyCCtNZEG3DEwhQZLnMQ_2_1"></a><a id="Tc_Z7strKhQHU6UY6CtOQNKJw_4_0"></a><a id="Tc_Lm7dYTL3mUGN6OHUC21tgA_5_0"></a><a id="Tc_4Sdv5Sr_R0qbGMA8MJyaiw_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityIncorporationStateCountryCode" id="Tc_IuBxkhTkukaAJmw4SGBV4Q_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityTaxIdentificationNumber" id="Narr_8uLDFUCUqkyF11YEnNmdbg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityAddressAddressLine1" id="Narr_ra0JVbjJmkeIv_leOzBAMQ"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityAddressAddressLine2" id="Narr_2N5oZ9gOaUek6fmi-KDSHw"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityAddressCityOrTown" id="Narr_9DnQZfCdlkiz6Z1CLGrpTA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityAddressStateOrProvince" id="Narr_FABw_24LRkyfXaQWZhXr0A"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityAddressPostalZipCode" id="Tc_TxKh7Pxod0u5lRNYJS910g_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:CityAreaCode" id="Narr_GX0ZQ6liFEy_dUZrxfgyQQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:LocalPhoneNumber" id="Narr_MybInQVo7kWYJ0zaOQyfsg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_jom1oJ6w0UaTrHWjrskJ-w_1_0"></a><a id="Tc_SqPeRAYL70egWQQHkpjK0Q_1_2"></a><a id="Tc_ZYukOrKxIUKtYcNf0pt63A_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:Security12bTitle" id="Tc_R6BD4iAfWUiM6oWQszFE-g_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:TradingSymbol" id="Tc_0iXSR1xaGUajYC1iqEEyrA_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:SecurityExchangeName" id="Tc_tm0Te8iX8E29uIIIy4_FfA_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityCurrentReportingStatus" id="Narr_Ov9qVew_9kyUu1mjnXaoZA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityInteractiveDataCurrent" id="Narr_K79iQ70NK0eXfJ4266vWUQ"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_nM4lFnQ86EWOibx5mGDW0w_1_0"></a><a id="Tc_JBFi0Ea0oEKw8hkd7CKM6A_1_1"></a><a id="Tc_yv59YteCPEyIKxtRcAtYVA_1_2"></a><a id="Tc_RWB_1pAFaUCkwGaxqImMmw_1_3"></a><a id="Tc_S8HeRuq4gUmHVkcIVjw4bA_2_1"></a><a id="Tc_AYjRgUTVWEWEM4klenyDfQ_2_2"></a><a id="Tc_YgXAB5dtMESS90B1GjGofg_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityFilerCategory" id="Tc_SeHj-nU3EUigOMpyYUVqsQ_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntitySmallBusiness" id="Tc_XlfLjRgufUyNshZVMcgPXA_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityEmergingGrowthCompany" id="Tc_2UNg9VEol0qgkirrseWi3g_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="dei:EntityShellCompany" id="Narr_2440yCXe20GY82uIV6JruQ"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On May&#160;1, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_5_1_2025_AUlgaLjEa0WUZCpYvk3KDQ" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_05ao0GJ0lUyXynVNdZuIRA">79,607,115</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_2095f030_6187_467c_b240_bf7fee3a51d5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of March&#160;31, 2025 and December&#160;31, 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity </span><span style="font-style:normal;font-weight:normal;">(Unaudited) &#8211; For the Three Months Ended March&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Three Months Ended March&#160;31, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4064c4ff_65a4_4648_8f54_647f9a9461b2"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_7zdMtktWZ0CxnUGPt_NZvw_1_2"></a><a id="Tc_otHw2Y4BVkiP97zuwYASnQ_1_5"></a><a id="Tc__E7dStngqkCx80nCjRJCsA_3_0"></a><a id="Tc_A-3A3iY-jkesttVnROui1g_5_0"></a><a id="Tc_G41AManQek6G_M-hJHASlQ_6_0"></a><a id="Tc_TIqeaKLJnUaCl3ALYYuoHw_6_2"></a><a id="Tc_jwFIJ-8cOkqgZVVC0UhxTg_6_5"></a><a id="Tc_Np43e4hP2ESxWZSRTWpHFQ_7_0"></a><a id="Tc_cFIIEZ_E6kqyLbcS0uoxlQ_8_0"></a><a id="Tc_AMXAWNtUuU-g_JRSkO1czA_9_0"></a><a id="Tc_fJUpFM_YlEajuSDUkxJmtw_10_0"></a><a id="Tc_qyDvgrZYMkibLZxoz8itJA_11_0"></a><a id="Tc_-05mQw1eZ0SjPBk4fJe5rQ_11_2"></a><a id="Tc_6myRYYbRNEGbzTAvD0c7BA_11_5"></a><a id="Tc_vSF6BBGvkUm-WdmOPrTr0A_13_0"></a><a id="Tc_9U8ZgDz6hUWp7FNcxLijmA_14_0"></a><a id="Tc_rYIkgu4dsUapELTzCCjJHw_14_2"></a><a id="Tc_x6OohFw4tkCPjF-GC9bjdQ_14_5"></a><a id="Tc_2Nj4YzuV70mv5G10gQkoDQ_15_0"></a><a id="Tc_5p2eihEy3EGb4XM_XzwAIw_16_0"></a><a id="Tc_Z9779HeU60KbBYc-GjvHiQ_17_0"></a><a id="Tc_tC3xMc6TLEGq4pR4KKL-rA_18_0"></a><a id="Tc_vezCLMr1NUyhxggJVsewFA_18_2"></a><a id="Tc_1E96Os3nfE-IefYFtBqfZg_18_5"></a><a id="Tc_LQSt9x1rXk2ssDHC3-fVvw_20_0"></a><a id="Tc_fk2TWwk5CUCRiXxh-EkLjw_22_0"></a><a id="Tc_YPXqWTXxX0iGkImE8O224w_23_0"></a><a id="Tc_7I2K395HcEOAT7fGWC_Wyw_24_0"></a><a id="Tc_KHK9j2-ipUmTjF0FlvhgKw_24_2"></a><a id="Tc_VVwKKpWxgE6frSkiso7bjA_24_5"></a><a id="Tc_qk1fuXuspUaLXaPR7AIIbA_25_0"></a><a id="Tc_c7GMQ-XUQkqCspnDx0lLWA_26_0"></a><a id="Tc__QGeiL4LY0aQFaOQ7SOtkg_27_0"></a><a id="Tc_Tp8-VMgBx0-Oj3QqY06rDw_27_2"></a><a id="Tc_sJLWt-9VD0qnWUxY9unYsQ_27_5"></a><a id="Tc_i6NwGACzrEigrMIWHMcSnw_29_0"></a><a id="Tc_1Ar1Ojrsy060zUH725x-XA_30_0"></a><a id="Tc_Sn7qkz5jekOdVkZGPKuqrA_30_2"></a><a id="Tc_ByayxW_xpkWQLK9mx-438A_30_5"></a><a id="Tc_p4mnX3iiuEqCUJfYIFefVA_31_0"></a><a id="Tc_jKsQTLQutEqivqcX9ZdW6A_32_0"></a><a id="Tc_k94NHyb4XkODhybpdF0YuA_32_2"></a><a id="Tc_J-CFrKUflU2bqznw0KX-6g_32_5"></a><a id="Tc_7poqaGr5XEeTA-N_3-SUug_33_0"></a><a id="Tc_WbKbVsKF6kaEKqI7E8WRGw_33_2"></a><a id="Tc_LAw2NZ3P90aj_uQREGA0gA_33_5"></a><a id="Tc_9IYR7rpRjEKeoLtgzLo_mA_35_0"></a><a id="Tc_P1I9tm0pm0CpgKSkLx1gSA_37_0"></a><a id="Tc_aj_POECQ0Eaq7JS7x-5AhA_38_0"></a><a id="Tc_QoprLJJKyk2gIozPdWMHRQ_38_2"></a><a id="Tc_bDEsjmCAW0WuGovP-5VpGQ_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Y9cpRAOSs0eFzEyRHDQeEQ_6_3">19,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_0SDRnSTt3k21AnH2c3RiMg_6_6">19,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_sMbG1-7GPkG-dxhWbsrFZQ_7_3">15,285</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_XOPCCnd0m0KvHXPIvWoS9w_7_6">15,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable &#8211; Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_wRl_QXQUOkC71B3tD8U_6Q_8_3">4,675</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_yHXuI7K3UU2dTRq7nsIRzQ_8_6">2,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_tsvYIKnix0q5p_GvfxomqQ_9_3">1,590</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_N5Y_baO0gEyJnK9x0_T6zQ_9_6">1,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_8mKh-T6hbku0Fyum8V4a2w_10_3">19,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_S3dLIMeOU0GWRLrbY2jF8A_10_6">21,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_Xuzik89rckiPDODqCu-rZg_11_3">60,514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ESblADCv9E-n8EJxdHLtXg_11_6">60,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_WoV-ezwUIk6tZiMnbjGBeg_14_3">459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_RPCtLAvE20C5KDgbaBSUJg_14_6">462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_tA1AVMPePkCLtXi0aF3vwQ_15_3">4,725</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qxjuQISDjk2hgFyIxKwaeA_15_6">4,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_0XzrGHmp-kieA1YteD_nQA_16_3">2,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_Mq3FJxVEBkSEbJofjDeyVg_16_6">2,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_I6JMCYCchkuyulKolY05Ow_17_3">5,225</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_rko8BqloLkWKKEYJcuW5qA_17_6">5,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_BBydNfPL8kq7vhXx4nfESw_18_3">73,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_a5PHMAcvIk6XIQhLxyn7iw_18_6">73,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_B6aDeqth80qN_XI-A0h6tw_24_3">4,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_BJ_YBCO4NEKm1m1W7SyobA_24_6">4,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_jWd1b05QkkuChel8aRLv4Q_25_3">18,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_d7489LY8fUmP7o0B1sNUzA_25_6">19,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_NpL2fYaCtUWL8M0VGBnvXA_26_3">1,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_B2chn85XskyaBFyPMl7XNw_26_6">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_-jDtqQIeNE6QmSy4gNARew_27_3">24,322</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_HREHp-SYdECJOMREJ0TYDQ_27_6">25,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_4qSrYWjqHUa6S7aZM6jcBA_30_3">551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_bjHPVaTelkeQfxkDLynfOA_30_6">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_bh-gN9IgLUyJWrOknOGvHA_31_3">3,811</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_eqiUMkTWoUKrJpE7-NTKQQ_31_6">4,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_OaFknihgxUuoRk4yMs09nA_32_3">4,362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_jU9oCQ0hb0inFNdFnmxc3Q_32_6">4,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_62bHHtloDUyOIZLkmrFiNA_33_3">28,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_LidYRO_8ukW2Dy9F-M--Dw_33_6">30,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mnYHrr5SS0CU0g2FYw2_pA_37_3">45,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_iJWOQ-zBmEWeOPAiRpJDlg_37_6">43,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.38%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_gfMpKjJZv0264jmbtU1WRg_38_3">73,892</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_Ux20Gjp9MUiAWFk5LP3EEQ_38_6">73,417</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_815c86c3_e9aa_4e1e_870d_60c6defdebc8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt -13.5pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_56f12b7f_6569_4577_8b68_5640a4558c2e"></a><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_miFOMPhMe0-28Uc0Wyfe6Q_1_2"></a><a id="Tc_7EGNXeJec0adRYyRk2s1lg_2_2"></a><a id="Tc_rnz-Qv3TFEqOYH1zSAZiKA_2_5"></a><a id="Tc_Paqd5BoQBUus1uQPQSDX3A_3_0"></a><a id="Tc_PkePiTCEXE-LbIn6UDVxmw_3_2"></a><a id="Tc_aPT3iIxtGk-YRCeeE2FjeQ_3_5"></a><a id="Tc_KnTUbirgY0yoxE8ZWBDyBA_4_0"></a><a id="Tc_pooSmgD8KkORSh3Sauj3_w_5_0"></a><a id="Tc_7NWNZiHwBUSZ56nwGAougQ_6_0"></a><a id="Tc_yEnf-MpaxUeU1mXYE7KiWw_7_0"></a><a id="Tc_tBRzug1ACkiymDAqJSfkjQ_8_0"></a><a id="Tc_JF6i2IVWOECoQE8syyD_vw_9_0"></a><a id="Tc_qtB2xbffkUO-ciDYcYdVsg_10_0"></a><a id="Tc_3UO1i332BkiumIu8FZL_qA_11_0"></a><a id="Tc_QCPNHJy8P0-mLOnX8nDAFA_12_0"></a><a id="Tc_Kg0BjxUxCkOa-tR8dqWUzw_13_0"></a><a id="Tc_E-LDkzGWS0yKpMrp9X-yZw_14_0"></a><a id="Tc_l6sK3VpsFU-JE8WQsscv4g_15_0"></a><a id="Tc_1idNztFShEaqpe3ukswcVQ_15_2"></a><a id="Tc_lolSHoF6UECIwkH0L6KfpQ_15_5"></a><a id="Tc_75rD7tr48kCAMos6hTUdHA_16_0"></a><a id="Tc_C53R787iW0ebW3oqtqSh3Q_16_2"></a><a id="Tc_yKiESTU_iUar_FqThnspyg_16_5"></a><a id="Tc_8Qa1dsleQk-VRgstXlDNEg_17_0"></a><a id="Tc__Lv8Vr1uB0SkxecYG0unJg_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.82870865%;padding-left:0pt;padding-right:0pt;width:101.65%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_eFpIevg1gkyo4OYmTwjTpg_3_3">9,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Pg4QVXPB_E-DOnhti01I-w_3_6">3,677</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_I0P_rLjZTEG85u8TprNDPQ_4_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_8llzS4G6H0OkTZ-cYp0_Bg_4_6">71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_RDBdw8TED0SQzWeqg4jw3Q_5_3">10,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_vawvG6JNIUm70X77HCiJSA_5_6">3,748</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_SvluBpTFIEi3cfpkzZrvxg_6_3">8,180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_ixOZfNGyjEWLljo0RyjVPw_6_6">2,602</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc__dsWtLPblEi7pcennhLIqA_7_3">3,475</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_Dp2uxrItVkyLjn2hnR6KJQ_7_6">2,887</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_-1UGxZIvmUmaUqBeqNySGg_8_3">2,603</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_56r9E1OqL0-ssZzCcsdzPQ_8_6">3,115</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING LOSS</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_9HiS5crlV0O6PJmzuqfD2g_9_3">4,145</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_tuoVy8dJqEqngiz_rYIffg_9_6">4,856</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_eqioKDVYSU-RXWnQ0wu4mQ_10_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_1JNuyZXtJka-GfRE8Ux8AA_10_6">390</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_voBBEjhlIk22uAzonA8E4A_11_3">419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_fdXVKX3Sh0WF2hcbBFtpgg_11_6">513</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME, NET</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_msr2LrXjtkuzk-Kcw83Hhg_12_3">413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_8twngDkZ40e-Pr1sGHRMqA_12_6">123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_XHpAgl2Zak2KUxQJ8R9WLw_13_3">3,732</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_9IuQ4kjEEUuSQbjauS0LqQ_13_6">4,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAX BENEFIT</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_yM9fGBVSfEutjkL9nN1s_w_14_3">113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_Z6ePgPXz2E6jDjedu-YMTg_14_6">138</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET LOSS</b></p></td><td style="vertical-align:bottom;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_j7TYlBnGyEmwhoRydxrW-g_15_3">3,619</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WgAg3mvWzUW9gEt89uOIGA_15_6">4,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LOSS PER SHARE OF COMMON STOCK - BASIC AND DILUTED</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_E7ITEF5KjEmco47dTg3fXA_16_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_E7ITEF5KjEmco47dTg3fXA_16_3_2">0.05</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_FiMWM5Pufk2puCOg-6wccQ_16_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_FiMWM5Pufk2puCOg-6wccQ_16_6_2">0.06</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING LOSS PER SHARE (basic and diluted)</b></p></td><td style="vertical-align:bottom;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_I9hpCZQJKkSx7cnwzNN8QQ_18_3"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_I9hpCZQJKkSx7cnwzNN8QQ_18_3_2">76,611,980</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc__IkDqh97fUGro3cDU5JcIg_18_6"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc__IkDqh97fUGro3cDU5JcIg_18_6_2">73,036,569</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_568e3741_d80a_4640_984a_7a1956956a74"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_8rK2bwRaekqE_6Guo2Q_og_1_7"></a><a id="Tc_DQ3QOS86H0SN0Gnxga4YzQ_2_2"></a><a id="Tc_GaQJd5fPhkyaE6H9g3nY4g_2_4"></a><a id="Tc_flX-w5AvfkKryMk4Z5Snow_2_7"></a><a id="Tc_JU-A4-mC2UKXDS5M604TkA_2_10"></a><a id="Tc_cdSKna2vmUup6eGY7mutjw_3_2"></a><a id="Tc_Ie5SGpTSG0SLj4OfwSAm6Q_3_4"></a><a id="Tc_BNLwe72u5UaMkFVH0LXVSg_3_7"></a><a id="Tc_2KK8uWaWpUCEGtW6-Z07Jw_3_10"></a><a id="Tc_xg3MDvImx02dtKKkdbhOOA_3_13"></a><a id="Tc_8Vn8IPF3FkOU_AKC5Jwwlw_4_2"></a><a id="Tc_6FrHRF_pG0SiDUN2UmUPoQ_5_2"></a><a id="Tc_Z7_gkc3vrECtpbkUxJBraA_5_4"></a><a id="Tc_zus-pdVpdUuglU7RvRP9_A_6_0"></a><a id="Tc_C6Kf7nrY8U-QrxXFVLbnpA_6_4"></a><a id="Tc_t0XXmw6mmkW0DVC6FQH1nA_6_7"></a><a id="Tc_UF_onXtrF0W1hr64C10ULg_6_10"></a><a id="Tc_jyEdMV8MYUaVbNopl-c3Rw_6_13"></a><a id="Tc_F8wkBnt0GU6nG16uEj_apQ_7_0"></a><a id="Tc_rcqahSlbpEudTcn2X5hkDg_8_0"></a><a id="Tc_Xu-_tAUGL0qYxL-oFDdBpA_9_0"></a><a id="Tc_1tuahg2oXUKSwSUshZa8VA_10_0"></a><a id="Tc_VQ5hrte5bEyp019JG2VUiQ_10_5"></a><a id="Tc_blbcDITpeEO-a48EGsSJsg_11_0"></a><a id="Tc__uXz9nuwPUGgY2WBD4JK5g_12_0"></a><a id="Tc_1zM-qyl7ykawa4fZhgtmMQ_12_4"></a><a id="Tc_7QyA8KP3bkykO-vgpDxCRA_12_7"></a><a id="Tc_u8UbZYLiyEmsldDnSzl-8g_12_10"></a><a id="Tc_yRHXXeePA0SjGDEw3vyIZQ_12_13"></a><a id="Tc_0OOAjtq8XkiAA5-ERtxwDQ_13_0"></a><a id="Tc_2mQWSqdRlUeV5FV2nyZcvQ_13_4"></a><a id="Tc_E2QkfpEdA0K3Mug80wdb-w_13_7"></a><a id="Tc_t98EHLF0ZU-zbOiMjmBi7Q_13_10"></a><a id="Tc_oy48XEGLWkiQjRaP5jcDvQ_13_13"></a><a id="Tc_atllSn176UqELSmESoLX4w_14_0"></a><a id="Tc_E8Gtt6n120iu7k-Crm08lw_15_0"></a><a id="Tc_VcJIVzobA0-zKeN6lRevsA_16_0"></a><a id="Tc_af5s81j3L06Hsc1m3OeHsQ_17_0"></a><a id="Tc_j1ZjLnqQKUKmpNlLX8UIKA_18_0"></a><a id="Tc_CN2TG7NxJ0u6JkN-_g2Acw_19_0"></a><a id="Tc_fcSRHQckOkCdPYzmna68Eg_20_0"></a><a id="Tc_fRSeMRsPlE6Oe7zP1cHqqA_20_4"></a><a id="Tc_s25eQUvjtkKV7IBZms5u7A_20_7"></a><a id="Tc_Z_1syWP0FEKXfK9V7Nae1Q_20_10"></a><a id="Tc_uCquguyFSUKNFrSi1R2PBQ_20_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_rmq72pKmPkelc_kfVf5utA_6_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0q10Q1vhvUGGYtui_Ld9dA_6_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_90621vYqvEa1pn7bmcTY_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Ga3ZAIXMSUWrWymKXw5HPg_6_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lSnbdXconU6DulGwTT8MFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_qzOjhZVh50iRJINS3VuPDg_6_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1Re7MFaLyEeE4aa3HeAuOQ_6_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_mMR0VvF-xkubS-wPGSZOXQ_8_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4HrirPbHHkGUdsaYl6N3qw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_oIQkYAZQoky4DC0yu0i71g_8_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_BmLMKInirk-W2LzHEG8PAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GNhPdNy_WEKbVi5XTfRkWw_8_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_pnOZAhi9rUe_WgumPUscMg_9_8">500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_SnmF-fcwm0OJTMUFzJCudg_9_14">500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7Tgj53JZECcqAlPLWNniA" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_AjRDmy9tBEad27ugDaseHg_10_8">481</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_H4iIR9ZAEUSC_T-fRjiuFg_10_14">481</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eW1ZtmVb80KFn9rh2Sehpg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_C43cnB8A0kKM4ewT6xVfPg_11_11">4,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YR4HIHROrkOx6bMK8sU5RQ_11_14">4,595</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_cLY55batqEe12Eox0KmcKQ_12_2">73,052,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pMi4htmvfka0rQRpJi5uOw_12_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lxOjswxMb0m6s5VE-STvCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3mcrCn4DB0S6paMfFFjDXg_12_8">415,633</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ds3ukx2XekWVsDH9lI71mw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Evu7j8K8uEK2C2VxnB0Kdg_12_11">385,920</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9tYqwtLsqEW4JGz39uxIwQ_12_14">29,786</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2">75,850,275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_448eJnejT0GQZzRtwqoFEg_13_5">76</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_prBuP7Wn10WQWwJPcpXf0g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_F_LefStl0kKH-G0qP_J73A_13_8">421,528</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m6Piq_wnjEaeFfGE5kdjsA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YDvKPqPVg0aPUG8-hxS78Q_13_11">378,393</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kVNKx1j8oEe2rmNQQzRYHg_13_14">43,211</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended March&#160;31,&#160;2025:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_D3oA6QxgOk6teZp4KIJaIA_15_2">1,325,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_IeP4rHtYZEKfF2m_ETMbrg_15_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_qplUGL3sl0m84fVnG-bF9Q_15_8">2,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_wNqaEuSB8U-MvZSsiNbzYg_15_14">2,861</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_svpamVYWgkWK1YkIHomWTA_16_8">336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bB2tEEVrH02XS_5DbsuqLg_16_14">336</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_02_x5qSVW0yEHxCQBZfXBw_17_8">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_nnkgaQdj_Eukm-0TrR4ITg_17_14">204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" scale="0" id="Tc_YtLlGAbz7060zZ-cwF33Pg_18_2">958,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_aXTaYk4D3Ue0ZX1RRRToJQ_18_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_vvApkqWZhUG9G3fZcB-aTg_18_8">2,214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_4B49NbwbRk223UbWya6-Kg_18_14">2,215</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F4FQvuyunUGq_SflJl8NoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZMqV7ZADSEu_BP_CzkSzSA_19_11">3,619</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_1NcpxM2Orku52iIsPq9DLQ_19_14">3,619</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_Xbxl8-joqECHr07q_Wk7jA_20_2">78,133,829</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_QxcrfEo3t0a-XOgbZmN--w_20_5">78</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WKF5iW7GJEWP-U2zSvqbMw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_z70Y6JriXUKbHJki9EcSOw_20_8">427,142</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ghu49akz20uatgeBd2X7xQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_bCn9d4bgJUCw9Mi9sKV9Jw_20_11">382,012</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_IMsrR3ksJEKgSv4GsfnVQw_20_14">45,208</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><a id="_c3493724_079a_487d_a703_63d3836f1c6f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_QlF9HKuia0Kh0wSWX7ZPMQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_skyon_ELj0ub-2eYTUqusQ">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of March&#160;31, 2025 and December&#160;31, 2024 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_vRM7f8f25Uu3U95OosYpCQ"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_4_n1MFNAU0yiqnDzSeC7Tw">185,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_cc783e76_2f1a_47cb_969a_65abb1094562"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_wQEZxSg6nkOUdIsEMHwTGw_1_2"></a><a id="Tc_OWsOegA6cUedg7AMQopTFA_2_2"></a><a id="Tc_weW5NI0SAE-ZoZ7qzKBNJQ_2_5"></a><a id="Tc_09NQLZjwNkqkAAjKMrivqA_3_0"></a><a id="Tc_qU-LiCld9UaADOr6AWPsAg_4_0"></a><a id="Tc_sHEjKqCZ00Cb8yImM-eI2A_4_2"></a><a id="Tc_BckN2PafHkOQRPAtH0LSvA_4_5"></a><a id="Tc_vXM1OLpXX0u76sJL5qe1Xg_5_0"></a><a id="Tc_0ZGGso9IeUGZWN2NreD_Kw_6_0"></a><a id="Tc_QkfrmWLtnkuZTDfqW-CCmA_7_0"></a><a id="Tc_9NNUZ5pwmUSNJ30LS_dtzw_8_0"></a><a id="Tc_pZJCN42XzUCZ8duIMLVNNQ_9_0"></a><a id="Tc_8UUeDj0SCkqVL-fG3rjGZw_10_0"></a><a id="Tc_wmb8n0NN_kWmGEgDbt5kNA_11_0"></a><a id="Tc_4GR5Ij4oPEifKdJo1aDqcw_11_3"></a><a id="Tc__sizbvIlwU-TMnMhQCcTSw_12_0"></a><a id="Tc_S1yad8I60UG7sTQRtaDqXQ_13_0"></a><a id="Tc_uY5sDjfviU68jNQaOdWCfw_13_3"></a><a id="Tc_nLqPEFelWU2Jtyv5DV6bUw_14_0"></a><a id="Tc_tZREOizbgkaR0WVxb5Ivpw_15_0"></a><a id="Tc_0uv1Pe41KUuVadcdDEGRDg_16_0"></a><a id="Tc_pY0E5_ov0k66dwslYgQofw_17_0"></a><a id="Tc_ioYE5H21sk6750quzAuerQ_18_0"></a><a id="Tc_3w5okX-XJkm-JyB3UTrpYg_18_2"></a><a id="Tc_C6wr4Bq56EGdZxRy887a_Q_18_5"></a><a id="Tc_nTsKehL3iUmxnB24IgPwdQ_20_0"></a><a id="Tc_Jl6jKFg6N0WPqOPpmlRvkg_21_0"></a><a id="Tc_TDlFViTugUqf88kW_JEHpg_21_2"></a><a id="Tc_1EiaaNd0wUGyrn6FTy5RNQ_21_5"></a><a id="Tc_sycS5OSfPUeigkgV_PoPFg_22_0"></a><a id="Tc_ahLwtab_ekmNsGG7X797JA_23_0"></a><a id="Tc_pNO7z3RqVk2RQ8EHPGQQsQ_23_2"></a><a id="Tc_Ng4NQynO60yZfppDXnXYDg_23_5"></a><a id="Tc_zIuoGAszEkK945VC7sy1XQ_25_0"></a><a id="Tc_sbZLnUupxU2VumgJC06lbg_26_0"></a><a id="Tc_TWeTJ0AtfE2rK2rZ7HdHYg_26_2"></a><a id="Tc_VSf7U1WGXUqYCRSDvRICVQ_26_5"></a><a id="Tc_W7oV9zzHVUiecIAfTD4yKQ_26_6"></a><a id="Tc_pjhzxO_KlUyqK4GWRsrX6g_27_0"></a><a id="Tc_9h0VLIpoi0OEYoGRnepLBA_27_6"></a><a id="Tc_hMVV6BBmE0KRGJeTcgR_JA_28_0"></a><a id="Tc_pEb-n9HrOkCP0iRMbKJ7Zw_28_2"></a><a id="Tc_73VcDLr3yUy7rjLOLFpuPQ_28_5"></a><a id="Tc_lG2jRhlLgkCu_EsFIJkIVw_28_6"></a><a id="Tc_ghdAEDQAqkKR19Zut7rMoA_29_0"></a><a id="Tc_ZpRuVKaP-UOVTtyCGBnJGQ_29_2"></a><a id="Tc_ngjV40b1zkSQ2g_KdPo9xA_29_5"></a><a id="Tc_jOqc2Gy2BEiP63Tb0f0TZQ_30_0"></a><a id="Tc_x70QCDTqGEWbds9S-v-Ung_31_0"></a><a id="Tc_NUjGEm4SP0qyWuVr20ps_A_32_0"></a><a id="Tc_2GBFLFFCzU6N8wA7pNn_5Q_32_2"></a><a id="Tc_lJgOvbL8CkGtPeVEwKtnZg_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_KcpPO3aTzEq1E5MVAruavA_4_3">3,619</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_lDs_1pk8j0iRvJc_YrxolA_4_6">4,595</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_f0RHtBLUCU6ubrWu7h-_Jw_6_3">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_gfu3clcMUEWhWN_pUi2m2Q_6_6">981</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_x2dWKK6mTkid7rPMSTm5Qw_7_3">346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_MT1wkaD36kywjxbno4hMBw_7_6">322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_rKqUm9cmykSr4AyV2u8acA_8_3">375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="Tc_HjtzN_UZAEa8KvVgP84Nng_8_6">471</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_eX2Bwbcg7kWOdaT2SZOmVQ_9_3">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_cXnHybNRWUiacLd_kjnnnQ_9_6">8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_aAtRR44sjEGox_EDP9A1xQ_10_3">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_j_Ji1KzviES3WGtfsyuXAA_10_6">138</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_zxw-c6rAxE6prIB22jF0yw_11_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Increase in contracts liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_qxIM1NCMYUSdB5_nT8KgzA_13_6">11,039</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_mXIpSjwWBkiLtUZEj7IbBw_14_3">2,275</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_bk1DY0_mnUyyNuW1K3xSHw_14_6">1,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_NCKM_5iY6k6-cLrWTpujGg_15_3">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_BaNckAlkckCGQb9ujMlY_g_15_6">14</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_2r3lJ35WCUacmK_1X2X8JQ_16_3">1,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_vrVePh_UEEa6Q6pIon41Ww_16_6">3,301</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_RfgkaGbGjU6cAQ7-7oe78Q_17_3">1,284</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_dDQKXqQ1X0iTAqh_zay6oQ_17_6">1,414</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Ml2icdSQt0WrgSBfP65Evg_18_3">5,058</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_w579qvKwlEy8wgat2ANlnw_18_6">4,188</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_ypDA6L4s80-SCk7jc5C8gA_21_3">306</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_m3QhI8-Fb0GTfrnO4Gt8dQ_21_6">598</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_dpDcT-MLW0eGe8PvnoK7Qg_22_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_zjRzed665UWBpjPsThw5iA_22_6">8</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash used in investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_PuskA3_YwUScdyJF5vnEQg_23_3">312</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_2ACUrL_XwE-YaLCO5GJ20w_23_6">606</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_2X0TEztaI0idJpF9kAQUAw_26_3">2,861</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWarrantsAndStockOptionExercises" scale="3" id="Tc_xLqDwK-Q9UG6swDFvvlFug_27_3">2,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Dl9n9Dsz-0eHMqJgrDV_yg_28_3">5,076</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_DuiZ_Ahky0WVWzObckWS4Q_29_3">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_5vT_G7zo3kukdGX8nClp_A_29_6">7</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_Aq5ffg5RhUu4nNwNQQQ31w_30_3">302</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_NFgOjojJuk2SwJBABC33hA_30_6">3,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Ij9rzwLxXUqkh6Lk1ntIWA_31_3">19,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_067AxH7vpkeu-lcQswnkWA_31_6">23,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_2UicSS9fc0Cdh8IMOcgVIQ_32_3">19,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_RPtaq6caeEWxd4C_r6PrgA_32_6">27,209</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Continued)&#160;&#8211; 2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_ESP8yAmVE0epz_KP2EJY2A_1_2"></a><a id="Tc_Ge1oEZk2bU2qr-riaVUBcg_2_2"></a><a id="Tc_1alW4KiuY0-f4nA05UmK6w_2_5"></a><a id="Tc_f1kHEEQyR0WNQ0PlV1cm7g_3_0"></a><a id="Tc_p05xNclh6E6KF4HvhFA3ow_4_0"></a><a id="Tc_OQSVs7ZAp0WmCy_viKBPvg_4_2"></a><a id="Tc_asN2GW9p5Em2OPCpnHjAJA_4_5"></a><a id="Tc_e0bdGOVMNkCFoSL7xNw7Ig_5_0"></a><a id="Tc_VDaoR4KuXEm2mKtxYVY_yA_5_2"></a><a id="Tc_KgFrb0vIrkWZ6RZ_H2xLlg_5_5"></a><a id="Tc_5brvB_tHyEiG3RaxzcW3cQ_7_0"></a><a id="Tc_WHvq4IB-rkeqq00bFlcjkQ_8_0"></a><a id="Tc_Fbf72gJSuUe-KvAsO6-XOA_8_2"></a><a id="Tc_6kDFcdOemkSYSaW9q1bO-w_8_3"></a><a id="Tc_sJgoP4f7nEqKoNOBV2oEmQ_8_5"></a><a id="Tc_l1BSbV3K80ezIg4iohhqBw_9_0"></a><a id="Tc_FUsJNSAa8kqziXZWNqZsYQ_9_2"></a><a id="Tc_fOeMX3VAy0mcDw_JIa6fDA_9_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc__1amH-tWeUCAbhnTYMgblg_4_3">427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_6cncF4hx7UGGqVB71tz9rA_4_6">146</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_uD98oP6d5kaa3YXBdFqXLQ_5_3">33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_E57N5wzMWUusww8qPsfQxg_5_6">186</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_piRujhfNBEGPmYpk8XCOLQ_8_6">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_BzbRpsqwXUSrv2gwhHIE_A_9_3">166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_zHbQSwLnKUCHWhErtVb54Q_9_6">33</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_SidqCRLA-0K4DwhfO0FIYw" continuedAt="Tb_SidqCRLA-0K4DwhfO0FIYw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_FAYgudVWCEeGr1xB0tm1Cw" continuedAt="Tb_FAYgudVWCEeGr1xB0tm1Cw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into <ix:nonFraction unitRef="Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_BqHONMmeHE-hXTSaYShZmw">two</ix:nonFraction> exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p></ix:nonNumeric></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_SidqCRLA-0K4DwhfO0FIYw_cont1" continuedAt="Tb_SidqCRLA-0K4DwhfO0FIYw_cont2"><ix:continuation id="Tb_FAYgudVWCEeGr1xB0tm1Cw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_Y_QC7Pagx0qp-Num1NGb4Q" decimals="2" format="ixt:num-dot-decimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_JuiIWNpPZE-PR5hvhrDbfQ">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_cwCPPKmRoE2aL8mQfof-kA">no</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_zMFjX5YNWkK3hpIfzpi-Eg">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_y6-CsnHhbUiWoMezhWCoiw" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" scale="6" id="Narr_4rYSn9sufkCGq3b1zJ25Xg">20.0</ix:nonFraction>&#160;million. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OiVYUMJ14ka7WcB5y23CLQ" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_l4IwlGo2gkS9YaK_dKDxog">19.7</ix:nonFraction>&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. Although ceasefire negotiations are on-going and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_SYKjAsG4b0e4IPp1ICVxxQ" continuedAt="Tb_SYKjAsG4b0e4IPp1ICVxxQ_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p></ix:nonNumeric></ix:continuation></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_SidqCRLA-0K4DwhfO0FIYw_cont2"><ix:continuation id="Tb_SYKjAsG4b0e4IPp1ICVxxQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_eF39j4eRRU66JyQ0vHzJWg" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_75AYESP9RUK-GveVvLuOfA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_zwu2z07czEekGfJY2OELVQ">18,216,366</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_nmHBOM5hwEqT3t2gduL9Wg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_KImh077cZEO4_8n00f7TKw">31,839,345</ix:nonFraction> shares of Common Stock underlying outstanding options, unvested shares of restricted stock, warrants and convertible notes of the Company, as applicable, for the three months ended March&#160;31, 2025 and March&#160;31, 2024.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:DebtPolicyTextBlock" id="Tb_C-1qFB4GmE-0nuf5qVyPAA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its <ix:nonFraction unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_jLrTiAYktE2BXNkVgYPROg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_oPtgTdbfrUmWsyxbQAj7HQ">7.50</ix:nonFraction>%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p></ix:nonNumeric><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_V1VhlSBie0KBVUvUxTRLwg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="Tc_vtYu80DzcE-gCPQbU4jIsw_1_2"></a><a id="Tc_fMYhmRwWy0WkWlLt09zEuA_1_5"></a><a id="Tc_IPgdfVx0CUeshsqmFmmk9A_2_0"></a><a id="Tc_nD54xqaI1Eylj9FQATkGNA_2_2"></a><a id="Tc_0YQgljGH2k6th3IlnJH5eg_2_5"></a><a id="Tc_7kNe4i9vIUGKf-pKwtfL1Q_3_0"></a><a id="Tc_jabqDRBypECOZp2wd8joUw_3_2"></a><a id="Tc_Rgq82jSvzUeEhtm5LJk4-A_3_5"></a><a id="Tc_Ul5zDTwjlkq_YdpXOAtFzQ_4_0"></a><a id="Tc_HSeGENhoSUCTvZDhruDF-Q_5_0"></a><a id="Tc_5uJ6oIBnJUevINKdWkvVng_6_0"></a><a id="Tc_rregRiP4akSYuO8zMmHqJw_6_2"></a><a id="Tc_nJer7Nd2Y0GMIZ4eAgUa4A_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_wXEJf3ve7U6tF9hFXBBxuw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Group_awHWg-BHlEaehZaZrKMk5Q" continuedAt="Group_awHWg-BHlEaehZaZrKMk5Q_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2025 and December&#160;31, 2024 consisted of the following:</p></ix:nonNumeric><ix:continuation id="Group_awHWg-BHlEaehZaZrKMk5Q_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_Ncu1bG-ss06nt5KEFsBzsA_3_3">4,484</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_EaVHYkHrHkibv7zCFxCtHA_3_6">4,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_25hunJbYiEu9cosIXuxPag_4_3">8,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_5fY7-5rOUEefGrKzU8auVg_4_6">11,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_AlACnlOqoEe8IdVgfopbAw_5_3">7,020</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_LyUdVx8j5k-ntnX__pwJhw_5_6">5,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_wm5kvcH7rkyprPbJmC46XQ_6_3">19,506</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_lhB-AOeDc0S0fWZ2KmAmnA_6_6">21,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_dehfHFbqgEakH1IYr9Ssow" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_00wfl_EeJUOfUpUNgAUoyA" continuedAt="Tb_00wfl_EeJUOfUpUNgAUoyA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company sold, in the aggregate </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_2LuDTnk0EUypn9b_YSEDUw">1,325,179</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg" decimals="-5" format="ixt:num-dot-decimal" name="plx:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_r3k46BbPzkaRFbje147amQ">3.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_bbRzSq8yOkyv7UVuyVXBsg">0.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_At0lw6Ef6UCB1BntdLYMzg">908,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_E7TeWzOcwEiLPcxjhp8UEA">2.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Lwwrp-grPUmPH5Z8rNY9-g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_R883z2tHYUK2zc_u1uDmGQ">no</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remain outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_00wfl_EeJUOfUpUNgAUoyA_cont1"></ix:continuation><a id="Tc_gIt0dl3nqkOSXGNesn_kTQ_1_2"></a><a id="Tc_NttNYRTAPUWoGLdhA32Aow_2_0"></a><a id="Tc__0hrJRntQkyQLvy9mPZW6A_2_2"></a><a id="Tc_eUnkYdzlDkezCmFdV6i4xg_2_5"></a><a id="Tc_60csdvRtn0WEp-CJbRNjww_3_0"></a><a id="Tc_6LohcQ2YqEanADKDP_nZrg_3_2"></a><a id="Tc_qNf_XkgtcEuq3V60Cc0e1Q_3_5"></a><a id="Tc_vMIxT1VfPU28uprEKNlL4A_4_0"></a><a id="Tc_d1g_joYAXk6wvM6N2sF8bg_4_2"></a><a id="Tc_dbOHxAWri0-sleVVgpqQcg_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Ks5J4iuFxUOwlGXCSMMncA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; TAX BENEFIT</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_Y3Da7sPgSka3hztilwsVQw" continuedAt="Group_Y3Da7sPgSka3hztilwsVQw_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p></ix:nonNumeric><ix:continuation id="Group_Y3Da7sPgSka3hztilwsVQw_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_SE9yU9aWl0O-U9QAVNit7g_3_3">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_nLwSHsOzB0aK-tF9msHV2Q_3_6">138</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ref7X-U8_UWEtC00Fis3Nw_4_3">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_mq6SIxmkvkC7uWhu2q59SA_4_6">138</ix:nonFraction>)</p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_ZS9WEgAIR0W7n2z1zKzfYg"><ix:nonFraction unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_G61aNaAp2UaEWoCPkpmM8w">3</ix:nonFraction></ix:nonFraction>)% for the three months ended March&#160;31, 2025 and for the three months ended March&#160;31, 2024. For the three months ended March&#160;31, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_VoeyvbTvC0GLrkWizYuMHQ">21</ix:nonFraction>% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p></ix:nonNumeric><a id="NOTE_7"></a><a id="_f10d0571_9307_4863_b1ac_d02a1bb9aefb"></a><a id="Tc_mQpO3UV8202oiwiw6bur9w_1_2"></a><a id="Tc_AC4udywF30qWNgK9vGQeIQ_2_0"></a><a id="Tc_w5CEN5ye1U-NkNy-PjE54Q_2_2"></a><a id="Tc_sbH2S4UzskipJ0qufX3cSA_2_5"></a><a id="Tc_36mR3p0wwUakfOmLprcPNQ_3_0"></a><a id="Tc_DmPNp54K-EKVYb6GptvfEw_3_2"></a><a id="Tc_oYyL_bkEwUqwNyonN-eOcA_3_5"></a><a id="Tc__ANq1nzqaESwUysq9jB36Q_4_0"></a><a id="Tc_kv_wDWiS30WtJv7FFWEaRQ_5_0"></a><a id="Tc_54V0DfvNbky9VhKynZqAFQ_6_0"></a><a id="Tc_op8l0BYmuku7r7cIsU2piA_7_0"></a><a id="Tc_AANYHmOL70-T1KkWH99L4Q_8_0"></a><a id="Tc_TOvt-55bIk-MtUW-2nD0ng_9_0"></a><a id="Tc_YSy-Um7N2EedY4K0SsqiZw_10_0"></a><a id="Tc_nIsRm-ut90mex6e4t48xGQ_11_0"></a><a id="Tc__FKfgYfckUKjoaTwjwQrFA_12_0"></a><a id="Tc_Ts25USZ6W0-WXwQ8z-LlHg_13_0"></a><a id="Tc_LgeDMk8-mkO2lLQ5cJuitA_13_2"></a><a id="Tc_27HrCCo06EiEpRS1zN6hEQ_13_5"></a><a id="_efea1927_263e_4853_975e_490fff50e12e"></a><a id="Tc_fDhI5Fdh1kOGwm5qKr5dng_1_2"></a><a id="Tc_zppsW_0Fz0CZ0X80s7N2fA_2_0"></a><a id="Tc_Fz4OblgXaEO0ZmwDw2xiLg_2_2"></a><a id="Tc_VyUUN3DyRUe-YEe9psPg9w_2_5"></a><a id="Tc_VhC_5J6Mu0mlkl6681Tcug_3_0"></a><a id="Tc_4D-mcD9KEUedie2_6UbCFQ_4_0"></a><a id="Tc_iwiwQKRhH0uz9dQGIMH9gA_4_2"></a><a id="Tc_LKrkESQtoE6CxBV6THJZXg_4_5"></a><a id="Tc_BieKXqbbVUGWdbYhBXkqaw_5_0"></a><a id="Tc_jaKi7Z_A7EScsrNx03_Gpg_5_2"></a><a id="Tc_RuOKUBCUxkyzUb6hw4mDbQ_5_5"></a><a id="Tc_48f_xF1FTUOfHdZrbHEWvA_6_0"></a><a id="Tc_ht5ShX6igkSrjAmKFr2Log_7_0"></a><a id="Tc_85A7kQHbFUOIGWtDGWZcTA_7_2"></a><a id="Tc_--nSW3jBSUiOEjFU2XLv3Q_7_3"></a><a id="Tc_4xGo0tkSsUO67rqpQuDaoA_7_5"></a><a id="Tc_VA2iiQZLn0uOO7uAaFstbg_7_6"></a><a id="Tc_arMCOwihpUSEaQdcQtphqw_8_0"></a><a id="Tc_EHa3E2ks50aIJXazn_nFAw_8_2"></a><a id="Tc_1SwZU7kmnUyDjBkhyrJEug_8_5"></a><a id="Tc_pQJk3xGbb0WhF8gEScTkuA_9_0"></a><a id="Tc_Cb_6Qb3D90CGVtdnp6covw_9_2"></a><a id="Tc_N5oYesiG8kmquWfjRMf4vw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_tw3kMhuR70-RjtR-VXYsYQ" continuedAt="Tb_tw3kMhuR70-RjtR-VXYsYQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_cSxaNzcnK0mLWtm562rZ5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Tb_xTJHn25IhUW-XFM2yvWaYg" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_bQEzuz-3o0SaxVkUwHdmCQ_3_3">10,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_1AtY4L41KU69-paSvZxtJA_3_6">3,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_1Or2i9u6uEyCYwpcBvf0WQ_5_3">5,205</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_fBk3vDQToEWatZyfz3ngSg_5_6">5,144</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_vIPO1OUbvEe3I8pbS8Up7Q_6_3">2,689</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_URBejJlP40yX-PXFChWayA_6_6">2,155</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_tJ8n4mIzhUqNX5yAYeKqfw_7_3">6</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingExpense" scale="3" id="Tc_QMhfOmW-aUeYqTZzZSV3ig_7_6">390</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_VRDEqwqWC0mMh37h5ychrw_8_3">419</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_XDb1IIpqs0yvYiN1FFzf9g_8_6">513</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_el5HVNy930em19L_LPN53A_9_3">346</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_O70bAoKls02S10_5W6QynQ_9_6">322</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_aMCF-J59Tk6TSIs2OOmMSg_10_3">6,018</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_EyneGA37l0aS0j0q5fjJ2g_10_6">983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before taxes on income</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_h6L5v3B_dUWFqtdOCgd7vw_11_3">3,732</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ESuF0bJaCU-PtoozAuMBEA_11_6">4,733</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_5UMYnaXAX0SGtX75G6HuMg_12_3">113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_yFEP28CErEWOPuVAnZUFqg_12_6">138</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_h6bdgPSV3E2O-pjLZYgKUA_13_3">3,619</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5a38jctklkKrRyrGMqgQYw_13_6">4,595</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* <ix:nonNumeric contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_CCM9Yf6ahk-krFQDUcpIyg"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_lsZJJ5CE80-NHRC85pNJUw">Other expenses included in net income includes raw materials, rent and utilities and others.</ix:nonNumeric></ix:nonNumeric></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="Tb_jX-u19dRv0e6L5bhoIgZMA" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4ybsI5_mqUqIV1P-uoYRHA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc__iY56oFBQEmI07o5UwTrHQ_4_3">6,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_F8q1dlZWwEuLw9hXrYpvwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_bRPBq7l8h0uEGgjqdiAppA_4_6">1,127</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_7lP2AsW-rUWHh6Iroj0Xlg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_SE4fSRbLFkCj09sNcU1feA_5_3">3,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZEZl7VBCOkKOl7NTRveViw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_GPhInPem6kG3T9Z-kPWRSA_5_6">2,550</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_CrUJT7JZGkuj0DZWQCJSCw_8_3">9,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_BU7fGt8U3E-qAIEUglR39A_8_6">3,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Pnq1f-E1_0OoHH4VNRR7Dg_9_3">118</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_frVXyN0go0-c4VgJqtrc-w_9_6">71</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><ix:continuation id="Tb_tw3kMhuR70-RjtR-VXYsYQ_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation><a id="Tc_q_YPJzZkS0S8W3xuY2ZiEw_1_2"></a><a id="Tc_-jk6-yIb-EyslqCxzxAvzw_1_5"></a><a id="Tc_jScS5oYH9EWw0W7E5gugRA_2_0"></a><a id="Tc_RUq4lPKmyUmYCxx18gdqww_2_2"></a><a id="Tc_fVjb0gbMZ02nJxUp-BoanA_2_5"></a><a id="Tc_l7lu3tFBQkmsltrH7rY8Tw_3_0"></a><a id="Tc_agFiKmJ0MU-jbWm5S-61Ng_4_0"></a><a id="Tc_5D2omjXiSEO37ElpvTQRUg_4_2"></a><a id="Tc_qzlevK9AukqVQfmni7bZiQ_4_5"></a><a id="Tc_4LCXdBRHlEK_Sroj69EPsg_5_0"></a><a id="Tc_KUbfkFZqkUajB2tL8VD9lQ_6_0"></a><a id="Tc_9-SA9U0d2EyjhONKsJxIUQ_7_0"></a><a id="Tc_0kQvQZeIkkudQCNZXBco8A_8_0"></a><a id="Tc_1MVdCMtBXUiQSTY3XgV05A_9_0"></a><a id="Tc_uC3NsJqAv0myNNeNSZ2oQQ_9_6"></a><a id="Tc_N8-8zhhdE0KqEo5U3FO74g_10_0"></a><a id="Tc_otVLjApzVEe163dyFP2RbA_10_3"></a><a id="Tc_OtSDyiPgcECYeadCEx3QWA_11_0"></a><a id="Tc_8PKXol5p-U6g7UMl5Ofgyg_12_2"></a><a id="Tc_dAKqGun6gU2ponDIx2HCSg_12_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_OVoAhAYmOkmwqBf7HU5jNA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_uYxUY0qvDUqERdjZgUKCDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_dI4ZsJP7KUCEOHpqY2IPrw_4_3">1,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc__nW8r97jOUWf9lTyDu8qhg_4_6">1,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_LiAHUEavCEe0j7aSfr9UEw_5_3">1,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_An2uKAcwWUyMrwyDoIxkwA_5_6">1,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_0yWwcYdIVEiJ-4FuSGxRKg_6_3">9,349</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_upMRGiHCJk6cSedElb6A-Q_6_6">9,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_dZ5iz6rYKEqa9gQRDrdXuQ_7_3">300</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_Zoeqf2RcyU20-cPhS21nmw_7_6">1,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_qfSnp1ZIrESY8LcCNY4Pwg_8_3">3,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_ptltZDLo1UCkaWciOYybeQ_8_6">3,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Advances from customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CustomerAdvancesCurrent" scale="3" id="Tc_FWigNfAO0kC1bZZUen4qyA_9_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="plx:PayableToCustomerCurrent" scale="3" id="Tc_l6pAzlH-2UauxGULeFB4-w_10_6">2,056</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_UIcsVuPBJU6NMjZ-UZKN7A_11_3">427</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_HRWg5gkSNkWGBcB7pDuQDA_11_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_qxUsuWjZDUq5p2ASYD2vKA_12_3">18,776</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_PdwOU65JYECPPVRWYeVShg_12_6">19,588</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" name="us-gaap:SubsequentEventsTextBlock" id="Tb_AsJfBkG7HEyFbzQYeaButw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended March&#160;31, 2025, the Company collected approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_Vzwfwx4x6UqY4cHH7H5agQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_cT6yuOSKAE2HBukEc1Fe-w">2.8</ix:nonFraction>&#160;million from sales to Pfizer and approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_oXa9IlN4NEi0krV8osIOWA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_1jP3uosiB062JeE2nwmiSw">1.9</ix:nonFraction>&#160;million from sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended March&#160;31, 2025, the Company sold, in the aggregate <ix:nonFraction unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_Dk85KvOzAE262GUzKfZA2Q">1,450,036</ix:nonFraction> shares of Common Stock under the Sales Agreement, generating gross proceeds equal to approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg" contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA" decimals="-5" format="ixt:num-dot-decimal" name="plx:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_IIPNnCHJx0-OYyay8skzFg">4.1</ix:nonFraction>&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_f1f021a7_e3e6_40b9_89e5_fd6ec08dba80"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2024. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company, our subsidiary or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors, including those set forth in this Quarterly Report on Form 10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the U.S.&#160;Food and Drug Administration, or FDA, approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to the war declared by Israel&#8217;s security cabinet against the Hamas terrorist organization located in the Gaza Strip, the military campaign against the Hezbollah and other terrorist activities and armed conflict, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict; </div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market of our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency, or EMA, or other health regulatory authorities for our other product candidates, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as <span style="background:#ffffff;">new or increased tariffs, new trade restrictions, </span>supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer Inc., or Pfizer, and Chiesi Farmaceutici S.p.A., or Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Funda&#231;&#227;o Oswaldo Cruz, or Fiocruz, an arm of the Brazilian Ministry of Health, or the Brazilian MoH, with its purchase obligations under our supply and technology transfer agreement, which may have a material adverse effect on us and may also result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="margin-top:10pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elelyso was first approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. We have licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer, and in Brazil to Fiocruz. Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. We have partnered with Chiesi for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, we are developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets. We have completed a </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:249.19pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">phase&#160;I First-in-Human clinical trial of PRX-115 and we are currently in the advance stages of preparations for a phase&#160;II clinical trial of PRX-115 which we expect to commence in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Product Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250331x10q005.jpg" alt="Graphic" style="display:inline-block;height:249.19pt;width:540pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture both of our approved and marketed products as well as PRX-115 and PRX-119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases. In addition, we continuously work on the further development and enhancement of our ProCellEx technology. Accordingly, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to receive FDA approval of a protein produced through plant cell-based expression, and with the approval of Elfabrio, we now produce two commercial proteins through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as its allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins that are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:199.65pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we continuously work on the further development and enhancement of our ProCellEx technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Plant Cell Production Advantages</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20250331x10q006.jpg" alt="Graphic" style="display:inline-block;height:199.65pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:205.5pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">ProCellEx</span><sup style="font-size:7.5pt;font-style:italic;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-style:italic;font-weight:bold;">: Protalix&#8217;s Differentiated Plant Cell Protein Expression Platform</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="plx-20250331x10q007.jpg" alt="Graphic" style="display:inline-block;height:204.8pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:485.3pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio. Our pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for pediatric patients. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.7&#160;billion in 2024, is forecasted to be approximately $1.7&#160;billion in 2025 and is forecasted to grow at a compound annual growth rate (CAGR) of approximately -0.46% from 2024-2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Cerezyme and Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). Similarly, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">disease. The FDA noted its determination that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase I/II clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Since the approvals by the FDA and the EMA, Elfabrio has been approved for marketing in Great Britain, Switzerland, Peru, Israel, Russia and Singapore for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the marketed ERTs for Fabry disease are agalsidase alfa and agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.3&#160;billion in 2025 and is forecasted to grow at a CAGR of 6.6% from 2024-2030 reaching approximately $3.1&#160;billion in annual sales in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Background of Elfabrio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA in May 2020. However, in April 2021, the FDA issued a CRL in response thereto. No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in the CRL that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, was required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The PRX-102 MAA was submitted to the EMA in February 2022 after a meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. In February 2023, we, together with Chiesi, announced that the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) had adopted a positive opinion, recommending marketing authorization for PRX-102. As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In December 2024, the EMA validated Chiesi&#8217;s Variation Submission for PRX-102. The Variation Submission seeks to add an additional dose and dosing regimen, 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease, to the current Elfabrio label.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;III clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. In the phase&#160;III clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;III program was preceded by the phase&#160;I/II clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BALANCE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study, completed in July 2022, demonstrated a favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure is 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21&#160;(40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time, a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BRIDGE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22&#160;patients completed the 12-month treatment duration. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. The majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;III BRIGHT Study</i><i style="direction:rtl;font-style:italic;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa) for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>&#160;(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase I/II Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;I/II clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Extension Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Two long-term open-label extension studies were available for patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase I/II study. Overall, 126 patients who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of the extension studies: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 patients who completed an extension study from the phase&#160;I/II study, 18 patients who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 patients who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 patients who completed the <i style="font-style:italic;">BRIGHT</i> study in </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the patients in the 2&#160;mg/kg every four weeks extension study were treated with 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">After the approval of Elfabrio in the US and the EU, sponsorship and administration of the extension studies was transferred to Chiesi. Over time, and as Elfabrio is approved for marketing in different jurisdictions, patients switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons. Accordingly, the 1&#160;mg/kg every two weeks dosage extension study is now closed as most patients have transferred to commercial or expanded access programs. In addition, most of the patients that enrolled in the 2&#160;mg/kg every four weeks dosage extension study are now being treated with Elfabrio on a commercial basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Pediatric FLY Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease&#8221; (NCT06328608). Recruitment has commenced. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Japanese RISE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently recruiting patients for its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan. The study involves both the 1&#160;mg/kg every two weeks and the 2&#160;mg/kg every four weeks dosages.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization of Approved Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elelyso &#8211; Pfizer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to Elelyso in all markets, excluding Brazil, pursuant to the Amended Pfizer Agreement under which Pfizer retains 100% of revenue and reimburses 100% of direct costs. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We retain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elelyso &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. Accordingly, we and Fiocruz discuss on a continuous basis, potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elfabrio (pegunigalsidase alfa/PRX-102) &#8211; Chiesi Farmaceutici</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have entered into two exclusive global licensing and supply agreements for PRX-102 for the treatment of Fabry disease with Chiesi; the Chiesi Ex-US Agreement and the Chiesi US Agreement, collectively, the Chiesi Agreements. Under the agreements, </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45&#160;million, and is entitled to more than $1.0&#160;billion in potential milestone payments tiered payments for drug product purchased from Protalix Ltd. equal to 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US), depending on the amount of annual net sales in the applicable territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Chiesi Ex-US Agreement, we granted to Chiesi an exclusive license for all markets outside of the United States to commercialize PRX-102. Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The exclusive license to develop and commercialize PRX-102 in the United States were granted to Chiesi under the Chiesi US Agreement. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of its net sales under the Chiesi US Agreement to Protalix&#160;Ltd., depending on the amount of annual sales, subject to certain terms and conditions, as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into a Fill/Finish Agreement, or the F/F Agreement, and a Letter Agreement, or the Letter Agreement, in each case with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The Letter Agreement changed the obligations of both us and Chiesi under the Chiesi Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the Chiesi Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services. Subsequently, in November 2024, we amended the agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of 10&#160;years, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme, which does not exist naturally in humans, converts urate to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower urate levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two animal species and a 6-month multiple dosing toxicity study in one animal species were conducted to support single- and multiple-dose studies in humans.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:258.1pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In March 2023, we initiated our phase&#160;I clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> study. The study was conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The study was initially designed to include seven sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and were analyzed for safety, pharmacokinetics (PK) and pharmacodynamics (PD) (concentrations of plasma urate) for 85 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">After a review of initial positive top-line results from the initial seven cohorts, and following the review and acceptance of the safety data from such seven cohorts by the safety and monitoring committee for dose escalation for the <i style="font-style:italic;">FIH</i> study, we decided to expand the study by adding an eighth cohort of eight new subjects to analyze a higher dose and its potential to result in increased exposure time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 64 randomized subjects were enrolled across the eight cohorts; 48 subjects were treated with PRX&#8211;115 and 16 subjects were treated with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key results from the full <i style="font-style:italic;">FIH</i> study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner. Detectable PRX-115 levels were observed in plasma for up to 12&#160;weeks from subjects in cohorts 6, 7, and 8. See Figure&#160;1.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250331x10q008.jpg" alt="Graphic" style="display:inline-block;height:258.1pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:415pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In all tested doses, a single dose of PRX-115 rapidly reduced plasma urate levels. The effect and duration of response were found to be dose dependent. Following a single dose, mean plasma urate levels remained below 6.0&#160;mg/dL for up to 12&#160;weeks at the highest doses. See Figure&#160;2.</div><div style="margin-top:10pt;"></div></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);min-height:277.8pt;"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250331x10q009.jpg" alt="Graphic" style="display:inline-block;height:277.8pt;width:415.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>All randomized participants completed the study. PRX-115 was found to be well-tolerated. See Figure&#160;3.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;3. Overall Summary of Adverse Events*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250331x10q010.jpg" alt="Graphic" style="display:inline-block;height:135.15pt;width:415.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">*Number of subjects reporting at least one adverse event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Only 25% of the subjects treated with PRX-115 in the study (12/48) having reported study drug-related adverse events. The majority of such adverse events were mild to moderate and transient in nature. One subject experienced an anaphylactic reaction in cohort&#160;2 immediately following the commencement of the infusion (6 minutes) and, accordingly, was exposed to approximately 5% of the applicable PRX-115 dose. The reaction resolved completely and the subject continued in the study for follow-up safety assessments. Premedication with anti-histamines and steroids were administered to all subjects following the anaphylaxis event. No other subjects experienced a similar reaction and no other serious adverse events were reported in the study. No related adverse events were reported for subjects treated in cohorts 6 and 7, and only for one patient per cohort in cohorts 4, 5 and 8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These results suggest that PRX-115 has the potential to be a promising treatment option for patients with gout. The results demonstrate that PRX-115 may offer an effective urate-lowering treatment with an added benefit of a potentially wide dosing interval, which may enhance patient compliance and treatment flexibility. Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have initiated preparations for a phase&#160;II clinical trial of PRX-115, and we expect to commence the study in the second half of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.9&#160;million adults in the United States alone. Based on market research we have commissioned, we estimate that approximately 25% of the gout population in the US and Western Europe do not have their gout controlled. Some of those patients cannot be treated with existing therapies; others stop treatment with existing therapies due to adverse events. In addition, such research shows that there are gout patients treated with existing therapies that continue to suffer from tophi despite having reached urate target levels. The risk of gout increases with age, and is more common in males. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and/or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently occurs in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout is when serum urate (sUA) levels are above the maximum medically appropriate level (6.8 mg/dL), as well as tophi formation and/or flares that cannot be treated with available urate lowering therapies. Currently available ULTs can be effective in treating gout. However, factors such as low adherence, under dosing, disease progression that cause high patient burden or patients that are not suitable for available therapy, require new, effective and safe therapies to treat these underserved uncontrolled gout patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering urate treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of methotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I, which we have designed for long and customized systemic circulation in the bloodstream, may potentially enable effective treatment for these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of March 31, 2025, we hold a broad portfolio of 15 patent families consisting of approximately 67 patents in Europe, the United States, Israel and additional countries worldwide, as well as approximately 42 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Research &amp; Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consistent with our corporate strategy, we are focusing on new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">molecules and oligonucleotides, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Three months ended March&#160;31, 2025 compared to the three months ended March&#160;31, 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $10.0&#160;million during the three months ended March&#160;31, 2025, an increase of $6.3&#160;million, or 170%, compared to revenues of $3.7&#160;million for the three months ended March&#160;31, 2024. The increase resulted primarily from an increase of $5.9&#160;million in sales to Pfizer and an increase of $0.4&#160;million in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.1&#160;million for the three months ended March&#160;31, 2025 and the three months ended March&#160;31, 2024. <span style="color:#212529;background:#ffffff;">Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. We expect to generate minimal revenues from license and R&amp;D services other than potential regulatory milestone payments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $8.2&#160;million for the three months ended March&#160;31, 2025, an increase of $5.6&#160;million, or 215%, from cost of goods sold of $2.6&#160;million for the three months ended March&#160;31, 2024. The increase in cost of goods sold was primarily the result of an increase in sales to Pfizer and Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the three months ended March&#160;31, 2025, our total research and development expenses were approximately $3.5&#160;million comprised of approximately $1.8&#160;million of salary and related expenses, approximately $0.8&#160;million in subcontractor-related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses. For the three months ended March&#160;31, 2024, our total research and development expenses were approximately $2.9&#160;million comprised of approximately $1.5&#160;million of salary and related expenses, approximately $0.5&#160;million of subcontractor-related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.7&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses for the three months ended March&#160;31, 2025 was $0.6&#160;million, or 21%, compared to the three months ended March&#160;31, 2024. The increase in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">the advance in our clinical pipeline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.6&#160;million for the three months ended March&#160;31, 2025, a decrease of $0.5&#160;million, or 16%, compared to $3.1&#160;million for the three months ended March&#160;31, 2024. The decrease resulted primarily from a decrease of $0.4&#160;million in salary and related expenses and a decrease of $0.1&#160;million in selling expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income, Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net was $0.4&#160;million for the three months ended March&#160;31, 2025, compared to financial income, net of $0.1&#160;million for the three months ended March&#160;31, 2024. The difference resulted primarily from lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes, partially offset by lower interest income on bank deposits and higher exchange rate costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Tax Benefit</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded a tax benefit of approximately $(0.1)&#160;million for the three months ended March&#160;31, 2025 and March 31, 2024. The tax benefit resulted primarily from deferred taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States, rather than deducting such costs in the current year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our sources of liquidity include our cash balances and bank deposits. At March&#160;31, 2025, we had $34.7&#160;million in cash and cash equivalents and short term bank deposits. <span style="color:#212529;background:#ffffff;">In September 2024, we satisfied the outstanding principal and accrued interest under the 2024 Notes with a cash payment of approximately $21.2&#160;million which was available primarily from the withdrawal of short term deposits. </span>We have primarily financed our operations through sales proceeds, equity and debt financings, business collaborations, and grants funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the quarter ended March&#160;31, 2025, we sold, in the aggregate, 1,325,179 shares of Common Stock under the Sales Agreement generating gross proceeds equal to approximately $3.0&#160;million. In March 2025, we amended the program to provide for the offer and sale of up to an additional $20.0&#160;million. In addition, during the quarter ended March&#160;31, 2025, we issued 908,000 shares of our Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately $2.1&#160;million. The warrants expired on March&#160;11, 2025. Accordingly, no warrants remain outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months from the date this report is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">Net cash used in operations was $</span>5.1<span style="background:#ffffff;">&#160;million for the </span>three months ended March&#160;31, 2025<span style="background:#ffffff;">. The net loss for the </span>three months ended March&#160;31, 2025<span style="background:#ffffff;"> of $</span>3.6<span style="background:#ffffff;">&#160;million was increased by a $</span>1.3&#160;<span style="background:#ffffff;">million decrease in accounts payable and accruals, a $2.3 million increase in accounts receivable-trade and other assets and $0.4 million financial income, net and was offset by a $</span>0.5<span style="background:#ffffff;">&#160;million in share-based compensation, a $</span>1.7<span style="background:#ffffff;">&#160;million decrease in inventories and $</span>0.3<span style="background:#ffffff;">&#160;million in depreciation. </span>Net cash used in investing activities for the three months ended March&#160;31, 2025 was $0.<span style="direction:rtl;">3</span>&#160;million and consisted primarily of the purchase of property and equipment<span style="direction:rtl;">.</span><span style="direction:rtl;background:#ffffff;"> </span><span style="background:#ffffff;">Net cash provided by financing activities for the </span>three months ended March&#160;31, 2025<span style="background:#ffffff;"> was $</span>5.1<span style="background:#ffffff;">&#160;million and consisted of $2.9 million proceeds from issuance of Common Stock under the Sales Agreement, net and $2.2&#160;million from the exercise of warrants and options.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Net cash provided by operations was $4.2&#160;million for the three months ended March&#160;31, 2024. The net loss for the three months ended March&#160;31, 2024 of $4.6&#160;million was increased by a $3.3&#160;million increase in inventories, a $1.4&#160;million decrease in accounts payable and accruals and was offset by an $11.0&#160;million increase in contracts liability, a $1.7&#160;million decrease in accounts receivable-trade and other assets and $1.0&#160;million in share-based compensation. Net cash used in investing activities for the three months ended March&#160;31, 2024 was $0.6&#160;million and consisted primarily of the purchase of property and equipment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso, and commercial sales of Elfabrio only commenced in the middle of </p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">2023. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the years ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> and 2024 exceeded our expenditures for the same period.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">As the 2024 Notes were paid in full during the </span>year ended December&#160;31, <span style="color:#212529;">2024, we are no longer subject to the financial limitations related to such notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our Common Stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months <span style="color:#212529;">from the date this report is issued</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7&#160;million remain available to be sold under the Sales Agreement. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. We do not believe currency fluctuations have had a material effect on our results of operations during the three months ended March&#160;31, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no off-balance sheet arrangements as of each of March&#160;31, 2025 and December&#160;31, 2024.</p><a id="_a5eb0403_0cd1_4f8c_b1c6_e8aa39e7648a"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 44% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.613</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.662</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.718</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.681</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_1539c0b0_a9f5_4ff0_a95c_01ba71d394a4"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended March&#160;31, 2025 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_5c0c9850_86fb_430e_81e2_4b5532dddcd3"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_8b54fd8a_8f14_41b3_a92b_6d6ef6a472c1"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2024<span style="background:#ffffff;">.</span></p><a id="_e509f916_1319_422b_a67c_c9f10df6542c"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_72a9f339_fb68_4f13_b776_64dfffc8bcd8"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_cadb4c68_3b5c_4bfa_b8bf_13fafcea4898"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_395f84b0_8b66_4939_95af_8442a8b6017c"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended March&#160;31, 2025, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_7OnY5WJhwEub5kZ9d08uGw"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_tu3x0uX5-0mbjE9BSB43cA"><span style="background:#ffffff;">adopted</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_wCaVbVAQ4USBE2aBzrtOPg"><ix:nonNumeric contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_-qWHtjj-PUyYP-t_wdl-Ng"><span style="background:#ffffff;">terminated</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">On May&#160;8, 2025, our Board of Directors unanimously approved and adopted an amendment and restatement of our Amended and Restated Bylaws, or the Amended Bylaws, effective immediately, to (i)&#160;provide that at any meeting of stockholders called for the purpose in the manner set forth in the Amended Bylaws, any director may be removed from office, with or without cause, by a majority of the stockholders entitled to vote at an election of directors; and (ii)&#160;remove the provision that prohibits stockholders from acting by written consent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">The foregoing summary and description of the Amended Bylaws does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended Bylaws, a copy of which is filed as Exhibit&#160;3.7 to this Quarterly Report on Form 10-Q and incorporated herein by reference.</span></p><a id="_a40fd0ee_0355_47c6_90ec_68c1a6ec3962"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">1.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837025003143/plx-20250317xex1d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Letter Agreement dated March&#160;17, 2025 to the&#160;At the Market Offering Agreement, dated February&#160;27, 2023, between the Company and&#160;H.C. Wainwright &amp; Co., LLC</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">1.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="background:#ffffff;">March&#160;17, 2025</span></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250331xex3d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250331xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250331xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250331xex32.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250331xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;margin-left:-10.0pt;margin-right:-10.0pt;max-width:100%;position:relative;width:calc(100% + 20.0pt);"><div style="padding-left:10pt;padding-right:10pt;position:relative;width:100%;"><a id="_4f1a45c1_4042_4bfa_93d1_f6dbbd54c2a3"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Eyal Rubin</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.7
<SEQUENCE>2
<FILENAME>plx-20250331xex3d7.htm
<DESCRIPTION>EX-3.7
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/8/2025 05:26:37 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:right;margin:0pt 0pt 12pt 0pt;">Exhibit 3.7</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SECOND AMENDED AND RESTATED <br>BYLAWS<br>OF<br>PROTALIX BIOTHERAPEUTICS, INC.<br>(Adopted May&#160;8, 2025)</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE I</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>OFFICES</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 1.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Registered Office.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The registered office of the corporation in the State of Delaware shall be 1013 Centre Road, Suite 403-B, Wilmington, DE 19805, New Castle County.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 1.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Other Offices.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The corporation shall also have and maintain an office or principal place of business at 2&#160;Snunit Street, Science Park, P.O. Box 455, Carmiel 2161401, Israel, and may also have offices at such other places, both within and without the State of Delaware, as the Board of Directors may from time to time determine or the business of the corporation may require.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 1.3</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Registered Agent.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors shall designate a registered agent for service of process on the corporation for the State of Delaware and for each state in which the corporation qualifies to do business.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE II</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>STOCKHOLDERS&#8217; MEETINGS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Place of Meetings.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Meetings of stockholders may be held at such place, either within or without this State, as may be designated by or in the manner provided in these Amended and Restated Bylaws or, if not so designated, as determined by the Board of Directors. The Board of Directors may, in its sole discretion, determine that the meeting shall not be held at any place, but may instead be held solely by means of remote communication as authorized by paragraph (b) of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Place of Meetings]</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>If authorized by the Board of Directors in its sole discretion, and subject to such guidelines and procedures as the Board of Directors may adopt, stockholders and proxyholders not physically present at a meeting of stockholders may, by means of remote communication:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font>Participate in a meeting of stockholders; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font>Be deemed present in person and vote at a meeting of stockholders whether such meeting is to be held at a designated place or solely by means of remote </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 3.6pt;">780810377.2 20657433</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">communication, provided that (A) the corporation shall implement reasonable measures to verify that each person deemed present and permitted to vote at the meeting by means of remote communication is a stockholder or proxyholder, (B) the corporation shall implement reasonable measures to provide such stockholders and proxyholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to read or hear the proceedings of the meeting substantially concurrently with such proceedings, and (C) if any stockholder or proxyholder votes or takes other action at the meeting by means of remote communication, a record of such vote or other action shall be maintained by the corporation.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">For purposes of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Place of Meetings]</u>, &#8220;remote communication&#8221; shall include (1) telephone or other voice communications and (2) electronic mail or other form of written or visual electronic communications satisfying the requirements of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.11(b) </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Fixing Record Dates]</u>.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Annual Meetings.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The annual meetings of the stockholders of the corporation, for the purpose of election of directors and for such other business as may lawfully come before it, shall be held on such date and at such time as may be designated from time to time by the Board of Directors.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.3</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Special Meetings.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Special Meetings of the stockholders of the corporation, other than as required by statute, may be called at any time, for any purpose or purposes, by the Chairperson of the Board, the President or the Board of Directors, acting pursuant to a resolution adopted by majority of the whole Board of Directors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the provisions of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Special Meetings]</u>, upon written request of any stockholder or stockholders holding in the aggregate not less than 25% of all of the votes entitled to be cast on any issue proposed to be considered at the Special Meeting (&#8220;Requisite Holders&#8221;) signed, dated and delivered in person or sent by registered mail to the Chairman of the Board, President or Secretary of the corporation in a form that complies with the provisions of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.3 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Special Meetings]</u> and all other applicable sections of these Amended and Restated Bylaws (a &#8220;Special Meeting Request&#8221;), the Secretary shall call a special meeting of stockholders to be held at the principal office of the corporation or at such place and at such time as the Secretary may fix, such meeting to be held not less than 30 nor more than 60 days after the receipt of such request, and if the Secretary shall neglect or refuse to call such meeting within 10 days after the receipt of such request, the stockholder making such request may do so. </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">The Board of Directors shall determine whether all requirements set forth in these Amended and Restated Bylaws have been satisfied and such determination shall be binding on the corporation and its stockholders. A Special Meeting Request shall only be valid if it is signed and dated by each of the stockholders that is one of the Requisite Holders and include: (i) a statement of the specific purpose(s) of the special meeting, the matter(s) proposed to be acted on at the special meeting (including the text of any resolutions proposed for consideration) and the reasons for conducting such business at the special meeting; (ii) the name and record address of </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">2</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">each stockholder of record signing such request, the date of each such stockholder&#8217;s signature and the name and address of any beneficial owner on whose behalf such request is made; (iii) the class or series and number of shares of the corporation that are beneficially owned by each such stockholder and any such beneficial owner; (iv) any material interest of each stockholder or any such beneficial owner in any of the business proposed to be conducted at the special meeting and a description of all arrangements or understandings between any such stockholder and/or beneficial owner and any other person or persons (naming such person or persons) with respect to the business proposed to be conducted; (v) a representation that one or more of the stockholders submitting the Special Meeting Request intend to appear in person or by proxy at the special meeting to present the proposal(s) or business to be brought before the special meeting; (vi) if any stockholder submitting such request intends to solicit proxies with respect to the stockholders&#8217; proposal(s) or business to be presented at the special meeting, a representation to that effect; (vii) all information relating to each stockholder signing the Special Meeting Request that must be disclosed in solicitations for proxies for election of directors in an election contest (even if an election contest is not involved), or is otherwise required, in each case pursuant to Regulation 14A under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;); and (viii) if the purpose of the special meeting includes the election of one or more directors, all the information such stockholder or stockholders would be required to include in a notice delivered to the corporation pursuant to <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u> and <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Nominations of Persons for Election to the Board of Directors]</u> of these Amended and Restated Bylaws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, a Special Meeting Request shall not be valid if (i) the Special Meeting Request relates to an item of business that is not a proper subject for stockholder action under applicable law; (ii) the Special Meeting Request is received by the corporation during the period commencing 90 days prior to the first anniversary of the date of the immediately preceding annual meeting and ending on the date of the next annual meeting; (iii) an identical or similar item (&#8220;Similar Item&#8221;) was presented at any meeting of stockholders held within 30 days prior to receipt by the corporation of such Special Meeting Request (and, for purposes of this clause (iii), the election of directors shall be deemed a &#8220;Similar Item&#8221; with respect to all items of business involving the election or removal of directors); (iv) a Similar Item is included in the corporation&#8217;s notice as an item of business to be brought before a stockholder meeting that has been called but not yet held; or (v) such Special Meeting Request was made in a manner that involved a violation of Regulation 14A under the Exchange Act, or other applicable law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stockholders may revoke a Special Meeting Request by written revocation delivered to the corporation at any time prior to the special meeting; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, the Board of Directors shall have the discretion to determine whether or not to proceed with the special meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If none of the stockholders who submitted the Special Meeting Request for a special meeting of stockholders appears or sends a qualified representative to present the proposal(s) or business submitted by the stockholders for consideration at the special meeting, the corporation need not present such proposal(s) or business for a vote at such meeting.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">3</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.4</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Notice of Meetings.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Except as otherwise provided by law or the corporation&#8217;s Certificate of Incorporation, as amended, written notice of each meeting of stockholders, specifying the place, if any, date and hour and purpose or purposes of the meeting, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting shall be given not less than 10 nor more than 60 days before the date of the meeting to each stockholder entitled to vote thereat, directed to their address as it appears upon the books of the corporation; except that where the matter to be acted on is a merger or consolidation of the corporation or a sale, lease or exchange of all or substantially all of its assets, such notice shall be given not less than 20 nor more than 60 days prior to such meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>If at any meeting action is proposed to be taken which, if taken, would entitle stockholders fulfilling the requirements of Section 262(d) of the Delaware General Corporation Law to an appraisal of the fair value of their shares, the notice of such meeting shall contain a statement of that purpose and to that effect and shall be accompanied by a copy of that statutory section.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>When a meeting is adjourned to another time or place, notice need not be given of the adjourned meeting if the time, place, if any, thereof, and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting, are announced at the meeting at which the adjournment is taken unless the adjournment is for more than 30 days, or unless after the adjournment a new record date is fixed for the adjourned meeting, in which event a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Notice of the time, place and purpose of any meeting of stockholders may be waived in writing, either before or after such meeting, and, to the extent permitted by law, will be waived by any stockholder by their attendance thereat, in person or by proxy. Any stockholder so waiving notice of such meeting shall be bound by the proceedings of any such meeting in all respects as if due notice thereof had been given.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>Without limiting the manner by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the corporation under any provision of the Delaware General Corporation Law, the corporation&#8217;s Certificate of Incorporation, as amended, or these Amended and Restated Bylaws shall be effective if given by a form of electronic transmission consented to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice to the corporation. Any such consent shall be deemed revoked if (i) the corporation is unable to deliver by electronic transmission two consecutive notices given by the corporation in accordance with such consent and (ii) such inability becomes known to the secretary or an assistant secretary of the corporation or to the transfer agent or other person responsible for the giving of notice; provided, however, the inadvertent failure to treat such inability as a revocation shall not invalidate any meeting or other action. Notice given pursuant to this subparagraph (e) shall be deemed given: (1) if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; (2) if by electronic mail, when directed to an electronic mail address at which the </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">4</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">stockholder has consented to receive notice; (3) if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A) such posting and (B) the giving of such separate notice; and (4) if by any other form of electronic transmission, when directed to the stockholder. An affidavit of the Secretary or an assistant secretary or of the transfer agent or other agent of the corporation that the notice has been given by a form of electronic transmission shall, in the absence of fraud, be prima facie evidence of the facts stated therein. For purposes of these Amended and Restated Bylaws, &#8220;electronic transmission&#8221; means any form of communication, not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.5</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Quorum and Voting.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>At all meetings of stockholders except where otherwise provided by law, the corporation&#8217;s Certificate of Incorporation, as amended, or these Amended and Restated Bylaws, the presence, in person or by proxy duly authorized, of the holders of at least one-third (33 1/3%) of the outstanding shares of stock entitled to vote shall constitute a quorum for the transaction of business. Shares, the voting of which at said meeting have been enjoined, or which for any reason cannot be lawfully voted at such meeting, shall not be counted to determine a quorum at said meeting. In the absence of a quorum, any meeting of stockholders may be adjourned, from time to time, by vote of the holders of a majority of the shares represented thereat, but no other business shall be transacted at such meeting. At such adjourned meeting at which a quorum is present or represented, any business may be transacted which might have been transacted at the original meeting. The stockholders present at a duly called or convened meeting at which a quorum is present may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum. Abstentions and &#8220;broker non-votes&#8221; are counted as present and entitled to vote for purposes of determining a quorum. A&#160;&#8220;broker non-vote&#8221; occurs when a broker holding shares for a beneficial owner does not vote on a particular proposal because the broker does not have discretionary voting power for that particular item and has not received instructions from the beneficial owner. Abstentions and, if&#160;applicable, broker non-votes, are not counted as votes &#8220;for&#8221; or &#8220;against&#8221; any proposals.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Except as otherwise provided by law, the corporation&#8217;s Certificate of Incorporation, as amended, or these Amended and Restated Bylaws, action on a matter (other than the election of directors) by a voting group is approved if the votes cast within the voting group favoring the action exceed the votes cast opposing the action.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Where a separate vote by a class or classes is required, at least one-third (33&#160;1/3%) of the outstanding shares of such class or classes present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter, and the affirmative vote of the majority of shares of such class or classes present in person or represented by proxy at the meeting shall be the act of such class.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">5</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.6</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Voting Rights.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Except as otherwise provided by law, only persons in whose names shares entitled to vote stand on the stock records of the corporation on the record date for determining the stockholders entitled to vote at said meeting shall be entitled to vote at such meeting. Shares standing in the names of two or more persons shall be voted or represented in accordance with the determination of the majority of such persons, or, if only one of such persons is present in person or represented by proxy, such person shall have the right to vote such shares and such shares shall be deemed to be represented for the purpose of determining a quorum.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Every person entitled to vote or to execute consents shall have the right to do so either in person or by an agent or agents authorized by a written proxy executed by such person or their duly authorized agent, which proxy shall be filed with the Secretary of the corporation at or before the meeting at which it is to be used. Said proxy so appointed need not be a stockholder. No proxy shall be voted on after eleven (11) months from its date unless the proxy provides for a longer period. Unless and until voted, every proxy shall be revocable at the pleasure of the person who executed it or of their legal representatives or assigns, except in those cases where an irrevocable proxy permitted by statute has been given.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Without limiting the manner in which a stockholder may authorize another person or persons to act for them as proxy pursuant to subsection (b) of this section, the following shall constitute a valid means by which a stockholder may grant such authority:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font>A stockholder may execute a writing authorizing another person or persons to act for them as proxy. Execution may be accomplished by the stockholder or their authorized officer, director, employee or agent signing such writing or causing their signature to be affixed to such writing by any reasonable means including, but not limited to, by&#160;facsimile signature.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font>A stockholder may authorize another person or persons to act for them as proxy by transmitting or authorizing the transmission of a telephone, telegram, cablegram or other means of electronic transmission to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder of the proxy to receive such transmission, provided that any such telephone, telegram, cablegram or other means of electronic transmission must either set forth or be submitted with information from which it can be determined that the telephone, telegram, cablegram or other electronic transmission was authorized by the stockholder. Such authorization can be established by the signature of the stockholder on the proxy, either in writing or by a signature stamp or facsimile signature, or by a number or symbol from which the identity of the stockholder can be determined, or by any other procedure deemed appropriate by the inspectors or other persons making the determination as to due authorization.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission created pursuant to subsection (c) of this section may be substituted or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">6</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.7</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Voting Procedures and Inspectors of Elections.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors to act at the meeting and make a written report thereof. The corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If&#160;no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before entering upon the discharge of their duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of their ability.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>The inspectors shall (i) ascertain the number of shares outstanding and the voting power of each, (ii) determine the shares represented at a meeting and the validity of proxies and ballots, (iii) count all votes and ballots, (iv) determine and retain for a reasonable period a record of the disposition of any challenges made to any determination by the inspectors and (v) certify their determination of the number of shares represented at the meeting and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless a court of competent jurisdiction, upon application by stockholders entitled to vote at said meeting shall determine otherwise.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided in accordance with the Delaware General Corporation Law, ballots and the regular books and records of the corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification pursuant to subsection (b)(v) of this section shall specify the precise information considered by them including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors&#8217; belief that such information is accurate and reliable.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.8</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">List of Stockholders.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">The officer who has charge of the stock ledger of the corporation shall prepare and make, or shall cause to be prepared at least 10 days before every meeting of stockholders, a complete list of the stockholders entitled to vote at said meeting showing the address of and the number of shares registered in the name of each stockholder. The corporation need not include electronic mail addresses or other electronic contact information on such list. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of at least 10 days prior to the meeting: (i) on a reasonably accessible electronic network, provided that the </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">7</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">information required to gain access to such list is provided with the notice of the meeting, or (ii) during ordinary business hours at the principal place of business of the corporation. In the event that the corporation determines to make the list available on an electronic network, the corporation may take reasonable steps to ensure that such information is available only to stockholders of the corporation. If the meeting is to be held at a place other than the principal office of the corporation, the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network, and the information required to access such list shall be provided with the notice of the meeting.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.9</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Stockholder Proposals at Annual Meetings.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Hlk182433767"></a>At an annual meeting of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought before an annual meeting, business must be (A) specified in the corporation&#8217;s notice of the annual meeting (or any supplement thereto); (B) given by or at the direction of the Board of Directors; or (C) properly brought by a stockholder of the corporation who (1) is a stockholder of record at the time of the giving of the notice required by this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u>, on the record date for the determination of stockholders entitled to notice of the annual meeting and on the record date for the determination of stockholders entitled to vote at the annual meeting and (2) has timely complied in proper written form with the notice procedures set forth in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u>. In addition, for business to be properly brought before an annual meeting by a stockholder, such business must be a proper matter for stockholder action pursuant to these Amended and Restated Bylaws and applicable law. For the avoidance of doubt, clause (C) above shall be the exclusive means for a stockholder to bring business (other than business included in the corporation&#8217;s proxy statement or information statement pursuant to Rule 14a-8 under the Exchange Act, or any successor thereto) before an annual meeting of stockholders.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>To comply with clause (C) of Section 2.9(a) above, a stockholder&#8217;s notice must set forth all information required under this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u> and must be given timely in writing to the Secretary of the corporation. To be timely, a stockholder&#8217;s notice must be delivered to or mailed and received by the Secretary at the principal executive offices of the corporation not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy materials or its notice of availability of proxy materials (whichever is earlier) for the previous year&#8217;s annual meeting of stockholders; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that in the event that no annual meeting was held in the previous year or if the date of the annual meeting has changed by more than 30 days from the one-year anniversary of the date of the previous year&#8217;s annual meeting, then, for notice by the stockholder to be timely, it must be so received by the Secretary of the corporation not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of (i) the 90th day prior to such annual meeting, or (ii) the 10th day following the day on which public announcement of the date of such annual meeting is first made. In no event will the adjournment, rescheduling, postponement or other delay of any annual meeting, or any announcement thereof, commence a new time period (or extend any time period) for the giving </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">8</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">of a stockholder&#8217;s notice as described above. &#8220;Public announcement&#8221; means disclosure in a press release reported by a national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission (the &#8220;SEC&#8221;) pursuant to Section 13, Section 14 or Section 15(d) of the Exchange Act or by such other means as is reasonably designed to inform the public or stockholders of the corporation in general of such information, including, without limitation, posting on the corporation&#8217;s investor relations website.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>To be in proper form, a&#160;stockholder&#8217;s notice to the Secretary shall set forth as to each matter the stockholder proposes to bring before the annual meeting (i) a brief description of the business desired to be brought before the annual meeting, the text of the proposed business (including the text of any resolutions proposed for consideration) and the reasons for conducting such business at the annual meeting, (ii) the name and record address of the stockholder proposing such business and any Stockholder Associated Person (as defined below), (iii) the class or series and number of shares of the corporation which are beneficially owned by the stockholder and any Stockholder Associated Person, (iv) any material interest of the stockholder or any Stockholder Associated Person in such business, (v) as to the stockholder giving the notice and any Stockholder Associated Person, whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of, or any other agreement, arrangement or understanding (including, but not limited to, any short position or any borrowing or lending of shares of stock) has been made, the effect or intent of which is to mitigate loss or increase profit to or manage the risk or benefit of stock price changes for, or to increase or decrease the voting power of, such stockholder or any such Stockholder Associated Person with respect to any share of stock of the corporation (each, a &#8220;Relevant Hedge Transaction&#8221;), (vi) as to the stockholder giving the notice and any Stockholder Associated Person, to the extent not set forth pursuant to the immediately preceding clause, (a) whether and the extent to which such stockholder or Stockholder Associated Person has direct or indirect beneficial ownership of any option, warrant, convertible security, stock appreciation right, or similar right with an exercise or conversion privilege or a settlement payment or mechanism at a price related to any class or series of shares of the corporation, whether or not such instrument or right shall be subject to settlement in the underlying class or series of capital stock of the corporation or otherwise, or any other direct or indirect opportunity to profit or share in any profit derived from any increase or decrease in the value of shares of the corporation (a &#8220;Derivative Instrument&#8221;), (b) any rights to dividends on the shares of the corporation owned beneficially by such stockholder that are separated or separable from the underlying shares of the corporation, (c) any proportionate interest in shares of the corporation or Derivative Instruments held, directly or indirectly, by a general or limited partnership in which such stockholder is a general partner or, directly or indirectly, beneficially owns an interest in a general partner and (d)&#160;any performance-related fees (other than an asset-based fee) that such stockholder is entitled to based on any increase or decrease in the value of shares of the corporation or Derivative Instruments, if any, as of the date of such notice, including without limitation any such interests held by members of such stockholder&#8217;s immediate family sharing the same household (which information shall be supplemented by such stockholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such ownership as of the record date), and (vii) a statement whether either such stockholder or any Stockholder Associated Person will deliver a proxy statement and form of proxy to holders of at least the percentage of the corporation&#8217;s voting shares required under applicable law to carry the proposal (such information provided and statements made as required by clauses (i) through (vii), a &#8220;Business </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">9</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">Solicitation Statement&#8221;). In addition, to be in proper written form, a stockholder&#8217;s notice to the Secretary must be supplemented not later than 10 days following the record date for the determination of stockholders entitled to notice of the meeting to disclose the information contained in clauses (iii), (v) and (vi) above as of such record date. </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u><i style="font-style:italic;"> </i>and <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Nominations of Persons for Election to the Board of Directors]</u>, &#8220;Stockholder Associated Person&#8221; of any stockholder shall mean (i) any person controlling or controlled by, directly or indirectly, or&#160;acting in concert with, such stockholder, (ii) any beneficial owner of shares of stock of the corporation owned of record or beneficially by such stockholder and (iii) any person controlling, controlled by or under common control with such Stockholder Associated Person.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Notwithstanding anything in these Amended and Restated Bylaws to the contrary, no business shall be conducted at the annual meeting except in accordance with the procedures set forth in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Place of Meetings]</u> and this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u>; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u> that nothing in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u><i style="font-style:italic;"> </i>shall be deemed to preclude discussion by any stockholder of any business properly brought before the annual meeting in accordance with said procedure. In addition, business proposed to be brought by a stockholder may not be brought before the annual meeting if such stockholder or a Stockholder Associated Person, as applicable, takes action contrary to the representations made in the Business Solicitation Statement applicable to such business or if the Business Solicitation Statement applicable to such business contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading. The Chairperson of an annual meeting shall, if the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting in accordance with the provisions of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.1 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Place of Meetings]</u> and this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u>, and if the Chairperson should so determine they shall so declare to the meeting, and any such business not properly brought before the meeting shall not be transacted.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Nothing in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u><i style="font-style:italic;"> </i>shall affect the right of a stockholder to request inclusion of a proposal in the corporation&#8217;s proxy statement or information statement to the extent that such right is provided by an applicable rule of the SEC. Nothing in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Stockholder Proposals at Annual Meetings]</u><i style="font-style:italic;"> </i>and <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Nominations of Persons for Election to the Board of Directors]</u> shall be deemed to affect any right of the corporation to omit a proposal from the corporation&#8217;s proxy statement pursuant to Rule 14a-8 (or any successor provision) under the Exchange Act.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.10</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Nominations of Persons for Election to the Board of Directors.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>In addition to any other applicable requirements, only persons who are nominated in accordance with the following procedures shall be eligible for election or re-election as directors at an annual meeting of stockholders. Nominations of persons for election to the Board of Directors of the corporation may be made at a meeting of stockholders only (A) by or at the direction of the Board of Directors, (B) by any nominating committee or person appointed by the Board of Directors or (C) by any stockholder of the corporation entitled to vote for the election </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">10</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">of directors at the meeting who complies with the notice procedures set forth in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Nominations of Persons for Election to the Board of Directors]</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>To comply with clause (C) of Section 2.10(a) above, such nominations to be made by a stockholder shall be made pursuant to timely notice in writing to the Secretary of the corporation, which shall be the exclusive means for a stockholder to make nominations whether or not the stockholder is seeking to have a proposal included in the corporation&#8217;s proxy statement or information statement under an applicable rule of the SEC, including, but not limited to, Regulation 14A or Regulation 14C under the Exchange Act. To be timely, a stockholder&#8217;s notice must be delivered to or mailed and received at the principal executive offices of the corporation, not less than 45 days nor more than 75 days prior to the date on which the corporation first mailed its proxy materials (or, in the absence of proxy materials, its notice of the meeting) for the previous year&#8217;s annual meeting of stockholders (or the date on which the corporation mails such materials for the current year if during the prior year the corporation did not hold an annual meeting or if the date of the annual meeting was changed more than 30 days from the prior year). </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>To be in proper written form, such stockholder&#8217;s notice shall set forth: </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(1)</font>as to each person whom the stockholder proposes to nominate for election or re-election as a director (a &#8220;nominee&#8221;), (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii)&#160;the class or series and number of shares of the corporation which are beneficially owned by the nominee and any derivative positions held or beneficially held by the nominee, (iv) whether and the extent to which any hedging or other transaction or series of transactions has been entered into by or on behalf of the nominee with respect to any securities of the corporation, and a description of any other agreement, arrangement or understanding (including any short position or any borrowing or lending of shares), the effect or intent of which is to mitigate loss to, or to manage the risk or benefit of share price changes for, or to increase or decrease the voting power of the nominee, (v) a description of all arrangements or understandings between or among the stockholder, any nominee or any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder, including a description of any compensatory, payment or other financial agreement, arrangement or understanding involving the nominee and of any compensation or other payment received by or on behalf of the nominee, in each case in connection with candidacy or service as a director of the corporation (a &#8220;Third-Party Compensation Arrangement&#8221;), (vi) a written statement executed by the nominee consenting to (A) being named as a nominee of such stockholder, (B) serving as a director of the corporation if elected and (C) being named in the corporation&#8217;s form of proxy pursuant to Rule 14a-19 under the Exchange Act (&#8220;Rule 14a-19&#8221;), and (G) any other information relating to the nominee that would be required to be disclosed about such nominee if proxies were being solicited for the election of the nominee as a director, or that is otherwise required, in each case pursuant to Section 14 of the Exchange Act;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(2)</font>as to the stockholder giving the notice, (i) the information required to be provided pursuant to clauses (ii) through (vi) of Section 2.9(c) above, and the supplement referenced in the last sentence of Section 2.9(c) above (except that the references to &#8220;business&#8221; in such clauses shall instead refer to nominations of directors for purposes of this paragraph), and (ii) a representation and undertaking as to whether such stockholder or Stockholder Associated </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">11</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">Person or others acting in concert with them intends, or is part of a group that intends, to (A) deliver a proxy statement or form of proxy to or otherwise solicit proxies from holders of at least the percentage of the voting power of the corporation&#8217;s then outstanding stock required to elect such nominee(s) (which representation and undertaking must include a statement as to whether such stockholder or any Stockholder Associated Person intends to solicit the requisite percentage of the voting power of the corporation&#8217;s stock under Rule 14a-19), or (B) otherwise solicit proxies from stockholders in support of such nomination (such information provided and statements made as required by Section 2.10(c)(1) and this Section 2.10(c)(2), a &#8220;Nominee Solicitation Statement&#8221;).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>At the request of the Board of Directors, any person nominated by a stockholder for election as a director must furnish to the Secretary of the corporation (i) that information required to be set forth in the stockholder&#8217;s notice of nomination of such person as a director as of a date subsequent to the date on which the notice of such person&#8217;s nomination was given, (ii) a signed and completed written questionnaire (in the form provided by the Secretary at the written request of the nominating stockholder, which form will be provided by the Secretary within 10 days of receiving such request) containing information regarding such nominee&#8217;s background and qualifications and such other information as may reasonably be required by the corporation to determine the eligibility of such proposed nominee to serve as an independent director of the corporation or that could be material to a reasonable stockholder&#8217;s understanding of the independence, or lack thereof, of such nominee, (3) a written representation and undertaking that, unless previously disclosed to the corporation, such nominee is not, and will not become, a party to any Third-Party Compensation Arrangement, and (4) a written representation and undertaking that, if elected as a director, such nominee would be in compliance, and will continue to comply, with the corporation&#8217;s corporate governance guidelines as disclosed on the corporation&#8217;s website, as amended from time to time; in the absence of the furnishing of such information if requested, such stockholder&#8217;s nomination shall not be considered in proper form and shall be ineligible for consideration at the annual meeting pursuant to this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 2.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Nominations of Persons for Election to the Board of Directors]</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font>No person shall be eligible for election as a director of the corporation unless nominated in accordance with the procedures set forth herein. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font>These provisions shall not apply to nomination of any persons entitled to be separately elected by holders of preferred stock. In addition, a nominee shall not be eligible for election or re-election if a stockholder or Stockholder Associated Person, as applicable, takes action contrary to the representations made in the Nominee Solicitation Statement applicable to such nominee or in any other notice to the corporation or if the Nominee Solicitation Statement applicable to such nominee or any other relevant notice contains an untrue statement of a material fact or omits to state a material fact necessary to make the statements therein not misleading. The Chairperson of the meeting shall, if the facts warrant, determine and declare to the meeting that a nomination was not made in accordance with the foregoing procedure, and if they should so determine, they shall so declare to the meeting and the defective nomination shall be disregarded.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(g)</font>No later than five business days prior to the annual meeting or any adjournment, rescheduling, postponement or other delay thereof, a stockholder nominating individuals for </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">12</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">election as a director will provide the corporation with reasonable evidence that such stockholder has met the requirements of Rule 14a-19. The failure to timely provide such update, supplement, evidence or additional information shall result in the nomination no longer being eligible for consideration at the annual meeting. If the stockholder fails to comply with the requirements of Rule 14a-19 (including because the stockholder fails to provide the corporation with all information or notices required by Rule 14a-19), then the Chairperson of the meeting may determine that the director nominees proposed by such stockholder shall be ineligible for election at the annual meeting and any votes or proxies in respect of such nomination shall be disregarded, notwithstanding that such proxies may have been received by the corporation and counted for the purposes of determining quorum.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.11</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Fixing Record Dates.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>In order that the corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than 60 nor less than 10 days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day preceding the day on which notice is given, or, if notice is waived, at the close of business on the day preceding the date on which the meeting is held. A determination of stockholders of record entitled notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting, subject to the Act.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>In order that the corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than 60 days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE III</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>DIRECTORS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Number and Term of Office.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">The number of directors which shall constitute the whole of the Board of Directors shall be fixed from time to time by resolution of the Board of Directors. With the exception of the first Board of Directors, which was elected by the incorporators, and except as provided in Section 3.3 of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article III </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[DIRECTORS]</u>, the directors shall be elected by a plurality vote of the shares represented in person or by proxy at the stockholders annual meeting in each year and entitled to vote on the election of directors. Elected directors shall hold office until the next annual meeting and until their successors shall be duly elected and qualified. Directors need not </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">13</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">be stockholders. If, for any cause, the Board of Directors shall not have been elected at an annual meeting, they may be elected as soon thereafter as convenient at a special meeting of the stockholders called for that purpose in the manner provided in these Amended and Restated Bylaws.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Powers.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The powers of the corporation shall be exercised, its business conducted and its property controlled by or under the direction of the Board of Directors.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.3</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Vacancies.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Vacancies and newly created directorships resulting from any increase in the authorized number of directors may be filled by a majority of the directors then in office, although less than a quorum, or by a sole remaining director, and each director so elected shall hold office for the unexpired portion of the term of the director whose place shall be vacant and until a successor shall have been duly elected and qualified. A vacancy in the Board of Directors shall be deemed to exist under this section in the case of the death, removal or resignation of any director, or if the stockholders fail at any meeting of stockholders at which directors are to be elected (including any meeting referred to in <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.4</b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> [Resignations and Removals]</u> below) to elect the number of directors then constituting the whole Board of Directors.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.4</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Resignations and Removals.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>Any director may resign at any time by delivering their resignation to the Board of Directors, the Chairperson of the Board, or the Secretary in writing or by electronic transmission, such resignation to specify whether it will be effective at a particular time, upon receipt or at the pleasure of the Board of Directors. If no such specification is made it shall be deemed effective at the pleasure of the Board of Directors. When one or more directors shall resign from the Board of Directors effective at a future date, a majority of the directors then in office, including those who have so resigned (prior to the resignation being in effect), shall have power to fill such vacancy or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen shall hold office for the unexpired portion of the term of the director whose place shall be vacated and until a successor shall have been duly elected and qualified.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>At any meeting of stockholders called for the purpose in the manner hereinabove provided, any director may be removed from office, with or without cause, by a majority of the stockholders entitled to vote at an election of directors, and a new director may be elected by of the stockholders in the manner provided by these Amended and Restated Bylaws.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.5</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Meetings.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The annual meeting of the Board of Directors shall be held immediately after the annual stockholders&#8217; meeting and at the place where such meeting is held or at the place announced by the Chairperson at such meeting. No notice of an annual meeting of the Board of Directors shall be necessary, and such meeting shall be held for the purpose of electing officers and transacting such other business as may lawfully come before it.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">14</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Except as hereinafter otherwise provided, regular meetings of the Board of Directors shall be held in the principal office of the corporation. Regular meetings of the Board of Directors may also be held at any place, within or without the United States, as determined by the Chairperson of the Board or by the written consent of all directors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Special meetings of the Board of Directors may be held at any time and place within or without the State of Delaware whenever called by the Chairperson of the Board or, if&#160;there is no Chairperson of the Board, by the Chief Executive Officer, or by any of the directors.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Written notice of the time and place of all regular and special meetings of the Board of Directors shall be delivered personally to each director or sent by telegram or facsimile transmission or other form of electronic transmission at least 48 hours before the start of the meeting, or sent by first class mail at least 120 hours before the start of the meeting. Notice of any meeting may be waived in writing at any time before or after the meeting and will be waived by any director by attendance thereat.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.6</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Quorum and Voting.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>A quorum of the Board of Directors shall consist of a majority of the exact number of directors fixed from time to time in accordance with Section 3.1 of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article III </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[DIRECTORS]</u><i style="font-style:italic;"> </i>of these Amended and Restated Bylaws, but not less than one; provided, however, at any meeting whether a quorum be present or otherwise, a majority of the directors present may adjourn from time to time until the time fixed for the next regular meeting of the Board of Directors, without notice other than by announcement at the meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>At each meeting of the Board of Directors at which a quorum is present, all questions and business shall be determined by a vote of a majority of the directors present, unless a different vote be required by law, the corporation&#8217;s Certificate of Incorporation, as amended, or these Amended and Restated Bylaws.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>Any member of the Board of Directors, or of any committee thereof, may participate in a meeting by means of conference telephone or other communication equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting by such means shall constitute presence in person at such meeting.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>The transactions of any meeting of the Board of Directors, or any committee thereof, however called or noticed, or wherever held, shall be as valid as though had at a meeting duly held after regular call and notice if a quorum be present and if, either before or after the meeting, each of the directors not present shall sign a written waiver of notice, or a consent to holding such meeting, or an approval of the minutes thereof. All such waivers, consents or approvals shall be filed with the corporate records or made a part of the minutes of the meeting.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.7</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Action Without Meeting.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">Unless otherwise restricted by the corporation&#8217;s Certificate of Incorporation, as amended, or these Amended and Restated Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">15</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">if all members of the Board of Directors or of such committee, as the case may be, consent thereto in writing or by electronic transmission, and such writing or writings or electronic transmission or transmissions are filed with the minutes of proceedings of the Board of Directors or committee. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.8</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Fees and Compensation.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Directors and members of committees may receive such compensation, if any, for their services, and such reimbursement for expenses, as may be fixed or determined by resolution of the Board of Directors.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.9</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Committees.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">Other Committees: </b>The Board of Directors may, from time to time, appoint such committees as may be permitted by law. Such other committees appointed by the Board of Directors shall have such powers and perform such duties as may be prescribed by the resolution or resolutions creating such committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Term: </b>The terms of members of all committees of the Board of Directors shall expire on the date of the next annual meeting of the Board of Directors following their appointment; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided,</u> that they shall continue in office until their successors are appointed. The Board of Directors, subject to the provisions of subsection (a) of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Committees]</u>, may at any time increase or decrease the number of members of a committee or terminate the existence of a committee; provided, that no committee shall consist of less than two members. The membership of a committee member shall terminate on the date of their death or voluntary resignation, but the Board of Directors may at any time for any reason remove any individual committee member and the Board of Directors may fill any committee vacancy created by death, resignation, removal or increase in the number of members of the committee. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Meetings: </b>Unless the Board of Directors shall otherwise provide, regular meetings of the committees appointed pursuant to this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3.9 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Committees]</u> shall be held at such times and places as are determined by the Board of Directors, or by any such committee, and when notice thereof has been given to each member of such committee, no further notice of such regular meetings need be given thereafter; special meetings of any such committee may be held at the principal office of the corporation required to be maintained pursuant to Section 1.2 of <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article&#160;I </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[OFFICES]</u> hereof; or at any place which has been designated from time to time by resolution of such committee or by written consent of all members thereof, and may be called by any director who is a member of such committee upon written notice to the members of such committee of the time and place of such special meeting given in the manner provided for the giving of written notice to members of the Board of Directors of the time and place of special meetings of the Board of Directors. Notice of any special meeting of any committee may be waived in writing at any time after the meeting and will be waived by any director by attendance thereat. A majority of the authorized number of members of any such committee shall constitute </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">16</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;text-transform:none;">a quorum for the transaction of business, and the act of a majority of those present at any meeting at which a quorum is present shall be the act of such committee.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE IV</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>OFFICERS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 4.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Officers Designated.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The officers of the corporation shall be a President, a Secretary and a Treasurer. The Board of Directors may also appoint a Chairperson of the Board, a chief executive officer, chief financial officer, one or more Vice-Presidents, assistant secretaries, assistant treasurers, and such other officers and agents with such powers and duties as the Board of Directors or the President shall deem appropriate or necessary. The order of the seniority of the Vice- Presidents shall be in the order of their nomination unless otherwise determined by the Board of Directors. The Board of Directors may assign such additional titles to one or more of the officers as they shall deem appropriate. Any one person may hold any number of offices of the corporation at any one time unless specifically prohibited therefrom by law. The salaries and other compensation of the officers of the corporation shall be fixed by or in the manner designated by the Board of Directors, or a committee thereof.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 4.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Tenure and Duties of Officers.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font><b style="font-weight:bold;">General: </b>All officers shall hold office at the pleasure of the Board of Directors and until their successors shall have been duly elected and qualified, unless sooner removed. Any&#160;officer may be removed at any time by the Board of Directors. If the office of any officer becomes vacant for any reason, the vacancy may be filled by the Board of Directors. Nothing in these Amended and Restated Bylaws shall be construed as creating any kind of contractual right to employment with the corporation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font><b style="font-weight:bold;">Duties of the Chairperson of the Board of Directors: </b>The Chairperson of the Board of Directors (if there be such an officer appointed) when present shall preside at all meetings of the stockholders and the Board of Directors. The Chairperson of the Board of Directors shall perform such other duties and have such other powers as the Board of Directors shall designate from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font><b style="font-weight:bold;">Duties of President: </b>The President shall be the chief executive officer of the corporation and, in the absence of the Chairperson of the Board, and shall preside at all meetings of the stockholders and at all meetings of the Board of Directors, unless the Chairperson of the Board of Directors has been appointed and is present. The President shall perform such other duties and have such other powers as the Board of Directors shall designate from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font><b style="font-weight:bold;">Duties of Vice-Presidents: </b>The Vice-Presidents, in the order of their seniority, may assume and perform the duties of the President in the absence or disability of the President or whenever the office of the President is vacant. The Vice-President shall perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">17</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(e)</font><b style="font-weight:bold;">Duties of Secretary: </b>The Secretary shall attend all meetings of the stockholders and, if invited, of the Board of Directors and each committee thereof, and shall record all acts and proceedings thereof in the minute book of the corporation, which may be maintained in either paper or electronic form. The Secretary shall give notice, in conformity with these Amended and Restated Bylaws, of all meetings of the stockholders and of all meetings of the Board of Directors and any Committee thereof requiring notice. The Secretary shall perform such other duties and have such other powers as the Board of Directors shall designate from time to time. The President may direct any assistant secretary to assume and perform the duties of the Secretary in the absence or disability of the Secretary, and each assistant secretary shall perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(f)</font><b style="font-weight:bold;">Duties of Treasurer: </b>The Treasurer shall keep or cause to be kept the books of account of the corporation in a thorough and proper manner, and shall render statements of the financial affairs of the corporation in such form and as often as required by the Board of Directors or the President. The Treasurer, subject to the order of the Board of Directors, shall have the custody of all funds and securities of the corporation. The Treasurer shall perform all other duties commonly incident to their office and shall perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time. The President may direct any assistant treasurer to assume and perform the duties of the Treasurer in the absence or disability of the Treasurer, and each assistant treasurer shall perform such other duties and have such other powers as the Board of Directors or the President shall designate from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE V</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>EXECUTION OF CORPORATE INSTRUMENTS, AND<br>VOTING OF SECURITIES OWNED BY THE CORPORATION</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 5.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Execution of Corporate Instruments.</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(a)</font>The Board of Directors may in its discretion determine the method and designate the signatory officer or officers, or other person or persons, to execute any corporate instrument or document, or to sign the corporate name without limitation, except where otherwise provided by law, and such execution or signature shall be binding upon the corporation.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(b)</font>Unless otherwise specifically determined by the Board of Directors or otherwise required by law, formal contracts of the corporation, promissory notes, deeds of trust, mortgages and other evidences of indebtedness of the corporation, and other corporate instruments or documents requiring the corporate seal, and certificates of shares of stock owned by the corporation, shall be executed, signed or endorsed by the Chairperson of the Board (if there be such an officer appointed) or by the President; such documents may also be executed by any Vice-President and by the Secretary or Treasurer or any assistant secretary or assistant treasurer. All&#160;other instruments and documents requiring the corporate signature but not requiring the corporate seal may be executed as aforesaid or in such other manner as may be directed by the Board of Directors.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">18</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(c)</font>All checks and drafts drawn on banks or other depositaries on funds to the credit of the corporation or in special accounts of the corporation shall be signed by such person or persons as the Board of Directors shall authorize so to do.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;text-transform:none;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">(d)</font>Execution of any corporate instrument may be effected in such form, either manual, facsimile or electronic signature, as may be authorized by the Board of Directors.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 5.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Voting of Securities Owned by Corporation.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All stock and other securities of other corporations owned or held by the corporation for itself or for other parties in any capacity shall be voted, and all proxies with respect thereto shall be executed, by the person authorized so to do by resolution of the Board of Directors or, in the absence of such authorization, by the Chairperson of the Board (if there be such an officer appointed), or by the President, or by any Vice-President.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VI</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>SHARES OF STOCK</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 6.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Form and Execution of Certificates.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Shares of stock of the corporation shall be represented by certificates, or shall be uncertificated shares that may be evidenced by a book-entry system maintained by the registrar of such stock, or a combination of both. To the extent that shares are represented by certificates, such certificates shall be in a form approved by the Board of Directors. Each certificate shall be signed in the name of the corporation by (A) the Chairperson or Vice Chairperson of the Board or the President or a Vice President and (B) the Secretary or an Assistant Secretary or the Treasurer or an Assistant Treasurer, and sealed with the seal of the corporation (which seal may be a facsimile, engraved or printed); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u> that where any such certificate is countersigned by a transfer agent other than the corporation or one of its employees, or is registered by a registrar other than the corporation or one of its employees, the signature of the officers of the corporation upon such certificates may be facsimiles, engraved or printed. In case any officer who shall have signed or whose facsimile signature has been placed upon such certificates shall have ceased to be such officer before such certificates shall be issued, they may nevertheless be issued by the corporation with the same effect as if such officer were still in office at the date of their issue.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 6.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Lost Certificates.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">The Board of Directors may direct a new certificate or certificates (or uncertificated shares in lieu of a new certificate) to be issued in place of any certificate or certificates theretofore issued by the corporation alleged to have been lost or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost or destroyed. When authorizing such issue of a new certificate or certificates (or uncertificated shares in lieu of a new certificate), the&#160;Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost or destroyed certificate or certificates, or their legal representative, to indemnify the corporation in such manner as it shall require and/or to give the corporation a surety bond in such form and amount as it may direct as indemnity against any claim that may be </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">19</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">made against the corporation with respect to the certificate alleged to have been lost or destroyed.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 6.3</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Transfers.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock may be transferred only on the books of the corporation by the surrender to the corporation or its transfer agent of shares in certificated form, properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, or upon proper instructions from the holder of uncertificated shares, in each case with such proof of the authenticity of signature as the corporation or its transfer agent may reasonably require. Except as otherwise provided by applicable law, the corporation shall be entitled to recognize the exclusive right of a person in whose name any share or shares stand on the record of stockholders as the owner of such share or shares for all purposes, including, without limitation, the rights to receive dividends or other distributions and to vote as such owner, and the corporation may hold any such stockholder of record liable for calls and assessments and the corporation shall not be bound to recognize any equitable or legal claim to or interest in any such share or shares on the part of any other person whether or not it shall have express or other notice thereof. Whenever any transfers of shares shall be made for collateral security and not absolutely, and both the transferor and transferee request the corporation to do so, such fact shall be stated in the entry of the transfer.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 6.4</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Registered Stockholders.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VII</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>OTHER SECURITIES OF THE CORPORATION</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">All bonds, debentures and other corporate securities of the corporation, other than stock certificates, may be signed by the Chairperson of the Board (if there be such an officer appointed), or the President or any Vice-President or such other person as may be authorized by the Board of Directors and the corporate seal impressed thereon or a facsimile of such seal imprinted thereon and attested by the signature of the Secretary or an assistant secretary, or the Treasurer or an assistant treasurer; provided, however, that where any such bond, debenture or other corporate security shall be authenticated by the manual signature of a trustee under an indenture pursuant to which such bond, debenture or other corporate security shall be issued, the signature of the persons signing and attesting the corporate seal on such bond, debenture or other corporate security may be the imprinted facsimile of the signatures of such persons. Interest coupons appertaining to any such bond, debenture or other corporate security, authenticated by a trustee as aforesaid, shall be signed by the Treasurer or an assistant treasurer of the corporation, or such other person as may be authorized by the Board of Directors, or bear imprinted thereon the facsimile signature of such person. In case any officer who shall have signed or attested any </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">20</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">bond, debenture or other corporate security, or whose facsimile signature shall appear thereon has ceased to be an officer of the corporation before the bond, debenture or other corporate security so signed or attested shall have been delivered, such bond, debenture or other corporate security nevertheless may be adopted by the corporation and issued and delivered as though the person who signed the same or whose facsimile signature shall have been used thereon had not ceased to be such officer of the corporation.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE VIII</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>INDEMNIFICATION OF OFFICERS, DIRECTORS, EMPLOYEES AND AGENTS</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.1</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Right to Indemnification.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person who was or is a party or is threatened to be made a party to or is involved (as a party, witness, or otherwise), in any threatened, pending, or completed action, suit, or proceeding, whether civil, criminal, administrative, or investigative (hereinafter a &#8220;Proceeding&#8221;), by reason of the fact that they, or a person of whom they are the legal representative, is or was a director, officer, employee, or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation or of a partnership, joint venture, trust, or other enterprise, including service with respect to employee benefit plans, whether the basis of the Proceeding is alleged action in an official capacity as a director, officer, employee, or agent or in any other capacity while serving as a director, officer, employee, or agent (hereafter an &#8220;Agent&#8221;), shall be indemnified and held harmless by the corporation to the fullest extent authorized by the Delaware General Corporation Law, as the same exists or may hereafter be amended or interpreted (but, in the case of any such amendment or interpretation, only to the extent that such amendment or interpretation permits the corporation to provide broader indemnification rights than were permitted prior thereto) against all expenses, liability, and loss (including attorneys&#8217; fees, judgments, fines, ERISA excise taxes or penalties, and amounts paid or to be paid in settlement, and any interest, assessments, or other charges imposed thereon, and any federal, state, local, or foreign taxes imposed on any Agent as a result of the actual or deemed receipt of any payments under this Article) reasonably incurred or suffered by such person in connection with investigating, defending, being a witness in, or participating in (including on appeal), or preparing for any of the foregoing in, any Proceeding (hereinafter &#8220;Expenses&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however,</u> that except as to actions to enforce indemnification rights pursuant to Section 8.3 of this Article, the corporation shall indemnify any Agent seeking indemnification in connection with a Proceeding (or part thereof) initiated by such person only if the Proceeding (or part thereof) was authorized by the Board of Directors of the corporation. The&#160;right to indemnification conferred in this Article shall be a contract right.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.2</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Authority to Advance Expenses.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">Expenses incurred by an officer or director (acting in their capacity as such) in defending a Proceeding shall be paid by the corporation in advance of the final disposition of such Proceeding; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>,<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> however,</u> that if required by the Delaware General Corporation Law, such Expenses shall be advanced only upon delivery to the corporation of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that they are not entitled to be indemnified by the corporation as authorized in this Article or otherwise. Expenses incurred by other Agents of the corporation (or by the directors or officers </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">21</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">not acting in their capacity as such, including service with respect to employee benefit plans) may be advanced upon such terms and conditions as the Board of Directors deems appropriate. Any obligation to reimburse the corporation for Expense advances shall be unsecured and no interest shall be charged thereon.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.3</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Right of Claimant to Bring Suit.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a claim under <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.1</b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> [Right to Indemnification]</u> or 8.2 of this Article is not paid in full by the corporation within 30&#160;days after a written claim has been received by the corporation, the claimant may at any time thereafter bring suit against the corporation to recover the unpaid amount of the claim and, if&#160;successful in whole or in part, the claimant shall be entitled to be paid also the expense (including attorneys&#8217; fees) of prosecuting such claim. The burden of proving such a defense shall be on the corporation. Neither the failure of the corporation (including its Board of Directors, independent legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper under the circumstances because they have met the applicable standard of conduct set forth in the Delaware General Corporation Law, nor an actual determination by the corporation (including its Board of Directors, independent legal counsel, or its stockholders) that the claimant had not met such applicable standard of conduct, shall be a defense to the action or create a presumption that claimant has not met the applicable standard of conduct.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.4</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Provisions Nonexclusive.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights conferred on any person by this Article shall not be exclusive of any other rights that such person may have or hereafter acquire under any statute, provision of the corporations&#8217; Certificate of Incorporation, as amended, or any agreement, vote of stockholders or disinterested directors or otherwise, both as to action in an official capacity and as to action in another capacity while holding such office. To the extent that any provision of the corporation&#8217;s Certificate of Incorporation, as amended, or any agreement, or vote of the stockholders or disinterested directors is inconsistent with these Amended and Restated Bylaws, the provision, agreement or vote shall take precedence.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.5</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Authority to Insure.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The corporation may purchase and maintain insurance to protect itself and any Agent against any Expense, whether or not the corporation would have the power to indemnify the Agent against such Expense under applicable law or the provisions of this Article.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.6</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Survival of Rights.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The rights provided by this Article shall continue as to a person who has ceased to be an Agent and shall inure to the benefit of the heirs, executors, and administrators of such a person.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.7</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Effect of Amendment.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any amendment, repeal, or modification of this Article shall not adversely affect any right or protection of any Agent existing at the time of such amendment, repeal, or modification.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">22</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.8</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Subrogation.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of payment under this Article, the corporation shall be subrogated to the extent of such payment to all of the rights of recovery of the Agent, who shall execute all papers required and shall do everything that may be necessary to secure such rights, including the execution of such documents necessary to enable the corporation effectively to bring suit to enforce such rights.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.9</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">No Duplication of Payments.</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The corporation shall not be liable under this Article to make any payment in connection with any claim made against the Agent to the extent the Agent has otherwise actually received payment (under any insurance policy, agreement, vote, or otherwise) of the amounts otherwise indemnifiable hereunder.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:none;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.10</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Indemnification and Insurance under Israeli Securities Law</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the Delaware General Corporation Law, the corporation may indemnify and insure any office holder of the corporation from and against any payment which the office holder is obligated to make to an injured party as set forth in Section 52(54)(a)(1)(a) of the Israeli Securities Law, 5278-1968, as amended (&#8220;Israeli Securities Law&#8221;) and from and against reasonable litigation expenses, including attorneys&#8217; fees, that an office holder may incur in connection with a proceeding under Chapters H&#8217;3, H&#8217;4 or I&#8217;l of the Israeli Securities Law. Subject to the Delaware General Corporation Law, the corporation is permitted to provide an office holder advanced payments to cover expenses covered under this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8.10 </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Indemnification and Insurance under Israeli Securities Law]</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE IX</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>FISCAL YEAR</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fiscal year of the corporation shall begin on the first day in January of each calendar year and end on the last day of each December following.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE X</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>NOTICES</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">Whenever, under any provisions of these Amended and Restated Bylaws, notice is required to be given to any stockholder, the same shall be given either (1) in writing, timely and duly deposited in the mail, postage prepaid, and addressed to their last known post office address as shown by the stock record of the corporation or its transfer agent, or (2) by a means of electronic transmission that satisfies the requirements of Section 2.4(e) of these Amended and Restated Bylaws, and has been consented to by the stockholder to whom the notice is given. Any notice required to be given to any director may be given by either of the methods hereinabove stated, except that such notice other than one which is delivered personally, shall be sent to such address or (in the case of electronic communication) such e-mail address, facsimile telephone number or other form of electronic address as such director shall have filed in writing or by electronic communication with the Secretary of the corporation, or, in the absence of such filing, to the last known post office address of such director. If no address of a stockholder or director </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">23</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">be known, such notice may be sent to the principal office of the corporation. An affidavit of mailing, executed by a duly authorized and competent employee of the corporation or its transfer agent appointed with respect to the class of stock affected, specifying the name and address or the names and addresses of the stockholder or stockholders, director or directors, to whom any such notice or notices was or were given, and the time and method of giving the same, shall be conclusive evidence of the statements therein contained. All notices given by mail, as above provided, shall be deemed to have been given as at the time of mailing and all notices given by means of electronic transmission shall be deemed to have been given as at the sending time recorded by the electronic transmission equipment operator transmitting the same. It shall not be necessary that the same method of giving notice be employed in respect of all directors, but one permissible method may be employed in respect of any one or more, and any other permissible method or methods may be employed in respect of any other or others. The period or limitation of time within which any stockholder may exercise any option or right, or enjoy any privilege or benefit, or be required to act, or within which any director may exercise any power or right, or enjoy any privilege, pursuant to any notice sent to them in the manner above provided, shall not be affected or extended in any manner by the failure of such a stockholder or such director to receive such notice. Whenever any notice is required to be given under the provisions of the statutes or of the corporation&#8217;s Certificate of Incorporation, as amended, or of these Amended and Restated Bylaws, a waiver thereof in writing signed by the person or persons entitled to said notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein, shall be deemed equivalent thereto. In the event that the action taken by the corporation is such as to require the filing of a certificate under any provision of the Delaware General Corporation Law, the certificate shall state, if such is the fact and if notice is required, that notice was given to all persons entitled to receive notice except such persons with whom communication is unlawful.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE XI</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>AMENDMENTS</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Board of Directors shall have the authority to repeal, alter or amend these Amended and Restated Bylaws or adopt new Bylaws (including, without limitation, the amendment of any Bylaws setting forth the number of directors who shall constitute the whole Board of Directors) by unanimous written consent or at any annual, regular, or special meeting by the affirmative vote of a majority of the whole number of directors, subject to the power of the stockholders to change or repeal such Bylaws and provided that the Board of Directors shall not make or alter any Bylaws fixing the qualifications, classifications or term of office of directors.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin-bottom:12pt;margin-left:0pt;text-align:center;text-indent:0pt;text-transform:uppercase;"><font style="white-space:nowrap;">ARTICLE XII</font><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>EXCLUSIVE FORUM</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">Unless the corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) shall, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on behalf of the corporation, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any director, stockholder, officer or other employee of the corporation to the corporation or the corporation&#8217;s stockholders, (iii)&#160;any action </p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">24</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">arising pursuant to any provision of the Delaware General Corporation Law or the corporation&#8217;s Certificate of Incorporation or these Amended and Restated Bylaws (as either may be amended from time to time), or (iv)&#160;any action asserting a claim governed by the internal affairs doctrine, except for, as to each of (i)&#160;through (iv) above, any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10&#160;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court, or for which such court does not have subject matter jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless the corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, against any person in connection with any offering of the corporation&#8217;s securities, including, without limitation and for the avoidance of doubt, any auditor, underwriter, expert, control person or other defendant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any person or entity purchasing, holding or otherwise acquiring any interest in any security of the corporation shall be deemed to have notice of and consented to the provisions of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XII </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[EXCLUSIVE FORUM]</u>. This provision shall be enforceable by any party to a complaint covered by the provisions of this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XII </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[EXCLUSIVE FORUM]</u>. For the avoidance of doubt, nothing contained in this <b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Article XII </b><u style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[EXCLUSIVE FORUM]</u> shall apply to any action brought to enforce a duty or liability created by the Exchange Act or any successor thereto.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0pt 3.6pt;"><font style="font-size:12pt;">25</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>plx-20250331xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/8/2025 05:26:37 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>plx-20250331xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/8/2025 05:26:37 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Eyal Rubin, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"> I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>plx-20250331xex32.htm
<DESCRIPTION>EX-32
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/8/2025 05:26:37 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>plx-20250331xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.10.0.134--><!--Created on: 5/8/2025 05:26:46 PM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended March&#160;31, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Eyal Rubin, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2) </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May&#160;9, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Eyal Rubin</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20250331x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'S!#@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^!- %VBJ\NH6L%L+B2YACMS@B5I $.>G/2FV>J66H,PM;N"Y*\D0RJ^/K@T
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MZUI]O/Y,M_;1S=/+>90WY9H NT4@(8 @Y![BJ]WJ=G88^U7<%MGIYL@7^9H
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MH **** "BBB@ K\5?CZQ3XV^,F'4:I*?_'J_:JOQ7^/'_)<?%_\ V%9?_0J
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M5+'G RS$GW-4OV:8UE^/W@!'4.C:U:@JPR"/,6OV6CTNSA8-':0(P[K&H/\
M*@#XK\-_!W5/A!^PMXX@UR)K;5]3M);N:V;K"NW"J?\ :ZYKQS_@FW_R<)=?
M]@.Y_P#1D-?<G[6G_)NGCO\ [!LG\J^&_P#@FW_R<)=?]@.Y_P#1D- 'DGQK
MN[NQ_:%\47%A(8KV/6':%Q_"^X8/YUZ9^T/^RIXR^%?@C2OB%K/BE]<U&[E1
M=01@ZS6DK@LNURQW#@@G"X., UY9\>99(/CSXNDB&94U9V0>I##%>N_M%_M?
M:O\ &'X;Z7X'N_#D^CZI#.DFI2R$DS2(I4!4QD DY.>XH ]@_9?_ &IM5L?V
M=/&5WKDDNJZAX5BW6LTQ+-*K#Y%8GK@\9]!7R9;^*IOCMX]GN?B1\0F\/6,H
M:5[RYMY[J./GB.*&,'U[X& ><]?I[]EC]FK6]=_9U\=PZG%+IL_B:'981RKM
M;"C*N0?4U\S^ [M?@%\2KE/'_@*#Q#9Q*]K<Z;J=N"!R"'C9A@-QP?0F@"MJ
MNO'X)^-;>?X;?$:7Q!9Q@2I?6EO/9@G/*20R#!_#<,'KFOH;]LKXB'XJ_LY_
M"SQ/(JI<7UPQG1>BR"-U;]1G\:Y:P^./A_QUXJBTSP7^SQX3O([B0)!'<V)>
M09[LR84#WKT#]OGP\GA;X+_#K3UTG3]#=+MFEL-+39;PN8F+*@],T ;_ .P'
M_P FQ_$C_K]N_P#TBBKYB_9%_P"3FO"7_7^?ZU]._L!_\FQ_$C_K]N__ $BB
MKYB_9%_Y.:\)?]?Y_K0!L?M\?\G-^)?^N-I_Z3QU1^)?P:^*=Y\*--^)WB>^
MBNM#E2)(+4W+&:"(\1GR]NU5^ASZBKW[?'_)S?B7_KC:?^D\=?5'[07_ "8;
MI_\ UYV7\Q0!P'_!/[XTZEI?@WXAV.L74VI:;X?T\ZQ;0R.6=%17,B*3G@[5
MX['ZFOFKQ-\4]5_:!^(S3^-_&1\/:-<R,3))'-+;6D>>%6&,$DX_/N:]C_X)
MZ>'E\77_ ,3=">0PIJGA][)I /N"0E,_ANKQF'PY??L\?%C9XS\'Q:Y964K)
M+9:A!O@N(\XW*2,>X- %?QA'I?PCUVPNOAM\4)?$:G+M<V5I<Z?) P(P&1QA
M@?8GIR*_3O\ 92^+MW\:/@UI&NZGM_M>,M:WC*,!Y$.-^.VX -CMFOAJ[_:'
M\'^(];@M/!W[/?A>Z67"+#=67FRLY]/+ &*_0KX)>&'\+?#S38;CPUI/A._G
M4SW.EZ+'L@B=N<>YQC)]: .\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YVZ^'7A.]N9+BX
M\,:-/<2-N>673XF=CZDE<DUT5% #(88[>%(HD6**-0J(@PJ@<  #H*<0&!!
M(/!!I:* .?A^'OA6WO4O(O#6CQWB2"9;A+"(2*X.0P;;D'/.>N:Z"BB@#-U?
MPSH_B *-4TJQU(+T%W;)+C_OH&DTCPQHWA_/]EZ38Z;G@_8[9(L_]\@5IT4
M-=%=2K ,I&"",@UC6G@CPYI][]LM= TNVO,Y^T0V4:29]=P7-;=% &#;^ O#
M-GJ"7T'AS28+Y'\Q;F.QB616_O!@N0?>M'5=%T_7;;[/J5A;:A;YSY5U"LJ9
M^C BKM% &/#X-T"WTV73XM#TV.PE_P!9:I:1B)_JF,'\J?HWA/1/#CR/I.C:
M?I;R##M96J0EAZ':!FM6B@"CJNA:;KD0CU+3[74(QT2Z@64#\&!JEIG@?PYH
MMP)].\/Z783CD2VME'&P_%5!K;HH *P+GX?>%KVZ:YN/#6D3W#')FEL(F<GU
MR5S6_10!%;6L-E D%O$D$$8VI'$H55'H .!2SV\5U"\,T:30N-KQR*&5AZ$'
MK4E% '/6?P[\*:==17-IX9T>UN8F#QS0V$2.C#H00N0?>NAHHH KWUA:ZI:2
MVMY;17=K*-LD,Z!T<>A4\$5FZ1X*\/>'[HW6EZ#IFFW)4H9K.SCB<J>HRH!Q
MP./:MJB@#\FOBU\$?B)J?QWU_4;3P)XDNK"75S+'=0Z3.\3IO'S!@F"/>OU*
MN_ _AS4+XWMUX?TNYO"=WVB:RC>3/KN*YK;HH :B+&H55"J!@ # %9FK^%-$
MU]@VJ:/8:DP& ;NU24C_ +Z!K5HH RM(\*:)X?<MI>CZ?IK$8)M+5(B?^^0*
M?K/AO2/$<<<>K:79:I'&=R+>VZ3!3Z@,#BM*B@#-TOPUI&AV<UIIVE66GVDQ
M)D@M;=(XW)&"650 > !S5.P\ ^&-+O$N[+PYI-I=QG<D\%C$CJ?4,%R*WJ*
M,/5/ OAK6[Q[O4?#VE7]V^ T]U912.V!@99E)/%7;K0-,OM,&FW.G6EQIP
MM)8%:( =!L(QQ]*OT4 9.C>$="\.2R2Z3HNGZ7)(-KO96L<)8>A*@9%2ZMX=
MTG7T5=3TRSU%5& +NW24#_OH&M&B@#&TKP9X?T*83:;H6FZ?,/\ EI:V<<3?
MFH%;-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5YP/C]X3=I?+.JS)&[(TL6E7#)D'!^
M8)BO1Z^>OAY\7X/ G@*Y%SX<UV\BM[JX8W5K;HT!^<_Q;\@>IQQ6L(\R>ESP
MLQQLL+4IQ4U"+4FVXN6UNS7<]Q\-^)=-\6Z1#J>E727=G+D+(O8C@@CL1Z&M
M2O"-!\4W7PT\&Q7+BP75O&&M37MG#<W06VMHY$#9>3C("IDXQEGQ6_IGQ<N=
M-\26NFZSJGA[6;>\B=H;G07(:-T7<5=#(_!'1LBFZ;Z$4,WI.,%7TD[7[)O;
MS5]'UM=7/6**\KTWQ?\ $#Q/H#>(M'T_11ITFZ2TTVY64W-Q$,X/FAPJ,V.!
MM(YZU=O?'/B36_$BZ#X=T^SL;RVM([G49M6#2K;M(,K$%C9=S>IW8J>1G4LR
MI.*DHRUMRZ?%?:WW7UMIKL>CT5XQXC^,WB'PEH/B*'4=+LF\2Z0UNZI!O-O=
M0RR! R@MN4\G@D\XJSKGCCXB>'-4T*QN-/T&[N-<+Q01PB5/L<BC=^\8N?,7
M;Z!>:?LY&+SC#JZ2D[6O[KTNW%)^?,K6^>VIZCK6L6OA_2;O4KUS':6L9EE<
M*6(4#).!R:FL;V+4;*WNX&+03QK+&Q&,JPR#CZ&O'?%WB[79/#_CSPWX@BL)
M;JTT9[R*ZTU'C1T88VE'9B#GONIVF^+/'F@_#G3O$3Z?I#Z-:V44TFF[9?M?
MV=4&7\S?MW;?FV[/;-/V>AG_ &M!5G'E?*HW>FJLVG?TMTO?I<]2MO$VGW?B
M*]T.*1SJ-I$DTR&-@H5OND-C!_"M6O)=9^,E];77BTV-O:36FE:/#J=JSJVZ
M1G .'^8<<]L57N_B/XXT'PKIOBW5[/1!H<[VWVBSMUE^T0QS.B*XD+E207!V
M[?QI>S;+6;4(\W,W*UVVEHHIM7>O2WSWL>Q45Y_XC\2>+$UBZCT_^Q-$TJ%%
M,5[K99_M3%02%59$V@9QDYZ=*Y>Z^-NMS>"_#NI:9IMA=:KJ.L_V/)"9&,#/
M\PW(P.0I(4Y.>,TE3;V-:N:X>C*4:B:M?IO9I.W7=KIKTN>T4@8-T(/TKS6+
MQAXNT+Q?I6A>(1HTG]LPS?8[JPAE4131A25=6D;</F'(*YQVJK^S\-9;0=7?
M4KRTN83J=P%$-NZ.'W#)+-(V5]!CCU-#A97N.&8QJ5XT(P=W>]]+-)/7U36Q
MZK17FWCSQ]XBT?X@:%X8T&PL;I]3M)IC->;\0%&4;CM/*X)&.I)'(JM=_$3Q
M)X5U+4-*\00:;/>&PEOM/NK".1(I?+'S*Z,[$'Z-0H-CGF="$Y1DG:+LW;2]
MKVOYW^_0]2HKQ;2?BQXQ'@>Q\5ZII^D?9M3CBAT_3;591/+=2,J(&<N5"$[B
M1C( '-;.I>,_&G@I].O/$EMH]SI-U,MO*VFQRI+:N_"D[W8.,]<;:?LWL9QS
M:A**G:5K)WMLGLWY/[[:NR/3PP)(!!(ZCTI:\,\/^)]4\$^(/BCKNMWME<Z=
MITB22PV]L\;NPBRBHS2,%'8@@Y)SQTJS-\9-9TC3K;6-0U/PC=6C.IN-*L;D
MF[A1B!\LGFD.PSR @Z4_9OH91SF@HWJIQ>MUH[)2<;OUL_/?M<]5TOQ-I^LZ
MKJFG6LCO=:8Z)<JT;*%+ E<$C!X!Z5JUXUXC^-NIZ3I?CZ]M;2SF30&M?L@=
M7_>K*"3O^;KZ8Q6CJ/CCQMX2DT6^\0VFBC2]1O([-[6T647%LT@.W+EBKX(P
M<**3ILJ&;4%=2;=MVHZ)<THJ^KZIKSM>UMO5**\@/Q0\1ZOJ^M0:7/X<L&TZ
MY-NFEZJ76[N,?Q!O,4*#VPK5ZO8337%C;2W$/V:X>-6DAW;O+8@$KGO@\9J9
M1<=SOPV,IXIM4[Z=>F]OZ3LR:1Q%&SMPJ@D_2L_P]X@LO%.D0ZGITAFLYBZH
M[(5)*N4;@\]5->=VGC3QGXSTC4M9T&TTB'18VDCMH+U)6N+I5R"V]7"IG''R
MM7+>"OB7-X6^&7@G3K86%GJNLRWK)+J\_EV]LB3R,Y<Y!8C(4 $9)ZBK]F[>
M9YDLXI1JQNFJ;BW=K?WHQ5O7FZ^3V/?Z*\ET[XOWMEK-[I=_<Z+XAF6PEOK6
M;P^YP_E_>1T+N5/3G/>I/!OQ"\3^)9-'NTN/#6I65ZX^T6-@[I=6:'N2TAW%
M>XV+TI>SDCHCFV'G)0C=M]+;;+]5M?OL>@Z%XFL/$<FI)8R/(VGW3V5QNC9=
MLJXW 9'(YZCBM6O)#\8]3%GK\:6%M<ZI#XADT/3;=-RK)CD/)R3P,DXQ4FK^
M-?'7A'Q'X8L=7MM%O;+6+V.T>ZL898S 6/*[6D;/'1OTH]FR(YK14.9WEW:B
M[*[LKZO]>[M<]7HKQW0_B!X]\6VWB:\TRVT&TL]&U"\LD^UQS.]SY,A ^[(-
MGRXYYR0> *?<?'3[9H7A=K#^S;+5-;C:1I-4GV6UJ%^^2<J6.>  1]:/9R&L
MXPO+SNZ35U=;ZI:?-I?CMJ>OU0UW6[3PYI%UJ=_(8K.V3?*ZJ6('T')KRZ+X
MX_\ ".W^IVFOWVBZND.GRZA:W>@R';+Y94-$R%Y"K$NN#NP>?2LOXEZO\0)?
MA=J5]J=AH_V"Z@'G65JL@N+9&(PQD+E7(XR HIJF[JYE6SBBJ-2=%-RBFVK7
MM;O;]-UJM#V^TN8[VUAN(CNBF19$)&,@C(J0,&S@@XX.*R=!$K>%-.$#(DYL
MH]C2*64-Y8P2 02,]LBO(? _BW5O!/AKQOJNJ2VNINNOW5O;V]M \327!G9<
M;FD;"$XP,94#J:E0O>QUUL>L.Z?M%I)-M]%97]3W6CI7EFJ>-?&W@BULM7\2
MV>CW&BR2I'=Q::DB3V@<A0VYG(?!(SPM=QXU^V?\(CK/V":*WNQ:R%))XRZK
M\ISP&4],XYX./I2<;6-H8R%2,VHM2BKM-6>NWWV?ZFT"&&0<CU%+7D7P_P!3
M\5Z7\'M!DLX+'5KZ=$2%F5H8K>,DY>8ER6QU^7&?2IK#XFZUIWBX:%JUSH6J
MM<Z=<7EO<:.&7RY(@NY)4:1R =W!R,X/%5[-W=CECFE+DISJ1<>9+IHG+97Z
M_+YV/5Z*\6\+?%KQ;?\ @@^,]7M-'MM#2%F%K;I*;B5P<+M8OM4$]L$U)XR\
M>_$?P5X+/B6ZT_0;B$A#)9113+):ARH4LQDP^"P! "XH]F[V,_[8P_LO;<LN
M6W-M]GOZ/[]'I8]EI&8*,D@#U->4ZK\6;R]\4ZCI&E:GX=T:+30J7%UKDI)D
ME*ABJ1B1#@9 +$FN1\=>/M6\;_#>Y^S76EV]YIVL65K>FW5IXIF-Q%L>)UD&
M%.>5.20",C.::I-M7)K9SAZ<9N"<G%2MYN.Z7I^CM<^A:*@LEN4LX%O)(I;L
M(HFD@0I&SX^8JI+$#.< DX]37+?#_P 8WGBSPG=:I=1013Q3SQ!(00I"$@9R
M2:RMI<]>5>,9QIRWDF_NM?\ ,["BO"M&^-?BSQ&G@>VT_3M)-]XBTV>[D>82
M"*!TD"Y #9*XSQG.2.16\WQ-\0Z'+XLTS6+?3)]5T?3QJ,$UDDB0RH> &1F)
M!SZ-6CI21Y5/.<+47/&_+WMI=QYK>O+_ )'J]%>)7WQ0^(&E>$M#\37&DZ+-
M;:K)!!'ID?FI.&FPL3>:7*X+%<KMX!ZUOP^/O$GAGQ-!IOBN/27M[FPFO4FT
MU)(S%Y0RR-O=MWL1CZ4.FRXYM0D[-26VK5DN;X6_7\.MCTZDW#=C(SZ5X>/C
M;K-QX<D\20:EX12S5&N%T66Z/VQXADX\SS,"0@<+L/)JS:ZIK'B#XV:)J-C?
MV0TJ\T(74,<EI)O\AG)P3YN-_P#M8QCC'>G[-K<R6<49\JI)R;<>RTEU_P"!
MOW/:**X_XL^,KOP#X#U+7+&"*YNK4*4BG!*ME@.Q![^M<AKWCOXB^'+W08+C
M2]#N9==D-O;VL?FHUI+MW_O'+D2 *&S@+R*F,')71UXC,:.&FZ<TVTDW97MS
M-I?>U:QZ_17E\'Q+UGPSJ?B"Q\5Q:?*=,TW^U%N=,1XE:,'!4J[-SD]<_A6!
M<?&O5].T"'Q%=:IX1EL2%FFT>WN2;R.)B.DGFD,X!Y78.AYIJG)F$\WPU-7G
M=-7NK:JSL[_\"]^A[?7*:E\3O#^D_P!H?:+J1?L-[%I\^V!VVS2!2@X'(.X<
MC@5A)XV\2^+_ !!J=GX5ATRVL--Q'-=ZI')*99B,[$5'7:!G&23]*\XTKXC:
MWX2M_&NL2:=:PZK/XFL[*>VEW/&H=8XV9<$'D?,,^HSFJC3ON<V+S>-+E=/2
M+YO><6U[J;=M5>S7E?6W<^C@=P!'0TM>;GQEXJ\5>(-7LO"T&EVUEI4GV::[
MU2.27SIP 65%1UP!G&23]*N2^)O&0\)Q2CP[;1:^;K[/(LLX^RQIGFX)SNV8
MYVYS6?(STECZ<KN,9-*^JB[.VCM\_OZ'<3S);PR2R'"1J68^@ R:S?#'BC3O
M&&CQ:GI<S3V<A95=D*$D'!X/->?:=\0=8D\577AC5[K0]3,^E37D5UHP9/+*
M8#(Z-(_=A@Y'2K7[.7_)*M._ZZS?^AFJ<+1NSFHYBL1BHTJ:TM*]]TXN/G;:
M1Z;17DFD>/O&_B_Q3XJTG1K;1+2#1+W[.+J]CED\U3&K*NU77!R6RV<8(XX.
M8O\ A><__"$Z5>O;V%KK5_?R:8!<SF.TCEC.'=F/.T=<9S[T>SD-9OAK.4KI
M:ZM;\KY7;YNWGT/8**\DL/C#/I'B6TT[7-5\/:Q:7D$\L=SH+D-"T49E970R
M/P45\-D<KTYK,C^-6LWN@GQ!!J/A*"T(\Y-&GNLWABZ\R>:%#X_AV4>RD2\Y
MPJ6[NKW756LWUMLULW>^A[=67:>)+"]U^_T:&5FU"QCCDGC*$!5<97GH>G:N
M&B^).K^--:M-.\'QV$<7V&*_N[_4HY)4A$GW(PB,A+<-U8=*X[3/&&N^&?%G
MQ+U?5M,MWU;3[&S!BM6;R9NH5QG+!<$$CDC!Y[TU3>M]R*V;4XN#IW<&VG*V
MEE&4G9]]/S2U/?J*\Y\$^,/$>MZC8&XN_#FLZ9=1EI9-'9EEM6VDC<K2/N&<
M#/RGGI78>*M1U'2]"N;C2=/_ +3U%0!#;%PBDD@98GH "2?I6;BT['I4L7"M
M2=9)V7EKWTM>_P O3<UJ*\JM?B-X@T?Q9H.EZW=>'M0BU60P&/2=ZS6TFW(W
M!I'W+VS@57\.^.?B!XVE\0MI%KH-I:Z5J,]C&]Y',[7)0C PL@V\$9;GD]!5
M>S9QK-:+:@HR<KM6MKHD_39]_+?0]=K+NO$EA9^(+#199674+Z&6>",(2&2/
M;O.>@QO7KZUYQIWQCU/Q9I7AJ#0-/M1KNKQO++]K+-;VJ(<.Q (9N00!D?6J
M4-YXA?X^>&;/Q!!9&2WTN^:&\L%=(IU8Q9&QF8J5V\_,?O"FJ;ZF4\UIRC!X
M>[4I05[.WO-:>O*[]KZ;Z'M%%<=\3?'X\!:5:/&MN]_?7 MK87<PBA#'DL['
MHH%<QI?Q7O;'Q1I.FZMJOAO6K?5&,$4FA2$203;20'0R/N4XQN&.2.*E0;5T
M==;,</0J^QF]=+^5]K^OX=;'K%)N&<9&?2O'/"'Q4\4>+[2TU.U?PXT<T^V3
M0B[I?P1[L'+&3!<#)(V <=:M:?\ V\?V@=6_TVR-DNEQMY!MGW^5O'R@^;@/
MG^+&/:J]FU>YSQS6G5C"=*+:DTNVC3=_PVW[H]:K+B\1V$WB*?0TE8ZC#;K=
M/'L.!&3@'/3KVKS;Q+\0O&F@Z3J>LW"^'-*M[0R21Z1?NQNYH4)Y\P2A59@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX\\#Z;<Z;XR^)^E: DD3)I]U%;PPDY^4\ ?05S^@);WOPIN=.O?$'AC28'O
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M_A)M9GMM"\F8V]PDDGRAP 05[D$'WZ&NK\,?%;PCXS>9-%U^TU!XE+ND;$,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI@X<2EEX !' ZB@#TG6_B]X2\.W=Y:WVK!+NTG2UEMH;>6:4RNA=45$0LYV
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MQGI,5O;?VEJOB5=4MSYH : 20,"6[$"-^/\ &@#MT^,GAS1X+IM5\0P7DO\
M:5W9Q1:?IMP95,,I1XS&OF.YCQM:0 *2,@ '%6=1^.'@G3+*RNY=;$L-Y$9X
MC:6LUPWE@X9V6-&* 'J6 QWKS/P_\*O&/@?QG>>*;+2[/6)9=3UAOL#W2QGR
M+F[::*17/ ."-RU6\7_#+XCZVJA+:UB6[T^2WEBTB[2S$,C-G#MC<Z8[#J:
M/3_!'Q&G\7?$+Q5I,9M9M&T^UT^ZL;F!6WRK<1NY+$G!'RKC '7O7H%>-_ 3
MX9Z]X!O;V;6888EET/1M/7RIA)F6VMS'+T[9Q@]Z]DH **** "BBB@ HHHH
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MY<$HY16(!'!ZC!'!Z]*\AU/]H#Q'9Z1!=):Z:9'\'V.OD-%)C[1-,R.OW_N
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%5Y[V.W?:^<XSP* +%%4_[4@_VORH_M2#_:_*
M@"Y15/\ M2#_ &ORH_M2#_:_*@"Y15/^U(/]K\J/[4@_VORH N453_M2#_:_
M*C^U(/\ :_*@ T_1M/TEIVL;&VLC</YLQMX5C\Q_[S8')]S5RJ?]J0?[7Y4?
MVI!_M?E0!<HJG_:D'^U^5']J0?[7Y4 7**I_VI!_M?E1_:D'^U^5 %RBJ?\
M:D'^U^5']J0?[7Y4 7**I_VI!_M?E1_:D'^U^5 %RBJ?]J0?[7Y4?VI!_M?E
M0!<HJG_:D'^U^5']J0?[7Y4 7**@@O([ARJ9R!GD5/0 4444 %%%% !1110
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M  %7_P"+H]C4_E#_ %CRC_H)C]Y[G17AG_#8W@+_ )Y:O_X"K_\ %T?\-C>
MO^>6K_\ @*O_ ,71[&I_*'^L>4?]!,?O/<ZUM*_X]F_WC_(5\[?\-C> O^>6
MK_\ @*O_ ,75^Q_;3^'UO"5>+6<EL\6B?_%T>QJ?RA_K'E'_ $$Q^\^AZ*\
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M #RUK_P$3_XY1[&I_*'^L>4?]!,?O/?Z*\ _X;:^'G_/+6O_  $3_P".4?\
M#;7P\_YY:U_X")_\<H]C4_E#_6/*/^@F/WGO]%> ?\-M?#S_ )Y:U_X")_\
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M?_BZ/^&QO 7_ #RU?_P%7_XNCV-3^4/]8\H_Z"8_>>YT5X9_PV-X"_YY:O\
M^ J__%T?\-C> O\ GEJ__@*O_P 71[&I_*'^L>4?]!,?O/<Z*\,_X;&\!?\
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M"&Z9(Y'3M73UC3J^U3D;U*/L6HA1116ID%%%% !1110 4444 %%%% !1110
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MJ3LCGKY?7PU/VE1:?/[]5Y>OD<S1115GFA1110 4444 %%%% !1110 4444
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MCRPDDO\ %_P#YZ;XOZ\L$<$"V-G"ES]K\NVM%16DVE26QURI(/K4;_%G7/\
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MA_X??\_FN_\ @5%_\:H^MTP_U$SCM'_P+_@'PA17W?\ \,/_  ^_Y_-=_P#
MJ+_XU1_PP_\ #[_G\UW_ ,"HO_C5'UNF'^HF<=H_^!?\ ^$**^[_ /AA_P"'
MW_/YKO\ X%1?_&J/^&'_ (??\_FN_P#@5%_\:H^MTP_U$SCM'_P+_@'PA17W
M?_PP_P##[_G\UW_P*B_^-4?\,/\ P^_Y_-=_\"HO_C5'UNF'^HF<=H_^!?\
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M^&-/ G_/WK7_ ($Q_P#QNC_AC3P)_P _>M?^!,?_ ,;H^MTP_P!1,X[1_P#
MO^ ?$U%?;/\ PQIX$_Y^]:_\"8__ (W1_P ,:>!/^?O6O_ F/_XW1];IA_J)
MG':/_@7_  #XFHK[9_X8T\"?\_>M?^!,?_QNC_AC3P)_S]ZU_P"!,?\ \;H^
MMTP_U$SCM'_P+_@'Q-17VS_PQIX$_P"?O6O_  )C_P#C='_#&G@3_G[UK_P)
MC_\ C='UNF'^HF<=H_\ @7_ /B:BOMG_ (8T\"?\_>M?^!,?_P ;J]8_L3^
M+F$L]YKF0V.+J/\ ^-4?6Z8?ZB9QVC_X%_P#X8HK[O\ ^&'_ (??\_FN_P#@
M5%_\:H_X8?\ A]_S^:[_ .!47_QJCZW3#_43..T?_ O^ ?"%%?=__##_ ,/O
M^?S7?_ J+_XU1_PP_P##[_G\UW_P*B_^-4?6Z8?ZB9QVC_X%_P  ^$**^[_^
M&'_A]_S^:[_X%1?_ !JC_AA_X??\_FN_^!47_P :H^MTP_U$SCM'_P "_P"
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M#_A8FNB/1$%YM71ABTVJ!M^OKQQSVKZT_P"&-/ G_/WK7_@3'_\ &Z/^&-/
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M_1AKMO\ AC3P)_S]ZU_X$Q__ !NO1/@U\#?#WPGU+4;O19K^66[A6*07<JN
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M0 WSD_O"CSD_O"G;%_NC\J-B_P!T?E0 WSD_O"CSD_O"G;%_NC\J-B_W1^5
M#?.3^\*/.3^\*=L7^Z/RHV+_ '1^5 #?.3^\*T=&=7DDP<\"J&Q?[H_*M#1U
M DDP .!0!J4444 %%%% !1110 4444 %%%% !1110 4TNJL%+ ,W0$\FN1^(
M'Q&LO!%H=Y62Z9<JG7 ]2!SBOFK7/C=XGU>]NI]!2]GGD4Q_:;.W-PR+Z(P_
M=1_4MFNJEAYU5=&\*2=G5G&$>\G;[DKRE_VZF?4GC#X@>'? -@UYK^K6VFPJ
M,XE<;F^B]37SWXE_:P\2^-9Y-,^%/@^\U21B575;V$B(>Z@\?F3]*\0OO"_B
MKQ#?M>79TNQNW;)O]=NSJ-P#_LQ1Y5#7TI\-?B5_PC'A[1/#%A87>N:F (I;
M^6$0I-(226P!PHSQ[ 5W/"JC'F^)_A_7S/7PN<9!@)>[1EB)KK/W*=_*"]^7
M_;UEY$OP"^%_CJRU^\\7?$G56U'6I8_+M+42EDME/WL*,*#VX%>]TU"Q12P
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M9'_\51_PFWAW_H/Z7_X&1_\ Q5?ES11_9,?Y_P  _MN7_/O\3]1O^$V\._\
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MO#O_ $']+_\  R/_ .*K\N:*/[)C_/\ @']MR_Y]_B?J-_PFWAW_ *#^E_\
M@9'_ /%4?\)MX=_Z#^E_^!D?_P 57Y<T4?V3'^?\ _MN7_/O\3]1O^$V\._]
M!_2__ R/_P"*H_X3;P[_ -!_2_\ P,C_ /BJ_+FBC^R8_P _X!_;<O\ GW^)
M^HW_  FWAW_H/Z7_ .!D?_Q5'_";>'?^@_I?_@9'_P#%5^7-%']DQ_G_  #^
MVY?\^_Q/U&_X3;P[_P!!_2__  ,C_P#BJU-+\=>&UMV!\0Z4#N/6]B]!_M5^
M4M%']DQ_G_ /[;E_S[_$_6;_ (3SPU_T,6D_^!T7_P 51_PGGAK_ *&+2?\
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M_BJ/^$V\._\ 0?TO_P #(_\ XJORYHH_LF/\_P" ?VW+_GW^)^HW_";>'?\
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MN?[TL4B3JGU8Q;1[L*U;7QYH.H6_AJ77;/4)-0T*);>(VCH(YD1BT8;/(QD
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M./\ H*Z!_P"!$W_QFOMRBC^TL1W7W!_9&%[/[SXC_P"&(_''_05T#_P(F_\
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MEB.Z^X/[(PO9_>?$?_#$?CC_ *"N@?\ @1-_\9H_X8C\<?\ 05T#_P ")O\
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M=_\  F?_ .,T?\,&^/O^@OX=_P# F?\ ^,U]Y44?VEB.Z^X/[(PO9_>?!O\
MPP;X^_Z"_AW_ ,"9_P#XS1_PP;X^_P"@OX=_\"9__C-?>5%']I8CNON#^R,+
MV?WGP;_PP;X^_P"@OX=_\"9__C-'_#!OC[_H+^'?_ F?_P",U]Y44?VEB.Z^
MX/[(PO9_>?!O_#!OC[_H+^'?_ F?_P",T?\ #!OC[_H+^'?_  )G_P#C-?>5
M%']I8CNON#^R,+V?WGP;_P ,&^/O^@OX=_\  F?_ .,T?\,&^/O^@OX=_P#
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M$3?_ !FOMRBC^TL1W7W!_9&%[/[SXC_X8C\<?]!70/\ P(F_^,T?\,1^./\
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ML:?WG_[ZH^QI_>?_ +ZJQ10!7^QI_>?_ +ZH^QI_>?\ [ZJQ10!7^QI_>?\
M[ZH^QI_>?_OJK%% %?[&G]Y_^^J/L:?WG_[ZJQ10!7^QI_>?_OJC[&G]Y_\
MOJK%% %?[&G]Y_\ OJC[&G]Y_P#OJK%% %?[&G]Y_P#OJC[&G]Y_^^JL44 5
M_L:?WG_[ZH^QI_>?_OJK%% %?[&G]Y_^^J/L:?WG_P"^JL44 5_L:?WG_P"^
MJKW.D03L&8,Q'<L:T*0X[T 9JZ':C^%O^^C3QHMM_=;_ +Z-7Q2T 4?['MO[
MK?\ ?1H_L>V_NM_WT:O44 4?['MO[K?]]&C^Q[;^ZW_?1J]10!1_L>V_NM_W
MT:/['MO[K?\ ?1J]10!1_L>V_NM_WT:/['MO[K?]]&KU% %'^Q[;^ZW_ 'T:
M/['MO[K?]]&KU% %'^Q[;^ZW_?1H_L>V_NM_WT:O44 4?['MO[K?]]&C^Q[;
M^ZW_ 'T:O44 4?['MO[K?]]&C^Q[;^ZW_?1J]10!1_L>V_NM_P!]&C^Q[;^Z
MW_?1J]10!1_L>V_NM_WT:/['MO[K?]]&KU% &=<6]CI5M/=SS"UMX8VDEFED
MVHB 99F)X  &23Z5RZ_%GX>NP5?'&@LQX &K0Y/_ (]5_P"*_P#R2WQC_P!@
M:\_]$/7P_P#L_?!SP_\ $[P)XRO-45X]0TY"]K=+*RB/";L%<X.?>O0P^'IU
M*<JE1M6:V\SS,5B:E*K&E3BFVF]?(^_;5;6^MX[BVG\^"0;DEBDW*P]01UJ7
M[&G]Y_\ OJOA;X)_'G5?AC\#?%$L2?;)K:^M[?3UGR4B>59"QQZ 1YQZUII^
MU1XO\.+H.I77C'2?$T5]@WNDP6*Q260.."X49(!_,=ZTEE]7F:CT_'J8QS2C
MR1E);J_IK;^K'VM]C3^\_P#WU1]C3^\__?5?*/AO]I3Q/X?U[QOI_BS4%G^R
M:=)>:5FVC0EL!D7Y5&<J>_I7-S?M/?$+0?A]H=QJ.HP'6-?G>2"\N+2-8[:U
M5A&&VJHR2P<DD'@#%0L!5;LK?UJ:/,J"5W?K^#MW/M(VD:@DNX Y)+5CZ+XG
M\.>)+NYM=)UVQU2YMN)X;.\25XN<?,%)(Y!'-?,?@O\ :8UVS^)6G^'-6\3Z
M;XRTC40L7V^SM!;^2[#T '0URW[/OC-?A[K?Q?\ $+P_:?L"&18LXW,;AE4'
MVR15?49J,G+?2WG=VZD?VC"4HJ.VM_*ROT/MW[&G]Y_^^J/L:?WG_P"^J^0F
M^-/Q<C^&B?$LZSIIT5KOR1H_V),[-V,[\;NH]:F\7?M)>.-5^(/@FP\+W=O8
M6GB"PMG^R7%NCJLTDLD;$L1NP"H.,]JGZC4;LFNOX%_VC22NT^G3=/KN?6_V
M-/[S_P#?5'V-/[S_ /?5?*VD_'OQUX:\;>+_  =XEU&VU&_LK266TOX+5(]C
MJ,CY0,$$'OFN"L?VC/C+J/P]O_$T&HV9T[3+E(KJZ-I#YA,A"JH79C&>_7FF
ML!5?5=/QV%+,Z,>COKTVMOU/N;[&G]Y_^^J/L:?WG_[ZKXLUC]ICXKZ1:^%/
M$UY_9]KX?U@[8K6.!&\[RRJR$DC<N2<\'O72>/OVF]?O/B6_AO3/$&G>"=-M
M4'G:C>VHN-SE0V,$'UP,8I?4*M^G7\!_VE0LWKT_'8^K_L:?WG_[ZH^QI_>?
M_OJOD+P_^U5XHU+X>>/H9;VUF\0:'&DUEJ]M NR:/[0D;'81MZ-D<=&]JYN[
M_:0^,.F^#=$\5W%[8_V-<SM;AOLL6^=E^]N&WY1],52R^JW:ZWM^%R7FE!)-
M)O2^WG;N?:]_=:=I0A-[?1V@FD6&(SS!-[L<*HR>220 .]6OL:?WG_[ZKX)^
M.^J^+_$/QL\'WRW,$5SJ,6G7>AQ\;(#(4*[QCM+N/.>,?2OMO1QK5IX M_[>
MGCDU^.P_TN:WP%,P3YF7   SZ 5C6PWLH0ES7YC>AB_;SG'ELH]3;^QI_>?_
M +ZH^QI_>?\ [ZK\[[/XH:W<^&/&%[?_ !-\1V.O65Q&NEZ='J,NRY4N1)G_
M '1CN/QKZ.T7]HW4?"W@;P38ZOHU[XA\;:Q;B06,1$+NF6"NQ(."0N<8K6K@
M:E/9W_X:YC1S*E4OS*WX];=.I] OI\4B[6+D>FZHO['MO[K?]]&O&;/]JO3+
MCP7XDU:;0KJTU?0&5;O1II@'P6"Y#XQU//%5-1_:%\1Z[\+=8\4:%X-N[*TC
MM4DM=1FN8W5F.0[!"O(1E(.>O'K6'U6K?56UMT.GZY1MH[Z7V>Q[C_8]M_=;
M_OHT?V/;?W6_[Z-?'_\ PO7Q\_[-U[J36>I"[FN3$?$8N5&U6/)0#E<?=&,8
MSQ71?#?XY7GPZ\ Z%'J]OXA\5>*_$5QNM+"_OQ*[QX4!T<CY$9B<*<G(;)K6
M6"J)-[N]C".84I-)II6O<^GO['MO[K?]]&C^Q[;^ZW_?1KP37?VA3XT^&/Q"
MMK:SOO"?BK1+-VDMVG_>Q'. RNN.?I7%1_$J^M_!/P3FU/6_$DE]JL\BRS6.
MI^4+@BY51]HW*QD&"!C(XR.]3'"5'OH[V_"Y<L=33]W56O\ C8^L/['MO[K?
M]]&C^Q[;^ZW_ 'T:\5\3_M3PZ5XAUW3=$\*7_B2WT(?\3&]@G6-(2#M/!!R,
M@\BO5O 'CK3?B/X5LM>TIF-K<K]QQAD8=5/N*PG1J4XJ4EH=,,12J2<(.[1J
M?V/;?W6_[Z-']CVW]UO^^C5ZBL#H*/\ 8]M_=;_OHT?V/;?W6_[Z-7J* */]
MCVW]UO\ OHT?V/;?W6_[Z-7J* */]CVW]UO^^C1_8]M_=;_OHU>HH H_V/;?
MW6_[Z-']CVW]UO\ OHU>HH H_P!CVW]UO^^C4D>G11+A2ZCK]ZK5% %?[&G]
MY_\ OJC[&G]Y_P#OJK%% %?[&G]Y_P#OJC[&G]Y_^^JL44 5_L:?WG_[ZH^Q
MI_>?_OJK%% %?[&G]Y_^^J/L:?WG_P"^JL44 5_L:?WG_P"^J/L:?WG_ .^J
ML44 5_L:?WG_ .^J/L:?WG_[ZJQ10!7^QI_>?_OJC[&G]Y_^^JL44 5_L:?W
MG_[ZH^QI_>?_ +ZJQ10!7^QI_>?_ +ZH^QI_>?\ [ZJQ10!4DTR"4@ON8C_:
M-,_L>V_NM_WT:O44 4?['MO[K?\ ?1H_L>V_NM_WT:O44 4?['MO[K?]]&C^
MQ[;^ZW_?1J]10!1_L>V_NM_WT:/['MO[K?\ ?1J]10!1_L>V_NM_WT:/['MO
M[K?]]&KU% %'^Q[;^ZW_ 'T:/['MO[K?]]&KU% %'^Q[;^ZW_?1H_L>V_NM_
MWT:O44 4?['MO[K?]]&C^Q[;^ZW_ 'T:O44 4?['MO[K?]]&C^Q[;^ZW_?1J
M]10!1_L>V_NM_P!]&C^Q[;^ZW_?1J]10!1_L>V_NM_WT:FMK&*T8F,$$C!R<
MU8HH **** "BBB@ HHJ FYR<"/'OF@">BJ^;KTB_6C-UZ1?K0!8HJOFZ](OU
MHS=>D7ZT 6**KYNO2+]:,W7I%^M %BBJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS
M=>D7ZT 6**KYNO2+]:,W7I%^M %BBJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS=>
MD7ZT 6**KYNO2+]:,W7I%^M %BBJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS=>D7
MZT 6**KYNO2+]:,W7I%^M %BBJ^;KTB_6C-UZ1?K0!8IC'!J+-UZ1?K6;J&I
M7%I<!#'&V5!SDT :X-.!S6"NMS_\\H_^^C4HUFX_YXQ_]]&@#:HK'_MBX_YX
MQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MB
MX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK
M'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@
M#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_
M]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_YXQ_]]&@#8HK'_MBX_YXQ_\ ?1H_MBX_
MYXQ_]]&@!/&>B2^)?!^NZ/!(D4VH6$]HDDF=JM)&R@G'8$U\HZ'^QY\2/#VF
M7NF6'C;3;+3K[ NH8#*!*/?Y*^M;6_N+J0J(XUP,]35K-UZ1?K752Q-2BG&&
MS..OA*6(DI3O=>=CP6S_ &1-(M_@_=^$'U!FU*XG6\.HA>!,H(7Y?[N"P_X$
M:SO#G[.?CNV?1K#4O$VBP:+IP$9_LZP7[1.@Z!V=,$X&,U]%YNO2+]:,W7I%
M^M5];JZW=[D?4:&EE:VFC/GWX]_LLW?Q3\3:=JVBZE:::T=N+:Z%R&!D5>%(
MVCTSUK9^+7[,UKXX\/>&;;1;R/2]0\/Q)!:R3)NC=%Q@,!GN,_B:]IS=>D7Z
MT9NO2+]:2Q55**3^'8IX*A)S;C\6YXEX)^"/B^U\51ZKXGU[29;6%?DL-(L5
MCC=@, L63(]3@UD_#O\ 99NM!N/'D.OZC:7>G>)8S&JV>_?%^\9P3N &02/R
MKZ#S=>D7ZT9NO2+]:/K576SM?]!+!T=+J]K]>Y\P?\,K^.'\*IX*?Q?I_P#P
MAJW7V@1B%_M'7..F/PS7G7QF\%GPU^T-\/\ PWH%T;&2ULK&"TNG&[9)Y\F'
M(_WCDBON3-UZ1?K61?>$-+U/5X-5O-#TF[U2#;Y5]/:H\\>TY7:Y&X8))&#Q
M6]/'3C*\]=_O?4YJN74Y1Y:>CT[[+HCPW0?V7]=E\1>)_$OB;7;'4==U.VE@
M@-M&ZQ(SC&XY&1C'09JIH7[*NOZ5\$O$W@J36-->^U6ZMYXKA?,\I!'(&(;Y
M<Y('85]*9NO2+]:,W7I%^M9?7*W?M^&QO]0H=N_7ON?-WC/]EC7O$OPU\!>&
MX-7TZ*Z\/&8SS2>9LEWE2-F%S_#WQ5OQ-^S%K,7CJ/Q7X5U72X+^2%4N;?5K
M<S0L^P*6 P>N*^ALW7I%^M&;KTB_6A8RJM+]_P =P>!H/6W;KVT1X*O[.GB*
M[^&7BC1=4\16=]KNL)''%*MN(K:W595<@;4#'.W^58NN_LJ:_JOP6T#P9'K&
MFI?:=>2W,EPWF>4P;H!\N<_A7TIFZ](OUHS=>D7ZTEBZJ=T^M]OD-X&C+1KI
M;?I>Y\^_$G]F;6_$]]X%U?1=9L;/6?#EG;6[&[1S$[P;2K# R1N!X..*]RT^
MPU)_"L5GJEQ#<:JUKY5Q/""(VD*X+ 'G&:T,W7I%^M&;KTB_6LIUIU(J,NAM
M3P].E*4H]=SQ7X"_L[/\,6\2-X@_LK6SJ4\<L!6'?Y0&_(.]>,[AT]*O?%[X
M(:IXM\9Z#XP\*ZK:Z1XATI1$@O(RT+I\W7;DY^8C%>N9NO2+]:,W7I%^M4\3
M4=3VC>I*PM)4E22T_IGSK!^ROJTG@SQBE]K=G<^*_$;+YMRJNMM&H<-@#&[G
M'IVKT;0/A-<6'P*C\!7=Y";H6+VK74()3<6+ C(!QR*] N)[FWB+E8VQVR:I
M_P!L7'_/&/\ [Z-.>)J3T;ZW%#"4J;O%=+?J>"V'[.7C-/@OJG@"[UO1I('E
M22REC20;,-N;>=O.?85>\2_LU:M>:7X#OM&UFTLO%?AB!(!-.C-;3*#GL,\$
MGMSN/3%>V?VQ<?\ /&/_ +Z-']L7'_/&/_OHU7UNK>]^M]N^A'U&C:UNEM^S
MNCP_2_V9M8?0_'EUK.M6=[XL\40/"9XD9;:'+9R.,_I5:^_9AUR[T'X6V"ZM
MIXD\)3/+=,?,Q,#.LGR?+Z+CG'->\_VQ<?\ /&/_ +Z-']L7'_/&/_OHT?6Z
MM[W_ *M;\@^HT;6M^/G?\SP;7?V:?%6G^(?%DW@_Q#IUAI'B8'[9;7T3EX\L
M6(0J#ZG!->Q?"GX=6OPL\$6/A^UF:Y$&7DF88WN>IQV%:_\ ;%Q_SQC_ .^C
M1_;%Q_SQC_[Z-9U,14J1Y9,UIX:E2ESQ6O\ 3T-BBL?^V+C_ )XQ_P#?1H_M
MBX_YXQ_]]&N<ZC8HK'_MBX_YXQ_]]&C^V+C_ )XQ_P#?1H V**Q_[8N/^>,?
M_?1H_MBX_P">,?\ WT: -BBL?^V+C_GC'_WT:/[8N/\ GC'_ -]&@#8HK'_M
MBX_YXQ_]]&C^V+C_ )XQ_P#?1H V**Q_[8N/^>,?_?1JU:W-S<QEPD:X.,9-
M %ZBJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS=>D7ZT 6**KYNO2+]:,W7I%^M %
MBBJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS=>D7ZT 6**KYNO2+]:,W7I%^M %BB
MJ^;KTB_6C-UZ1?K0!8HJOFZ](OUHS=>D7ZT 6**KYNO2+]:,W7I%^M %BBLZ
MZO[BU<*8XVR,]34']L7'_/&/_OHT ;%%8_\ ;%Q_SQC_ .^C1_;%Q_SQC_[Z
M- &Q16/_ &Q<?\\8_P#OHT?VQ<?\\8_^^C0!L45C_P!L7'_/&/\ [Z-']L7'
M_/&/_OHT ;%%8_\ ;%Q_SQC_ .^C1_;%Q_SQC_[Z- &Q16/_ &Q<?\\8_P#O
MHT?VQ<?\\8_^^C0!L45C_P!L7'_/&/\ [Z-']L7'_/&/_OHT ;%%8_\ ;%Q_
MSQC_ .^C1_;%Q_SQC_[Z- &Q16/_ &Q<?\\8_P#OHT?VQ<?\\8_^^C0!L45C
M_P!L7'_/&/\ [Z-']L7'_/&/_OHT ;%%8_\ ;%Q_SQC_ .^C5K3[V2[=PZ*H
M R-IS0!>HHHH **** "BBB@ HKXQ^,?QL\2^'_BI\3]/A^)DGAHZ&+)M%T(:
M=#<"]:2VC=TR4W\L3W_B]J;>_&WQ1J7Q!-AXD^(6I?#J'^P[&\%E8:&+W]_(
MN7!'E.R^O)KJ6'DTG?\ /_(XWBH)M6\NG^9]H45\Y>*/'OBKQ;\1](\ >%_&
M,>@6=AX<37-7\43V2--*I*JN(Y $0G[[9& #VQBK/@OXYW/@;P[=GQKXAT[Q
MG;Q:JMA;:UX=E@F<QN<1R7,:.!%SQQGZ5'L96N:>WC>SV[GT)17S5\<_VB+F
MVFM=-\'7=Y8W6G>*=.TK4KTPQ/!.DP9FCC8EL\ 9.!CL:[27]I[PU;^)TT63
M2/$&)+J2Q@U,V*BTN)T!+)&Q<,2<8!VX/K2]E.R=A^WA=JY[#17S=\-_VL4O
M/"VMZKXIT?5HKA=<DT[3K6TLE+W1) CMXAO^:4<ELD#GJ:[*3]J'PC!X7NM6
MN+36+:\MM072I-"DM5_M 7+#*QB,.5.1SD-CWH=&:=K J]-J]SU^BO"_@/\
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MIW0?VE2[/\/\S]4J*_*W_AL7XP_]#I-_X!6W_P :H_X;%^,/_0Z3?^ 5M_\
M&J/J%3N@_M*EV?X?YGZI45^5O_#8OQA_Z'2;_P  K;_XU1_PV+\8?^ATF_\
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MM'D1_P!VCE8<Q3HJYY$?]VCR(_[M'*PYBG15SR(_[M'D1_W:.5AS%.M;2O\
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MTT:[%C?"2UF66*<G 3RBF]B3TP#FK4JL;)K\#-PHRNTU]_D>.>#OV:M6\0?
MKP787=\FGZZNN0>)=1DNHRS2,#]SCD';MZ]*F'[)?B-_B#8>(KKQ5:7XLM7;
M48VN89&G:,D_NR<X& <#%?35E>1:A96]U"6,,\:RH70HVUAD94@$'!Z$9%87
MAOXB^'?%VN:UI&CZG'?W^C2"*^CB5ML3D9V[L;6/K@G'>I]M4U:*]A25D_ZL
M>!ZU^R+K.M:%?Z/-XBL)+!->?7]-CDM6.R9^'27GYE()'%3Z?^R+=Z?X0,-O
MK.G67B:+5X]6MKNULMMO&R @(R_><8/4G->XZ-\3/#/B'7=<T?3M5BNK_1 #
M?HBMM@R,\OC:3QT!.*X_PK^U+\-O&SWJ:+K=S>FSM)+Z8KI=VH$*8WL"T0W8
MR.!D_E5*I6>WY$^RH)ZO?S$^#WPDU_P-XM\5>(?$6N6FL7^O-&[_ &2W,*QE
M1@X'I7)>*?V=/%QUKQM_PB7C&UT?0?&#;]2L[JT\V1&*;)#&W;<N<_6O>M(U
M:TUW3+74;"=;FRN8Q+#,G1U(R#5RLO:R4KFWL8.*B>,^%/V?F\(_$SPUXAM-
M3C?3=%T/^QUM70^:YQC?NZ?A7'C]E#6+&]NM8TWQ+:VNOQ>)9=?T^9[<O$BR
M*5:*13UX/45]+44>VGW!T*;Z'@'BOX ^-?%OA/2K._\ '"7>J0ZA+>WGFPLM
MK.K](@JD$*O85R:_L=ZQ'X%T_0&UC0[W[+?75UMN[!FC*S!<;3G<C*5['!!K
MZKHIJO-:(EX>FW=GREK'[$]S-9>'39^(+:]U'3],_LVYEU>!IDE&]F#H <@C
M=@ \8 KZ$^&7@B/X=>"-+\/QR1R_8X]K20Q")6;N0HX%=314SJSFK29<*,*;
MO%!11161L%%%% !1110 4444 %%%% !7Y??\%*&Q^T)8_P#8!MO_ $=/7Z@U
M^77_  4L;'[0UA_V +;_ -'3UW8/^*>?COX/S/G[1/#<.I>#/$6M/,Z3:9+:
MI'&H&U_-9P<_38/SK;L/AG?:[X;\,W6B07.IZKJTU^ALXE!VI;+&Q8?\!=B?
M]VJGP^U729/#GB7P_JVI#1UU,6\L%[+"\L2/"S$*XC#, =_4*>E=[HOCKP[X
M/M=(TFRUTWO]GZ/KJMJ=M!-'&;J\M&CBCCW*K\,J#<5 &[T&:]ARDMOZT_S/
M!48M:_UK_D<'-\,O%-KJ]KI<NBW*WUS&9H8@ =Z D%@0<8!!'6GK\+O%;:PV
MEC0[K[>L(N#%@<1_WLYQCWS7IOA;XD^%U^$.E^$[O5!IVHS6E]:SWIMY6%IO
MN%DCW%5)96 .=F2.,BLZQUKPM:^&M8\)?\)@SF]L8476I;>X-JCI*',*KY?F
MB,@'G8.<<52G/L+DAW_%?<<3:_"+QC>WFH6L/A^[>:P\K[4N !$)03&22<88
M*V#[5HVWP.\5W'A[4-3_ +.E22RO%LGLV \TN?09KJ_'?Q'T.Y^&EUX8TS69
MM1N;>'2+071BDC6]6'[>\I&Y00B&YB10X!(0''''7ZC\5O!>J:G),FO):I%=
MZ=>*TEI/^^\J,+(HVQG#9'\6 ?6I<ZG8I4Z??\?4\7D^#OC.'5)M.?P]=I>P
MQ^;+$VT&-=VW+'.!SQS7<?#S]GU?$FE7\FN37ND:C:7LEH]J$7@+") 3GW./
MI5.?Q7H7BL?$C3+KQ%_8Z:UKD6JV>H7,$[PSQQO<CRY!&C2+D3JXRI&8\'!Q
M7IF@?&WP7I5K)9RZ[-<?9S%;I=2VLV;D1V2P^;C:2 SJ>&Y]12G*I;1#A"G>
M[>GJ?.__  KSQ)_8!UO^Q[G^RQ'YIN,#&S.-V,YQGOBMS2/@]KDWA_6-9U/3
M[JPT^TTLW\,Q"XD.Y @(Z@$.3T[5Z5JWQ7\,7^DC5+6YT6TOQX=;2C9S:?>2
M7S.86B:/<&6 1L&SNSD;B=I(&<SQ%XR\,:O>^.?$L?BO$^OZ1]G@T-K:X\Z.
M5FB/E,PC\K8FQ@I#'@#I5<\WT)]G!=;_ #_K[CSOP3X,L=6T;5_$&MW,]MH6
MEA$D%H 9IYG.$C3=P.Y)/0 TNJ^%M&U>/2&\'W-Y?7=[)) ^DW84W43K@A@5
M 4HRG@]BK9Z5=\">(=%F\'Z]X3UNZ_LI+^6*\M-4:)Y8X9XL@+(J MM96894
M,02.*]0T'XM>&?#FB6.E:GK5AKNHS3SAM:TO23;BP@>W,2C)ACD<[CDX4\$\
MDTY2DF[(48P:5V>,W?PM\5V-Y%:SZ%=)/+%),BA0=R(,N00<<#K5[P/\(/$7
MCQ6ELK1H[4VMQ=1SR8"RB$#<J\]<LH_&O2/!/C[PKX"L--T*3Q,-9BEEO&GU
M""UG%O9K+"T2X5XUD.2VYMJGIQFET;QAX.\/Z+X;T$>*K>\\K3M7M;K4(K.Y
M$$$EPJ>5PT0=E^3!(0D'MCFDYSV2_ :IPW;_ !7D> .C1NR,,,IP1Z&DITBA
M'90P< D!AG!]^:;72<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >E_LZ^.S\/?BUH>HM(4M9)A;W'/'EO\
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MB2&,DDA6&58X' ([UY G@#QMI_A>STJ+2+E2='FM&ETZXM%D69YICLE>5_\
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MTZUM;B>XAMH8IYR#+*D85I".FXCD_C6"J63BEN=#I7DI-ZK^K'RG\,O!FC>
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M/4_SC_\ BJ_7VBCZ_4[(/[-I_P S/R"_X9'^,'_0AZG^<?\ \51_PR/\8/\
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M2_\ ?-6** *_VL?\\I?^^:/M8_YY2_\ ?-6** *_VL?\\I?^^:/M8_YY2_\
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M?:Q_SRE_[YJCI/\ Q\M_N'^8K6H K_:Q_P \I?\ OFC[6/\ GE+_ -\U8HH
MK_:Q_P \I?\ OFC[6/\ GE+_ -\U8HH K_:Q_P \I?\ OFC[6/\ GE+_ -\U
M8HH K_:Q_P \I?\ OFC[6/\ GE+_ -\U8HH K_:Q_P \I?\ OFC[6/\ GE+_
M -\U8HH K_:Q_P \I?\ OFC[6/\ GE+_ -\U8HH K_:Q_P \I?\ OFC[6/\
MGE+_ -\U8HH K_:Q_P \I?\ OFC[6/\ GE+_ -\U8HH K_:Q_P \I?\ OFC[
M6/\ GE+_ -\U8HH SM1N@;1OW4@Y'4>]9'V@?W'_ "K>U+_CT?ZC^=8U $7V
M@?W'_*C[0/[C_E4M% $7V@?W'_*C[0/[C_E4M% $7V@?W'_*C[0/[C_E4M%
M$7V@?W'_ "H^T#^X_P"52T4 1?:!_<?\J/M _N/^52T4 1?:!_<?\J/M _N/
M^52T4 1?:!_<?\J/M _N/^52T4 1?:!_<?\ *C[0/[C_ )5+10!%]H']Q_RK
M5TNZ MS^[D/S'H/85GUK:5_Q[-_O'^0H E^UC_GE+_WS1]K'_/*7_OFK%% %
M?[6/^>4O_?-'VL?\\I?^^:L44 5_M8_YY2_]\T?:Q_SRE_[YJQ10!7^UC_GE
M+_WS1]K'_/*7_OFK%% %?[6/^>4O_?-'VL?\\I?^^:L44 5_M8_YY2_]\T?:
MQ_SRE_[YJQ10!7^UC_GE+_WS1]K'_/*7_OFK%% %?[6/^>4O_?-'VL?\\I?^
M^:L44 5_M8_YY2_]\T?:Q_SRE_[YJQ10!B:K<@S)^[<?+W'O5+[0/[C_ )5I
MZM_KT_W?ZU1H B^T#^X_Y4?:!_<?\JEHH B^T#^X_P"5'V@?W'_*I:* (OM
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MT^87,BEU3'51U.>E->S?83]JNX[_ (3/Q!_T'=2_\"Y/\:/^$S\0?]!W4O\
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M.*[%<S[EP:M?8_X_+C_OZW^-/&JWN/\ C\N/^_K?XU2'2GCI4\J[#4GW+O\
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MU""/6X86CAMF!.Q@F5SQC &#7#_"RTU.S\5^.+:ZU WVI*R#[2ZX4N5X.WL
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M<Y_"LKQ'K.E7V@W(-];7E^Z0K"]M#-#*VW&?.!^0X (&TGD"J/\ PJ;Q?_T
M;K\E_P :/^%3>+_^@#=?DO\ C5+V*=U/\42_;R33I_@SD:]:\#:=_9^A1%AA
MYOG/]*YFQ^$?BN2\A671+F.(L-S$# 'YUZS!X/U6&)46PD"J !TJIUJ=K*2^
M\*&'J)MN+^XSQTIXZ5I#PKJV/^/&7]*>/"VJ_P#/C+^E<[J0_F7WG;[*I_*_
MN,U>U2CI6E#X2U>5L)82L<9P,?XU8'@S6\?\@Z;]/\:7M(?S(I4I_P K^XQU
MJ0=:U1X,UL?\PZ;]/\:D'@_6L_\ (/F_3_&I=2'\R*5.?\K,D=:<.M:P\(:S
MG_D'R_I3AX1UC/\ R#Y?TI>TA_,BE3G_ "LRAUIZ]:U!X2UC/_'A+^E/'A/5
MP?\ CPE_2I]I#NA^SG_*S,'2GCI6F/"FKX_X\9?TIP\*ZM_SXR_I4<\.Z+5.
M?9F:.E/K1'A;5?\ GQE_2G_\(OJO_/E)^E)SAW'[.?9F:.E/'2M$>&-4_P"?
M*3]*</#.J8_X\I/TI<\>Y2A+L9].'2M#_A&M3_Y\Y/TIP\-ZGC_CSD_2IYX]
MQ\DNQ17K3UJ\/#NI9_X\Y/TIX\/:B/\ ETD_2I<X]RN278H#K3AUJ\/#^HY_
MX])/TIPT#4<_\>DGZ4N>/<I0EV*5.'2K;Z)?1*6:V=5'<TP:=<X_U+4G./<:
MA+L0CI3QTJ46%QC_ %34X6,__/)JGFCW*Y9=B):>.E2+93_\\FIXLYL?ZMJG
MFCW*49=B,=*<O6I!:38_U9I1:3 _ZLTG)=Q\LNPP=:=3Q:RY^X:=]FE_N&ES
M+N-1EV&#I2CK4@MY,?<- MY,_<-',NX^5]A!UIZTH@DS]TTX0O\ W34<R[C4
M7V$'6G4HB?/W32^6WH:3DNY7*^P+2CK2K&WI2A&STH;7<=GV%H'6EVGTJ6*U
MEE&Y$+#ID4KKN.S[$=.'2IOL-Q_SR:E%E/C_ %35-T59D2TZI193C_EFU+]C
MF_YYM1=!9D2TX=:D6SF_YYFG"TFS_JS2;0[,CI].^RR_W#3OLTO]PTFT59D=
M.'2G?9I?[AIPMY/[AI-H+,CIR]*?]FD_N&E%O(/X#2NK#L[#*4=:?Y$G]TT"
M"3/W32N.PE%/\A_[IH\A_P"Z:+A8:O2EIPA<?PFE\I_[IHN%A!TI::\BPD!S
MM/7FF?:8O[XJ2NA..E+4(NHL??%+]JB_OBD!,O6EJ 74(/\ K!3OM</_ #T%
M $M%1?:X?^>@H^UP_P#/04#)AUIU5Q>0Y_U@IWVR#_GH*3 FHJ'[9!_ST%'V
MR#_GH*0$U%0_;(/^>@H^V0?\]!043K3JKK>P?\]!2_;8/^>BT$LGHJ#[;!_S
MT6C[;!_ST6@HGHJ#[;!_ST6C[;!_ST6@">BH/ML'_/1:?'/',2$<,1Z4 244
M44 %%%% !114?GQ#_EHG_?0H X2X^'IO?$OBB&YB)T+7H(7EDBD"O'*G!4#K
MR ISCUKL+[1K?4-%ETN7?]EDA\AMIPVW&.OK5O[1%_ST3_OH4?:(O^>B?]]"
MM)5)2M?H91I1C>RW_K]3FIOAQI$UIH,&;A/[$</:2))AQZACCD'O5,_"/0)-
M,U"SE6XF-[/]IEN9) 9M_8AL<8KL?M$7_/1/^^A1]HB_YZ)_WT*:JS6S$Z--
M[Q_K8JV.C6E@(F2%'GC4)]ID4&5L#&2V,DXJII7A6RT;6=4U.W\W[3J+*T^]
MLKD# P,<5J_:(O\ GHG_ 'T*/M$7_/1/^^A4<SUUW+Y(Z:;&+!X+TV#4]7OP
M)6FU1!'< O\ *0!CC'2L>Q^'-EX3M=0N])6[OM4>U:W@-U<;F0<X12< #//X
M5V7VB+_GHG_?0H^T1?\ /1/^^A5JI-=2'2@];&%X!\-MX4\*V6GRD&X52\Q!
MR"['+5T-1_:(O^>B?]]"C[1%_P ]$_[Z%1*3DW)]32,5"*BMD245']HB_P">
MB?\ ?0H^T1?\]$_[Z%24245']HB_YZ)_WT*/M$7_ #T3_OH4 245']HB_P">
MB?\ ?0H^T1?\]$_[Z% $E%1_:(O^>B?]]"C[1%_ST3_OH4 245']HB_YZ)_W
MT*/M$7_/1/\ OH4 245']HB_YZ)_WT*/M$7_ #T3_OH4 245']HB_P">B?\
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M_P!P_P Q6M0!'Y$?]Q?RH\B/^XOY5)10!'Y$?]Q?RH\B/^XOY5)10!'Y$?\
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M)+AO,VYRR_+&1NZ-R:OQ?$#Q'<>(_$B(FGKI&B.3(&1_.D7:2 O.,Y[FMO\
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M* "BBB@ HHHH JZE_P >C_4?SK&K9U+_ (]'^H_G6-0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !6MI7_ ![-_O'^0K)K6TK_ (]F_P!X_P A
M0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#*U;_7I_N_
MUJC5[5O]>G^[_6J- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB6,Q,X\DJC:[7?E_DON1Q]A\)_#6FM<F"R<>?"\!#3,P1&&&"9/RYSVJ[8^
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M7_@.G^%+_P (WI'_ $"[+_P'3_"I_P"(9XC_ *"E_P" O_,K_7BC_P! [_\
M E_D?%J2O'G8[+GK@XH,CEBQ9BQXSGFOM+_A&](_Z!=E_P" Z?X4?\(WI'_0
M+LO_  '3_"C_ (AGB/\ H*7_ ("_\P_UXH_] [_\"7^1\6F5V4*78J.Q/%*9
MI&()=B1TR>E?:/\ PC>D?] NR_\  =/\*/\ A&](_P"@79?^ Z?X4_\ B&>(
M_P"@M?\ @+_S#_7BC_T#O_P)?Y'Q<9Y"03(Q(Z'<>*3SI-V[>V[USS7VE_PC
M>D?] NR_\!T_PH_X1O2/^@79?^ Z?X4?\0SQ'_06O_ 7_F'^O%'_ *!W]Z_R
M/BT32*20[ GJ0>M-)R<GK7VI_P (WI'_ $"[+_P'3_"C_A&](_Z!=E_X#I_A
M2_XAG7?_ #%+_P !?^8?Z\4O^@=_^!+_ "/BNBOM3_A&](_Z!=E_X#I_A1_P
MC>D?] NR_P# =/\ "E_Q#*O_ -!2_P# 7_F/_7FE_P ^'_X$O\CXKKZ>^!'A
MW^Q?!:7+KMFOG,IS_='"_P!?SKMO^$;TC_H%V7_@.G^%7XHD@C6.-%C11@*H
MP /85]9PUP6\BQCQE6JINS2LK6OUW?33YGSV=\3_ -JX98:G3<5>[UO>W3;N
M.HHHK]1/A HHHH **** +ND_\?+?[A_F*UJR=)_X^6_W#_,5K4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 5=2_X]'^H_G6-6SJ7_'H_
MU'\ZQJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *UM*_X]F_W
MC_(5DUK:5_Q[-_O'^0H NT444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!E:M_KT_W?ZU1J]JW^O3_=_K5&@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ J_I'^LD^@JA5_2/]9)]!0!J4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %8FLKF['^Z/ZUMU#+;1S-N= QQC)H YX+BG**W180?\ /-:7
M[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-:/L4'_/-: ,.BMS[%!_
MSS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-:/L4'_/-: ,.BMS
M[%!_SS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-:/L4'_/-: ,
M.BMS[%!_SS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH H:3_Q\M_N'^8K6J..W
MCA;*(%/3(J2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M"KJ7_'H_U'\ZQJZ%XUE7:PW+Z&HOL4'_ #S6@##HK<^Q0?\ /-:/L4'_ #S6
M@##HK<^Q0?\ /-:/L4'_ #S6@##HK<^Q0?\ /-:/L4'_ #S6@##HK<^Q0?\
M/-:/L4'_ #S6@##HK<^Q0?\ /-:/L4'_ #S6@##HK<^Q0?\ /-:/L4'_ #S6
M@##HK<^Q0?\ /-:/L4'_ #S6@##HK<^Q0?\ /-:/L4'_ #S6@##K6TK_ (]F
M_P!X_P A4WV*#_GFM21Q)$NU%"CK@4 /HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#*U;_ %Z?[O\ 6J-;\EO',070,1QS3/L4'_/-: ,.
MBMS[%!_SS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-:/L4'_/-
M: ,.BMS[%!_SS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-:/L4
M'_/-: ,.BMS[%!_SS6C[%!_SS6@##HK<^Q0?\\UH^Q0?\\UH PZ*W/L4'_/-
M:/L4'_/-: ,.K^D?ZR3Z"KOV*#_GFM/C@CA)*(%)]* )**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20250331x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $J M4# 2(  A$! Q$!_\0
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MA&D\#5<VU[U^CT\D+NHW4E%;'SXNZC=244 +NHW4E% "[J-U)10 NZC=244
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M[7';$R'9\O,JL,9XR.#1[6H_M!_8N6_] \/_  %?Y#?^&7_AK_T+W_DU-_\
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M4W_Q=>K8HQ1[6I_,P_L7+?\ H'A_X"O\CRG_ (9?^&O_ $+W_DU-_P#%T?\
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MX9?^&O\ T+W_ )-3?_%UZMBC%'M:G\S#^Q<M_P"@>'_@*_R/*?\ AE_X:_\
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M#&(XY(XP-S'A4FD '^UZ@5?U+P'H^JWEY<7$,K&\7;<Q).Z13'9L#,@(!.W
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MMTQG(:1L%S;FW)Z_\\F*_KUJ&U^%OAZUN9+G[//-<2 AY9[F21FS$8>K,?\
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M'X&QW!N=0OE++ P>(QA6/)V%<#IV;/U%>%_$I[RWU'6%><F7.W"-T/F)@GZ
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MC>C#*G!YZ5Q.N?&&WT.[\36DMI*UUI4T44*I#*Z3!XT;+.J%4^^1R>WO2VU
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M--E\^UNI)(H&68*/*FD4/'$V&)W%2#QD?,,GFBS0'9T4@Z4M !1110 4444
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MU]J^BLE12?;]#PE=U';^M3],?^"7#(WP$UO9G UZ8$GN?*BKZZO?]6:^1?\
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M2!O7(8;AP<4O,;W')\,](3P['HV;AK5;U;\ON57:82B3)VJ% +#D  5/X<\
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M1)#( N4VM(@YQ]X4#ZB6WPCT6UCBACFO!:J\<DMMYH\NX:.0R1L_RYRK'/!
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M=%E>2%K.7S(EC56=G7;E0%=3DCH:$,2P^$^AZ5#!'8FYLTM[J2\A\J0?NW>
MPG&0> AX![^M7?#?@J/PI=.;&[D:WN))+B[25$!GF8(H?Y555PJ8PH&<Y.3S
M523XK^'$0'[5<,QD>/REM)3("D:R,2NW(&QU;)XP:H6'QCT>ZU75+:9XX(+*
M5HTE#L[7"A+=E9%"\Y-RB@9SG& <\ %NW^$>AVRZB%:Z_P!/:,S;I1_!<R7
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M%% !1110 4444 %%%% !1110 4444 %4-9_X]%_WQ5^J&L_\>B_[XH L6/\
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M<YJO\1D6A?ZF;_KH?Y5=O+.#4+66VN88[BWE4I)#*H9'4C!4@\$$=C5+0O\
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ML2#B/ D+ CY=NY<[L8W#U% &!IGP@C\-V:/IFH2O>VUW+?VQN$!3S6M1;A6
M_A  /'-;'B[X?6OCF/2EU.=U-HQ:580 MP"O*-GG;O$;X]8USQFII?B?X5@L
M?M<FMVT<'F-$2V00ZKO(*XSPI#=.G/2I5^(OAI[![Q-9MGMDD$.]&+98KN&
M!E@5^;(R, GH,T=D(Y6P^!ECIOV1X=6NC-;QVD?F2(C&0PF<EF&.K_:9,^A
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MI+" D2#.&0<'GOS73AL/'#0<5U.:O6==IL/AC\*U\*?:+B34;[4);DEF^TL
MH8L22% ')S7K6DZ:$(PH%/T[3-L:+CH.:Z'3[#!QBNI(P+%K!B+ 'Y4R2#<>
M?RK72TV1@=.*;]E!IV)1CBTXZ<4HL@16RMD1QCBI5M..>#2&<W/8 ]JH7>F
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M&R.-LR6Z,4^?Y2/L^1G(^?G.*K67P!2RU>TO8]8)2WNS<K&8,D@W33[<[O\
M:VY]L^U>JZ?JUCJOFFRO+>\$3[)#!*K[&]#@\'VIVH:I8Z3;B>^NX+.$G;YM
MQ(L:Y^I..U CS?P7\,;OPUXFT8R2F;3M'TF.T$A4*MS.H,:2JNXE2L3,ISC.
M[C@<>I"LXZ_I1DM$_M&T+W@W6R^>N9QZIS\P^E5YO$]I::M+83F2'RH?/>YD
M7;"J^[G@47"W4VJ*R$\6:+)Y>-8L"9(C,F+E/FC&<N.>5&#STX-2#Q+I#"T(
MU6R(NSBW(N$_?'T3GYOPH&:=%4+76]/O_M'V6_MKDVY*S>3,K>41U#8/'0]:
MSM*\<Z#KEK8W%GK%G*E\";9?/4--@D':I.3T/2A@=!17(Z3\3-!UFSN+J"\V
M1PQI*?M&(MP9"ZA=Q )VJ3CMBMJ#Q+I5Q/)!'J=H]Q$ADDA$Z%T4=2RYR .Y
MH%<U**YX^-])DN[*"UNEU#[7(8TDLF$R*PVY#%2<<.I^G-= .M Q:*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:S_P >B_[XJ_5#6?\
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M/.;C3I-#9&U)1;0@Y6*21?.G_P!S!PO..3QQ5QKZ'QBL^EW4;RW$*;V1H]A
M[8[9 QR.O%7IM(TN&Y2UUOP_/87**Q\R-L\8R3]!BNDT?P=/H4*WFCQSWRW"
MJ8H+A>$3.2=V.,]!2A14(W2W)E.4GJS+UO1$TOP7\.K=&W"#4IGR_P![OC\>
M35@Z5K7B9;-6TJS6*V0QJ]R3(S?,2&Q]"*W/B-+HXT'PE;:W83B:6[E,,EC+
MEK5\ $YQSUQ7HWPI\-:/<>&(GTJ]NK^U$C*6O"3*C#[R'(&,>E2P/K__ ()Y
M:-<Z+\'-6AN71G;6)& CC" #RHN./I7TQ>_ZLUX[^R58)IWP[OXT& =0<_\
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M8]J[O_A&]/\ ^??_ ,>/^-'_  C>G_\ /#_QX_XT<Z#E9PP7!Z\4[;R*[?\
MX1S3_P#G@?\ OH_XT?\ ".6'_/#_ ,>-3S)BY&</M'&*".*[C_A'-/\ ^>'_
M (\:/^$<T_\ YX'_ +Z/^-',@Y&<$XSGCM526/@\\5Z.?#6G'_EW_P#'C_C3
M6\+::W6W/_?9_P :7,A\C/(KV+(.![UR_B'0AJ%LPQ\W8U[^_@O2)/O6I/\
MP-O\:C?P)HL@PUGD?]=&_P :+@HL_/\ \9>#UTG7["Z^Q^9"MP&RO6"3/WA[
M&O&_%_AO2-;UB>2[N[B>]%Z\T<%M$'DC;) PQ!V\=AZFOU/U/X-^$M81ENM+
M$@;KB5Q_(UB6?[-/PZL)FE@\.HDK$L7\Z0DDG)R=U)2:V'RW/S?N?!VI>)K2
M.)-!MHTCP%N-3C5G.!CG YXJ2?X5:U<V,PGU;[1.L96"VC!B@#8X!"\XK]*3
M\ _ [-DZ-D^]Q)_\54L7P(\$P'*:, ?^NTG^-/F74.5GYE^#/"EYK<>F:)XG
M\.7,UQ!DR7$2';;29X96[ ^H/:O;]$\+6GA^PCL[5&V*2Q>1MS,3U))ZFOLS
M_A3'A'&/[*Z?]-G_ ,::?@GX.;KI/_D>3_XJDVF)19SG[-47D^"+U<?\OS?^
M@+7J-XFY#]*J>&_"NF^$K)[32[?[-;N_F%-Y;YL 9Y)]*TI4W U)HBGHR%(9
M0?\ GH:?KFC6OB+1[W3+Y&DL[R%X)D5RA9&!# $$$<'J*C!DM'8H P/4&F/J
MDZGB '\:!C_#GAZR\*:!8:-IL;16%C EO CN79448 +,23QW-<%KOPBEU76-
M:U:/49DNKF_M[V"W-U-]DD6*-%,<\(.QPVTG.TD':>V*[C^UKC_G@/S-)_:L
M_P#S[K^9I >/^*?A%X@:5]1A^QW\R2.!;"1]LPDO8)LF/ 1 HC;.,D]<D\5I
MWWP7U2^UC^UOM]K!.TQNS9Q[O(#_ &FVF$6<9,9%N0QP#ER<=J]-_M2?_GW7
M\S1_:LX_Y=U_,U0'$VWPXU:#P/-I7G6"7LNKR:DR0[A%L:X,WEABI96P<;PN
M<C(Q6!I/P,U*STR\MY[^TDGE@DAC?,CF,MJ$ET#N;YN%<+G.<KFO5?[5G_Y]
MU_,T?VK/_P ^Z_F:0>9QWA;X<ZCHGC6RU2XEL7L[*PN[*-X]QN)S-<1RAI,@
M#@(1U/)SWKG+KX&:B]Y:746I01O:M)(L<;-&)6-Y+< ,P!P-L@&<'!7."*]4
M_M6?_GW7\S1_:L__ #[K^9H!:'F3?!;4#J&CWJWEDLFG1SH+=A(Z2F=I#(69
MLG*>9F,@  E^%#X&9'\!-8'AJ_T5[W3D2<"5;V,/YN\6"6NPC;]PE2V<YQQB
MO8/[5G_Y]U_,T?VK/_S[K^9H X?PA\*[WPUXFCOI;Y+FVBN)KI&,LF_=(@4I
MLX7:O8DG@+\H(S534O@S<7\-XJWMO ]QJ&H7;2*AR4N(RJJ?7!VY&>@X[5Z'
M_:L__/NOYFC^U9_^?=?S- ' 7/PHU#5-8NM4N9-/MIKBWN8/LUNK-'&SVZ1*
MP)49/RY/ XP!G&:JV?PIUY[)K6_?2YGALK>QM+I)9,Q1Q"-BOEE,?O'C^<[N
M5P.<8KTG^U9_^?=?S-']JS_\^Z_F:+L#S#5/@EJ6KW'B&\DN[&"YU>ROH%AC
M#-':R3I;HI0D X'V?<QP"2W2F^*/@QK.LR:]'!>V*6^I&[V$O)%)&9XXEW%D
M7+8,9^3(!R">F*]1_M6?_GW7\S1_:L__ #[K^9H X_3/AI<6GA+6M*N6M[Z:
M]U WT?[Z2(*<H5^=1N5@4SD ]NO-0^'_ (?:]H]Z;FYO-/U*6X@2"22Y3YK8
M))*Z>6 @#G;* 2=N2NX]<5VW]JS_ //NOYFC^U9_^?=?S- 'CG_#/VLWCXN=
M5MK96BM8F:WDD8@Q0W<;.JD!4S]I4A5  VD>]=OX.^'FHZ$)7FU62RF?R$86
M+B42I$I #^;&0 <]$ 8 ??/;K/[5G_Y]U_,T?VK/_P ^Z_F: /%]0^$GB72K
MCP_-!%IVJ+ITFG6<<6Y@#'!-*[3297Y?E<<+NP1WKM=;^%]YJ?@K3-&2\@2X
MM[Y[R1R&\L;C(Q1.,X!DP/9:[/\ M6?_ )]U_,T?VK/_ ,^Z_F:%I]]Q-'+^
M"/AY=>$[>6,W-OE]&LM.'E1Y420QNK/M/4'</RKDM&^"^N:9JJ:D]Y9336XL
M=EH9I&AF:!;E&W97" B=6"JN%*#KUKU7^U9_^?=?S-']JS_\^Z_F:.MQG%:E
M\-]2U"/Q!;;M.2'68D+2%6+6KK L7EQKCF,[<_>'#,,<U WPHOM0\1SZO>3V
MEF;B"[B:"R#$0&6&&)70D#D>423@=0.V:[S^U9_^?=?S-']JS_\ /NOYFC;8
M-SS-/A+KK:F+UWTJ/;%9P>3;O)&9%ACG0N9 FY2?.4X7L"-V.:K:9\!K^S\/
M65A)J=L+F"YT^4W408/M@A\MPI/.3R1D]\$UZK_:L_\ S[K^9H_M6?\ Y]U_
M,T <!)\,M7DT30K7?81SZ0HB7R97072>28M\AV<-SG&#W&><BYK_ ,)Y-7\+
M>&]$CNXHXK"%;&\9@[">U**)(UR2?F*)]XGC/)-=G_:L_P#S[K^9H_M6?_GW
M7\S0(\GTWX$:M8ZEI6H2ZI:7E[;QVS7+NK#SY4N7E=LX) *N%'TKJ_A]\-;C
MP9=:=))<6[I;Z'!I<BP*5WR([,7^AW?6NM_M6?\ Y]U_,T?VK/\ \^Z_F:86
M.%L?A??H?#-O='3I+;0[_P"T^?M+37:>5.@+Y4 -F8'J>C'/-8R_!;6530H?
MM]F4T]K!RZR2(?\ 1W+,NT##[@3@L>.@'>O4_P"U9_\ GW7\S1_:D_\ S[K^
M9I#/)8OA%J7A/3O#T\3IJ$NDV>G6QM;9#Y<\EOYH9G&,[#YN00"0R@X.*/!'
MP;U6'6-*UO4A96RQE9)-/"D[,&^X QC_ )>T^FUJ]:_M6?\ Y]U_,T?VK/\
M\^Z_F: /'(/AIKNC2>%]%BM8]0CM+K2Y[G49 <1"V4!O*)[';T.#ECP0<CH=
M3^'^K^(?%?B3=%;6.G3:C;7<5\V?M$GEVJ+M7 ^Z6RI).<;A@YS7H7]JS_\
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MC<* (/LB^E'V1?2I]PHW"@"#[(OI1]D7TJ?<*-PH A%N!VJ18]M.W"EW T
MXHI:* *ES<B)B"0*IOJB+_$/SKS#X^>+]1\/+:6NGSM:M<,2\L9PV !P#VZU
MXG_PF^OGKK5\?K.U 'UO_:J?WA^?_P!>C^U4_O#\_P#Z]?)'_";:_P#]!B]_
M[_-1_P )MKW_ $&+W_O\U 'UO_:J?WA^?_UZ/[53^\/S_P#KU\D?\)MKW_08
MO?\ O\:/^$VU[_H,7O\ W^- 'UO_ &JG]X?G_P#7H_M5/[P_/_Z]?)'_  FV
MO?\ 08O?^_QH_P"$VU[_ *#%[_W^- 'UO_:J?WA^?_UZ/[53^\/S_P#KU\D?
M\)MKW_08O?\ O\:0^-=?/_,8O?\ O\: /KC^U4_O#\__ *]']JI_>'Y__7KY
M(_X3;7A_S&+W_O\ &C_A-M>_Z#%[_P!_C0!];_VJG]X?G_\ 7H_M5/[P_/\
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M[53^\/S_ /KT?VJG]X?G_P#7KY(_X3;7O^@Q>_\ ?XT?\)MKW_08O?\ O\:
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MDC_A-M>_Z#%[_P!_C2?\)MKW_08O?^_QH ^N/[53^\/S_P#KT?VJG]X?G_\
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M +53^\/S_P#KT?VJG]X?G_\ 7KY(_P"$VU[_ *#%[_W^-'_";:]_T&+W_O\
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MJ-Z-0CC>W%HX+2#/EDE5#_AG/X5K2^$8[/PY#IUS;^7JSW\8EE1-TB(WF*%
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** />_V?S_ ,4Y>?\
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MM;'2=USI;:J[RRNL=OB-F^SR,2 K@@ L>!G.!BG8#H_^&=O"G]Z__P"_X_\
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M!YG_ ,,[>%/[U_\ ]_Q_\31_PSMX4_O7_P#W_'_Q->CMJ%NDBQM/&)&^ZA<
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M$G^Z?Y4 0Z7S80_0_P S11I7_(/A^A_F:* &6W_(3O?^ ?R%7JHVW_(3O?\
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MQZ ?[*_ACI706\<R#$KK(WJJ[?ZFIL =J"..*S;-4K!4-Q9PW0 GBCF Z"1
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M>_\  /Y"HM=\06OAZ&W>YWL]S,(((84+R2R$%MJ@>RL?8*3VJ6V_Y"=[_P
M_D*Q_'PTQ=*M9M22Y=XKN,VGV)BL_P!H;*((SD8)#,#DXP3GC-("C#\7O"LD
MUS#-JD5G/;2>7/!> PO&=@<DJ^#@*PR:G?XG^#U3>WB#3 /+,O,ZC"[MN3_P
M+C'7-<'<Z=\-;^RDNM2DN4E@N)EGCN9IGN%F*K%(&"EBQ_=*.,C(XZT^PT?X
M7>)[^[-C>"XGU";YS#+*!/)([290XP_.[.,J!G/%4M1>IWH^(7AF2TU*X@U6
MSNDTZ'[1="W<.T<>,[B!VXJNWQ4\'Q/.LFNZ=$(I#&7>90C$1K(=K=#A7'\J
MXK3+'P/X9L-:M--T?5)[!K9TOV@W2)'$'D4GELG<R2'(R<#)P,5FZS:?#+XC
M7\SV\%UXANIU6>6/1[H,,>6F2<2!0554! (.2.#FIZE6T/2E^*'@]X?-77].
M:,NL8(F4Y8[L#ZG8W_?)]*;I_P 6?"%^EJ8=?LM]RD4D43R!9") "GRGD$@C
MCKR*XZ?1OAOJFEG6)WD@M)+B.,LTLBEW.^9!M!)Y$[MTR <\8XHZ#%\+['Q7
MI,6C--=:@]RJP-#)(R+)'&D:LQ)&1L50&Y!QD=Z:U$>W#E:QK"TUN+Q+J=Q=
M:A;3Z)+%$+.SCMBLT+C/F%Y-QWALC P,8K97I01Q0!P?Q4\+W_BQ?#=O9VUG
M<I!J@GN%U"W^T6XC%O,N7CW+N&YD&,\$@]J\RM/#'Q.TNU^Q:;++I7E0M]F2
MVACDMEN#/,9  9E"0E3%L#*Y5>@##!]>\=^.X? O]D2W-L\MK>W;6\TZL +=
M%@EF:0Y/( B.0/?Z'DX/VCO"EUM%G'?7Q,;2M]D2*0(@:%<LRN1UGCX!)&3D
M#!H$<='>>/Y+OQ+;Z8NN3""W:UAANYXFEANGM[9U?);&W<9B#DXR>Q JY'X=
M^(\-B[K=7]N#J 1HH763;;?9R0T:++&/]=MS\P.,\$9KNM,^,VA:IJ$=O':Z
MC%NG2UEGD@41PSM-) L;D,?F,D+KP".G.#2>(?C7H7AOQ"NAW-O>RZE(P2&&
MW6)S,3)''P/,ROS2IRX4'.1G%,=S$\3>&?%ESK6A:G9S7C7EGHXBEF1TA\V<
MW%N6$B!B#E%D.,D=<'I7G4:>,-3CM?"UQ=7S:OY86>UM+F(0Q0K# 1E5/R.'
M+G=@ GU&!7KUC\9M.UG5]'LM,L+RZBOKH6LUTRA$M9# TVQN22^U1P!CYASV
MJ2X^(UQ;6-_KAT/?H5N]S$UU'<+]H)@+*28R!\K.C*,,3T) &<+J'8\U>P\?
M^'/$E_=&>X)U&]BTFV,UPK/);M+=!91U):)&B?)YQG.:[KQ_;>+O[7OSHXU.
M2,Z<J:<;&:)8UN?WGF&82,,\>7@\\].]=#I/C*:3Q$=%UNQ@TS4&M5O;<QW'
MFI(A;8R[BJX=25R,8.[@GFM?PKXAC\3:=)<)&898+B:TGA)R4DBD*,,]QE<@
M^A%)JZ$>.R:%\1KS6]5DAGUB#1EBC_LV&XNX_-.9XQ()<').SS2,GH1WQ3?#
MGA?QOI&CV$5P=<%I;00VS6EK>)Y@VV:C*[FQ_P ? .23Z=LU[[CVHQS57Z#/
MEWPSX)^*FD:AJ-U<M/:R7TT;7D]J4F9V"W!W(HECX\QD.-PZC@@&N_\ !FB^
M+D\;6%]KPU&>>"VOXIKN>2);4[Y(C;[(T8[6V*=V.X;DY!KV/:/2C'7BE<'J
M?-/A:^\=>++R4:?JNHS/:Z0'N)?MD;6[:D8FQL(./++X.T\  9 Z'4U33?BM
M#J(NM"?47TTN)!9ZG<Q&8>3'&X0G)XFD,R'G@ =!BO?TB6/[J!03DX&*?@>E
M >9\Y:%\./'&A>*=5OUFU&6Y5U9+LW2[+DM/;M(=I/W2BR_*0,?E7>^-K?Q8
MVMZH=.757C:. 6)L)8EA5,-YX<.P._\ NG!Y*8P V/3R.>E 'M0]582T/GW4
M='^+#QZS<:5<WT,R/$-&AN[B-E$9N)@WGCG<1&8SSDXV_P 0-9EUX!\8:AK\
M5XECK'V,7UO<R?;+J,S,4:QW<JYX_=SG;G'R].E?2V/:C%&PT?/6C:'\35T3
M3+.=M2MKY;A4O9(KB%8!:>9%M$0!^5PF_<0 >'Y.5KJ/!5KXWLO%]O\ VJVH
M7.G>=<Q-]I=1'% 'F\EPRN?,)40@AE5N<[B 17KH ':D('I1<1XWHFB>.K3Q
M%]ID>Z2S75D MA*@A^R-).96* \G!BYZ^G>L.Z\ ^+[/QIXAU735U"%_,NY[
M.078\N5I);4J,%ON[4DRIP.#[5]  >U&/:C8>YXI9Z%XYO\ X>>*;36YKR^U
M6YLT6*!(TB'GY;>87,SY!^7&0BC P,D@48M)^("^*9+JYBU4^'6=U5()H1?B
M#]X44ONSG>0>OW2N?XA7O6*,>U%];BL?/>E:%\6!HUE)J6HWR7\LEQ]J,.R=
MD8)'Y!11+&@7/G9YP25R,=)A;_$R?Q&9)H=7BT)UB-W#;7$?G[A)-O$+%^"0
M83QM& 1V->^[<T8]J+@?/^G>'_'NE#54M(=9@\^ZGN+(/=1';+)<[]T_SD%?
M*(X&1D/@9QGI+VR\1Z=X"\$V]U<W$FK/*GV^6[D\PBZ-O(8PY'\(N/+X''3M
M7KI'M05!'(!HZ6'?6YXU8S>,-$^'>J3:O?7BW_\ HS-).B0>4H9/M 20S/\
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M]]"N:P/048'H* .E,\/_ #U3_OH4>?#_ ,]4_P"^A7-8'H*,#T% '3">$?\
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M/_/5/^^A7,8'H*,#T% '3_:H?^>J?]]"C[5#_P ]4_[Z%<Q@>@HP/04 =/\
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I_OH4V:>,PN ZG(QP<USJ*/05=M@/2@#5LEV6L:^F?YT5)#_JEHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20250331x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $T MH# 2(  A$! Q$!_\0
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE<4?A!
MX6_X2,ZW_9S"\-Q]K\O[1+Y!G_YZ^3NV;^^[;FNU8X!KEA\3/#?]KC3?[1'V
MAI_LH?R9/),V<>7YVWR]^>-N[.:I2<?A9$HQDO>0T?#/P^&1OL39347U4?OG
M_P"/EP0S]>X)XZ>U8OB3X&>&-<\/PZ=%9M:RVMG)96DZSR@HCY.U\,/,7<<[
M6R,UV;^(-,C2=WU*T5('\N9C.H$;?W6YX/L:>=9L%%L6OK9?M7^HS*O[[_<Y
M^;\*:J36S)=.#T:.&A^!7ABYM]/.IV37=];VUM!+/'<2Q)*T&#&Y16"D@C@D
M9P2.E;5G\+O#5AXH;Q#;Z;Y>J%VEW^<YC$C##2"/=L#D<%@,FMEO$^CHQ#:K
M8JPD\H@W*#Y_[O7K[55T[QUH&K1W<EMJUH\=K=M8RLTH4+.O5.>IINK-]1*C
M32^$I^*OAKH'C*[BN]2M91>1H8A<VES);2E/[A>-E)7/\).*HZE\%_!^JVFG
MVTNC)'!8H8H5MY7BS&3N9&VD;U)R2K9!/)KKH]3M);R2T2Z@:ZC&YX%D!=1Z
ME>HJE;^*M)N-Y%_#&4E> B9O+.]6VL &QG!XR.*2G-628W3A)W:,VY^&WAZ[
M6^22P^2]G@N9E65U!DAV^40 > -HX''K56S^$GA73]9O-4@TI5NKM)4D#2NT
M8$G$FR,G:A8=2H!-=&^O:;'&9'U"T6,,4+M,H 8<D9SU ZBG'6;'SA%]MM_-
M*[Q'YJ[BN,YQGICG-'/+:_\ 7]('3AO8Y>S^#WA2RL7LQIK3VSV7]G&.YN9)
M1Y&XL$^9CT)X/48&*T?#7P^T3PGIEY8Z=;2+%>$FXDGGDFEE)7;\TCL6.%X'
M/ Z5L0ZS87,:/#>V\JNI=6252&4=2"#T'K2PZM9SS"*.[@DD,8E")*I8H?XL
M ]/?I1[235FQJG%.Z6QQNC?!'PMH,1ALX]3%L8'MOLTFKW4D(C=2I C:0J."
M<<<=JC\7?!G2-?\ #UY8V*_V?>2Z9'I4-T^9A'"CAT&QC@X(^]]X=00:Z:P\
M:Z)JNK:AIMIJ=O<7FGQ1SW21MD11OO"$MTY\M^_&.:?I7C+1-;TZUO['5;.Y
ML[IS'!,DR[96!P0O/)SVI^TG>[9*I4TK*)P?@#X%VOANUN#K5PFK7LM]#?"2
M'S(T22)=L9^9V9CR2=S')-=5:_#+PY:Q6$2Z<&CL1<B!))790)R3*""<,&R>
M#G&>*T-&\::+X@GO(-/U*"XGLYI+>>('#I(G#C!P>/4<5;77],>S:[74+4VR
MML,PG4H&]-V<9]J<JLYN[8HT:<-$CE+/X)>#K'2[_3X])+V][L$OFW$DC@(2
M8U1F8E I)VA2,9XK1T3X9>'?#SZ;)8V+12:>\TD$C3R.V^48D9RQ)<D=VS70
M'4K474=M]IA^T2+O2+S!O9?4#.2/>EMM1MKTRK;W$4[1-MD$3ABA]#CH?K4N
MI-[L:I070YZQ^&GA_39[>6VL6C> 7"QGSY#@3G,O5N<G\NV*\[\:_LVQ:_>6
M4>DZE%I>D1:>FFO:R0O(_E*<@APXW$#IY@8#J,5ZCJWCC0=%TR[U&[U6U6SM
M0K321R"3RP6V@D+D\GCI5Y]>TV.6>)]0M4D@&Z9&F4-&/5AGCMUJH5IQ=TR9
MT:<URM?UI_DB'4_#5AK'AR70[V(SZ?- +>2/>5+)@#&001T[5A^(?A+X8\4W
M=M<:EIQFE@B6#*3R1B6('(CD"L/,7/.ULBM2\\<Z!8W.GVT^LV*3ZA.;6UC\
M]29I0,E%P>H K3FU*UM[J&VEN(H[B;/E1.X#OCK@=3^%0I26J9HX1:LT<S<_
M";PO>>(H];DTM3>HZ2X65UA9T&$=H@=C,N!AB"1BJNI_!7PCJR,L^FR*S333
MM)#=S1R,96W2*65@2C'JA./:M[5O&NAZ+ LUYJ4$<37<5CE&WXGD<(D9VYP2
MQ Y]>:J_\+(\.'0H-9_M2/\ LR>[%A'<;'PTYE\H)C&<[_EZ8IJI/378GV4'
MHX[F]IVGV^E65O96D*V]K;QK%%$@PJ*!@ ?A5JL2U\7Z/=Q1RIJ-NBNS(HF?
MRF8JY0X5L'[P(SCGM5\ZO9B>: W< GA7?+'YJ[HU_O,,Y ]S4/S-4K:(N456
MLM0M]2@6>TGBNH&Z20N'4_B.*LT#"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#(\5^)[
M#P?H5UJNHR-':VX&=BEF9B0%50.K$D #U-<WX?\ BSIVK7L]GJ5C?^&;N*W-
MWY6LQK%OA! ,@8,1@9&><C/-7?BCX0NO&GA*6RL9HX-0AGAO+9IP3&98I%D4
M-CG:=N#]:\P^(/ASQ9XDT;7]?U[3;32OL.@W=G;6%E<FZ>9Y%&YRVU<#"\*
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M ,) VE^< JZ>-2^V[U^S^46*YWY]OI5^V\7:)>6]I/!J]E-#=L5MY([A"LI
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M8_'_ ,(:I8VUY;7LJ03M;E6O;6:V)BF#&.50Z E"$;YNG!Y%+?4-M#C?@/\
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M:[B< [ER,$\UW'Q0^,%S\/\ 4HHK:SM-0AB-LUY%OE,\:33")6PD;*HZD%V
M.TBETO\ (.MCU(&@L!WKY_\ ^&C_ !"\%@(?"0OKN^AN;V"UL!<7+M!#+Y6T
M^7$=LC-C&<*,\FNF^*OQ3US0M+FM_#VGVZ:K_8<^LNVIR&,6Z(  N,'<^YNA
MP..3S3=UN!ZUN'K1D&OD7Q!\>OB->2A=$N=/LHH()6E>Y16=W%Q;0Y \O  \
M\D#\R>!7J'@KXO\ B+Q!J\VAVVG6E_=Z8)9=1N;NY\HM&+J6!?*"1X8_N6/(
M7L,\\%M+C_X8]JW"C<*^<O$W[1.NW-OX0CT>QM;*[UFWLKUFF<R*!+/Y9B^[
MT[[AS[5LGXI>*+'X;?"[7[AK*6;51'-JQ7(\R/[*\Q\L8X)V^W/M3MI?SL'^
M5SW3(HKR_P &_%Z[U?[2-8TR&T/]BQ>((/L4YFS;2;\(V0,2#9VR#G@UQQ_:
M<U2Q\&W7BJ_\(7,&B01V]W]HD$MN)(96*A$,R('E4F,X4[2&.#D<JP;GT#D4
M9KPE/C_K]FD]YJ7A[3X].@O(-/D^RW[2R^=-"LB$#9@H"P!.<XR1P*@\.?M$
M^(]9N-+A_P"$/:ZDN+2SOKB/35N)]D5SR@#B+8"J@EMY4<8!HU%<]]S1N'K7
MAW_"^/$9LKU3X62/58)XP^GD7)FMH69U,LL8AW,H*8WQ!U.>N!FM?Q]\9)_"
M_@/0?$MC;V^H"\265HH)_P!T^RVEEVARF2-T>,X!_44=+AN['K=%<1\-_'.H
M^*YM7L]6L;:QO].>$.+.9I8F66)9%(+*IR,D'CM7;T G<:XRA!Z5XQ8_LRZ-
MIVDZCI5M/;6NG7L;VTIMM,@BNGMGD#R1/.!O;<,KG(X/.3@CV>0D(2N"<<9K
MPK1/V@=9BT&[N=3T"WN)=-MY]0U)[:]*K%:K<21J8P8\R/B-CM.T<=<G% ]2
M31?@+J=KKFH:=<:W*?"8M]/AAB\I#).MN[LB%LY7:/+4MCY@.W-7[C]FK1II
MM'G,MM<W.GV;6!DU'38;L/&9FE!59 0C@NPW<C!Y!P*UO'OQANO!NOW-E!H(
MU*SLM*&L7MU]M$31P^84(1-AWM\I.,J/<5BZ;\?]2UF&.2R\*12>?_:$UL)-
M3V%[>SF\J5V_=?*Q8KM3G.3EACDU%YEFX_9]MI[[5+@:C;(M\C)):C28/L\^
M9$?-Q%]R5AL"AL*P!/.>:=H7[/=GHGB+1=7.MW=S-ILB2K%(@VMM6X 49)*J
M/M!P,G 117)Z]^T_?BQTO7]'\/QR>&&NKF&>:YNMMQ*8K"6Y**@7"<HHWDMT
M/R\@UV-[\;;EO%/_  CNE>'A?ZQ(T/D)->B&-P]J;ABS[&VX VC@Y)'0468W
M?^ON.1D^!NNZ!JVG:5H4DS:&;^POKZ[F>'9*;=LGC.]6VJJX (. <KR*ZK7O
MA/J?B[QSXCFO=2>S\-7XL&^S0HC-.\&YOO=4PVW/'..,<U8\/?&]O$7C-]$B
M\.7JVL5Y)I\MZJR.(9HUR^_$?EA V5W"0G./E KD9_CAXQL?%VHV1T73;ZRM
M;W54\H7;1,8+6&W=3N\LX;]ZW&#DD#(QFG=MK[R=K_)%B^_95M=0LM/LY?$E
MR]M9/#)"9;5'D0QPF+:C$_*A!)V@=2>>U='!\!;6UU?1-1@U>=;C2XK"*/?"
MK*XMEE7D9_B69OH0"*YT?M4V]S97^H6'A;4+[2[2)V>=!("LBVWGD.?*,:IR
M$W>83N(^7'-:FK?'^[\/R:.NI>'[-#>RVD4\5KJIFEMC<'$9*B$#'(SN9?;=
M25]!]_2WR-/QC\#T\6Z[>WW]MSV5M>W=K?7%HD"OOEMUVH0Y.0" ,C'4=:S+
MK]FS2;VSTVUN-4NI;>STZPTUEV*/,2V$H!]BWFG/I@8K)C_:B>'3]$?4/"KV
MNH:];6]WIEM#>-<K(DI(_>,D)9",$D*C^U;$7[01ET[49W\-75I<64=F6M[R
M1H69I[EX.C1A@H*;@Q7+*PX%+9:=_P 1_P"1D:?\!=;C\?S:C+K[I;Z?8Z?!
MI5Z+>,D>4EW%)&\>>?DG4[CC)Z#@BM/P[^S1H_AO5--O8I[6\FMH[9)9K[2[
M>>=V@SM:.1@3$2,9VCMQM/-8_A;]H+6YXK>TU+1;>YUN[-M':P6]WMA>2:>\
M0;G,>4 6U))VGZ5Z'XF\?:UH3^&+.W\.17>L:R\J&UEU 11VYCB:1LR!&W#Y
M<#"]Q[XK5"W9FZK\#],OO'UUXJA:RBO;F2&:1KG2X+F5)(E"J8Y7!,8("Y ]
M."#S7)V_P U;PMKNA-X<\07$=K]INKS4+JZB25A/-!MED"DC/F/@E1PIZ<<5
M8T']H^\\67=O%I/A572[N(;.U>ZU+RBTSV_GD.!$VU54,-P+9(&!SQ2'[2-]
M!JMZ\^AH;)A;6EI:I,[R_;'EFCD5]D3'8#"V&4,< ''. K6L/>[-J?\ 9IT*
M71CIQN?M")=VEY +ZVCN(U>"#R</&W#AEW$CCD\8Q5B3]GZU-YI4T&HP:>;#
M85?3M*M[64;7+E$>,#$;$X9&# C/J2<A/VA]1N/$%CI=KX3G&H7QMX8[2_N&
MM0DCM> L6:+=LQ:9!V@D.#@'BM7PW\?AXAUO0[1M$_LVTU-4"W5Y=%-TIW@I
M%^[V2X9,$;U;D$*:-1/]"A)^S%IMW;/!<ZO+% SLWD:?;):PJ3!+%O6-<JKG
MS=Q( !*C@"MR/X*"X\2MXAU/79K_ %:6&:"21;=8HRCPB( ("<;0">IR2>@P
M*H>+_P!HO3O!/BFXT74]+G5K>>19IHY0VR(0"2*3&/\ EHS",#^]W-<-)^T1
MXRN+Z<6^AV%ND9CC:VGN2\@F.HM;,FX(!C P&['G!Z4XW>J'ZGK$GPI:WT7P
MC:Z;K,MAJ'AJW^S6M\8$EWH8A$VY#QD@ ^Q'<5S=Y^SM_:7B&/5[OQ'+>W,4
MUS*DEW80S.?.@:)D8MD%!G(0*!Q@@\$;!^-D%G\-_$'BB_TIX9]$NYK"XL()
MQ*'G241@)(57*L67YB!C/(XKB[K]J#6;?4K70AX =_%;W,]O-IAU>(1Q;+<7
M 83;,,"A/& 01WI=?ZZAT_KH;"?LW6R0PQ#61$L<QEC\BPCC-IDKQ:L#N@&%
MZ E3N)Q4EA^S7I&E6U]!8SVMJLSEX9XM*@6Y0F83 23 ;Y ",8R..N>#7%Z'
M^U1K/B/5+F>+PU%:^'GFT:.UG-V&GS>2A&#KMQQ\W3^[[C"6?[9-[/IWVZ3X
M>W,=I]C74S*FJQM_HGGF%Y,; =P;&$[@]11J%]?ZZG7S_LR:5/K3ZG+=VMY<
MO+<L?[0TJ&Z"I-<-<,%$F0K!WDPWHV"#BNH\*?"2#POXRN=?BOES-'+$;6UM
M$M4EWLIW3"/"RLH7"L5! )ZYKSS4/VE]=L7@33/!B^(I+K7[S18H5U18)R89
MBFY8_*8LH4;B<@#N:I6?[:^CWFI>)[5/#EVPTE9!;.DV?M4J3I!L<E L67=<
M'<V1DG&,%ZL/\_U.FUG]F>RU^"WLK[6Y;G2[&%XK"QFM(W2'-S'<*7S_ *W#
M1*,$ %20?6KLW[/-E+!8117EEI_V:1I ^FZ/;VKQ$N&)A>,!HR0-I)+9'6KW
MP2^(WB'X@7/C&/Q%I4&BW.D:K]BCLH)1-Y:>3&^&D'#G+GD <8XKU( 4--63
M_J^HNI\]:Y\#M=M=132=#EG_ +&O+VTO+^[E>'8WE3-(?E)WJ=N%P P. <KS
M6SJ_[+VBZS'HHNK]KEM)T^WLK=;FU2:)C%*SAWC;A@=[*5_7->V4FWFE=_J,
M\?3]GJ&TADM]/UI=+M+N>SN+ZVL=-A@BF:VG$J;%0 1@XVGJ2 .<Y)]A48%&
MV@<4=+"MK<6BBB@84444 %%(:6@ II(!KDOB'\5?#7PPTPWFOZE':D@F.W4[
MII?94ZGZ]*^/?BI^VIXC\4F>Q\+1?\([IS?*+GAKIQ_O=$S[<CUKKHX6KB/A
M6G<X<1C*.'7OO7L?97C'XD^&? 5L9M>UNTTX8RL<L@\QOHHY-> >,OV[M L/
M-A\.:-<ZK(,A9[H^3&??'+8_*OBO4=3O-7NY+J^NIKRZD.7FGD+NQ]R>:K9K
MW*664X:S=SYZKFU6>E-6/>?$O[:'Q%UPLMG<V>B0G.%M+<,V/]Y\G\L5YSJG
MQG\=ZR3]K\7:O(#U"W;H/R!%<9THSFO1CAZ4/ABCRYXFM4^*3/:_V8?$.J:E
M\=/#27>I7=TA>3Y9IV<?ZMO4U]T?%PE/AKX@93AA:G!';D5\#?LJ?\EW\,_[
M\G_HMJ^^/B]_R3/Q#_UZM_,5X6/26)A;R_,^BRYMX2;;[_D?&,&OZI:MF'4;
MJ(@_P3,/Y&MW3OBOXOTME,'B"](7HLLN\?B&S7*'K25[3IPENCP8U)QVDSV/
M1/VG_$U@R+J$%IJ48ZDIY;_FO'Z5Z9X;_:6\,ZPR1Z@D^D3-QF4;X_\ OH=/
MQ%?*%%<<\%1GTL=M/'UZ?6_J?H#IFL66LVJW-A=PWENW22%PP_,5<'-? NA>
M)=4\,78N=+OY[&8'DQ/@-]1T/XU[KX#_ &GMQCM/%%L 3@?;K9?_ $)/ZC\J
M\JME\X:PU7XGLT,RIU-*FC_ ^AJ*I:5K-EKEE'=Z?<Q7=M(,K)$V0:N9Q7F-
M-:,]A-/86BBBD,**** "BBD)H HZEHUEJSVCWMK'<FTG%S!Y@SY<@! <>X#'
M\ZPM9^&/A3Q#J,E_J.AVES>R9WSNI#-E0AR0>Z@*?4<'(K-^+^O:KX?T'3Y=
M-N7TZ&?48+>^U*.%96LK9B=\H5@R\':,L"!NR1Q7S[K&L>+=>UY)I/$>K1>?
M)96]C/%#'&+F!=55/M 01@%C'@G^$@_=P<!15WIW_P @;L?2O_"L?"GVLW0T
M"Q%P2&WB( Y'EX^F/)B_[X'I5>#X9Z3:^)=&U2"&&&'2(KA;*U2/_4R3D>8X
M8G."%QM  Z_AX9)\3OB.FM3:2=5AM(;*>\@M]2U%$B.HO'=O&B2*ELX<^6$.
MV(1$YR#7=Z+XE\91_!WQ-XDFU*YU'7!<7JVML]I$$M4BNI(E\M5C5GPBAOGW
M$X_"G?3F"VMCT?5_ /A[7KR:[U#2K>YN9?+WS,"&S'G8P(/#+N8!AR 2,\U+
M<>"-!N]"M]%ETNV.EV[*\%JJ;5B93E63'*D'G(YKPCQ#\1O%MOJ6FV6@^+4O
M],:UEFBUO4HHX%N[H2*/L[!+1Q(%5ONQA&;)PV5-.^"^M^)8O'?B5KBTU#5_
MW4NVW\_8B_Z?<?,OFD # 'OC'X+N'F>Q7_PH\*WMA+:C1;.(M$L22K$"\>TL
MR$'KD,S-]2:K>"O@[X9\$:)HUE;Z=!<3Z9' ([V5,R,\4917]N&?@<#<<=:\
M4T'XE:[H6D)%'KFIWD#"[2^5;2,OI4GVS;"WF2(< JS9,F\;5R!@8-?0/C!X
MVE,$][KTMS;6NHW%JMK;P0B[OD6<+&WS6X28%&'$7E-_%R*IIK1"/?W^%7A&
M5[AFT"T+3L6;Y3\I+AR4Y^0EP&RN,D TMG\+?"=C=P75OH=I%/ ZR(ZJ?OJ2
M5=AG#,"20S9()ZUX79?$_P"(L\5U/<:I;VJ-,(]0MHT6:XTB,W:1F54^S*$"
MQESB5Y<\,/E!%:_AK7]>M/@]X@O=/\42/=#Q'.D6LZD@4R6_V@ [3Y3I'E<A
M7,909S@"E9[_ -?UJ/?^OZ['J"?"/P_+XRUOQ)?6L>HWNI202!;A,K 8XA$-
MO/)P"<XR,G%:4OPT\+3?V?OT.S8:?#';VP\OA(HR"B8[JI&0#G!KQBT^)WC6
MXN=+TNWN;H-K5K]JL]2O[*)_LZV^X7.X1( ZOA&4@<^9P!P!S5WX]\93V.D:
MA%K6H:MJNESW!4Q"W:RO9FLG9(PR6Z$C>"-A4,-V"2<&G;H&Y]#S?"SPG.Z.
M^AVC,CRN/E/_ "T</(.O*LP#%>F1G%3Q_#GPS"+M5T2S47>W[0!'_K-LAE7/
MKAV9OJ:\.TWQKX^U>STF"/Q6#'=WC(]]I\45S/&HLI96C9FM(XUQ(J8 0L,D
M,2<5E#XE?$&VL;+[7XI>%;C3K'4IIKBVM[:0/*D_F0Q.;=XU^9$.)%R<$!@2
M*+,#Z-T+P-H/AFYFN-+TN"RFE3RV>,<[,YVC/W5R2=HP,U6M_ACX6M;6:WBT
M.T6"5XW>/9E6,;%X^#_=8D@=!FM#PAJDFN>%])U"6.XAENK6.9H[N,1RJ64$
MAU'"MZ@5L8I;,2V.-M_@[X-M93)%X=LTDV)&'"G<JHX=%4YX"L,@#&#TQ5W7
MOASX;\3WWVS5=&M;ZZQ&IDE7E@C;DR.AVMR,YP>E=-10,Y>\^&7A>^L;2SGT
M2U>VM0ZPQA2H17.77@\JQZJ>#WJ?Q)X!\/\ B^WAM]8TBVOX8HVB1)%Z(PPR
M<8^4@#(Z<#TKH:*0')CX6>%%+[?#]B-P*G]UU!='/_CT:'ZJ*DG^&/A:YN8;
MB70K-YHI&E5S'SN:3S6SZ_/\V#D9YKJ*3K3 XZV^$'@VSO$NX?#=@ERC(R2>
M7DH5?>N,] &R0!P"36D/ N@KI6G:8-+@^P:<ZR6D&/E@9<@;>>, D8Z8..E;
M^** ,+0/ VA>%A.-)TNVL1.BQR>6G5%SM3GHHR<*.!DX%4+;X4^$K-T:'P_9
M I(LB;H]P0J&"X!S@#>^ .!N.!7644 >=^&_@9X6\.:QJ=_'IL$YNYA+%%(G
MR6JB$1;4&<?=!YQD!B*W7^&?A>5[%VT.T)LH8[> ;,!8XSF-,="%/(!S@UT^
M*6@#CA\(O!X0J- M%R5*LH(9-N=H0YR@&YL!2!R:TKWP)H&HZ1:Z5<Z1:SZ=
M:J4@M7C&R,%"A 'NK,/Q-;]% K&?IVA6.E7-S<6EI';S76SSG08+[%VKGZ*,
M5H444#$;D5Q$WP;\'S.&DTC<=[N5%S,%?<_F,C+OPR;_ )MC J"3QS7;.<*3
M7PIXC_:+\;:[X1\6V\7B:VO)_P"S]4,UMIUDUM<:/Y$I6"5I5;G?]WM[=Z2U
M=D&]D?5GB'X0:3XJ\?)XCU4M=Q)IRV L-SHAQ(9-SE7 =3D#8RD<9J_=_"?P
MK?:=;V,FD@6]O)/+&(IY8V4SN7F&Y6#%78DLI.T^F!7SWXG^._C#PCHWB31M
M3\4VEMK^G:NMI9ZK'HX:&=3:+<+"RM)A22VT$;F;L,U2@^.WQ(U_P_K.NV6N
M:=I\5L=$MHK,Z:LH\V\BMWDD+ELX4R/A??KQ56Z?UJ*_]>FA]#W/P2\%7=^E
MW+H,1>/?MB6618 6A,+'R@P3)C8H3MSCZ"FI\$?!D5O)$FDR*SR)*9Q?7'GA
ME0QJ1+YF\?(Q7 ;!!P>*\%T;X^^.M(DO+GQ'KME<Z9"NM6;-9Z1^]22R= MQ
MM\SYLA^4R  ,YZXR--_:7\77>A*MWXQTC2K2/4[JW7Q9/I)E@N D,<D$7E(V
M 9"[ %22=ORY-%F!]2Z7\./#NB:O_:5A8&VNLYVQW$HB+;0N[RMVS=M &[;D
M^M1M\,/##ZM>:FVE@WEV9C,_G28;SD1)<+NVC<L: X ^[ZU\\ZG\?_&5UXON
M]/6^M89&F^RKX973I8KIK0VP<ZBLKX9%#$\,H Q@_-6/\.?C7XSN? OA)=;N
M/LNKK?V,*VDI\QWLWT]Y([AI V9#*ZL3G@%2N,@TO/\ K7^OZL/K;^OZ_KJ?
M20^#/@Y8IHET<I!-";>2W6ZF$3KY7E9,8?:6V87?C=CO1K'P>\*:Y=?:[C3"
M;D&%E87,RH'AQY+F,.%9DP,$C/&,U\MW?[37Q3\.^%X[FXN-/UJYU3P_:ZS#
M-;V*0C35>[\F1FW.%<!2#ERJ@]< &HM3^-WQ N+&+6=6\0VVGBX\(7]W:Z;
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M$\TSG"QQJ2S'T %>T_#W]FK4-8\J\\1R-IMF?F%JF#,_U/1?U/TKV[P-\*]
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ME=R6-Y!<1';)$X=3Z$'- 'US2U5TV^34M/M;N/[D\:R#\1FK5 !12$\9I-U
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MHHK<\\**** .Y^!W_)7/"O\ U_)_6OT)U1BFG7!!P0AY_"OSV^!W_)7/"O\
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MT;AEE1'!63:P!V$<C->.:AX5\>7\<(MK/4+:TN+V1Y)[5/L$]PC3VI,L\<;
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MB2S0+'\_!()(9AW89;G_ &C0&YR?@[5=%^S2+#HDPENXT$\"IYGEQ;5PK9.
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MV09R9,MG@;>IJQ=?LFZWJ$FKV,VLZ-;:2JZ@VFW=K9.+^=[J0R%;QB<.B'C
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MF4]5WQLK $<$ \@D'@UKT4K7#8IZ7I=MHVG6MC90):V=K&L,,$8PJ(HPJCV
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%%% !1110 5Q_P 5?A9H/QA\'7GASQ#:B>SG&Y)%XD@D'W9$/9A_];O7844
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M6\JE)(I%#*ZGJ"#U%3T4 ?%GQ_\ ^">.E^)WN=:^'<T6BZDY+OI%PV+64_\
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M=Q;-%%O*LN?E('/?(Z4W2OV@/"VJ>&]3UP_VA9V%BJ.7N[1D\]7.$,74-N/
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MD,T"X212002>20P(.3QBJLO[/VA23+<"^U%+S)D>Y#QEY)_/:<3'*8#!W;@
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-44 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20250331x10q008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N K0# 2(  A$! Q$!_\0
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M-2_[_FC_ (7'XW_Z&C4O^_YKCJ*[_9P_E1YGMJG\S^\['_A<?C?_ *&C4O\
MO^:/^%Q^-_\ H:-2_P"_YKCJ*?LX?RH/;5/YG]YVZ?%;Q](H9/$.K,IZ%9&(
MILGQ<\=QL%?Q)JB-Z-*P-?:GP2MH[']GW3-0M-!@UC4([<LENT:[I3NZ9(JK
M\??"ND:I\-=*UJ^T:VT?5X[F!EC"*K*S,-R' YKR'BX>UY'36]CW%@:GLO:*
MH]K]?S/CG_A:GC__ *#^L?\ ?;5'_P +;\=B3R_^$CU7S/[OFMG\J_1F]T>2
M#3=,.D^'],O"P43_ &A53:N!R..37@G[6=_HG@'4_"VLZ;;6,7B&WN-\D,<:
MY>''1EQT)]:FEC(U9J"IK4JM@)TJ?M'4=EZ_YGS"_P 6_'<;!7\1ZJK'HK2L
M":)/BUX\AP9/$>JQ@]-TK"ONC2_!'A'XU67A/QF+"*$VR^<(DA"JY(^ZPQS@
MU\O?M)^+9OB5\09/#_AO2B]II99!':6X#.P^\Q &<5M2Q$*L^3DM;?R,*^%G
M1I^T]HW?;?4\T_X7'XW_ .AHU+_O^:D;XN>.TC#MXDU14/1C*V#72?"3X0V.
ML^)Y8/&\\WANPM8A<-]I'E&49Z#=_2OH3]JC0]!TSX$Z<VAVMO'9B:(0R1Q@
M$KCCG&:UJ5J4*D::C>YC2P]>=*564VK=+ZGRJGQ@\<NP5/$VILQZ!9B32M\7
M?'22;&\2ZHK_ -TS$&OH[]E;X6^"H(='US4-0AU'Q#?Q,\.GR%2(P.IV_P"-
M<S\5_#UM?_M8:9IZ00P6[S0[HP@"8')XZ5*KTG5=-0V3=_0OZK55%57/=I6O
MW/'/^%J>/_\ H/ZQ_P!]M4#?%_QPK$-XGU,$=09C7Z*Z[836[M%HNB:%>&.+
M(BG*K(Q], <"OSB^*+7C>/M::^L$TRZ:X8O:I]U#GH/:EA:\,0VN1+[AXO#S
MPL4_:-W]2ZOQ8\?2)O3Q#JS+_>$C$4D?Q:\>3$^7XCU5\==LK&OMK]F?1M+N
MO@EH9NK*VD::-E+R0J6;)(ZXI_P*^%-IX-3Q";ZQ@9[K4I/)\V)6_=Y^7&1T
MKGGC:<.=."O'\3IIY?6FH-3=I*_H?#[_ !@\<Q,5;Q-J:L.H:8@TW_A<?C?_
M *&C4O\ O^:]M\>_ S4/BQ\?_$-AI7DZ=8VQ5IIRN%3(&  .]5?&G[&.H:'X
M<O-3T?7H-8>T4M+ $VM@=<?2NN.(PWN\UDW;IW..6%Q5Y<MVDWU['CG_  N/
MQO\ ]#1J7_?\T?\ "X_&_P#T-&I?]_S7JGP\_9+D\6^&K?5]4\36>DK<?<@!
M#L/0'GK[5#XB_9-U#PYX^T30I=6CFLM4W>7>QH05(Z@KZU?ML+S..EUY&?U?
M%\JGK9^?<\Q_X7'XW_Z&C4O^_P":/^%Q^-_^AHU+_O\ FO?C^PC=&:ZC'BB#
M>BYB0Q_.W'!8=J^9/%'AZX\*:_?:3=,&GM)3$Q3H<'%52J4*S:A9V\C.M3Q-
M!)SNK^9T:_%?Q](H9?$&K,IZ$2,13&^+GCN)MK>)-45_[IE8&OMOX0VR6'P!
MT>_L] M]8U!+8,D'EKND.?4BLOX_^%M(O/!/A_6;K1;;2]76]M_W2HH8$L,H
M2!S7 L7#VG(Z:WMT/3>!J>R]HJCV3/CF3XN>.X0/,\2:I'GINE85'_PN/QO_
M -#1J7_?\U]._M2_#\>+-=\$:-IL=K837:-NE8+&H'&2<=:YO_AATW-O*EGX
MOM;G4(TW&%8\C...1TS71'$T'%2FDK^1SSP>)4W&FVTO/_@G@W_"X_&__0T:
ME_W_ #1_PN/QO_T-&I?]_P UZ/\ #?\ 93U/QI#JMSJ.J1Z3:Z?.UN[!#(Q9
M>N .U,\;?LQ'PEXBT"QB\16M];:K<+ &48EC)[E/2M?;X;F<=+^AS_5\7R\V
MMGYGG?\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\ -?0;?L&S"Y:+_A*X1E,H
M#%\Q/T]*S#^PSJL6CWLS^(;4W\"LRV\:94@<C/H36:Q6%?5?<:/"8U=']_\
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M2_[_ )KCJ*?LX?RH/;5/YG]YV/\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\
M-<=11[.'\J#VU3^9_>=C_P +C\;_ /0T:E_W_-'_  N/QO\ ]#1J7_?\UQU%
M'LX?RH/;5/YG]YV/_"X_&_\ T-&I?]_S1_PN/QO_ -#1J7_?\UQU%'LX?RH/
M;5/YG]YV2_&3QN"#_P )1J0/;]\:]E^ W[6.O:5XAM-(\5WK:GI5TXB^TSG]
MY"3P#GN.U?-%/@8QSQLO#!@01]:QJX:G4@XN)O1Q52E-24F?K[#(LL*.A!1@
M"".XHK"\ 3-=^"-"EDY=K*(D_P# 117Q,ERMH_0X/FBGW/A']LG_ )*_<?\
M7%:\*KW7]LG_ )*_<?\ 7%:\*K[;"_P(>A^>8W_>)^H4445UG$%%%% 'VIX$
M^-NA^#_V<8;>RU^T@\1VUJ?*MG.7#YZ8KYSU_P"-WBGXB:QI*^(=5:6SM[F.
M3RU&V-<,/F(%>;T5Q0PE.$I3W;=ST:F-JU(1ALDK>I]U_%;]I#1_#]IX3NO#
MNN07S0W"B]MH&SF(J <_2L#XY+\-_C)J/A[58?%>G6<\<BK>;G(9H>N.G4=*
M^,Z*YXX",&G&335_Q.B>9SJ)QE%-.VGH?>FL_M->#OAYJ?ACP]H$]O?:, (K
MJX@^[ N,#\>YKS/XP>/-"\!?$"+Q[\/]6TV_O;U&BN[0?,%8]7Q[U\KT54,#
M3@[W]?/U)GF56<7%I>7EZ'=?%3XOZS\7M1M;S65@22W3RU%NNT8SGFO=?CA\
M1O#>N_L]:!I%AK%M=:G"L(DMXWRPPH!S7RA171+#0?);11=SECBZD5+FU<E9
MGKO[+GB;3?"GQ;L=0U>]BL;)(95,TQPH)' KIOBQXZ\*ZE^T3'K4TW]JZ!A%
MDEM)"I'&-P(YXKY\HIRP\9575OTL$<5*-)4DM$[GW5H'B?X2>#_$LGC&Q\9,
MV;81_P!GO.TG;L#SFOD3XL^,X_'_ (_U?6X(_*@N928U[[>V:Y"BLZ.%C1DY
MW;>VO8O$8R5>"ARI*]].Y]B?#_XQ^'O"GP$\/VHUFW35[2XC9[7<=^-_.1]#
M7HGB#]H;PA+XN\*QVVO6GV,F26[E#';'\H !]\U^>]%82R^G*3DWO?\ $ZH9
MG5A%126EOP/M7PM^T%X5\/?&SQ4+K48O[)U-D:+44YC! Q@GTK4\?_&KPQH7
MAC56M/'O]J7%PKK#96<*<A@1@G'3!ZU\+44?V=3YD[[6_ ?]J5;-66M^_4^Z
MOAO\3/A?HWPZT[R-9L-*O8U5[E;B/S92_P#$,'OGO5KQY\8O!FL>,/!%_:>(
MK*6VM9G:9]^-@*C&>*^"Z*/[/@Y.7,^OXA_:E3D4.5=/P/NO3_C)X3C_ &@-
M4U-_$EJ-(?3(XDF,A\LONY'UKY#^+NIVNL_$?7KVRG2YM9KEFCD7HR^HKD**
MWHX6-"7,GTL<M?&2Q$>62MK<^UO"WQQT7PA^SI;6^FZ_:1>)+:UQ';,=SAL]
M,5\Z:K\;/$_Q!\1Z,_B353+9V]TC^7]V-0",M@5YI112P=.$I2W;"KCJM2,8
M[)):=['V[\2OB=\.=>\>^"I[_5;;4--M8F$K1L2D;\8W8KT+3_C;\.-+UEDA
M\4Z:D+QC8D<04(!ZOC)K\X**Y99="22YGH=4<UJ1;ER+4^T?AM\2?#.C^)/%
M,L7CU--DN;MY(X+B,/;/GHRGK5CXJ?&+P)JNM>#T34K+4M3MK])KC4+=-J1*
M.N3BOB:BK_L^'-S<S%_:E3EY>5?B?>&I?&7PC+\=-,U!/$MJ=*CL&1I1(?+#
MYZ'WJKX(^,?A6U\>^/;F\\1VRVETP^RL\AVN-O\ #^-?#-%3_9T+6OTL"S2H
MG?E6]_T/MGX0?$+X9:7X5U#S=5L=.U=KB1Y9;M-^[+$@@'@C'2JG[2?Q6\)>
M,_@^MGHVO6M_=K*I\I1L9@.^WM7QC15K 053VG,[W)>9S=-T^56:L=O\'?B!
M_P *S\?:=KC1M+#$VV5!U*GKCZ5]9ZWK/P/^(7B6R\9:EKT"WL" FVD<@$CL
MRXYKX5HK>MA8UI<Z;3VT.?#XN5"'LW%25[Z]SZ\\-_M%> _#OQFNY]-T^+3?
M#]Q"(&O88MNYO[Y [5U=E\1_AC\)XO$VN:9XG&L7NL%I1:1MN(8C@ =A7PQ1
M6,L#"3W?2_F=$<RJ1^RNMO*Y]B0?%_P_<?LZW%D=:M[;6YY&D^RAR'&7SC\J
MTO'_ ,<O#&G^%?!-S::I;ZE=6$L37$$3Y=1MYKXIHH^H0O>_6X_[2J6LDMK'
MVYXWO_@_\5]:LO%&I>-&LVBM_+:TAE:-OH<#.:Y_X(?&KP#X#\5Z_HMM>W%I
MH=TVZWU"]?>2W0Y-?(=%"P$5%P<FU^1+S*?.IJ*3Z^9]Q?$;XU>&]"\+7R67
MCPZQ=7(*Q6MI"H&#ZX'2L_Q[\7/#-[X$\$VUIX@MVN;>Z@>YCCD.4 ^\3[5\
M6T5*R^"2UV+EF=25]%KZGV/\7/C#X6?XO>!M9L]6@OK&SR+B2 DB//<U>\>>
M*/A]J'Q9\-^,K3Q9;32JXCEA#?*B?WB<5\5457U&*M:3T1']HS;;<5J_N/HS
M]HWQ]X>\5_&/1KF/4QJ7AZ)(Q/\ 9W)7&>:^A=/^,7PNT1-*?3_$>G6ELJA1
M D6Y^G=L96OSNHHG@83C&/,] AF4X5)3Y5=GVZOQD\':;^T5+J[ZY;/I=UIX
MA%TA)17ST8U3\*^*? 7A+X]:GK=OXJM9[/4;9I))7;"I(3]T<5\744OJ$4K<
MSVL4\RFW=Q6]S[5\%?'7P9/J?C/PUJVJQV5CJ%P[07X^XZL,'GUJGXN^*O@3
MX<?"Q/!_AS6UU^::3'F#Y@@+9)8U\;44_J$+WN[=O,/[3J6MRJ_?R/MSX@_%
M[PM=K\/ULO$5NZV=Q&UT(I#\B@#.ZJ_C7XH^$-0^.>DZM;^,AIUO%8^6+RU
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MZ_UI*6/_ %J?7^M)[,M;H_5SX<?\B%X?_P"O*+_T$44?#C_D0O#_ /UY1?\
MH(HKX&I\;/TFE\$?1'PO^V3_ ,E?N/\ KBM>%5[K^V3_ ,E?N/\ KBM>%5]I
MA?X$/0^ QO\ O$_4****ZSB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HJ:RC2:[ACE;RXW=5=O[H)P37Z!>&O@7X%TW0=!AM_!T.NPWL:F?4&.=GRY
MW-SW]JXL1BHX:W,KW/0PN#GB[\KM8_/>BOKG2_@EX3B_:<ET.SM([O1H;8SS
M6;_,D3'^'\Z]'^(7@#P=X;T'5IX_AEYZ11.%N+= <'!PV,YP#S7/+'PBXQ2;
MNK_>=,,LJ24I.25FU]Q^?]%6'M9I)V"0289R% 4^M?0OPL_9,\57FH:)K>J6
MEHVEO(LDMI/)AVC/JO\ 2NVI7A25YNQP4L-4K2M%7/G*BOJ/]HSX(I?_ !+T
M70/!>BP6LMQ;;WCA&Q!SRS'M7*:S^QKX\TC2Y[W_ $"Z\E"[Q0S9? &3@5C#
M&4I1BV[7-ZF!KQDXQC>W5'@]%>I7?[._B6V\ #Q<'M9]/XW1QOF1><$$>QJI
MXW^!.N^ /"5AX@U2:U6VO<>7$LG[PY&>16RKTV[*7D8/#54FW'1*_P CSBBO
MH+]CGP;HGC/QEJEOK>FP:C#';;D29<@'.,BO<OB'X7\$^%=/U<?\*ME>WMH6
M/]H11#RQQ]X'-<M7&QI5?9<MV=E#+Y5J7M>9)?,^"Z*]D\&?LP>,?B)I[:OI
M]M!8:=,Q,)NY-A8=L#TK;^&WP,U#PE\:M)T/QCI45Q:SABN3OBD 'KWK>6*I
M*]G=KH<ZP=:3C[MD^IX!17W'X;^$WA&Y^/OB/29-!LWTZ&S1X[8Q_*K'TKP8
M_L^^(/B)\0?$5OX:L(;;3+2[>,2RG9$F#]T>M94\93G>^EE?4UJ8"I32MJV[
M:'BM%>P^)OV6O&?A/4+&WOEM?L]Y*(4NXY<Q*QZ!O3-)+^R[XOC\<1>&/]%:
M\D@^T"97S&%]SZUM]:HVOS(Y_JE>]N1]CQ^BO7M/_9A\6ZAXPU+P\#;1W5A&
M))99'_=%3T(/>O--6\/7.E:S/IS@320RF(R1@[2<XR#Z5I&M3F[1=R)T*E->
M]&QF45ZUKO[-?B?P_8Z)=W,UH8M6E2* +)DAF'&[TJW=_LK^++/QA9>'7FLO
MMUU$9HV$GR[1ZGUK/ZS17VB_JE:_P/\ X<\:HKWC4?V,_'^GV-U=%;&7R 6\
MN.;+N!Z"O#;BUDL[Q[>9#'-&Y1U;L<\BKIUJ=7X'<BIAZM%KVD;7(:#UK[Z\
M-?#WX?Z)\)M%US4_"$&HR201[S#;EY&+<9P*XG]I+X Z"^@:/JG@_1_L&HW<
MJQ"T@7;YFX=QV(KACF$)5/9M->?H>C++*D:7.I)[.Q\=T5[R_P"QA\04T[[3
MML3*$WFV$PW_ $^M8/@7]F;Q?X]@U!K-+>VELI3!-%<R;6#"NOZS1=Y<RL<3
MP==22Y'=GDE%?7/PG_9VO/!^H:K8>(]!TKQ!<FW$J*]QS$/6O(_#7[._BOXF
M:QJTNC64%E807#IYDTFV-<'HI[UG'%TFWKHK:FLL#6BEI=OH>145Z9\0?V>_
M&'PZN+2._LEN([MQ'%-:OO4L>@)KV#X-_LD:]I?BC3-3\46%C=:2REI;1Y-S
M#(XR*J>*I0AS\U_U(IX.O.IR<K7?R/E.BO7/VH/#>F>%?BM>Z?I-E#86:(A6
M*)<*.*ZC]FCX6:3K6D:_XM\0VBWFFZ;"VRWD&59@,YQ3>(BJ*K-;B6%DZSHI
M[=3Y[HKVCP]^SCXF^*FG7/B708[*+3KBX<16V[:P&>F.PJGXR_9E\6> Y]*&
MK&V2VOIU@%Q%)N6-F]:?UFE?EYM1?5*]N;E=NYY'17T['^P_J#HK?\);I@R,
MXP?\:\W;X :N_P 4AX-LYTU!T*F:[@'R(G<FE'%4972EL4\'7@DW'?0\JHK[
M7^+GP7\%^"O@+J,NF6%K<ZE9HJ/J"C,A?(W<_P!*N_!_X-^"T^%6D:NOAF/Q
M7?W@4SN3\R9.#WX KF>80Y'.SWL=:RNI[3V?,MKGPW17U/\ &[P'X*^&/Q5\
M*RV>FP?9;QQ]LTM^8PIXSC\:X7]J/X56?P\\5VUYH\*PZ1J<8EAC3HA]![5M
M3Q4:G*K;['-5P4Z:DV[\NYXE1117<>>%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4L?^M3Z_UI*=%_K$^H_G2>S+6Z/U;^
M''_(A>'_ /KRB_\ 0113OAM_R(/A_P#Z\HO_ $$45\#4^-GZ32^"/HCX;_;-
MLY;?XL--(A6.> ,A(Z@<5X)7Z'_M ?!%?C-I<(LV2WUJS!,$S_=93U4U\:ZU
M^SY\0=#NW@G\,7LF"0)(4WHWN"*^IP6)IRI*+=FCXW,,)5C6E-1NF>=45VG_
M  I;QS_T*VI?]^31_P *6\<_]"MJ7_?DUZ'M8?S(\OV%3^5_<<717:?\*6\<
M_P#0K:E_WY-'_"EO'/\ T*VI?]^31[2'\R#V%7^5_<<717:?\*6\<_\ 0K:E
M_P!^31_PI;QS_P!"MJ7_ 'Y-'M(?S(/85?Y7]QQ=%=I_PI;QS_T*VI?]^31_
MPI;QS_T*VI?]^31[2'\R#V%7^5_<<717:?\ "EO'/_0K:E_WY-'_  I;QS_T
M*VI?]^31[2'\R#V%7^5_<<717:?\*6\<_P#0K:E_WY-'_"EO'/\ T*VI?]^3
M1[2'\R#V%7^5_<<717:?\*6\<_\ 0K:E_P!^31_PI;QS_P!"MJ7_ 'Y-'M(?
MS(/85?Y7]QQ=%=I_PI;QS_T*VI?]^31_PI;QS_T*^I?]^31[2'\R'["I_*_N
M.:T">VM=<L)KQ-]JDZ-*N,Y4,,_I7Z.IK,/B.'PQ?^&O%NGZ9HMLH:YM/,0>
M:F/N]>,5\#_\*6\<_P#0K:E_WY-2)\'_ !]&I5?#>JJI[+&0*X<32IXAI\Z5
MO1GHX2K5PO,O9MI^JV/J+7_%G@[6_P!H)ULO$LFAW#6JPR:A9.HCFDS]TL>/
MQKM='NH?A3H7BF_\2^.(=?LK@,UK%),K.HP?EQGDDFOB7_A3/CK.?^$7U+/_
M %Q-.?X/^/I5"MX:U1@.FZ(FL)82FTH^TTT[=/,ZHXVJFY>RUU[]?(]BM?VM
M='M],333X)LV4'9]I*KNQG[W3K7T%J=UI_Q"B\&Z[IGBRUTRRLG666'[0%\P
M$?=(SU^M?#'_  I;QS_T*VI?]^34B_![Q\J[1X:U4*#D 1'%54PM&5G&=G]^
MY%+&8B-^>#:TZ6_)'V7XP?P_KGQ[TDW>OK:)'I^8VM[H()&W?=+ ^G:O0-.U
M#1=-DU>V34M-$LT;,H2\WR,,$ L6/7Z5^>C_  ?\?.P9O#6JEAT8Q'-*/A#\
M0 Q8>'-6#'J?+;)K!X*$DE[39'1',*B;?LGJ_/\ R/J#]F'Q#%XC?Q9X(U5#
M-;+<O-$#RI4MR ?K7F?[:'C--2\9VGARU;_1-*B"LJGC>:W_ (?_ !&^)'P]
M\*Q:59_#5Y;N*,HM\T)$A]"V.M>,>(OAM\1?%&MWFJW_ (:U*2ZNI&D=O).,
MGM6E&G%5W4DTETUZ]S.O6D\,J<$V^NCV['I_[#U];6'CG6'NKB*W!M  TKA,
M\]LFJWQ__: \61>-?$/AVUU:*706;RA$J*P*$<C<*\KC^#OCV$DQ^&M41C_=
MB(IK?!GQW(Q9O"^IL3U)A-=+I495W5E),XU6KQH*A&+5NNNI]@6%_IWQ@^$/
MAVRT'Q1;Z%<V1B,Z-+Y;#;C*D9'I5[Q5\0O#]W\5_!NC6^I6UW=V08SW*R J
MOR]-W2OC./X.>/8<E/#6J)GKMB(I!\'?'B/N'AG5 W][RB#7-]4I<S?M--;;
M=3L6-K**7LW?2^_0^S?"^M:>O[1_B>=K^V6%K% )#*H4_0YYJEX$\7:)XCT3
MQKX3@UN#2-7DNIPDS2!<[CPP.>?PKY"'PA\?ABX\.:L&/4B-LFF#X.>/ V\>
M&=4#?WO*.:7U2G_S\[?@/Z[5_P"?3Z]^I]5?%+Q?IWPM^"%OX=NM?AU[7P5\
MN2.0.Y(;.X\\8KN=+^*N@1_"ZW\;R3VS:I%8A"K2+YA(ZKC.>M?#C_!SQY*V
M7\,ZFS>K0DTO_"GO'VPI_P (UJFS^[Y1Q^5#P=&44G/6]WYB6.KQE=4]+66_
MWGVUXW^)^@Z?\*M1\86<ULNJZA9*F%D7?DC & <\5\\67[5.G1>$8]&F\'VD
MEQY(B>](7?GNW3K7EA^#WCYHPA\-:H5'13$2*9_PI;QS_P!"MJ7_ 'Y-:4L+
MAZ:]Z5]>YE6Q>(J-.,6M+;?\ ^X9%\.?$CP7X/O'\0VEE'I\L5S@S+EF ^Z>
M>*75;^UO_P!H3PZUK<PW"C3W&Z)PP_,5\0K\'_'R*%'AK50O4#RC@5V_PCTO
MX@_"SQ;'K@\&ZEJ+)&4\J1& Y[YK"6$A%-QG?>RTZG5#&SDXQG3:U5WKT^1]
M>6]E;>#?'GB;Q)JOBJW;3YX@!823C,) Y&TG]!7YZ^.]3M]9\<:Q?6AS;7%V
M[QGU4MQ7H'Q.\*_$#XB^,+_77\(:G9_;"&-NB$J,"N2_X4MXY_Z%;4O^_)KJ
MPE.%+WI33;7D<F,K3K^[&#23\]3[2;XIP_#K]G[2M4L7LKV]@M8P+:24<GZ
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M-O@5X6O[VZCU*>*6":>(2JTCXZYP:^8-7^%OCO4=1N[B+PIJ=K#-(SB!8SA
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M $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3
M]*,#TI:* $P/2FR*&1E/<&GTAH Q[8[$91V8BBFV_23_ 'S10!9T+_CQ/^\:
MTJS="_X\3_O&M*@ HHHH **** "BBB@ KAO&F@RW7BOPSJ-K:>;/#-())><*
M-GRY]!FNYHH \I\$>'=?TWXEZI?ZG:*5NK1?,NTD+*6#'"CZ#M7H^I//;PF:
M*4*J8RI7.>0.M7ZI:Q_R#IO^ _\ H0HZ6#K<N*<@4M(OW1]*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-:FZ-25-] G%PDXL6BBBLB HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ^#N;?4/%MH?^66IN0/3=S7IV>:Z<9)SKRD^IK6UFV+1117&8!1110 4444
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M8KXT^Z7Y&U;XD_)#J***Y3$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534K^'2K*:[GW^5$"S;%+'
M'T%6Z:RA@0PR#U!&0: /.Y_CKX92%F1KMGQD VS $_6J&G_M Z'=3;9X;F!
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M%N,8KV;1M1.KZ5:WIMY+0SQK)Y,XPZ9'0^] %^F2+YB,N2N1C(ZBGT4 >?\
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M&.4TJT*$I2O*^O+*VGR_(]6&58J<'-15EYK_ #/6,<YJ)[J&.01M,BR'HI8
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MS1!-&XR"1CK7N$,*6\:Q1HL<:C"JHP /05X%IO[./B[2?$&HZW:_$N]BU+4
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M<QM<0JQ0^V15E-+LXYO-6VB638(]P0 [?[OTIEEK-E?V%M>Q7,;6]R@>*0L
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M 4444 %(:6D- &);=)/]\T46W23_ 'S10!:T+_CQ/^\:TJS="_X\3_O&M*@
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MOT-1+#-KFI/F7EO]PG3=KPU1Z-15:._MIC'LGC;S1F/:P.X>HJS7*9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,D<(,DX]Z?5'5M+@UFPGL[C=Y,R[6V,5./8CI0K=1JU]1\^HVU
MK"\LLR(B#+$MP!5:V\1:;>3)%#>0R.Z>8JJP.5]:X"Z_9X\+R6TD<3:@CLN
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M@\2>"O"B:K<Z1IFJW+F\DM)/+D=47(7=VKV^N+^(7PG\/_$TV7]MPS.UFS-
M\$S1LI/7D4 >=? BZD\*>.O&G@M]8N-2TS3'BFM)+Z;?(H<<KN)YYKW=6#J"
M#D'N*\:C_9-\ Q3R3)!J"32??D6^D#-CU.>:]9TG2X=&TVVL+;?Y%O&(TWL6
M. ,#)/6@"]1136SM..N.,T !( K@?BOK.H:7I42609$D8B251G;Z?2G^&=1U
M>Z\3R1'4$U*SC5Q=-&N(XI-WRHA[\=:Z;Q T;V+Q20M*K@ G;E>HZUX^;8*M
MF&"J8:C5=.4EI);HZ<+5A0K1J3CS)=#C_A/XFN];MKBWO&:9H""LK=P>QKT,
M#(KB-*FLO"GB>\L6:.WM[H++%V&>A%=PI# $=*\GACVU' +"8FK[2I3;4GUW
MTOUV.K,>65=U*<>6,K-%>]TZVU)%6Y@295.5#C.#ZBLF_P# V@ZE:M;W&E6L
MD3G)S$,Y]<]<UT%!K[",YQ^%V/(E",OB5SP^7X1:YI6NO>^'[RYT\I(5A\R<
M21K$>V#S^%;6LZC\0_".GM-/<:5K$?W5;887R>![5ZK@8Q4<D*RIM=%=?0C(
MKN>-E.WM(IV\M?OW.-811OR2:^?Z'E_@/XOPSA=*\3-_9VL(=N^0?NI/3#=*
M[3Q;X8L_&FBO:3$<_/#.AYC<<JP-6=4\,:5K5F]I>:?;S0/U4QC\P1T-<4W@
MOQ'X'8S^%K\W]@.3I-\V0!Z1OV_&LZL*&*NE[K?1[?)] _>TH\LUS1[K?YKJ
M7? 'BN[6[E\-Z\=FLV8^61N!<1]G7UKO@1S7A_C3QCIWB'3&N9(+C0/%^ECS
M8(9EP[D=54]&4U)\,/VAH->M6C\2H-+N%;:MP5(B?V)[&O$E4>#J+#U].S?5
M>HZ>)A?D<K]G_F>W"EJGI^J6FIPB6TN8KF(]&B<,/TJWFNU-/5'<+1115#"B
MBDS0!PGQ ^"_A+XDQYU?2T6]7F._M3Y-Q&?577G\Z\\'AOXJ_!T[M"U!?B!X
M=C_YAVH$)>Q*.R2=&_&O?1T/-&./6M8UI15GJNS,W!-W6C/*_ _[17A?Q;>C
M2[YI_#.OCY7TS5T\F3=Z*3PWX5ZFKJX!4@J>XKE?''PO\,_$6R-MK^D6]]C[
MDK+B2,^JL.0:\N/PS^(WPF)E\"^(#XET9#G^P==?<ZK_ '8IO\:OEIU/A=GV
M?^9/-./Q*_H>^X%8GB7PKIOBG3Y+;4+"&\0@X65>A]CU%>;>%OVE-$O-131O
M%EG<^"M>)V_9=47;'(W^Q)]TC\:]?@GCN8EDBD62-AE74Y!%9VJ49)[,UA-;
MQ9XK8?"'Q7X+NX[WPUK,4B@$'3]0S)&BY^ZC=16_;_%Z[T"1;;QAH5SH[YQ]
ML@4RV[>^1T'UKTX'@U'/;Q7431S1I*C#!1P"#^!KJEBO:_QHI^:T9T.KS_&K
M_F4M&\1:9X@MEN-.OH;R)AD-$X-:0KSS6/@MHUS<M>Z/+<>'=1Z_:-/?:"?]
MI>AK..H?$+P1Q>6L/BW3E_Y;6W[NY ]UZ&I]A3G_  I?)Z/_ "#DC+X']YZI
M]#2_6N&\.?%[P]K\XM7N#IFH=#:7P\J0'\>M=NC!AN5@RGTKFG3G3=I*S,I1
ME%V:'T445!(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4AI:0T 8EMTD_WS11;=)/]\T4 6M"_P"/$_[QK2K-T+_CQ/\ O&M*@ HH
MHH **** "BBB@ ICH)$93T(P:?10!S_A_P $Z5X8=FTZ)X%8L2GF$J23DG![
MYK3UC_D'3?\  ?\ T(5=KB_BAXAN?#7AYKJV596'6(CD@$'/X4 <O\5_"EP9
MAK4,AD10JM'@DK[CVJ]\//B0E\(M-U [;GI&X& 1Z'WK9^'?BV3QUH9N9X8Q
M%]P\@Y/<8]*3_A56C_VE)=XD!8DA%; !/<5^6XSA[,<!F_\ :>335JC_ 'D)
M-V?FM_R/HZ6.H5L)]6Q:=X_"T=F,'!!_&C/H:\[\6^%-7L-*;^Q[^[F4GF M
MD@>QZT[PDWBW3M)07%JEP,D@328<#T->\N(*U/&_4Z^$G'2_,ES1]-#B^HPE
M1]K"K%ZVL]'^)Z#C)YI>@^E>47/Q.U>T\2"UGLA%"K8>)5+-CN<]Z[RV\8:1
M<V[2B]B4*,L&."OU!KJR_B7+LQE4C"?*X.S4O=>G57,J^7XB@HMQNI=M?R-S
M)[4=JS]+UBSUF$S6=PDZ XW(<U? KZ.E5IUH*I3DI1>S6IP2C*#<9*S1S/CG
MPC:^*]#N();*&YN-I\IGX*GU#=J\UT;X6>*/"T4UOI7V*YTMOG.GZF%EWL>N
M& XKW#]*,?6N^%=QCR-)KS5SBJ86%27.]'Y'S[<V>EZ1=9U32=5\$WI.!>:<
M[26Q/KQQCZUE:7J?CF3XCQC1_$%MXAMDAW(9)0J2)Z,!T:OI.:WCN(S'*BR1
MD8*L,@_A7E.H_ N&[U22\MIXM,G>;S/M-GNCD"^F.E<\L'@\1JVZ;6ONO1_(
MXZE"K!KV>JOZ/_+\#6_X63KND\:UX0O80.LUDPG3ZC'-7;#XR^%[U@DEZUC*
M?^6=[$T1_45G?\(QXY\._P#(+U^#68%Z6^I1X8CTWBJ>H>,981Y7B[P5,J=#
M=01"XB_QI?4ZZ_@U%+UW_0V56<?CNO5?JCTBSUBQU- UK>07"GH8I W\C5L>
MQKR*P\/_  U\52;M*N8]/NCU6UF:WD!_W3WK97X>>(=+&[1O&-WL'W8K]!,O
MTSUKGD\12=JE/[G^C-XU7)72NO)GHPXH/->=?VG\1-%'^D:;IVMQ#^.UD,3G
M_@)I4^+ZV)VZUX>U72#_ 'FA\Q/S6H^LP^U=>J?Y[%^UCUT]3T049KE-)^)_
MA?6&"6VKVWF=/+D?8P_ UT\-Q%<(&C=9%/\ $I!%;QJ0FKQ=S12B]F8_BOP5
MH?C?3GL=<TNVU*W<8VSQAB/<'J#]*\:U+X->*_A1#<:C\-O$LOV&)3(WA_6"
M9X& YPC'YEKZ!XI" 1@UTPJRAINNW04H*6O4^4_#'[5OB+2=5MX?&/AO4?+E
M5FE&FVHN$CQW4H2Q'UYKU+2OVI_AOJ;!)-=.F2_\\]2MY+=A]0PKTNST'3]/
MN);BUL;>WGD^_)'& S?7%0:KX2T37$9=0TFRO0W43VZ/G\Q6TJE*;^"WHR5&
M<5O<@TCQYX;UY%?3M=TZ]#=/*ND8_D#6ZKJZY4@CU%>5ZM^S#\-=7D>4^%[6
MQN&Y,UB6@?/U4UB/^R_!IK%_#?CCQ3X>?J%CO3-&/;:_:IY:+VDUZK_(=YK=
M'J7B/P3HGBN!H]4TZ"Y]'*8<?1AS7%-\-/$/A$^9X2\0R^0O(T[4_P![']%;
MJ*Y\_#KXR:!DZ1\1;'5T!XCUFPRQ'IN6E'B[XW^'P1J'@O1/$$:GE],OC&[#
MV5A6\'.&D9IKL]OQ-(UY15FG;[SHHOB[>^'Y%M_&&@W.E-G'VVV4S6[>^1R!
M]:[S1?$FE^(K59]-OH+R(\@Q.#7CTO[1=W8QM#XI^&7B?28S\KR"V%S$?Q7/
M%<O/\0?@UK5[]HL_$,W@?66/#-&]J2W^TI&TUHZ4*F\7%^6J_P T:>THSW?*
MSZ='Y4'BO#=&^)FN:2JFVU;2/'6G#H]E<HEUC_=SS7<>'?C'X<U^86LER=+U
M#H;2^'EOGVSUK">$J17,ES+NOZN-TW:\=5Y'=BEID<BR(&5@0>XI]<9F%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !2&EI#0!B6W23_?-%%MTD_W
MS10!:T+_ (\3_O&M*LW0O^/$_P"\:TJ "BBB@ HHHH **** "BBB@!N:Q_%&
ME6^K://#<IOCP,KTR,CCZ5K#GZ^U<G\3=<NM \)7UY;0JXCC)+O($"'C!YZU
ME.I[.+FU>W;4NG!U9Q@G:_?0XOQ%8R?#77([O05N(]+E3_388D+*F!PP]\5T
MGA;XNZ3XGNTL[<.)>A,K <>M<OX0^+NF^,;.'1M>#VMQ*NYI3*!'*H&<@CJ#
MZ5TEM\,/!TXVPPARV)0ZR$, >A!]*PH8JEB%>,O\UY-'3B,)6PTN6I'_ ":[
MIGH6<CBE'2O*O$?A[5O"EGYN@^(9C&I^6SN2'XQS\WI]:?X9\4>,6T[?+I]K
M>ONY+7(5OR]*Z>>'<YN25KV/2'L+5IO.:",R]G*C/YUA>*/!-GXBL9$$:07!
M'RRJN#7!W'Q2\26>NBUN=';R=^&^SX=@,] :Z:?XOZ19P[KNUOK1P1E)H"N!
MZYKS\1@,)C*4J-6"E&5[_/\ 4TIUJM&2G%M-%?P]X'UGPA"SV%Y%<,YR\$BX
M4_0]JVX/&J6T@AU:UETZ7IO89C/T:FZ#\2]!U]':&\BA4':/.<*6^@K>,MAJ
M414RV]RC=@RL*\G#Y)_9M)4LMJ.,5M%^\OQU7R9TU,7]8DY8B-V^JT?^3)K6
M\ANXQ)#*LJ'H5.14^<@XYKBM?\'+:V-Q<Z-+)97 4D1QOA#^!Z5SO@>'Q=&9
MQYR*N<A;L[L^XQVKDJYYBL+BZ>#KX23<D_>CJM/ZV-H8*G5I2JPJI6Z/1GJ^
M:0D=.]<P1XJ Y>P)]@PKSA_$'B-?&0B-RK2B3;Y0;$9]JO'\1?4?9WPU27,T
MM%M?J30P'M^;]Y%65]SVX'V%#*&&",BN675_$4.-VD0S#_IG.*5O%FIQ'$OA
M^ZQZQLK"O4_MG#KXE*/K"7^1S_5*CV:?S7^9-K?P^\/>(LF]TN!Y/^>B+M<?
MB*YP_"W4M%._PWXFO; #I;W1\^+Z<\UO#QS''Q<:;?0?]LB?Y4]?B!I.,.\T
M1_Z:0L/Z5UT^(,+%6==)=I:?@SFEELY/F]F[]U_P#G/^$A\=^'/^0EH=OK=L
MO6?3I-LGU*&KEA\8?#E[(+?4#-I-P>##J,)C&?3)X-;T7C;1)NFH19]R11>W
M&@:]"8[DV=Y&>-LNT_SKLAFF7XC[47Z-?D<\L)B:>U_FOU*]SX7\+^*X=[V-
MA?*W\<:J3^:UAR_!C2;=S+I-]J.C2=A;7+;!_P !-,NOA-H#R>?HM[<:'<=0
MUA<87_OG.*C%AX_\.#-KJ-CXCMA_RRN5\N;'^\.#6KP^#Q&L)IOST?WK0YI<
M\7^\I_-:_P#!'CPOXZT;G3_$T&IQCI%J$&&/_ A2'QIXST52=4\*+>1*.9=-
MG#DCUVFG1_%Q]+81^(_#^H:,W0RA/-B^NY>U=3HOC30_$* Z=JEM<Y_@60 _
MEUK*6!J4U>#:7WK]1QE!NT)6?;_@,\Q\,?M)6>IZY?VFI:7<Z?;PMA)!&SL/
M9P!Q7<VGQ;\)W> -:@C)Z+-E#^M;UGI6E0W5T]M;6RW$IS.44;B?]JDN_"VD
M7P(GTRTES_>A4_TKEIT\537O23?I;]32*JI:R3^06GBC2;X9M]2M)<_W)E/]
M:T(YXY1E)%8>H.:Y*Y^$7A&Z))T2WC<_Q1 H?T-4)/@IH:\VMUJ5BPZ?9[QE
M _"M.:NMXI_/_@%7J=E]_P#P#T#-'4\UYV/AEK-IG[#XSU2(=DG*R ?G2?\
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MF3<>&[!F/<1 ']*5\++HU]S_ ,@_=>9TUOKVG7:@P7]K,#TV2J?ZU>5PZY#
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&XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>plx-20250331x10q009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '/ K4# 2(  A$! Q$!_\0
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M?^9CO_\ OZ:3_A;GC'_H8K__ +^FN1HKN]E3_E7W'G>VJ?S/[SKO^%M>,?\
MH8K_ /[^FC_A;7C'_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\
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M!N+.1O#4%B+I(_,(/S< ;OK7-_M8?!CPW\-;?P__ ,(S8R02WLCHX,A<M@<
M5S1Q&'G.,%'5Z[(Z9X7%4Z<IREI%VW9XS_PMKQC_ -#%?_\ ?TT?\+:\8_\
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MMKQC_P!#%?\ _?TU]F:_^SQ\'/#%WIEIJ=H]K/J,GE6RO<-\[^E<!XN_9?\
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MN^(XN4@_X1>\+NN\8 QCZYJM8_ #X@ZE<7D,'A>^:2U;;*"@&#Z#/6IYL/\
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M1AO7!]A6EZ%[:7^1C;%6YO>M\S/_ .%M>,?^ABO_ /OZ:/\ A;7C'_H8K_\
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M'9?J?:O8M-_M=OV;=*'PW,?]I>3'M\O&[.?GS[U\3>+OBQXM\=0+!KFN75_
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M %%%% 'WG^QPVWX-P_\ 7Y-_,45'^QW_ ,D=A_Z_)OYBBOB,5_&EZGZ)@_\
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MBSX7T[3K%K73K>X58HW.6(R"S-Z<"M7]MKQE9ZAXCT;PW9NL@TJ',S*<[7/
M7\JTHPG"=*+5FD[^AA7J0G3KRB[Q;5O4^9:***]X^;"BBB@ HHHH **** "B
MBB@ HHHH ^[OV//^2/0_]?DW\Q14_P"Q_;2VWP?M_-5X_,N977(ZJ3P:*^(Q
M7\:7J?HF#_W>'H=9\3_V>/#OQBL+2YO&DL-3B3:MY !N*^C#O7EW_# >E_\
M0UWG_@.E?4VD_P#(/A^E7,BIABZ]./+&6@5,%AZTN><-3Y-_X8#TO_H:[S_P
M'2C_ (8#TO\ Z&N\_P# =*^L<T9-:_7\1_,9?V=A?Y#Y._X8#TO_ *&N\_\
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M_P" Z4?\,!Z7_P!#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y3Y._X8#TO_ *&N\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !24M% "48I:* ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B
M@"_I'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **BFF2WC:21UCC499
MF. *YUOB'HITR"_BN'N8;B5H8A!&6:1E^]@>U '3T5C/XJTQ/#XUDW ^P%=P
MD Y/.,8]<\8J30_$5GXAADDM2X:)MDD4J%71O0CM0!JT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8E]_R$)?]U?ZT47W_(0E_P!U?ZT4 7](_P"0?#]*N53TC_D'P_2KE !1110
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MCU%(751R0* NAU%1M,B]74?4TTW,2\F5 /\ >%.S"Z)<BC(J'[9!_P ]X_\
MOH4S^TK3_GZA_P"_@_QHY9=A<R[EJBJ?]KV/_/Y;_P#?Q?\ &L^?QAI5OJMI
MIQO(FNKG/EHC!NGKCI34)/H2YQ74W****DT"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B@"_I'_(/
MA^E7*IZ1_P @^'Z5<H **** "BBDW#UH 6BBB@ HHI"0.IQ0 M%%-!##(.:
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M2CX27K1[9/&>N/ZGS%']*]'HJ?K57O\ @O\ (?U:GV_%GFZ?!Z4 A_%FMO\
M]MP*$^"T2MEO$NML/3[617H^?\YHS1]:K?S?@A?5J78\V_X4?I[2;VUW7&.<
MG-\W-.;X'Z2QR=4U<G_K]>O1\^]%/ZU6_F#ZK1_E/.V^"&B/C=>:FV/6\?\
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MF'PTG\2W?PL\10:G%<B :"IC:X=3_P M!SC:*J^(OVEKCPM\-M+\6ZA\.O%
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MY_*IPO%.!QU!8B@I-/M%]/.UOQ(J997IU/9SM?U7Y;_@//A[QM(.?$EJG/\
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M17?T47ZDG$_$'PM?^(M5\*3V2HT>G:B+F?<VW"!2./4UV]%%!04444 %%%%
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MOTWQ:/ >K227=[):'3PI\V,(,[SQT-9_@S]M>]\67M] WP]UBQ%M9RW8>92
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M  UMH[H7^MW,FMZCUW7!_=H?]E>E=G'&L2A44*HX"J, 4^BM!A1110 4444
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M$3Q2+!-$DB0\;R7P%7ZY-3>&_$_]NS7UM-9O8WUDZK-;NX?&X9!!'7BN=N/
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M%4='MA9:590 8$4*)^2@5=Z5Q5)<TY2[L[:<>6$5V05R'Q5UAM%\#ZC)$?\
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M+Q5=YPL>DVC2*3_OXP*Q/ '[*FCZ;JJZKXJBA\1:A''L$MT[S&1R<F0[N![
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MH;F*W^1]/LX1][V!ZU/VM/ZU0_LZ_P!:'T_\&;J.\\%0R1^%)/!B^:X_LN0
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M7 ]*6BI)(XXDBR$14!Y.T8J2BB@ I*6B@ HHHH **** "BBB@ HHHH ****
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M5JB^)]Y-\3?&EE\/M.D86$)6ZUN>,\+&#E8L^K5Z9JFM:/X&T2-KJ:*QLK=
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M0"I<5$ZS:Y(*T>W^?<<**B^:3O+O_D%&*6BL#H"BBB@ HHHH **** "BBB@
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MZ1\O\RE\-OA'X?\ AE9NNFPM<7\WS7.I7)WW$[=RS'^5=R!BJ']JG_GSN_\
MOU_]>C^U3C_CSN_^_7_UZXI2E-WD[LZXQC!<L59&A16?_:Q_Y\[O_OU_]>C^
MUC_SYW?_ 'Z_^O4EFA16?_:Q_P"?.[_[]?\ UZ8^MI&Z(UK=!GX4>5U_6@#3
MHK/_ +6/_/G=_P#?K_Z]']K'_GSN_P#OU_\ 7H T**S_ .UC_P ^=W_WZ_\
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M_?K_ .O0!H45F1:VDV_9:W3;6*G]UT([=:?_ &L?^?.[_P"_7_UZ -"BL_\
MM8_\^=W_ -^O_KT?VL?^?.[_ ._7_P!>@#0HK/\ [6/_ #YW?_?K_P"O1_:Q
M_P"?.[_[]?\ UZ -"BLPZXBRK&;6ZWL,@>5_]>G_ -K'_GSN_P#OU_\ 7H T
M**S_ .UC_P ^=W_WZ_\ KT?VL?\ GSN_^_7_ ->@#0HK/_M8_P#/G=_]^O\
MZ]']K'_GSN_^_7_UZ -"BL_^UT#(KV]Q'O8*&>/ R?QK0H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@#$OO^0A+_NK_6BB^_Y"$O\ NK_6B@"_
MI'_(/A^E7*IZ1_R#X?I5R@ HHHH **** "BBB@ K)UWPW8>(X8H[Z(R")M\;
M*Q5E.,<$5K44 8A\(Z6VF_8#:C['Y7D^3D[=N<_GGO4VA^'+#P[#+'8P^6)6
MW2,S%F8].2:U:* ,W4]4TVQD@2_NH8'9@T:RN 21W%:"L&4$'(/(->2_$2,V
M_B?5Y+N!I(KO1OL]CB$O^_W=!@'!Z5Z1X=AFM_#^F17.?M"6T:R9Z[@HS^M"
MVN+K8U****!B4M%% %6>YMEE2VFE19)P0D;-@N,<X%5[#6-.NYGM+2[AFEA&
MUHHW!*XXKC/&&C/)\1/#5Y;QR-*T=TK2<E4_=X7V'-<YX"MY&UCPM!#"\=Y8
M1W0U-C"4Y).T,2.<FA:@]#VBBBB@ HHHH HZAK5AI.S[9=PVV\X7S' S4*ZO
MI=I<162W<"3L,I#O&2#SQ]:XKXI:UIMG-;Z?):++J=_"T*74L#/';QG[S$@'
M!]!7%+I9T^+4-*@\VZU":]LWT^X:%BS0J!E@V. ,'-"U!Z'OU%%% !1110!7
MO+V#3[=I[F9((5^\\AP!5"37M(MHX[U[^W2.?Y$E,@P^.PJ#Q=-9V^EJ]] T
MT D7#+%YHB;LY7N!7BNBVDND74D^J027&DR1WL5K,UN2)9&.5;9CY<]!]* /
MH2.1945T8,K#(8'((J2N>\!6UU:>#M(AO PN4MU#ANH]C^%=!0]'82U5Q:**
M*!A6;<ZGIT32R374*FT/[QF<?NLCOZ9I^LR7L>EW3:=$D]\(SY,<C;5+=LGM
M7S_8Z-K>G7VO/J6F311#4[*ZO96D\\2@*=^ !R.G2CK8.ESZ&L;^WU*!9[69
M+B%NCQMD59KA_ABK&+7;F-&CL+G49)+12A0;,#D ] 37<4 %%%% !65+K6E3
MWAL7NX6N4;)AW?,".>:U:\3URQN+.YU6+P])>7&K7L\_VJWNH,"-&0_,IQ],
M<T >O6&M6&JF06=W#<F,X;RG!Q5ZO)_ANGG^(].ELX6AMK;14M[S,1C!GW#@
MY R>O->L4VK %%%%( JC>ZQ8Z;)&EU=16[R'"+(P!-7J\:\=:?>+XSU:XG:5
MXYK.%=.@$)=)9 WS(3CC]*.H'J=OJNF)=_V=#=P?:5_Y8*XW#OTK2KPS0;6[
M^V:=8R6S1Z]'KAN9R(B-L&/[^/N]NM>Y#I1TN M%%% !5+4M8LM(C5[VYCMD
M8X!D.,U=KD?B;)*OA6>.WM_/N;ATMHR(]Y3><%O; SS2] -.#Q-HB1Q/'J-K
MLNF+(PD&'.<$BMH'/(Y%>(>)M!A\,WFJ:<MJ3%-I$5MIH2 O^]#?-@@<'/->
MPZ-'+#H]C'/_ *]8(U?/]X*,_K5=+@7Z***0!44TR6\322.J1J,LS'  J6N6
M^),,]QX*U2*V@:YE>,+L0\@;AD^^.N/:DP6YI-K^CF 7YO[?R4/E^=Y@P">U
M:-M=17D"302++$XRKH<@BO!;&UDL?$%M?7)>_P! AO5:>Z^RE$<^5M'[H#^$
M]\5Z=\*K>XM_",?GHT:R3RR0HZ[2L9<E1CMQ3 [*BBB@ HHJ.9/,A=,D;E(R
M.O2@"A_;&EWC2H+R"0VQWR ./DQW-3:?JUGJ\32V5S%=1J<%HV!P:^>M8T'6
M+VQAM-*4F/3H[@7++"Z2R*7SA\CD]>F:].^'92Y\2:Y>V,;1Z3)#;I'^Z,:F
M14^; (%-:@]#T2BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 8E]_
MR$)?]U?ZT47W_(0E_P!U?ZT4 7](_P"0?#]*N53TC_D'P_2KE !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 @Z4$UXO^T'\+M6\8V#ZSIWC#4O#HTVTD<V]D0%F(!/->
M2? 'P+KU_P##Y/B%JOCO6[V);:Y:33#(-I"@CACWJ5U;Z!;;S/L2D-?-/A[]
MHVP\#?#CP-,NE:OK0UUY(H1+,LEQN!X!/?)J_%^ULT[ZQIX\!ZW_ ,)#I>7N
M=+&TLD0&2[-T Q5/0$?1%)TKQJZ_:9T&/X>:'XFM+&[OKG6I3;V6E0@>=),.
MJ>G'K6[\+?C+;_$6^U+2;O2;OP]X@TX*UQIM[@NJGHP(X(HL[M"OI<])HKQ?
M]I#QGJ&DV?AKPUH]P]IJ7B#48[;SXSADB!!?'U'%3>,?CS#X-\66_@_1_#^I
M>*]8M[=9;J.RQF"/'WF)ZFCI<9[!U-&,&OE?X#_&F>P\'>/_ !)K']I:FD.K
MLEM9;2\PSG$8';FNU\.?M,OK&L:GHFH^#]2T37;6P?48+&Z=<W$:C=P1T.*/
M\K_J'4]UHKQV\_:-TN#X1Z5XW@TZ:X.HS1VT6FJX$HE9MNPGU%9.H?M/3'Q#
M>Z5HG@K5-?;3BJWTEK(@\ER 2H4G+8SVHZV#I<]W(ZT =*\*^,7CG4O!NK_#
M[Q= US9Z==W2V-_I\W&%E P6']X&O=$<.H8<@C(I6TN+J.HHHIC"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B@"_I
M'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N [
MB@!:*3</44;AZB@!:*3</44%@.XH 6D(K%\6^)(/"/AN_P!8N1NBM8RY4'&X
M] /Q.*Y3X5?$K4?'LNH1W^GV=O\ 9]K)-I]V+B/G^!B.CCN*%J&QZ-17D=U\
M9-6@\022QZ'"_A*'41I<VHFXQ,),X+!/[H.!6\_QR\"*TZ_\)+9Y@5F<9;@
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M* -.BLS^VO\ IW;_ +Z%']M?].[?]]"@#3HK,_MK_IW;_OH4?VU_T[M_WT*
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0VB+*6/4\FBKL4.%HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>plx-20250331x10q010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250331x10q010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A K4# 2(  A$! Q$!_\0
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M8U;_ *]K;_T UPU?4X>G!THMI;'QV)J3C6FE)[FK_P )EXF_Z&75?^__ /\
M6H_X3+Q-_P!#+JO_ '__ /K5E45O[*'\J^XY?;3_ )G]YJ_\)EXF_P"AEU7_
M +__ /UJ/^$R\3?]#+JO_?\ _P#K5E44_90_E7W![:I_,_O-7_A,O$W_ $,N
MJ_\ ?_\ ^M1_PF7B;_H9=5_[_P#_ -:LJBCV4/Y5]P>VJ?S/[S5_X3+Q-_T,
MNJ_]_P#_ .M1_P )EXF_Z&75?^__ /\ 6K*HH]E#^5?<'MJG\S^\U?\ A,O$
MW_0RZK_W_P#_ *U'_"9>)O\ H9=5_P"__P#]:LJBCV4/Y5]P>VJ?S/[S5_X3
M+Q-_T,NJ_P#?_P#^M1_PF7B;_H9=5_[_ /\ ]:LJBCV4/Y5]P>VJ?S/[S5_X
M3+Q-_P!#+JO_ '__ /K4?\)EXF_Z&75?^_\ _P#6K*HH]E#^5?<'MJG\S^\U
M?^$R\3?]#+JO_?\ _P#K4?\ "9>)O^AEU7_O_P#_ %JRJ*/90_E7W![:I_,_
MO-7_ (3+Q-_T,NJ_]_\ _P"M1_PF7B;_ *&75?\ O_\ _6K*HH]E#^5?<'MJ
MG\S^\FT?QIXG;[;GQ+JO%TX_X^/I[5?_ .$R\3?]#+JO_?\ _P#K5S&B];[_
M *^I/Z5I4>SA_*ON#VU3^9_>:O\ PF7B;_H9=5_[_P#_ -:C_A,O$W_0RZK_
M -__ /ZU95%'LH_RK[@]M4_F?WFK_P )EXF_Z&75?^__ /\ 6H_X3+Q-_P!#
M+JO_ '__ /K5E44>RA_*ON#VU3^9_>3:UXT\3I;PD>)M5_UR#_CX]_I5_P#X
M3+Q-_P!#+JO_ '__ /K5S&N?\>\'_7=/YUI4>SA_*@]M4[O[S5_X3+Q-_P!#
M+JO_ '__ /K4?\)EXF_Z&75?^_\ _P#6K*HH]E'^5?<'MJG\S^\U?^$R\3?]
M#+JO_?\ _P#K4?\ "9>)O^AEU7_O_P#_ %JRJ*/90_E7W![:I_,_O-7_ (3+
MQ-_T,NJ_]_\ _P"M5"/QIXG_ +<F7_A)M5QY*G_CX]_I4-9L7_(>G_ZX+_.C
MV</Y5]P>VJ=W]YT__"9>)O\ H9=5_P"__P#]:C_A,O$W_0RZK_W_ /\ ZU95
M%+V4/Y5]P>VJ?S/[S5_X3+Q-_P!#+JO_ '__ /K4?\)EXF_Z&75?^_\ _P#6
MK*HI^RA_*ON#VU3^9_>:O_"9>)O^AEU7_O\ _P#UJKZAXS\3+I]R1XEU7(B8
M_P#'Q['VJE5;4O\ D'W7_7)OY&CV4/Y5]P>VJ?S/[S6T_P 9^)FT^V)\2ZKD
MQ*?^/CV'M5C_ (3+Q-_T,NJ_]_\ _P"M6#IO_(/M?^N2_P A5FCV</Y5]P>V
MJ?S/[S5_X3+Q-_T,NJ_]_P#_ .M1_P )EXF_Z&75?^__ /\ 6K*HH]E'^5?<
M'MJG\S^\U?\ A,O$W_0RZK_W_P#_ *U'_"9>)O\ H9=5_P"__P#]:LJBCV4/
MY5]P>VJ?S/[R:Z\:>)QJ]@O_  DNJX(D_P"7CV^E7_\ A,O$W_0RZK_W_P#_
M *U<Q=_\AK3_ /=D_E6E1[.'\J^X/;5/YG]YJ_\ "9>)O^AEU7_O_P#_ %J/
M^$R\3?\ 0RZK_P!__P#ZU95%+V4/Y5]P>VJ?S/[S5_X3+Q-_T,NJ_P#?_P#^
MM1_PF7B;_H9=5_[_ /\ ]:LJBG[*'\J^X/;5/YG]YJ_\)EXF_P"AEU7_ +__
M /UJH:%XT\3R:;&3XFU7.6_Y>/\ :/M4-9OA_P#Y!<?^\W_H1H]G#^5?<'MJ
MG\S^\Z?_ (3+Q-_T,NJ_]_\ _P"M1_PF7B;_ *&75?\ O_\ _6K*HI>RA_*O
MN#VU3^9_>:O_  F7B;_H9=5_[_\ _P!:C_A,O$W_ $,NJ_\ ?_\ ^M6513]E
M#^5?<'MJG\S^\U?^$R\3?]#+JO\ W_\ _K50UKQIXG2UC(\2ZK_K4'_'Q[_2
MH:SM<_X]8O\ KLG\Z7LX?RH/;5/YG]YTW_"9>)O^AEU7_O\ _P#UJ/\ A,O$
MW_0RZK_W_P#_ *U95%/V4?Y5]P>VJ?S/[S5_X3+Q-_T,NJ_]_P#_ .M1_P )
MEXF_Z&75?^__ /\ 6K*HH]E'^5?<'MJG\S^\U?\ A,O$W_0RZK_W_P#_ *U'
M_"9>)O\ H9=5_P"__P#]:LJBCV4/Y5]P>VJ?S/[R6S\:>)VU;45_X275<+Y>
M/](_V3[5H?\ "9>)O^AEU7_O_P#_ %JYBR_Y#.I_]LO_ $$UI4>SA_*ON#VU
M3^9_>:O_  F7B;_H9=5_[_\ _P!:C_A,O$W_ $,NJ_\ ?_\ ^M6511[*/\J^
MX/;5/YG]YJ_\)EXF_P"AEU7_ +__ /UJ/^$R\3?]#+JO_?\ _P#K5E44>RA_
M*ON#VU3^9_>6]5\:>)ETVY(\2ZKD(?\ EX_^M4MKXR\3&UA/_"2ZK]Q?^7CV
M^E8>L?\ (+N?]PUD>+[R?3_ >H7-M(T,\5IN21>JG Y%1*%.$7+E6A<:E64E
M%2>OF=Q_PF7B;_H9=5_[_P#_ -:C_A,O$W_0RZK_ -__ /ZU?/W@WQ1K>EL^
MJ7<NK7ND1V1EN/[00#,F!M$9]":ZJ;XJ2:6DJ:IIGD7+0+<6\<4@82!C@ GL
M>:R4J+5W&WR-Y0KIV4K_ #/5_P#A,O$W_0RZK_W_ /\ ZU'_  F7B;_H9=5_
M[_\ _P!:O&_$7C[4/LLMC+"=+U2&>V<F&3<K1NV.O\ZLV_Q@AGUR6U%A(UHD
MKPF9 2P*CDD8QBCFHWLTON%RU[73?WGK?_"9>)O^AEU7_O\ _P#UJH7GC3Q.
MNK:>/^$EU7!\S/\ I'^S]*\IM?&^JZYXF\+R"$V.FWS2LJK(#YJ@<;AV-=_>
M_P#(9TW_ +:?^@UI"-.:;4?P,ZDJM-I.3^\Z;_A,O$W_ $,NJ_\ ?_\ ^M1_
MPF7B;_H9=5_[_P#_ -:O%?BMJVHVOB;2[2TO-2MX9('=DTU0SLP/&0>U6=!\
M9:]8:;8:;<V+7NL-"]R_VEPA$*GC=_M&LN:ES.+CMY&O+5Y%)2W\SV'_ (3+
MQ-_T,NJ_]_\ _P"M1_PF7B;_ *&75?\ O_\ _6KRB/XJ2:G&K:5IAN#':_:[
MD2R!=BY(*CU/!K,?XH?8;[4]3)EFLFMK=K>V8X"L]-RH+HON$HUWU?WGM7_"
M9>)O^AEU7_O_ /\ UJ/^$R\3?]#+JO\ W_\ _K5Y)9_%>;4+>WA@TMCJ4]S]
MF2-F*QGC.X$CIBM+X7ZQ?ZQI^IR:@[--'>R1A6;.P _=!]*J/LI2Y8Q7W>A,
MO;0BY2D_O/M+X+W%U??#'1;BZNKB[N)!(SS2N79CN/4T4WX'?\DHT'_=D_\
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M_P#9^DVB//$NEN'MY$?# ^Y[T*-7J^W_  0YZ2V11^)%PVGZ:MXVL3:;#&&
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MSH.FW4=Q#:$O&695=RRAFZG'K5C2? ^CZ+??:[6UV3#(3<Q(C!ZA0>E>V?\
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MKVZ'K%>7>/O#NJW7BV2]MXKNYAELEAMU@4-&LH<$^9G^$BH/^$?M/^FW_?\
M?_&C_A'[3_IM_P!_W_QJ?8ZWN/ZQY'J=JKK:PB0 2!%#!>F<<U+7D_\ PC]I
M_P!-O^_[_P"-'_"/VG_3;_O^_P#C3]EYA[?R/0O%G_(MZC_UQ:K>D_\ (*LO
M^N*?^@BO(?$6@VBZ'?$>=GRC_P MW_QJSIOA^T.G6I_??ZI?^6[^@]Z?L=-Q
M>WUV/8*XSXJ:'K'B/PU-8Z683'(C^?$Y(:4;3A5(]37-?\(_:?\ 3;_O^_\
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M4,71,NTD^G'I78^-/$.I0:O:V-C<&R7[!-?/)Y8;<4&0G-'MNM@^KO:Y@_\
M"2Z?_P ]G_[\O_\ $U&/%FEM,8A<L90-Q3R7R!Z_=KJ?!?C"YUK4_LET!F;3
MX;],#&T-PR_G6G:_\CS>_P#7FG_H55[7R)='S.'_ .$ET_\ Y[/_ -^7_P#B
M:/\ A)=/_P">S_\ ?E__ (FNY\<7&K0Z*%T4*;^65(U)91A2>2,\9Q7%_P#"
MQ[KR;RWAG(N--M99+IKE1GS0P0)QQU/45'M_(KZN^Y%_PDNG_P#/9_\ OR__
M ,31_P )+I__ #V?_OR__P 35C1_$FOZII>IQ-=R07MH4=8VA7[0ZE-VT+G'
M7]*Z'1=:U#Q%X#L+Y+N.VOIT^>14R<@D$*I_BXI^V\@^K^9RW_"2Z?\ \]G_
M ._+_P#Q--D\4:;&C.\[*JC)8PO@#_OFM'PWXZU&2'16OVW/<7TNG3QE-KJX
M^Z3Z'UKN?$7_ " -3_Z]9?\ T T_;>0G0MU/-8_%&FRQJZ3LR,,AA"^"/7[M
M._X273_^>S_]^7_^)KTCP[_R -,_Z]8O_0!7)^./$6J>&=4LKN.[#:<US'#-
M"L8*QJ<Y+MU!/:E[;78%AV^IA_\ "2Z?_P ]G_[\O_\ $T?\)+I__/9_^_+_
M /Q-37'BSQ#?6%AJD+>7IACFNKDPE-Z(&(4 'KP,TFC^/=2U&^M=12Y+Z?<:
MK_9RVC1 ?(5!$F>N:?MM;6']7TO<B_X273_^>S_]^7_^)H_X273_ /GL_P#W
MY?\ ^)J[XD\9:K8^(-5:"?R[339[6'[-Y8/G>;]XYZUU?A+79M5DU>TN3NGT
M^[: N!@,O53^5+VU^@/#VZG!MXLTM)4C:Y82/G:IA?)QUQ\M2?\ "2Z?_P ]
MG_[\O_\ $UW&K?\ (X:#_N7'_H(K"^(/BK5--UJRTO3%=#);2W<DR@'"IVYX
MINM:V@E0;OJ8G_"2Z?\ \]G_ ._+_P#Q-'_"2Z?_ ,]G_P"_+_\ Q-;6C^,M
M1\0:+K=]8O"PLX0L1D4@%PFYF(_I7/-X^URZTV.X6Z$#VNDQW\N(@1.[/M*^
MPQZ4O;>0_J[[D_\ PDNG_P#/9_\ OR__ ,31_P )+I__ #V?_OR__P 34_AW
MQUJVI:KI]U-+_HE]?RV?V,Q@>4JJ"&SUS4NJ>,=6A\07KQW'EVEKJ<.G_9?+
M!WJXY?/7-'MO(7U?S*?_  DNG_\ /9_^_+__ !-1P^+-+N(P\5RTB'@,L+D?
M^@UWO@O7I=<L;M;C!N;.ZDM9648#%3U'X$4G@+_D6;?_ 'Y/_0VI^VTO87L-
M;7.'_P"$ET__ )[/_P!^7_\ B:/^$ET__GL__?E__B:Z7Q]J6M6-U:'3BR6,
M44D]X\;)O"@<8#=:YZ\^(M]J-FTVFRL8I+R&SA"1@S."FYV /?I2]MY%?5WW
M(_\ A)=/_P">S_\ ?E__ (FC_A)=/_Y[/_WY?_XFG7?C+7AX0L];CO$+PMLG
M@CB!Q^\VEI.?E 'IWKJ/'FIZG9Z"U_I=UM:&$S^3'&'>3C(//11WH]MUL'U?
MI<Y7_A)=/_Y[/_WY?_XFHYO%FEVZAI+ED4G +0N.3V^[76^%/%D^J:R;*X9)
M!+80WT3QC  888?G5[QM_P @NV_Z^X?_ $*G[76UB71LKW.(_P"$ET__ )[/
M_P!^7_\ B:/^$ET__GL__?E__B:]9KRSQ#XZU;PCKDL=S<+>6UQ;N\#>6!'Y
MFX *A'7 /.:7M?(KZN^Y#_PDNG_\]G_[\O\ _$T?\)+I_P#SV?\ [\O_ /$U
M;U?Q1KOAW4KF\U&1O[)B"0Q&'80\NPDAAU&6%6_ GBC5+_5;:"^N/M27NFC4
M%'EA?*;?C;QU&*/:^0OJ_F9/_"2Z?_SV?_OR_P#\31_PDNG_ //9_P#OR_\
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MIZ/JVL/OTW4=2\JXL]/6ZN[I8@#O;G '3 %+VOD5]7?<R/\ A)=/_P">S_\
M?E__ (FC_A)=/_Y[/_WY?_XFE;5?$:>!X]3?69/MU]<^78Q^2O*NV$W?AS7<
MZW-JFC^#[B6&:.XU&WMF9II%PI95)+8'N.E#K6Z!]7UM<X7_ (273_\ GL__
M 'Y?_P")J-O%FEQR)&URRR29VJ87R<=<?+73:+XMO'N/"JW3+*NL618[5QME
M5 Q/T(-:VM?\C;X=_P"WC_T"J]KY$NCYG#_\)+I__/9_^_+_ /Q-'_"2Z?\
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M[.'8?M9]S.62U6V:$>$I &<.7^WKOR!@?-UZ<58;4XVL19_\(HZVR@!8UOD
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M[TO_ *&:*\^?Q,]"'PHYW6/"MSK/Q!\12IJTEHH6V 185;_EF?6G?\*]O/\
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M:1T5;A6%N#CY<DY;.#S[T>TG8/9T[E#3X[;4(]XU^^@_?)"RSV2*59QE2>>
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M:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3OM5]_T M6_P#
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M_P#GQ@_[X%.^U7W_ $ M6_\  ;_Z]'VJ^_Z 6K?^ W_UZ.;S#E?8;_8>G_\
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M*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O3YO,.5]AO]AZ?_ ,^,'_?
MIC>'=,>1)&L+<NF=K;!QGK4OVJ^_Z 6K?^ W_P!>JL^M7-O>VMJ^AZJ)+C=L
M'V?^Z,GO1?S%R^18_L/3_P#GQ@_[X%']AZ?_ ,^,'_? IWVJ^_Z 6K?^ W_U
MZ/M5]_T M6_\!O\ Z]'-YCY7V&_V'I__ #XP?]\"C^P]/_Y\8/\ O@4[[5??
M] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C!_WP*/[#T_\
MY\8/^^!3OM5]_P! +5O_  &_^O1]JOO^@%JW_@-_]>CF\PY7V.X^%-M##X"T
MY4B55W2\*./OFBF_"JX:3P'IQ:WGB;?*"DJ[6'SGM17GSOS,]>E\")HO^1X\
M2?[MK_Z+-9'Q6FF@^'FNO;W<UA,+9MMS;QF1X_< <_E67XBU/6K+XA^(5LI[
M9(F2V.)(R3_JS43:_P")64@W-B0>"#":KV4I1T.;VT82U[G@GACXG^(?!/A#
MQ!_8J3:C<Q26P%V\S3VB;^&<%QD'N0>!7::#\2O'OBZSMHYYK.RC_LBYO+EH
MH/,\\J2J[3QMS[5W\=]K<4#PI_9:0O\ >C6UPK?4=Z<NJ:]& %?35 78,6^,
M+Z?3VJG1DP6(@NAY?'\9/%6DV&E0PR0VQAL+66*QFM6DDU)G;#*C?PXK;A^.
M6NRZI!I9,*:G_:%W%-;O;-^[A2/='DX]>_>NT.I:Z6B).FDQ?ZL_9ON?3TH_
MM+7//,V=,\XG)D^S?-^=-T9,/K$.QB_ 'XG:_P".VUJVUZ6&>>UVLDEO!L0
MY^7=T/\ .O)O"9\0Z9XJTC5;E;FTMKC5;K9?_:I9/M&TMMMWC/RJ&XP:]UM]
M5UZTW"!]-A#'+>7;[<GU.*0ZGKK1JA;32BMO"_9N WK]:7L973%[>%FCQ>U^
M,/CCQKH&O1ZG#%:Q12PO%]E^6: ^>%V, /3UJ;5OC;XSUW6_$NB65PL%B+"\
M\B5;0K+!)$HQSU)//7\*]A&H:XOF '3 )#N?_1OO'U/K2#4-;$C./[+#MU;[
M+R?QH]C(KV\+WL>3:)\;O'5OXF\-:-;K;:E8&UM1)-,@1[LNF79>,Y4\<=^M
M:O@/XA>(/&'QB\.#4=24ILOQ+I<,#1_9MO"B0]&..>?6O1(]0UN-HV3^S$:,
M81EML%1Z#TI4U+7(YC,ATQ)B<F1;;#?G5>RE>_J3[:%K',^,/ =E<?&_33YF
MH+!<:=/>2I'=2",RJ?E. <#Z5P?P8\16^DW%SJVI3P27=LEW*=VH3/<,5+8!
MB/RU[,VM>(FD$AFT\R ;0Q@.0/3-55DU17+K!HX=NK"S&3GKVJ%1DBGB(/<\
M,T?Q9XHT?2/$XU:VUBS'B+2Y;VVDO&.U9@<XC(/RC81Q7J/[-<MK+#<,);5[
MMK6,N(+^6X8^I8/]TY]*ZF;4M=N%596TV15&%#VV0![4RTO-9L&9K5=+MF88
M)AM0I/Y52HR0G7BU_7D94GQ \2P&XG>1)H)+J]MHX%M]IC$291MW>F:GIVNV
M$VF:U:7LES%)9*PC#DL?W>7&/<G.:VVU37F4J7TX@YS_ */Z]?SIMGJ&O:?:
MQ6\,UBL40P@,).!Z4O8RL'MX%:P\97>I:9X?O(X6@FCU)+-D5B5EC9?F//7'
M\Z]6KRZ2XUJ2:UE+:>&MF+1!8" I/4X]:N?\)!XF_P"?JR_[\FG[&1/MHG2>
M#_\ F-_]A2?_ -EKH:\KTF\\2Z7]MQ>63?:+E[C_ %)XW8X_2K__  D'B;_G
MZLO^_)INE)L2K12/1:\@FN[H>-9I#+)_:8UN.!(PY_X]"O/R],>];7_"0>)O
M^?JR_P"_)J+^U=?^T?:-^F^?C'F_9_FQZ9ZU/L97N5[>-K'I5%>=?\)!XF_Y
M^K+_ +\FC_A(/$W_ #]67_?DT>QD+VT3I/&O_(.LO^OV'^==#7E>LWGB75K>
M&,WEBOES)+_J3_":O_\ "0>)O^?JR_[\FJ]E*PO;1N5-<OM2T7Q1XIEBN9[@
M)I2R1*WW8R7Q\H]A4VJK?6?B#P<]M>3S1R6\W[K/R,PB!!;U)/K1-JWB"X61
M9)=/82+L?,!Y7T-,M=2U^SMX(8YK$)"-L>822H]C4^QE:Q?MX%'X8ZA<IJD$
MVH3;[FZMG>Z(E;$+B0@"0'C)[=*TET"TU+QYK5Q$LEM!IUML++(X#S2*26/.
M.!3/[2US,ASIN9#E_P#1OO'W]:6XU3Q!<0S1/-8A)EVR;82"PQBAT9![>!U7
MP_U*XU;P?IEU=9\]XR&+=3@D _B *+7_ )'F]_Z\T_\ 0JY:UU?Q#96\4$,]
MC'#&H5%6$X %58[SQ+'K4VH?;+',D*Q;?)/8YJ_92U(]M'0]4HKSK_A(/$W_
M #]67_?DT?\ "0>)O^?JR_[\FH]C(?MHF=\3+F5?$5V)97B6'3/-L KE<W'F
M < =3CM7INFM+)IUJTPQ,T2%_P#>P,_K7GTVJZ_<LC3/ILK1G*,]ODJ?49Z5
M+_PD'B;_ )^K+_OR:/8RM8;KP/1:SO$7_( U/_KUE_\ 0#7%_P#"0>)O^?JR
M_P"_)J#4-6\2WUA<VQN[)1-$T>?)/&01_6FJ,KB=:-CN_#O_ " -,_Z]8O\
MT 5HUYGI^K>);&PMK87=DPAB6//DGG  _I4__"0>)O\ GZLO^_)H]C(%6C8[
MZ^:5+&X:$9F$;%!_M8./UKR[X:7,K:[IPBFDE:>PDDU$-(S;9O,(&0>A_I6G
M_P )!XF_Y^K+_OR:BAU77K9G:%]-B:0Y=DM\%CZG'6DJ,KC]O&UCTJBO.O\
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M\)!XF_Y^K+_OR:H:'>>)=&TV.T%Y8N%9CGR3W8G^M/V4K6%[:-[GJE%>=?\
M"0>)O^?JR_[\FC_A(/$W_/U9?]^34^QD/VT3$L;NZ_X3!)#+(=6;6Y()(MY.
M+4+Q\O3'O7L%>:C5=?6X-P'TT3D8,OV?YL>F>M2_\)!XF_Y^K+_OR:/8RM8;
MKQ;N>BUSOC;_ )!=M_U]P_\ H5<Y_P )!XF_Y^K+_OR:H:U>>)=6M8XC>62;
M)5ESY)_A.::HRN3*M%H]4HKSK_A(/$W_ #]67_?DT?\ "0>)O^?JR_[\FE[&
M0_;1-GXH3W-OX/N6MF9"9(UD9"01&7 ;D>U5_AM(?^)W# YDTR&]*6C%BXV8
M&0">HS6;)KOB25&1[BQ=&&"K0D@TR#6/$-K$(X9=/AC7HD<&T#\!0J,A^WC8
M])HKSK_A(/$W_/U9?]^31_PD'B;_ )^K+_OR:/8R%[:)TFC?\C=XC^EM_P"@
M&NAKRNSO/$MKJVH7OVRR)N_+RODGC:I%7_\ A(/$W_/U9?\ ?DU3I28E6BCT
M6O)/B)=3IXBU4O*\4]O90OIBJY7=(9 &P!U/]*UO^$@\3?\ /U9?]^344VJZ
M_<21R2OILDD?*,]ODK]#VJ?8RN5[>)Z+;,[6\1DXD* M]<<U+7G7_"0>)O\
MGZLO^_)H_P"$@\3?\_5E_P!^33]C(7MHG7^+/^1;U'_KBU6])_Y!5E_UQ3_T
M$5YGXDU_Q(V@WX:YLBIB;.(C5G3?$'B4:;: 7-ECRDQ^Z/\ =%/V,K"]M&YU
M?Q"CN)/!NJ&VN9+65(&<-#]XX'0'M7''6(I$9=<O9[33;31X)2T;E&<L!N.>
MY[?C5YM>\22*5:XL64\$&$D&J=S-K%Y<)/-_9LKHAC&ZWR-I[$>E3[&1?MX&
MEX+O9--\,ZE>VQ-VDTKRV.G),))$7'"=>IZX[5QFBZYK$>@^+[N\:_CU"UOX
M9HQ=(4 )(_=J,].<8KI;>^UJSP(!I<(!R/+M0N#Z\4V]NM;U!%2>2P=1(LI'
MDD98="?6G[&5[B]O ]-A8R0HS#:S*"1Z5@ZU_P C;X=_[>/_ $"N;_X2#Q-_
MS]67_?DU0O+SQ+=:KI][]LL0;7S,+Y)YW+BFJ4KDNM&QZI17G7_"0>)O^?JR
M_P"_)H_X2#Q-_P _5E_WY-3[&0_;1+?Q+DS>>'X;F0Q:5+/(+IMY0<)E,D>]
M:GPWN+JZ\%Z;)>%FG*MR^<E0Q"G\L5SEQK'B"[C,<\FGS1_W9+?</R-/77O$
MB*%6YL54< "$X%'L9#]O$]&HKSK_ (2#Q-_S]67_ 'Y-'_"0>)O^?JR_[\FC
MV,A>VB=UX _Y%.U_ZZS?^AFBJ'PM>[E\"V#S.C3-),6*+@??-%826K.B+T1S
MGB;_ )*%KW_7.V_] -5JU]0\&Z-K?C_Q'->V*W$NVV^9G8?\LSZ&N \7W6G^
M%_&6FZ!#\.YM2_M%F6VNH]0"*^T9;@G(P*ZX58Q21R2HRE)R1U%%<5X-\1:!
MXR\0'3X/!*6]NER]L]Q)JR;U*'!/E;MQ%3:7XJ\$:IKWB/35\,RQ#2899HKA
MIVV7HC^_Y?S=CZU7MH"^KSV.OHKF?AC?:!\2&1QX.BTZTDA\Y)?[56=L'H"B
M-E?QKH]$T7PGK7B77M'30_*DTEHUDE:9]K[UW<?-QBCVL2?82'T50M+[X67T
MNIQP3V<CZ:I>Z ED^10<$]>>?2JDGB#X3KH*:NDUK):22-%'M>7<TBC)7;G.
M?PI>VAN/ZO,VJ*Y#0/&7PYU;3S?WFF1Z59"V2Y,L]R[$!W*J" <\D5MG5OA2
M-'BU3S[7['),;=7WRY,@ZKMSGCZ4_;1#V$S4HK$\3:Q\-_#7A.P\1&R6]TR^
MN$MX);=I#N+-C/7H*TM/;X9ZIK_]BVK6LNI=H1))R<9(!SC/MUH]M$/82+-%
M<AXX\3>#_!?C"/P^/"<VH3^4D\LD=R8]J,V!M#-ES["KWAWQ%\-/$6M:AIB6
M7V:YM+M;("=I5\R1AD!>:2K1>P.A-;G0T5A^)->^%WAO1WOYA;S?+*8H8Y)"
MTC1YW*.>.1C)XJSH5Y\.-:T>VOOL\-LTIAC:WDED+I)*N40X/)-/VT6'L)K<
MTZ*YCQ=?:)X=\676B6/@2?6FL[(7]S/#>;!'&21PK'+'CM5RU\0?"JX2'<88
MI9+5;PQ,TNY(R,Y;!P*7MHA]7F;=%5=1D^&6DPS27;6L2PK$SYDD)Q(,I@ Y
M.1Z5I^&_#O@7Q?IOV_2+:&]M-[1^9'))C<.HY-/VT1>PD5J*D\+_  _\/W?]
MK>=IRR>5J$T2;I7^51C ^]6W_P *S\,_] I/^_C_ /Q5#JQ0*C)F!16__P *
MS\,_] I/^_C_ /Q5'_"L_#/_ $"D_P"_C_\ Q5'MHA["1@45O_\ "L_#/_0*
M3_OX_P#\51_PK/PS_P! I/\ OX__ ,51[:(>PD8%%2>+/A_X?L[*U:#3EC9K
MN)"5E?E2>1]ZMO\ X5GX9_Z!2?\ ?Q__ (JCVL=P]C(P**W_ /A6?AG_ *!2
M?]_'_P#BJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#B
MJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#BJQ+?X?\
MA]O%]W;'3E,"VJ.(_-? 8MU^]0JL6'L9$=%;_P#PK/PS_P! I/\ OX__ ,51
M_P *S\,_] I/^_C_ /Q5'MHA["1@45O_ /"L_#/_ $"D_P"_C_\ Q5'_  K/
MPS_T"D_[^/\ _%4>VB'L)&!16_\ \*S\,_\ 0*3_ +^/_P#%51USX<^'+?1=
M0ECTQ4D2WD96$CY!"D@_>H]M$/8R,ZBM'0_ASX<N-%T^633%>1[>-F8R/DDJ
M"3]ZKW_"L_#/_0*3_OX__P 51[:(>QD8%%;_ /PK/PS_ - I/^_C_P#Q5'_"
ML_#/_0*3_OX__P 51[:(>PD8%%;_ /PK/PS_ - I/^_C_P#Q5'_"L_#/_0*3
M_OX__P 51[:(>PD8%%/U+X?^'XO%&C6Z:<JPRK,702OAL*",_-6Y_P *S\,_
M] I/^_C_ /Q5'M8B]C(P**W_ /A6?AG_ *!2?]_'_P#BJ/\ A6?AG_H%)_W\
M?_XJCVT1^PD8%%;_ /PK/PS_ - I/^_C_P#Q5'_"L_#/_0*3_OX__P 51[:(
M>PD8%%;_ /PK/PS_ - I/^_C_P#Q58G@WX?^'[[P_!-<:<LLK/("S2OGAR!_
M%1[6-KA[&5[$=%;_ /PK/PS_ - I/^_C_P#Q5'_"L_#/_0*3_OX__P 51[:(
M>PD8%%;_ /PK/PS_ - I/^_C_P#Q5'_"L_#/_0*3_OX__P 51[:(>PD8%%;_
M /PK/PS_ - I/^_C_P#Q58GBSX?^'[/3X'@TY8F:YC0E97Z$\C[U"JQ8G1DE
M<CHK?_X5GX9_Z!2?]_'_ /BJ/^%9^&?^@4G_ '\?_P"*H]M$?L)&!16__P *
MS\,_] I/^_C_ /Q5'_"L_#/_ $"D_P"_C_\ Q5'MHA["1@45O_\ "L_#/_0*
M3_OX_P#\51_PK/PS_P! I/\ OX__ ,51[:(>PD8%%2:5\/\ P_-XFUV!].5H
M81!Y:&5\+E"3CYN];?\ PK/PS_T"D_[^/_\ %4.K% J,F8%%;_\ PK/PS_T"
MD_[^/_\ %4?\*S\,_P#0*3_OX_\ \51[:(>PD8%%;_\ PK/PS_T"D_[^/_\
M%4?\*S\,_P#0*3_OX_\ \51[:(>PD<=XD_Y %]_UR:K.F_\ (-M/^N2?^@BM
M3Q1\-_#<7A_4'32T#+"Q!\Q__BJM:7\-?#3:9:,=+0DPH3^\?^Z/]JG[:-A>
MQE<RJ*W_ /A6?AG_ *!2?]_'_P#BJ/\ A6?AG_H%)_W\?_XJE[:(_82,"BM_
M_A6?AG_H%)_W\?\ ^*H_X5GX9_Z!2?\ ?Q__ (JCVT0]A(P**W_^%9^&?^@4
MG_?Q_P#XJL/5?A_X?A\3:' FG*L,WG>8@E?#83(S\WK0JL6#HR0RBM__ (5G
MX9_Z!2?]_'_^*H_X5GX9_P"@4G_?Q_\ XJCVT0]A(P**W_\ A6?AG_H%)_W\
M?_XJC_A6?AG_ *!2?]_'_P#BJ/;1#V$C HK?_P"%9^&?^@4G_?Q__BJ/^%9^
M&?\ H%)_W\?_ .*H]M$/82-+X7?\B)IW^]+_ .AFBD^&NEVMEX,LX((?+B22
M;:FX\?.?>BN.5KL[H?"A8O\ D>/$G^[:_P#HLUG>(/!HUSQ9X<UHW'E'2&F8
M1;<^9O7;U[8K1B_Y'CQ)_NVO_HLUJT=@[GC'AWX$ZEX9UZ]OK/5=-V7%Q-.)
M'TY3<)YF>!)UXS5:T_9@L-)BTZ?3]7NHM4BCFCN[B1RZW"RJ0XVGA>3GCTKW
M"N(^-&O7_AGX;ZOJ.F7'V2^B5!'-M#;-SJN<'V-3LK%IMOU,7X2_".^^&LR(
M][IMS;+!Y/\ HU@L,S8Z%G'6K%Q\./$-KXVUC6=)\06]I9:L8_M-I-:"1L*N
MWY6SQD5Q&J?$'Q%X)OKS2;K6VUQ!!:W27HB1)(S)*$:-L<=\U?7]I46FL:]:
M:CHIM8M/BDDA_? R3["!TZ8.?7BG>^_F)7Z>15TS]E:UTBVUR.UU80RWT3PP
M7"0?O8PS[SN.?FYXJ31_V9YM LXC8:^L.H1W4LZS-;!DVR)M==I/Y&MJX^-&
ML6>FZ:DV@6PUG4K@0VL"7R-#M*;]SO\ P\=JQ[K]I"]DM[>73?#?VK%A+?7:
MO<!?*$4FQPI_B]J+=/Z[AKO_ %V)[']FU+735M7U@R_N;>(L8@,^5*7SCWSB
ML_XB?!_Q!IEPFK^%$2^U!M1FNFB;8H2.1-C !N#4</QF\27>J:JT\4=MIT>J
MV5O;>2P,GERIN*L/ZUH:?^T5?S6\US=^'!;VC6EW<VLBW 8R>0Q# CMG%#U7
M]>H:_P!?<;&D_"._NO@YHGAF\O%LM3LY8[HRJH=5D5R^,=^N*70_@6^E>);2
M]FUHW&F6M[)J4-F( KBX<?,2_4K[56UK]H*'2['4)DLX99;>WLY(U:? =YUW
M!<^U<4/VBO$7B)HKVRL8]/TM]'GNY%W@RK+')L)7/4>U.^K?]?UH)+2W]?UJ
M>@?%'X)3_$;6/M/]M"VM71(WAEMED:+:<[HGZHQJG=? 2[6YNYK#Q ;=VOH=
M0MVD@#M'(B[3N_O BH+7]H&5;RW5M(,NEI/!837C3 3>?(@((CZE?>M+X>_&
MB_\ &'B*RL;S0AI]I?QSO:W"SARWE.5;([9I)=%_74&WU_KH8LG[.-W'ID,5
MKXD\N]:"YM;FXDM5<2QS,6.%/W2">M2^'_@W>6?Q0TJ]EB9-%TG3XHC(S@B\
MN$7:DFP=-HSUKH6^+=S'-=-+IT:6:7-U:1NKDN7A7=DCT-4+_P 6^*=,NM.U
M!U:72YK59694&SYD+-D^H[>PH7<;N[IFCXN^&.M:QXRO-;TC7X]+2^L%T^YB
M>V$K&,$G*D]#S4-E\"["PLM<LX;MA!J.FQ:<IV@O&$!^;/?).:NP_$47>E:3
M?VSR,GVV.SNHY$P6WCAA_.O0Z+:6%=IW_K^M#YV\4? OQ1I>F_VIIVI)KWB"
M">UD@5HUB55A4KC!X/'K7H_P-\)ZKX/\$_9M:58]1N+J:ZDC0@[-[9QQQ^5>
MA44[[B.>\'_\QO\ ["D__LM=#7/>#_\ F-_]A2?_ -EKH:<MR8[!7 7GQ!O(
M?$$\2Q0_V;;ZA%ISYSYA=QG<.V!7?US-QX!T^XUPZDTDXW3I<O;AOW;2J,*Q
M'K26Y?0Z:BBBD(Y[QK_R#K+_ *_8?YUT-<]XU_Y!UE_U^P_SKH:;V1*W9Q6I
M>/I]*\1:K9W-FL5G9V'VM)-V6D._:!["DU'QU?:7J>A03V*+;WL$DTTN[H5C
MW[5%:VM>"[+6KJ]NI"PN+JS^QDY^4+NW X]<TO\ PB<-Z-'EOV\ZYT^-HU*G
M"MN7:V1]*70O2_\ 7D8O@+QY=>++O]]%'#!/!]H@7:RN5W8[_>'N*=-X@U]?
M%]SID'V.XMK>V:YE;:P9,_<7/J:T=)\!V>BS>9;W%P'6/R8=SY\F/=N*K[9J
MZOAR.UFUBZM787NHJ SR'(4A=JX]A0_(1+X9UR/Q'H5GJ,8VK.F2OH0<$?F#
M5*U_Y'F]_P"O-/\ T*KWAO1(_#NAV>G1'<L";2WJ2<D_F35&U_Y'F]_Z\T_]
M"JUU)?0Z&BBBH*.&\8^.+[1=6N+6RB@9+.R^W7!FSEEW[=JX[UV=G<B\LX+A
M1A98UD ^HS6%XB\#V7B2]%S--/ [1>1*(6P)8]V[:WMFN@AB6"%(D&U$4*H]
M .!3Z#8^L[Q%_P @#4_^O67_ - -:-9WB+_D :G_ ->LO_H!H6Y+V#P[_P @
M#3/^O6+_ - %:-9WAW_D :9_UZQ?^@"M&A[@MB*ZN%M+6:=N5B1G/T S7%>#
M_'-]K6I64-[% L6H6K7=OY.<HJOC#9[XKN)(UEC9'&Y6&"/4&N=\/^!;+P[?
M"YAFGG:.,PPK,^1"A;<57\:2W*Z'24444".>U;_D<-!_W+C_ -!%=#7/:M_R
M.&@_[EQ_Z"*Z&K?0E;L*YKQAXBN]'N-)L;!8C>:C,T://G8H5=Q)Q72UC^(O
M#,'B)+;S)9;:>VD\R&>!L.AQ@X^HJ"T-\':^WB;P[::@Z".23<'5>@96*G'M
MQ6U5#0]&M_#^EV]A:@B"$8&XY)R<DGWR:OTV(*Y[P%_R+-O_ +\G_H;5T-<]
MX"_Y%FW_ -^3_P!#:GT9/VD=#1114E' ?\+!O/[>9?)A_LL:F-+QSYN_'WO3
M&:[^N9_X0&P_MPZB99R#<?:_LN[]UYV,;\>M=-3Z#>^@5SOC;_D%VW_7W#_Z
M%715SOC;_D%VW_7W#_Z%3CN1+8Z*BBBI*,/QIXB;PMX=N=01!)(A5$5NFYF"
MC/MS4'A+Q!=ZI<:I8WZQ?;-/F$;O #L8,,@C-:FN:+;^(-+GL+H,890,E3@@
M@Y!'N"*K^'O#<'AV.Y\N:6YGN9/,FGG;+N<8&?H*:'T->BBB@1SVC?\ (W>(
M_I;?^@&NAKGM&_Y&[Q']+;_T UT-.6Y,=@KA?&'CJ]T75[JVLXH&BL;-;RX\
M[.64N%VKCO7=5S?B'P+8^(K_ .U32SPLT0@F6%L"6,-NVM^-26K=3?M;@75K
M#.HPLB*X'U&:EIL<:PQK&@VHH"@>@%.H$9/BS_D6]1_ZXM5O2?\ D%67_7%/
M_0153Q9_R+>H_P#7%JMZ3_R"K+_KBG_H(JOLD]2GXLU>XT'P_>W]K;?:IH(V
M<1EMHX!.3[5A6?C+4-:6"#3K>!KPZ?'=R^<Q"(SXP/YFNKU+3XM5T^YLYL^5
M<1M&^TX.",&N5OOAS%-NAMKR>SM9K);*5H7VRE4^Z0WKC@U)>A=\'^(KW6K7
M43=112/:3M"DUOGRY\#JN??BLBU^(=X="U;4KJRCA&GZB;62(-D^6"!G/K\U
M=%X?\,KX=LX+6&\GD@AX5'QC&.E9^I> X+C2;^PMI#'%J%Y]JN2YR3D@L!^0
MH#0ZE'$B*RG*L,@U@:U_R-OAW_MX_P#0*WU41JJJ,*HP!6!K7_(V^'?^WC_T
M"KCN1+8Z&BBBH*.6\8>)+S2;[2]/T]83=WQD(><':JHNX]/6M+PGKG_"2>';
M+4B@C,Z$E1T!!(/ZBF>(_"]OXD^RO)--:SVS,T4UNV&&X88?0BKVCZ3;Z'IM
MO8VJE8(5VKDY/UH6PV7****8BIX _P"13M?^NLW_ *&:*/ '_(IVO_76;_T,
MT5G+<N.R.4U?Q<=$^('B&$Z==7.5MB&B Q_JS3_^%D#_ * M_P#D/\:J>)O^
M2@Z]_P!<[;_T U7KOA3C**;//E4E&32-/_A9 _Z M_\ D/\ &L_7_%&G>*-(
MN-+U7PW>7MA<+ME@D VL,Y[&F457LH=B?;3[F-IUCX2TG3I;&U\$S1VLSK)(
MA&[<RG*DDL3P:6*T\)0ZE>:@O@B3[7=HR32%,[U;[PP3@9]JV**/90[![:?<
MP5TCP:FC/I0\#2_8&D\XQ8_C]=V[(_.KROX9CA6)?!DRQK:FR"J@ \DG)3KT
M)YK0HH]E#L'MI]S*,/A4WC71\%S>>QB8OMZF,8C.,]0*EBD\-0PQ1)X-F$<4
M<L2+L& LAS(.O\6>:T**/90[![:?<YR+P_X(AT^>R3P%(MM,R-(FT\E/NG.[
M/':I1I'@Q8H(QX%D"0H\<:A> KG+CKT)K>HH]E#L'MI]S*$/A4:S#JP\%2_V
MA"H5)M@R !@<9QD#OUJ[INJ:'H\UI+9^$[BWDM ZP,BC,8<Y?'/<U8HH]G#L
M'MI]R!M6T5T9?^$5N@&EDF^Z/ON,.W7J14UCXFM+73;6SET.^NDMD,<;2*N0
MI&,=?3BEHH]E#L'MI]R@E]I-N+*.U\.WMM:VMQ]I$$:C:\F."<GM71?\+('_
M $!;_P#(?XUF44>S@'MI=S3_ .%D#_H"W_Y#_&C_ (60/^@+?_D/\:S**/90
M[![:8SP_XUETW^TO-T6]_P!(O9+A-H'W6QC^5:W_  L@?] 6_P#R'^-9E%/V
M<7T$JLUU-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\ "R!_
MT!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTQGB/QK+JEK;QPZ+>[H[B.4[
M@!PIYK6_X60/^@+?_D/\:S**?LX]A>UGW-/_ (60/^@+?_D/\:/^%D#_ * M
M_P#D/\:S**7LH=A^VF:?_"R!_P! 6_\ R'^-'_"R!_T!;_\ (?XUF44>RAV#
MVTS3_P"%D#_H"W_Y#_&LF'QK+'XFN;\Z+>^3);K$.!G(.:?13]G'L+VL^YI_
M\+('_0%O_P A_C1_PL@?] 6__(?XUF44O90[#]M,T_\ A9 _Z M_^0_QH_X6
M0/\ H"W_ .0_QK,HH]E#L'MIFG_PL@?] 6__ "'^-5-6\?->Z5>V\>BWWF30
MO&N0,9*D"J]%'LX=A>UGW+&D^/FLM*LK>31;[S(84C; &,A0#5O_ (60/^@+
M?_D/\:S**/9P[![6?<T_^%D#_H"W_P"0_P :/^%D#_H"W_Y#_&LRBCV4.P_;
M3-/_ (60/^@+?_D/\:/^%D#_ * M_P#D/\:S**/90[![:8R^\:RW'B#2[U=%
MO?*MEE#Y S\RX&*UO^%D#_H"W_Y#_&LRBG[./87M9]S3_P"%D#_H"W_Y#_&C
M_A9 _P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^
M-9E%'LH=@]M,T_\ A9 _Z M_^0_QK)\+^-9='T:*UGT6]\Q6<G: 1RQ(_G3Z
M*?LX[6%[6=[W-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\
M"R!_T!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTS3_ .%D#_H"W_Y#_&LG
MQ)XVEU6RABAT6]W+/'(=P X!R:?13]G%=!.K-]33_P"%D#_H"W_Y#_&C_A9
M_P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^-9E%
M'LH=@]M,T_\ A9 _Z M_^0_QH_X60/\ H"W_ .0_QK,HH]E#L'MIC-/\:RVN
MO:O>/HM[Y5T(=F ,_*I!S6M_PL@?] 6__(?XUF44_9Q["]K-=33_ .%D#_H"
MW_Y#_&C_ (60/^@+?_D/\:S**7LH=A^VF:?_  L@?] 6_P#R'^-'_"R!_P!
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M]LT4=P=JL]P)  ?3;WJ/XA?#?4/ >G275MI;:AHW]K6]Q_94#.Z.HCVL7 Y
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M#K+_ *_8?YUT-/VDK+4GV4+['#?\*\U+_H9'_P# */\ QH_X5YJ7_0R/_P"
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M3_PKS4O^AD?_ , H_P#&JNK>!]4LM+O+A/$;EX87D ^Q1]0I/K7H=9WB+_D
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MC?\ /V__ 'XD_P#B:.5]@YEW.6\=^./$NE^--,\/>'-/TVZFNK22[>34)'0
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M'#0?]RX_]!%=#7"ZIXPTF3Q7HDJW+F-$GW-Y$G&5&/X:W?\ A-M&_P"?M_\
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M $,T57^'5_!<>#[216.TRS8W*RG[Y[$45G*]S6.QU\'_ !_7?_ ?Y59]***
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MBB@ HHHH AO/^/67_=-/A_U,?^Z***?074?1112&%%%% !5:?_C]M?\ @?\
A*BB@19HHHH&%%%% !1110!4LO^/5?]YOYT445+-%L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>plx-20250331.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/8/2025 5:26:54 PM-->
<!--Modified on: 5/8/2025 5:26:54 PM-->
<xsd:schema xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:currency="http://xbrl.sec.gov/currency/2024" targetNamespace="http://www.protalix.com/20250331" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:plx="http://www.protalix.com/20250331" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2024" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:us-gaap-ebp="http://fasb.org/us-gaap-ebp/2024" xmlns:cyd-af-sub="http://xbrl.sec.gov/cyd-af-sub/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2024">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails">
        <link:definition>99940501 - Disclosure - TAX BENEFIT (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>99940701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>99940401 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails" id="DisclosureTaxBenefitAdditionalInformationDetails">
        <link:definition>99940502 - Disclosure - TAX BENEFIT (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>99940601 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" id="DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails">
        <link:definition>99940602 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99940801 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995210201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>995210301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>995210401 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxBenefit" id="DisclosureTaxBenefit">
        <link:definition>995210501 - Disclosure - TAX BENEFIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995210601 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>995210701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995210801 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>99930203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxBenefitTables" id="DisclosureTaxBenefitTables">
        <link:definition>99930503 - Disclosure - TAX BENEFIT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99930603 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>99930703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndWarrantsMember" id="plx_OutstandingStockOptionsAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PayableToCustomerCurrent" id="plx_PayableToCustomerCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesOtherCurrent" id="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromWarrantsAndStockOptionExercises" id="plx_ProceedsFromWarrantsAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SalesAgreementMember" id="plx_SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" id="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockValueOfCapitalSharesReservedForFutureIssuance" id="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrossProceedsFromIssuanceOfCommonStock" id="plx_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>plx-20250331_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/8/2025 5:26:54 PM-->
<!--Modified on: 5/8/2025 5:26:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638823220130830960" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638823220130830960" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638823220130830960" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638823220130830960" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638823220130830960" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638823220130830960" xlink:to="plx_ShortTermBankDeposits_638823220130841313" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638823220130830960" xlink:to="us-gaap_AccountsReceivableNetCurrent_638823220130841313" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638823220130830960" xlink:to="us-gaap_OtherAssetsCurrent_638823220130841313" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638823220130830960" xlink:to="us-gaap_InventoryNet_638823220130841313" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638823220130841313" order="2" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638823220130841313" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638823220130841313" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638823220130841313" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638823220130851293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638823220130851293" order="5" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638823220130851293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638823220130851293" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638823220130851293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638823220130851293" xlink:to="us-gaap_LiabilitiesNoncurrent_638823220130851293" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638823220130851293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638823220130851293" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638823220130851293" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638823220130851293" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638823220130851293" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638823220130851293" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638823220130851293" xlink:to="us-gaap_LiabilitiesCurrent_638823220130861325" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638823220130861325" xlink:to="us-gaap_AccountsPayableTradeCurrent_638823220130861325" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638823220130861325" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220130861325" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638823220130861325" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638823220130861325" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638823220130861325" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638823220130861325" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638823220130861325" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220130871315" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220130871315" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638823220130871315" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220130871315" xlink:to="us-gaap_OperatingIncomeLoss_638823220130871315" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638823220130871315" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638823220130871315" xlink:to="us-gaap_Revenues_638823220130871315" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638823220130871315" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638823220130871315" xlink:to="us-gaap_CostOfRevenue_638823220130871315" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638823220130871315" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638823220130881334" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638823220130871315" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638823220130881334" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220130871315" xlink:to="us-gaap_NonoperatingIncomeExpense_638823220130881334" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638823220130881334" xlink:to="us-gaap_OtherNonoperatingExpense_638823220130881334" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638823220130881334" xlink:to="us-gaap_OtherNonoperatingIncome_638823220130881334" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638823220130881334" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637041422967477240" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638823220130881334" order="2" use="optional" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638823220130891420" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220130891420" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220130891420" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220130891420" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220130891420" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638823220130891420" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220130891420" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220130891420" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638823220130891420" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638823220130891420" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220130891420" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638823220130891420" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_ProfitLoss_638823220130901326" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_ShareBasedCompensation_638823220130901326" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_Depreciation_638823220130901326" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638823220130901326" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638823220130901326" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638823220130901326" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220130911337" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638823220130911337" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638823220130911337" order="8" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638823220130911337" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638823220130911337" order="10" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638823220130911337" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_IncreaseDecreaseInInventories_638823220130911337" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638823220130921417" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220130901326" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638823220130921417" order="12" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638823220130921417" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638823220130921417" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638823220130921417" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638823220130921417" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638823220130921417" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638823220130921417" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - TAX BENEFIT (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220130931423" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220130931423" order="1" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638823220130931423" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638823220130931423" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638823220130931423" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638823220130931423" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638823220130931423" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638823220130931423" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638823220130931423" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638823220130931423" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638823220130940994" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638823220130940994" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638823220130940994" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638823220130940994" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent_638823220130940994" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_CustomerAdvancesCurrent_638823220130940994" order="7" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638823220130940994" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_PayableToCustomerCurrent_638823220130940994" order="8" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>plx-20250331_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/8/2025 5:26:54 PM-->
<!--Modified on: 5/8/2025 5:26:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20250331.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>plx-20250331_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/8/2025 5:26:54 PM-->
<!--Modified on: 5/8/2025 5:26:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">GOODS</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">LICENSE AND R&amp;D SERVICES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues from customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME, NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAX BENEFIT</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total tax benefit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Tax benefit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">LOSS PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Number of shares issued as a result of exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial income, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred income tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase in contracts liability</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (increase) in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Proceeds from Warrants and Stock Option Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAX BENEFIT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAX BENEFIT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net loss per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxes on Income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Information of Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">BRAZIL</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SalesAgreementMember" xlink:to="plx_SalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding stock options and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Amount of increase in gross sales price of shares available for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Increase in aggregate gross sales price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate value of common shares reserved for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Value of Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain available, total gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings (loss) per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The gross cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Employee salaries and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Sub-contractors expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment reporting description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerAdvancesCurrent" xlink:to="us-gaap_CustomerAdvancesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerAdvancesCurrent_lbl" xml:lang="en-US">Customer Advances, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerAdvancesCurrent_lbl" xml:lang="en-US">Advances from customer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PayableToCustomerCurrent" xlink:to="plx_PayableToCustomerCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable To Customer, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable to customer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>plx-20250331_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.10.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/8/2025 5:26:54 PM-->
<!--Modified on: 5/8/2025 5:26:54 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureTaxBenefit" roleURI="http://www.protalix.com/role/DisclosureTaxBenefit" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSegmentInformation" roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureTaxBenefitTables" roleURI="http://www.protalix.com/role/DisclosureTaxBenefitTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSegmentInformationTables" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureTaxBenefitAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250331.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638823220131171015" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638823220131171015" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638823220131181416" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638823220131181416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638823220131181416" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638823220131181416" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638823220131181416" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638823220131181416" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638823220131181416" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638823220131181416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638823220131181416" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638823220131191365" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638823220131191365" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638823220131191365" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638823220131191365" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638823220131191365" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638823220131191365" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638823220131191365" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638823220131191365" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638823220131201313" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638823220131201313" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638823220131201313" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638823220131201313" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638823220131201313" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638823220131201313" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638823220131201313" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638823220131201313" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638823220131321371" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638823220131321371" order="24" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638823220131331311" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638823220131331311" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638823220131331311" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638823220131331311" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638823220131331311" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638823220131331311" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638823220131331311" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638823220131341302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638823220131341302" xlink:to="us-gaap_AssetsCurrentAbstract_638823220131341302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638823220131341302" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="plx_ShortTermBankDeposits_638823220131341302" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="us-gaap_AccountsReceivableNetCurrent_638823220131341302" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="us-gaap_OtherAssetsCurrent_638823220131341302" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638823220131341302" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="us-gaap_InventoryNet_638823220131341302" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638823220131341302" xlink:to="us-gaap_AssetsCurrent_638823220131351325" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638823220131341302" xlink:to="us-gaap_AssetsNoncurrentAbstract_638823220131351325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638823220131351325" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638823220131351325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638823220131351325" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638823220131351325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638823220131351325" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638823220131351325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638823220131351325" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638823220131351325" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638823220131341302" xlink:to="us-gaap_Assets_638823220131351325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638823220131351325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638823220131351325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638823220131351325" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131361336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131361336" xlink:to="us-gaap_AccountsPayableTradeCurrent_638823220131361336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131361336" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220131361336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131361336" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638823220131361336" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638823220131351325" xlink:to="us-gaap_LiabilitiesCurrent_638823220131361336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638823220131361336" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638823220131361336" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638823220131361336" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638823220131361336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638823220131371330" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638823220131361336" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638823220131371330" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638823220131371330" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_LiabilitiesNoncurrent_638823220131371330" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638823220131371330" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_Liabilities_638823220131371330" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638823220131371330" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_CommitmentsAndContingencies_638823220131371330" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638823220131371330" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_StockholdersEquity_638823220131371330" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638823220131351325" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638823220131381355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638823220131381355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131381355" xlink:to="srt_ProductOrServiceAxis_638823220131381355" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638823220131381355" xlink:to="srt_ProductsAndServicesDomain_638823220131381355" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638823220131381355" xlink:to="us-gaap_ProductMember_638823220131381355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638823220131381355" xlink:to="us-gaap_LicenseAndServiceMember_638823220131381355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638823220131381355" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131381355" xlink:to="us-gaap_StatementLineItems_638823220131381355" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_Revenues_638823220131391344" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_CostOfRevenue_638823220131391344" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638823220131391344" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638823220131391344" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_OperatingIncomeLoss_638823220131391344" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_OtherNonoperatingExpense_638823220131391344" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638823220131391344" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_OtherNonoperatingIncome_638823220131391344" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_NonoperatingIncomeExpense_638823220131401334" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220131401334" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638823220131401334" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_NetIncomeLoss_638823220131401334" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_EarningsPerShareBasic_638823220131401334" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_EarningsPerShareDiluted_638823220131401334" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638823220131401334" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638823220131401334" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131381355" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638823220131401334" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638823220131411325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131411325" xlink:to="us-gaap_StatementEquityComponentsAxis_638823220131411325" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638823220131411325" xlink:to="us-gaap_CommonStockMember_638823220131411325" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638823220131411325" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638823220131411325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638823220131411325" xlink:to="us-gaap_RetainedEarningsMember_638823220131411325" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638823220131411325" xlink:to="us-gaap_EquityComponentDomain_638823220131411325" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638823220131411325" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131411325" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638823220131411325" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638823220131411325" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638823220131421304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638823220131411325" xlink:to="us-gaap_TypeOfAdoptionMember_638823220131421304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131411325" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638823220131421304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638823220131421304" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638823220131421304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638823220131421304" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638823220131421304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638823220131411325" xlink:to="us-gaap_StatementLineItems_638823220131421304" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_StockholdersEquity_638823220131421304" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_CommonStockSharesIssued_638823220131421304" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638823220131421304" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638823220131421304" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131431413" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638823220131431413" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638823220131431413" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638823220131431413" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638823220131431413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638823220131431413" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638823220131431413" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638823220131431413" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638823220131431413" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_NetIncomeLoss_638823220131431413" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638823220131441420" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_StockholdersEquity_638823220131441420" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638823220131441420" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638823220131421304" xlink:to="us-gaap_CommonStockSharesIssued_638823220131441420" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638823220131441420" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638823220131441420" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638823220131441420" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638823220131441420" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_ProfitLoss_638823220131451009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_ShareBasedCompensation_638823220131451009" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_Depreciation_638823220131451009" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638823220131451009" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638823220131451009" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220131451009" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638823220131451009" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638823220131451009" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638823220131461345" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638823220131461345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638823220131461345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" xlink:to="us-gaap_IncreaseDecreaseInInventories_638823220131461345" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638823220131461345" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638823220131461345" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638823220131451009" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638823220131461345" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638823220131461345" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638823220131461345" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638823220131461345" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638823220131471329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638823220131461345" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638823220131471329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638823220131461345" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638823220131471329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638823220131471329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638823220131471329" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131471329" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638823220131471329" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638823220131471329" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220131471329" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638823220131471329" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638823220131471329" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638823220131481356" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638823220131481356" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638823220131481356" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388232201314813561" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6388232201314813561" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638823220131481356" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638823220131481356" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638823220131481356" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638823220131481356" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638823220131481356" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638823220131481356" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638823220131491437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638823220131491437" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638823220131491437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638823220131491437" xlink:to="us-gaap_InterestPaidNet_638823220131491437" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638823220131491437" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638823220131491437" xlink:to="plx_InterestReceivedNet_638823220131491437" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638823220131501008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638823220131501008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="995210201 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638823220131501008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638823220131501008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="995210301 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638823220131501008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638823220131501008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="995210401 - Disclosure - STOCK TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638823220131501008" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638823220131501008" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxBenefit" xlink:type="extended" xlink:title="995210501 - Disclosure - TAX BENEFIT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638823220131511359" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638823220131511359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995210601 - Disclosure - SEGMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638823220131511359" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638823220131511359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="995210701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638823220131511359" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638823220131511359" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995210801 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638823220131521367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638823220131521367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638823220131521367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638823220131521367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638823220131521367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638823220131521367" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638823220131521367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638823220131531368" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638823220131531368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxBenefitTables" xlink:type="extended" xlink:title="99930503 - Disclosure - TAX BENEFIT (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638823220131531368" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638823220131531368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99930603 - Disclosure - SEGMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638823220131531368" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638823220131531368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638823220131531368" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638823220131531368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="99930703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638823220131541307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638823220131541307" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="us-gaap_TypeOfArrangementAxis_638823220131541307" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638823220131541307" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131541307" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131541307" xlink:to="plx_AmendedPfizerAgreementMember_638823220131541307" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="dei_LegalEntityAxis_638823220131541307" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638823220131541307" xlink:to="dei_EntityDomain_638823220131541307" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638823220131541307" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638823220131541307" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638823220131541307" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="srt_StatementGeographicalAxis_638823220131541307" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638823220131541307" xlink:to="srt_SegmentGeographicalDomain_638823220131551339" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_BR" xlink:label="country_BR_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638823220131551339" xlink:to="country_BR_638823220131551339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="us-gaap_DebtInstrumentAxis_638823220131551339" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638823220131551339" xlink:to="us-gaap_DebtInstrumentNameDomain_638823220131551339" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638823220131551339" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638823220131551339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638823220131551339" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638823220131551339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638823220131551339" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638823220131551339" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131551339" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638823220131551339" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131551339" xlink:to="plx_SalesAgreementMember_638823220131551339" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638823220131561387" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638823220131561387" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638823220131561387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_OutstandingStockOptionsAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsAndWarrantsMember_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638823220131561387" xlink:to="plx_OutstandingStockOptionsAndWarrantsMember_638823220131561387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638823220131541307" xlink:to="plx_SignificantAccountingPoliciesLineItems_638823220131561387" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638823220131561387" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638823220131561387" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638823220131561387" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638823220131561387" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638823220131561387" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638823220131571326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638823220131571326" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638823220131571326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638823220131571326" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638823220131571326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638823220131571326" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638823220131571326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638823220131561387" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638823220131571326" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638823220131571326" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638823220131571326" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638823220131581010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638823220131581010" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638823220131581010" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638823220131581010" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638823220131581010" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638823220131581010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638823220131581010" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131581010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131581010" xlink:to="plx_SalesAgreementMember_638823220131581010" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131581010" xlink:to="us-gaap_PrivatePlacementMember_638823220131581010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638823220131581010" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638823220131581010" xlink:to="us-gaap_ClassOfStockLineItems_638823220131581010" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131591340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_638823220131591340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638823220131591340" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131591340" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="us-gaap_ProceedsFromWarrantExercises_638823220131591340" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638823220131581010" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638823220131591340" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - TAX BENEFIT (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638823220131591340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638823220131591340" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails" xlink:type="extended" xlink:title="99940502 - Disclosure - TAX BENEFIT (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638823220131591340" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638823220131591340" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638823220131609086" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638823220131609086" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NumberOfOperatingSegments_638823220131610980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_Revenues_638823220131610980" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_LaborAndRelatedExpense_638823220131610980" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638823220131610980" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherNonoperatingExpense_638823220131610980" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_OtherNonoperatingIncome_638823220131610980" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_Depreciation_638823220131610980" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638823220131610980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638823220131610980" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220131620988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638823220131620988" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638823220131620988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638823220131620988" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638823220131620988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_NetIncomeLoss_638823220131620988" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_638823220131620988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_638823220131620988" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940602 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638823220131620988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638823220131620988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638823220131620988" xlink:to="srt_MajorCustomersAxis_638823220131631383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638823220131631383" xlink:to="srt_NameOfMajorCustomerDomain_638823220131631383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638823220131631383" xlink:to="plx_PfizerMember_638823220131631383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638823220131631383" xlink:to="plx_FiocruzMember_638823220131631383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638823220131620988" xlink:to="srt_ProductOrServiceAxis_638823220131631383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638823220131631383" xlink:to="srt_ProductsAndServicesDomain_638823220131631383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638823220131631383" xlink:to="us-gaap_ProductMember_638823220131631383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638823220131631383" xlink:to="us-gaap_LicenseAndServiceMember_638823220131631383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638823220131631383" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638823220131620988" xlink:to="us-gaap_SegmentReportingInformationLineItems_638823220131631383" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638823220131631383" xlink:to="us-gaap_Revenues_638823220131641373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638823220131641373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_AccruedVacationCurrent_638823220131641373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638823220131641373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638823220131641373" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638823220131641373" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_TaxesPayableCurrent_638823220131641373" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerAdvancesCurrent" xlink:label="us-gaap_CustomerAdvancesCurrent_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="us-gaap_CustomerAdvancesCurrent_638823220131650993" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="plx_PayableToCustomerCurrent_638823220131650993" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638823220131650993" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638823220131641373" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638823220131650993" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638823220131650993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638823220131650993" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638823220131650993" xlink:to="us-gaap_SubsequentEventTypeAxis_638823220131650993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638823220131650993" xlink:to="us-gaap_SubsequentEventTypeDomain_638823220131660988" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638823220131660988" xlink:to="us-gaap_SubsequentEventMember_638823220131660988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638823220131650993" xlink:to="us-gaap_TypeOfArrangementAxis_638823220131660988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638823220131660988" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131660988" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131660988" xlink:to="plx_PfizerAgreementMember_638823220131660988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638823220131660988" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638823220131660988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638823220131650993" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638823220131660988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638823220131660988" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131660988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638823220131660988" xlink:to="plx_SalesAgreementMember_638823220131660988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638823220131660988" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638823220131650993" xlink:to="us-gaap_SubsequentEventLineItems_638823220131660988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638823220131671416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638823220131660988" xlink:to="us-gaap_ProceedsFromCustomers_638823220131671416" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131671416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638823220131660988" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638823220131671416" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250331.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_638823220131671416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638823220131660988" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_638823220131671416" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131671416" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638823220131660988" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638823220131671416" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>May 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,607,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 19,458<span></span>
</td>
<td class="nump">$ 19,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">15,285<span></span>
</td>
<td class="nump">15,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - Trade</a></td>
<td class="nump">4,675<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,590<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">19,506<span></span>
</td>
<td class="nump">21,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">60,514<span></span>
</td>
<td class="nump">60,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">4,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">2,969<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">5,225<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,892<span></span>
</td>
<td class="nump">73,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">4,121<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Other</a></td>
<td class="nump">18,776<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,322<span></span>
</td>
<td class="nump">25,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">551<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,811<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">4,362<span></span>
</td>
<td class="nump">4,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">28,684<span></span>
</td>
<td class="nump">30,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="nump">45,208<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 73,892<span></span>
</td>
<td class="nump">$ 73,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 10,113<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(8,180)<span></span>
</td>
<td class="num">(2,602)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(3,475)<span></span>
</td>
<td class="num">(2,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(2,603)<span></span>
</td>
<td class="num">(3,115)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING LOSS</a></td>
<td class="num">(4,145)<span></span>
</td>
<td class="num">(4,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">419<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME, NET</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE TAXES ON INCOME</a></td>
<td class="num">(3,732)<span></span>
</td>
<td class="num">(4,733)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAX BENEFIT</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (3,619)<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">LOSS PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">LOSS PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</a></td>
<td class="num">$ (0.05)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC (in shares)</a></td>
<td class="nump">76,611,980<span></span>
</td>
<td class="nump">73,036,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED (in shares)</a></td>
<td class="nump">76,611,980<span></span>
</td>
<td class="nump">73,036,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 9,995<span></span>
</td>
<td class="nump">$ 3,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance (ASU 2020-06) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(385,920)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,786<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,052,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,325,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">958,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,619)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 427,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (382,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,208<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Mar. 31, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">78,133,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of March&#160;31, 2025 and December&#160;31, 2024 &#8211; 185,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (3,619)<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial income, net</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(471)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred income tax asset</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Increase in contracts liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (increase) in accounts receivable-trade and other assets</a></td>
<td class="num">(2,275)<span></span>
</td>
<td class="nump">1,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="num">(18)<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="nump">1,737<span></span>
</td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals</a></td>
<td class="num">(1,284)<span></span>
</td>
<td class="num">(1,414)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(5,058)<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(306)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWarrantsAndStockOptionExercises', window );">Exercise of warrants and options</a></td>
<td class="nump">2,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">5,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(302)<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">19,760<span></span>
</td>
<td class="nump">23,634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">19,458<span></span>
</td>
<td class="nump">27,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWarrantsAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWarrantsAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. Although ceasefire negotiations are on-going and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 18,216,366 and 31,839,345 shares of Common Stock underlying outstanding options, unvested shares of restricted stock, warrants and convertible notes of the Company, as applicable, for the three months ended March&#160;31, 2025 and March&#160;31, 2024.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">New accounting </b><b style="font-weight:bold;">pronouncements</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company sold, in the aggregate </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,325,179</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended March&#160;31, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remain outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAX BENEFIT<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAX BENEFIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAX BENEFIT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; TAX BENEFIT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (3)% for the three months ended March&#160;31, 2025 and for the three months ended March&#160;31, 2024. For the three months ended March&#160;31, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_cSxaNzcnK0mLWtm562rZ5w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,748</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,205</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,144</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,689</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,155</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (419)</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (513)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 322</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,018</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 983</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before taxes on income</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,732)</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,733)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,595)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,127</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,550</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,677</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">71</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Advances from customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; SUBSEQUENT EVENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended March&#160;31, 2025, the Company collected approximately $2.8&#160;million from sales to Pfizer and approximately $1.9&#160;million from sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;">Since the end of the quarter ended March&#160;31, 2025, the Company sold, in the aggregate 1,450,036 shares of Common Stock under the Sales Agreement, generating gross proceeds equal to approximately $4.1&#160;million in connection with such sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (3,619)<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">On May&#160;5, 2023, the European Commission (&#8220;EC&#8221;) announced that it had approved the Marketing Authorization Application (&#8220;MAA&#8221;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#8220;FDA&#8221;) announced that it had approved the Biologics License Application (&#8220;BLA&#8221;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;">The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#8217;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7&#160;million remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#8217;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#8217;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#8217;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#8217;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. Although ceasefire negotiations are on-going and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#8217;s business, operations and financial conditions. The situation could disrupt certain of the Company&#8217;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;). The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net loss per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic and diluted loss per share (&#8220;LPS&#8221;) is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 18,216,366 and 31,839,345 shares of Common Stock underlying outstanding options, unvested shares of restricted stock, warrants and convertible notes of the Company, as applicable, for the three months ended March&#160;31, 2025 and March&#160;31, 2024.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"><i style="font-style:italic;">Recently issued accounting pronouncements, not yet adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at March&#160;31, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,484</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19,506</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAX BENEFIT (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAX BENEFIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Taxes on Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td></tr><tr><td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total tax benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138)</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,748</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,205</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,144</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,689</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,155</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 390</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (419)</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (513)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 346</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 322</p></td></tr><tr><td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,018</p></td><td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 983</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss before taxes on income</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,732)</p></td><td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,733)</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Tax benefit</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (138)</p></td></tr><tr><td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net loss</p></td><td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,619)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,595)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Disaggregation of Revenues</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended March&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,979</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1,127</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,016</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,550</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,677</p></td></tr><tr><td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">118</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">71</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Schedule of Supplemental Information of Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,346</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,349</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Advances from customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">-</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 427</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,776</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember', window );">Outstanding Stock Options And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,216,366<span></span>
</td>
<td class="nump">31,839,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares remain for sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance', window );">Increase in aggregate gross sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance', window );">Shares remain available, total gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in gross sales price of shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,484<span></span>
</td>
<td class="nump">$ 4,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">8,002<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">7,020<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 19,506<span></span>
</td>
<td class="nump">$ 21,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 12, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="nump">$ 2,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">1,325,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GrossProceedsFromIssuanceOfCommonStock', window );">Gross stock issuance proceeds</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAX BENEFIT (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAX BENEFIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="num">$ (113)<span></span>
</td>
<td class="num">$ (138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax benefit</a></td>
<td class="num">$ (113)<span></span>
</td>
<td class="num">$ (138)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAX BENEFIT (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAX BENEFIT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Segment Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 10,113<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee salaries and related expenses</a></td>
<td class="nump">5,205<span></span>
</td>
<td class="nump">5,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Sub-contractors expense</a></td>
<td class="nump">2,689<span></span>
</td>
<td class="nump">2,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Interest expense</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Interest income</a></td>
<td class="num">(419)<span></span>
</td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">6,018<span></span>
</td>
<td class="nump">983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE TAXES ON INCOME</a></td>
<td class="num">(3,732)<span></span>
</td>
<td class="num">(4,733)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Tax benefit</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (3,619)<span></span>
</td>
<td class="num">$ (4,595)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment reporting description</a></td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 10,113<span></span>
</td>
<td class="nump">$ 3,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">9,995<span></span>
</td>
<td class="nump">3,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">LICENSE AND R&amp;D SERVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">6,979<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,016<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 1,346<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,349<span></span>
</td>
<td class="nump">9,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">3,476<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CustomerAdvancesCurrent', window );">Advances from customer</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PayableToCustomerCurrent', window );">Payable to customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">427<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 18,776<span></span>
</td>
<td class="nump">$ 19,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PayableToCustomerCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PayableToCustomerCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerAdvancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of prepayments received from customers for goods or services to be provided in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerAdvancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 09, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,325,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GrossProceedsFromIssuanceOfCommonStock', window );">Gross stock issuance proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="nump">1,450,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GrossProceedsFromIssuanceOfCommonStock', window );">Gross stock issuance proceeds</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ($XJ5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ($XJ5H?7[^"\0   "L"   1
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MRF+/RA)8)G&^SX 9[]#N4I_'+"HJXAN5J<@TN/33&R#!*R *HD+!8WQ<76;
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M6-O5L=:UX8L.-EE1D: 7-?M+.?X?^,\FD>1!^J%(R$@GN-KB9E+TKE*!!%M
M@EF08#8DF ,$5A*GOA.G+A7/,I5A/YU->\B- K'$2"C/Y_GYF,LCE*23%11M
MTNN-4QXI1==A"1)LKM<:@:XHE6X+DM""!+,AP1QY493$8^S$8WRW>$3*>.R[
MZ5FN(_I$X^:9LY2LJXP@P>9&K>PT$U=D!$EH08+9D&".O"A*,AKN9#3\OV1T
M.)0VC9QRXI:1<UC+(E;2?Y5Q4XK=56&08 M(, L2S(8$<X# 2IHU=YHUI=*Y
M8APYH5"KF,U]B))&]4VE$%T[-$BP.238 A+,,FN-KZ_IH\I2PX:D=(Y1E@0R
MV@ED)!7(//0JR[J/--Y-\[4FN8R.+^NDG%U%,*IWY5@WU KG I+3JG.*99T^
M(I7.U88D=>JD9#0TC>8*QLK>652Z5'%E57>LNB^/H+<,3D54:5VG*DWK.CE^
M5[& HBU T2Q0-!L4S8%"*VOTP/W&WV<P-?9$!6BI*S*J\I(2=Y87KG=&!.O$
MK'1&H*Q6 VM?'9HU&]0&I76:,JL2W#*-QGN'&7>VF-N=IN8^24[0UB>1>I^D
MF[I"AGI5-)#V[AP4;0&*9H&BV:!H#A1:6:9[SQO+36\G2;:9.J/[=+V7O@_+
MUW3;T&,QXBN&EG3-$C1YB!E+W]J<H) UO;J9XKICBZN2 [7""[327,(TJI82
M**<%BF:#HCG-Y='6D^TM<RSWM+]1(L?L@".L;=U;W4K'*M'Q<%25&JB5#HJV
M $6S0-%L4#0'"JTLW;VACG^ HR[GZ&H=@*+-<=U)5E6CV@."NNJ@:#8HFG.D
M.,HJVCOK^(=:ZW*VSGH"-==QW5(FBE;5$ZB]#HIF@Z(Y1XJCK*>]Q8[E5O?\
M*XM=/\D&5*&2F(8\033TI)W0\/CD"M0$QW7GG1!<DP*HO0V*9H.B.<WET6),
MXKUUC>7>]3$M')U%R>';9E%UFW6DFVI]B0AJ=(.B+4#1+% T&Q3-@4(K2W1O
MGF.Y>_ZBURMRC,Z#&JBW#HJV $6S<),);^#JEU6@I,Y1TO)'E7L3GG0RX2O&
MN][X%:52=S<K/N-,SMI5#0V,&AEBC52&-E!6JX&UKYI$P15:&Y36:<JL3A2S
MI:;W5C:16]DO?]W25.N71]!;1BU2MVJ')E9%,587_W+\SHJ!1%N HEF@:#8H
MF@.%5M9HZL"7K^S-3B(W.X6NI@<&U@EZK9PJ"D8;&J-'NMZR]VBRY:LH]O\5
MZ[@WKTR"\7M$DW1R)C3MKO+4/2L[FZ?-F,N"SRPNW=)VP=C43Q1%2?^*%G+:
ME+G!P::*@,4/V8Z<1*PVMR'/OV#>72UV_1#US,ZW_=3N$'&'--W!9Y?YOIX]
M1;[-2&3NP1>3S36[%W3*Z5"TL3C?N9.?\&B3;>OX''$>!=GABE&/Q>D#XOY]
M%/'GDY1@MW]J_!]02P,$%     @ @3BI6HH,9<%R @  'P8  !@   !X;"]W
M;W)K<VAE971S+W-H965T-2YX;6RU5>]OVC 0_5>L;-H/J<-)@*[J0B0:Z(K6
M FMHIWUTDX-83>+4-M#MK]_922,ZT:Z3-CX0GWWO^=TC=P1;(6]5!J#)?9&7
M:N!D6E?'E*HD@X*ICJB@Q).ED 73&,H5594$EEI0D5/?=0]IP7CIA('=F\LP
M$&N=\Q+FDJAU43#YXP1RL1TXGO.P<<E7F38;- PJMH(8]%4UEQC1EB7E!92*
MBY)(6 Z<H7<<]4R^3;CFL%4[:V(JN1'BU@23=."X1A#DD&C#P/"Q@0CRW!"A
MC+N&TVFO-,#=]0/[J:T=:[EA"B*1?^.IS@;.D4-26+)UKB_%]@R:>OJ&+Q&Y
MLM]DV^2Z#DG62HNB :."@I?UD]TW/NP O-X3 +\!^"\%=!M UQ9:*[-EC9AF
M82#%EDB3C6QF8;VQ:*R&E^97C+7$4XXX'4:SZ6@\C<<C@JMX=CX9#1<8Q M\
M7(RGBYC,3DET-IQ^'L=D,L6#6?3E;'8^&E_&;\GXZ]5D\9V\FS,)I<Y \X3E
M[\D'\II0HC+<50'5*--<1I-&TDDMR7]"T@63'=+U#HCO^OT]\.AY^ B2%MY[
M#*=H3NN0WSKD6[[N?W1HGPGUK;W]MYKF/5852V#@8'<JD!MPPC>OO$/WTSY+
M_A'9(X.ZK4'=Y]C#2!0%-F2L17)[0/!5($)BQ#2DY)KE:R!SP WS-NSSH28_
MLN1FYFQ"M^.Z7D WNP7^*>N1\EZKO/<7RJU"189KG0G)?T*Z3VU-V-_1X1WU
M7?OY3?%+,FO5=*=]S>C$!ECQ4I$<EHAU.Q^11-;CJ ZTJ&Q'WPB-\\$N,YS@
M($T"GB^%T ^!&1+M?T+X"U!+ P04    " "!.*E:67D^T','  !4(   &
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MVPT RFZ.S>V\(29A_ 35A M8<%I[ZUT;]VBO:G!=ZHQ2JZ%)X;*]X[?Z>[E
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M9U:5R@=KV]T_^7P\$M(J,=.F7DID9<:*0,6,I6KEQ-P@;R ".4^[Y@I:F1I
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MG7#!G'Y!)//?)@&^O"GYQR5Z/F7I 7P_-V %\1?:H/UCM;?_#5!+ P04
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MQ)SIKEQA02>95#DSM%6+GEXI9*ECRD4O]/U!+V>\\";'CG:K)L>R-((7>*M
MEWG.U-,I"KD^\0)O0[CCBZ6QA-[D>,46>(_F^^I6T:[7H*0\QT)S68#"[,3[
M$AR>]NU]=^%OCFO=6H.U9"[E#[NY3$\\WRJ$ A-C$1A]'O ,A;! I,:_-:;7
MB+2,[?4&_<+93K;,F<8S*?[AJ5F>>",/4LQ8*<R=7/^%M3VQQ4NDT.X_K*N[
MH>]!4FHC\YJ9-,AY47W98^V'%L/H+8:P9@B=WI4@I^4Y,VQRK.0:E+U-:';A
M3'7<I!PO[*/<&T6GG/C,Y'[Z]6IZ/8/+ZXN;NZLOL\N;Z^.>(6![W$MJD-,*
M)'P#)((K69BEAFF18OJ:OT<*-5J%&ZU.PW<!KYCJ0A1T(/3#^!V\J+$R<GC1
MGUE9@?1W@]CT.-0KEN")1_&O43V@-_GX(1CX1^^HV&]4[+^'_JLJO@]R?3.;
MP@ ^?AB%07 $.S"!=6&V1#B3^8H53T#9K9A!#;R 2ZT8"F :&&A>+ 36Q[0&
MC0O*1?.*V\D9'FFX)7_PE(Z!%2F<+3EF,'W$I+0I!S=9QA-4P#48RWQS?E7#
MT(J"^0>)3S'A-M$UN&37LE0) A-")LRF;X?4TFC_@%1RQ:B@"S)SD/.2]*53
M)SZ7!3=2::*F"RIK#ZATJ6W^ETQ8;$I8)X9!0@*EX"EY(+7)S747YEVXKVPE
MGU15C^0?.J?ZT=$??V=+A?@J88#"/5FZ>-__WKWO0BJ%8,J]B5G*4I-5^J !
ML#G1WO3A#A^P*,DUF9)Y737(Z.;2'@1^)PBB%B'J#/LC^$8^^WW+IOE*R"<R
M0C-2DV/E=H7"N1$?J6'8=_J9+>Z$?KR#&O3[<%_./]-C&$6O9)^N!MFZ'78&
MH_$.:A#'<%D8I-<U;S(/MBC1V']AXT5";MNZL]\/Q@?;U#B(#N <J1(DW$7(
M-GA_A\ PA!N*6+7)I\9=G[;5[?C!:(LZ'D7P35*HSY&"$\&P1W31_);Z]-)1
MN,. /M')A!E[)*@",VZV[P36R&UJ-#IH<J2@#!-6GY?8(I&#ML_VK+!X'+]0
M/M5.:&*%E!>E304*>8M8&U.3-2BVID)!#\69T!V*M;K44($1W&Q"4%I02N&D
M*B\9I9%<V^)EV)R*635X\&>LZ]!/12SEFBT6"A?5<U)I475>_0^2?SOIO[(R
ML3XDM9'&DE_7\38C%RC8O[096Z3M=QITQL-Q:Q]T@G (%UPFJGR&_5/%GKEH
M,T04HX/6/NS$L0\7;*Z>?E^QS=?V#\U)0</$4UO:YU?KF32NGK=K'XU[PC[X
M0LJT'9+CSG@<O])[,!S^5#<%-2E;-FPDW7UD^>KH'&R7)_*K4MI*RCT8!LTF
M[5)BDFQ!/2]U[8K:#*,4=3VLBNVJQ79WS0N]UA!'U7OA1E5-+:HL3#7/-=1F
M&OY2#8$OUZM1FD)JP:F5"LR(U>\.8P]4-9Y6&R-7;B2<2T.MPBV7--&CLA?H
M/)/2;#960/,;8?(?4$L#!!0    ( ($XJ5K*7E ]'@,  #D(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;+56;6_:,!#^*Z=LFC:)D5<@:P$I=*V&
MU%($=-,^FN0@T9PXLQTH_WZV RGK &F:]@7G+O<\]YSMW-'?,OY#I(@2GG-:
MB(&52EE>V;:(4\R):+,2"_5FQ7A.I#+YVA8E1Y(84$YMSW&Z=DZRPAKVC6_*
MAWU629H5..4@JCPG?#="RK8#R[4.CEFV3J5VV,-^2=8X1_E43KFR[(8ER7(L
M1,8*X+@:6)%[-0ITO GXFN%6'#V#KF3)V ]MC).!Y6A!2#&6FH&H98,W2*DF
M4C)^[CFM)J4&'C\?V.],[:J6)1%XP^BW+)'IP HM2'!%*BIG;/L%]_5T-%_,
MJ#"_L*UC@ZX%<24DR_=@I2#/BGHES_M]. *$SAF MP=X1G>=R*C\3"09]CG;
M M?1BDT_F%(-6HG+"GTH<\G5VTSAY'#^-)W>WS[<3A;1[#O<C2?1Y&8<W<-\
M$2V,&\:3N\?90[08/T[ZME0I-=".]_2CFMX[0^_# RMD*N"V2##Y'6\KJ8U>
M[Z!WY%TD?""\#;[; L_Q.A?X_*9^W_#Y_ZO^FCXX3:\_J2M1DA@'EOIF!/(-
M6L-W;]RN<WU!?-"(#RZQ_[OXR_23Q\4M].#=F]!SW6OXJVPP(I04,8*YFN+*
ML#C^]3^OZ@+$J;D!GS'&?(G<&.^?VO,V)(Q2P@5D!<B458(4B?C00/65.38"
MB.*858444)(=65($!5"-(N85H:(IG,D4^=]7,"4[KO083HZ42$P GU4W%2B:
MH+?@MOR@^\KV8<K9)C.=3S5>V)"8F";V.H?;"GOA*:_KZN)X=2KG8?VD,GTZ
MX>UT0YBQ':$RPY>M>1WG.\Z)Q$[HP+B(68X@R?-Y<"OH=<]XHV2C;XZ %6?Y
MO@>J4WX=[+6<$PH^ZFTW*24[C_UXBJW3U;M>(I<[<V;XL\I*-7^DFEAE23/D
M+UL8>+T_*3K!'SYUG&&KU_OM?-4&A\V9G>H"]E$[5^K79F@),%>U[NR-MYF+
M43T.7L+KH:J^EG56"*"X4E"GW>M8P.M!51N2E68X+)E46V4>4S7;D>L ]7[%
MF#P8.D'S;V'X"U!+ P04    " "!.*E:$O5+VL "  !0!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q-"YX;6RE5>]/VS 0_5=.84*;5#4_VK(.VDJ4%6T?
M8!T!]MDDU\3"L8/M4."OW]EI,S:@FL27Q#[?>W[G^%XF:Z5O38EHX:$2TDR#
MTMKZ, Q-5F+%3%_5*&EEI73%+$UU$9I:(\L]J!)A$D4'8<6X#&83'UOJV40U
M5G")2PVFJ2JF'^<HU'H:Q,$V<,&+TKI .)O4K, 4[56]U#0+.Y:<5R@-5Q(T
MKJ;!<7PX'[I\GW#-<6V>C<%5<J/4K9M\SZ=!Y 2AP,PZ!D:O>SQ!(1P1R;C;
M< ;=E@[X?+QE/_6U4RTWS.")$K]X;LMI, X@QQ5KA+U0ZV^XJ6?D^#(EC'_"
MNLV-*3EKC%75!DP**B[;-WO8G,,SP#AZ Y!L (G7W6[D57YEELTF6JU!NVQB
M<P-?JD>3."[=1TFMIE5..#M+K^;IXN?5XOP2%M?T3">A)5JW&&8;BGE+D;Q!
M,8 S)6UI8"%SS/_&AR2GTY1L-<V3G81G3/=A$/<@B9+1#KY!5^/ \PW>4V-+
M,7R=PK7&H:E9AM. [KY!?8_!;'\O/HB.=@@<=@*'N]C_3^!NBO,?EPL8P_[>
M.(GC(WC!""F7&8(M$5#FH%9^>-<P;5&[$.9 YYZ5W<'W?,:)JFHF'X'NF6LD
MRF)UK=4#IX9 \0@?DOZ8[J40KL566E5@F$ #5L%RQ9^(F\D7F+C_Y0W,*5>9
M;I[@XURS)RX^]=^KVRB1]X!+'V1%H;$@$1#WAJ.H%PT.P)2,/J@C)DA%@E*K
MLEMHB%E[4.JU'1,2R8QL#PJ4J)GELH!"*V. :LL0<P-(NH0KXY]ZA_VXJY>D
M9$K*C2FMN2W)$$F^/X*^_X#1X-5+%3[K\@IUX;W,$%LC;=OP7;2SR^/6)?ZD
MMUY+)U9P:4#@BJ!1__,H -WZ5SNQJO:><:,L.9 ?EF3YJ%T"K:^4LMN)VZ#[
MB<Q^ U!+ P04    " "!.*E:RI*E)TL"  "A!0  &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6RM5&UOTS 0_BM6F- FL3FOA94DTMJ"F,10M3+X[";7
MQEIB!]MIMG^/[:2AF](*(;XTOO,]S]US]5W<<O$H"P"%GJJ2R<0IE*JG&,NL
M@(K(*UX#TS<;+BJBM"FV6-8"2&Y!58E]UYW@BE#FI+'U+44:\T:5E,%2(-E4
M%1'/,RAYFSB>LW?<TVVAC .G<4VVL +U4"^%MO# DM,*F*2<(0&;Q+GQIO/0
MQ-N 'Q1:>7!&1LF:\T=CW.:)XYJ"H(1,&0:B/SN80UD:(EW&KY[3&5(:X.%Y
MS_[9:M=:UD3"G)<_::Z*Q/G@H!PVI"G5/6^_0*\G,GP9+Z7]16T7&T4.RAJI
M>-6#=0459=V7//5]. !XQP!^#_!? \(C@* '!%9H5YF5M2"*I+'@+1(F6K.9
M@^V-16LUE)E_<:6$OJ4:I](E>48[B98@[(M@&: %E5G)92, 7:*'U0*=GUV@
M,T09^E[P1A*6RQ@KG=LPX*S/,^OR^$?R!.B.,U5(](GED+_$8UWS4+B_+WSF
MGR2\(^(*!=X[Y+M^-%+/_._AX8ER@J&/@>4+_J6/8^WJZ,)Q.C.[4UF3#!)'
M#Z<$L0,G??O&F[@?Q[3^)[(7RL-!>7B*/?VF5\TMRW@%Z/PKE_)B3&U',;$4
M9K'LTLM@XEW'>'<H8R0JC*ZC(:JK#Q^\]@K$UBX!B3+>,-6]G\';[9F9WC-V
M'E_Y]?ZYL6.'_]!TRTN_CBUE$I6PT93NU7L]O:);")VA>&UG:LV5GE![+/0.
M!6$"]/V&<[4W3()A*Z>_ 5!+ P04    " "!.*E:$ZV'ZT0"  "*!@  &0
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MN5J6,:Q $+M$R$9YE"\R%&<R5R5F)?XM+78>I,]KWW!N&Y.=5>T?F&0 59'
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M48>8)H^F0F2SNLFL] [5.($RN,>:!PF21P-$QY)GU$W)=-BH"*FAHG?:-[&
M,TW!_0_;U!W]B@H]-M,:^ ^Z5VY#@[L(J8"8*38>+@9*,X/I&[)H3L<%U&+V
M7-AC=D(27<-V#'IA!CY(BLC%LW?]W#8]&>RKU_-$M1%J[(4%Y=D\T%EZWFY^
MMX*4Q.EK[8AX9+U&1F='1WC)/?<0:!J+S'S/U7F]M/]\E$$'C-ABB(BL[Y$=
M["O2-QX5<5DZ?^XX.<*FL?T2)E1[V&&*VY2^*P5U9@T]2ZMO>ZFA,=2V,-G%
MC$TG(+T.UZ^TA5 ]:<ARZ1@'H0!4#OF4_J ^%7@IS\,$:X&I]JC$$4#E[]0=
M,XY;0QN)%$6R:ZA5I2-?=+"5FZTVFC*3M29V%4XWN1KV"%0)Z)@<IFANTW\>
M?$7Z+3O-"I!3(&MLN?UQW-[^.-YZB>-<QN,DOEE2>=[W37=!MHN9@MMMDL0[
M0\4IFX70I*DD,);BCU @W&W 7V".O)GYYD4/$:!7.6.R@(0;^G'S<#N%Z%]&
M[7GB*QGW0?G4 "5<1G'=NNCP%"8=Y[T_.[L>G.?QT;(N>XJ"ZO%=KL"_UTKQ
ME<@-QV#LKO<;,[V!\3B:9FY;J4B8-'OPFPIU5['1.LP>&+%K7<5.%C -A6#H
M#TD^ ?\3!"88<Y=().;"S-2 H4S!Q\&2@O,)[P:PC!3H^KVL@IA),(!VXJZ]
M1$G9M:VU9"# B#:Y2PX!>=V^16. ^7P):,,G^MODL..3'9-2FD\LP@6#.[6N
M#(=1+ ,"<)%O1<G<<ELINOAURY'V][P2T$'I:DJS2G9!C/D35),WM.6_/=$_
M$1@=\2SL]5=%A_F$TG154$P.]OZK70$I+T*CX2WLP=PX@M33$807P7WZ0=/J
MP^?C-X%4I@.NR_ML(:NY&ASMKY7IX7'72+@-;53BB+P#4UEP\(5[GS#_ \VZ
MCCK\2]^U79*>D39CG@_[2:;C>6V_>U8ATQ(39&K!JV!+FK6LU(_]>/U0,,UR
MF=73 "$TYN?;]"N;L V<G[7@_&PKJGZ&&9DNM*V33<B\748V%@_%,%B'&S"Y
M+AI:Z-H+"?T^7M^TX!?N3-5-K*-S4%5FRU62'QUNR9=6N7M#=ZI4KW9[I U!
M]"DU',FX?",BA'UT,UFT)V@8G)2&=D!7Y8;X.NA;3)Z/#B?/1D?/GO%RL3W/
MCUZ,CIX>/Z8+MR\*SE5]M4P=J5]3@5S0Y-UXNFAD-2-,;'Z!>]%U )?*>!C"
M,_\."#],9]S0D^$FR90.&I)_^855*K&$X&=#.L+B!X^V^MU)ZW<G6WWF8EWA
M36ZW703V[8$42E,WE(?+V#9Y.NS*42K7'(:,S[T\V=^(F+=CFZ:]YU7+%3>B
M0O>)^-O)^/C@'Y@0*=$&N(/]^DI= WN :72&^9GU(U[*,-5'/G[ WP^1C[1=
M]=/@PVWF#.1#[4Y71 *8\"&V1X)/=V&[+AH1U#'TTMR6:WNM+:YO9.L]VW2Z
M(@BM2I 7,Q]YF2AT.MW=S=74A^NU1#BHOP#1IN+V<5@,IX'@^4]2U_GA,F.6
M=<KSV5.XK$/5(AVA<9+FA<5# A4%/@B"Y4)523H1 _ PRVC-.6*C+?JZT&KX
M5H9M DH_9@&ZN4357&N(V&+(23^4CI#W@[.U\]N"Z7D;3,]_ N++(>TTX9X9
M*[DIL+:+^\J- +(JUP"/BQXQ**XH$^>&R2_"KTU3W>G'NS;#G76B;LBCI 5Y
M.S?XI[LP=W9SWLL'K,'&8=]J+F;2N+.;;^TPFGKOX$6*KZN*S^EOY3V1[EMP
MV$R</#UX\E)<E7SW+NPFPJ%[4[S5+D/*H0)S' 4C*)&@YHT.%8!V\>IFJ/3C
ME=@ JW1,2%5#%2^7YBK3Y.I[C5. 'NXI\!U2GL]COKPW7ZAITHD!4PTLKUU6
MNFNJ.4_0E5]$EW*1-D0]\K[P?A4 ="L#M07XAXY29#1T:MAJ0<TK:<,]6+(S
M75?!)A:ZW[),$]#I P$K-RU2K4,<,'9C,;NB_N"?0"I'K:'8@^@M2J>V#_$\
M6L<,JLC H8G1S77%9]F2SY9:+YL<1]Y'.I%_<B4?N")5BRTEC9! IS%\5LB-
MU>A,=%[<C2Q6#R]RMZVN>&,LG%OVO8&,I\(QINJW2G2H$9A+4D,V'#?^A/X-
MG %!]9F<=)C2*$[:^ AV?+IW<+3F\S=))H/YX6D@_*0]K<ZJ1>R!AM?C2Y?A
M*)U"()TTD>EZ$2%V;YJIYT#"9'L<2VMO4Y]J30<1!;M1"JAPT!6KT?ZRA9PB
MZX186M7I\,]%NM.>]:<:CQ- ;.7%+ZDQ$CJ#77$8NU'1;UM[CP<&_-\YXK-1
M1QIZ!6ILY/TE42?Q B1?A@\0R_%+/D8_*@@SI3-A(G>4][6/5_<Z=Q8,$?]O
M/5QLS('[O=^&E<K.^1=P+EPR"S\3:Y^V/[(["[\MZUX/O] #?9W3;9!"S3#T
M8'QRO!,N&:0/\&3^I1G@RYN2_UR@W%:67L#W,P,6$C_0!.U/#]_\!U!+ P04
M    " "!.*E:R(54P[("  !P!@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6RM5=MNXC 0_14K756MA$@PH:44(I5>M#RT6T$OSR89$JN.G;4-M'^_
MXP1"NJ7LR[[$GO&<,V?BS&2X5OK-9 "6O.="FI&765L,?-_$&>3,M%4!$D\6
M2N?,HJE3WQ0:6%*"<N'3(#CS<\:E%PU+WZ..AFII!9?PJ(E9YCG3'V,0:CWR
M.M[6,>5I9IW#CX8%2V$&]KEXU&CY-4O"<Y"&*TDT+$;>56<P#EU\&?#"86T:
M>^(JF2OUYHQ),O(")P@$Q-8Q,%Q6< U"."*4\7O#Z=4I';"YW[+?E;5C+7-F
MX%J)5Y[8;.3U/9+ @BV%G:KU3]C4TW-\L1*F?))U%4NI1^*EL2K?@%%!SF6U
MLO?->V@ ^L$W +H!T%)WE:A4><,LBX9:K8EVT<CF-F6I)1K%<>DN968UGG+$
MV6CR\'+[\/1K.KF=D9,G-A=@3H>^169W[L<;EG'%0K]AZ9)[)6UFR*U,(/F,
M]U%1+8MN98WI0<)[IMNDVVD1&M#> ;YN76:WY.O^N\Q]U57@<#_8]<7 %"R&
MD8<?O@&] B\Z/NJ<!9<'I(6UM/ 0>S3#/DN6 HA:D(E<@;1*?^P3>9AF"^5@
M"+,$7V"<U6^0,)F0&X@AGX/>>D,2*VPN8R%QN6T&9*$$=BF7Z8 <'_5IT+W\
M;^M.T"<=V^,3\MR>M4F" I@VA$O4HY8&=9O3.J@LI6&$M3%E:^P*"YHS86KO
M#Q*VPG[XR>Z%%[7]B@/#I2JT2O%B=\!^*PCHEQ(ZG18-=P+NN.38> E)E4IV
MV/-60(,OV%XK;"1^4I8)S+RY[8; SD6K%YPU'-0E[?[-M^^[\QM3( >=EK/.
MX"4OI:T&0NVMQ^E5-45VX=4LQLM*N31$P *A0?N\YQ%=S;?*L*HH9\I<69Q0
MY3;#7P)H%X#G"Z7LUG )ZI],] =02P,$%     @ @3BI6A3.EP-[ @  V04
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M^6D NADDC6%5[9MWJ2R- K\M:?:B=@'D+Y2R6\,EZ*9Y^@=02P,$%     @
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M:)1&@.XW0N@380Q4*W_T+U!+ P04    " "!.*E:;[.OK8X&  !?,P  &0
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MC3/+!TT8?L8QQ4]4C?HEDYB6@LLXBPA9B:-J \U%E+3+>@!P>3$Z&/R#^O1
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M%5KQ8C='<2)9EN\->&)2LB0_W!*\(ES?H'Y?,Q5YER?:P7Y/S>1?4$L#!!0
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M-#C,ZF6.OQM0U@'/%U*:=\-.M.X'EOP!4$L#!!0    ( ($XJ5IL8(J-7P,
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MI2.""'RI);#Z6\,8HD@KJ3C^Y*)&X5,;[K>WZM]3> 4SQP+&+'HB@0R'1L]
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M2P$"% ,4    " "!.*E:'U^_@O$    K @  $0              @ '#
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " "!.*E:F5R<(Q &  "<)P
M$P              @ 'C 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ($XJ5I++"3N]04  .L?   8              " @20(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " "!.*E:X[M'&TP%  #Z%0
M&               @(%/#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ @3BI6E'7&"K+!   VQ$  !@              ("!T1,  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ($XJ5IX",K(+@<
M $LU   8              " @=(8  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " "!.*E:B@QEP7("   ?!@  &               @($V
M(   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ @3BI6EEY
M/M!S!P  5"   !@              ("!WB(  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( ($XJ5H8,S1^5A0  +@V   8
M  " @8<J  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " "!
M.*E:LXKW2:@"  !R!@  &               @($3/P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ @3BI6K:,8 -"!   W@D  !@
M         ("!\4$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( ($XJ5H[YF/B#@,  "$'   9              " @6E&  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ @3BI6CF,Q\E% P  U@<
M !D              ("!KDD  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " "!.*E:E[L;#<($   O#   &0              @($J30
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ($XJ5K*7E ]
M'@,  #D(   9              " @2-2  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ @3BI6A+U2]K  @  4 8  !D
M ("!>%4  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " "!
M.*E:RI*E)TL"  "A!0  &0              @(%O6   >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ($XJ5H3K8?K1 (  (H&   9
M          " @?%:  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#
M%     @ @3BI6MNX^/B:%   AC@  !D              ("!;%T  'AL+W=O
M<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "!.*E:R(54P[("  !P
M!@  &0              @($]<@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM
M;%!+ 0(4 Q0    ( ($XJ5H4SI<#>P(  -D%   9              " @29U
M  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ @3BI6L\A
M.[XS!   9@L  !D              ("!V'<  'AL+W=O<FMS:&5E=',O<VAE
M970R,"YX;6Q02P$"% ,4    " "!.*E:HYP Z#4#  #^!P  &0
M    @(%"?   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M ($XJ5IOLZ^MC@8  %\S   9              " @:Y_  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ @3BI6K5E?H&* @  S 8  !D
M             ("!<X8  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " "!.*E:;&"*C5\#  !?#@  &0              @($TB0  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ($XJ5HG"T#<<P(
M $<&   9              " @<J,  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ @3BI6D<+]WIH @  ;08  !D              ("!
M=(\  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "!.*E:
MV@=AWQP$  #7#0  &0              @($3D@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( ($XJ5H*2EY1@ ,  *\/   9
M      " @6:6  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ @3BI6HV6[W%8 P  R H  !D              ("!'9H  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "!.*E:JH4;2*D#  "F$@
M&0              @(&LG0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( ($XJ5K]6;3:,0,  $@3   -              "  8RA  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ @3BI6I>*NQS     $P(   L
M         ( !Z*0  %]R96QS+RYR96QS4$L! A0#%     @ @3BI6D[D>^Y,
M P  FA0   \              ( !T:4  'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( ($XJ5IDA-5Z5P$  )$2   :              "  4JI  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ($XJ5HY:2-U@@$
M $P3   3              "  =FJ  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     F "8 00H  (RL      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>49</ContextCount>
  <ElementCount>155</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - TAX BENEFIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxBenefit</Role>
      <ShortName>TAX BENEFIT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>99930503 - Disclosure - TAX BENEFIT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxBenefitTables</Role>
      <ShortName>TAX BENEFIT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxBenefit</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - TAX BENEFIT (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAX BENEFIT (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxBenefitTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99940502 - Disclosure - TAX BENEFIT (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails</Role>
      <ShortName>TAX BENEFIT (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxBenefitTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Segment Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940602 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20250331x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20250331.xsd</File>
    <File>plx-20250331_cal.xml</File>
    <File>plx-20250331_def.xml</File>
    <File>plx-20250331_lab.xml</File>
    <File>plx-20250331_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20250331x10q.htm">plx-20250331x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20250331x10q005.jpg</File>
    <File>plx-20250331x10q006.jpg</File>
    <File>plx-20250331x10q007.jpg</File>
    <File>plx-20250331x10q008.jpg</File>
    <File>plx-20250331x10q009.jpg</File>
    <File>plx-20250331x10q010.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="241">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>56
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20250331x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20250331",
   "dts": {
    "schema": {
     "local": [
      "plx-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20250331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20250331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20250331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20250331_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20250331x10q.htm"
     ]
    }
   },
   "keyStandard": 136,
   "keyCustom": 19,
   "axisStandard": 12,
   "axisCustom": 0,
   "memberStandard": 10,
   "memberCustom": 9,
   "hidden": {
    "total": 8,
    "http://xbrl.sec.gov/dei/2024": 5,
    "http://fasb.org/us-gaap/2024": 3
   },
   "contextCount": 49,
   "entityCount": 1,
   "segmentCount": 19,
   "elementCount": 340,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 241,
    "http://xbrl.sec.gov/dei/2024": 30,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "995210201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "995210301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "995210401 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureTaxBenefit",
     "longName": "995210501 - Disclosure - TAX BENEFIT",
     "shortName": "TAX BENEFIT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformation",
     "longName": "995210601 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "995210701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "995210801 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R16": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "99930203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureTaxBenefitTables",
     "longName": "99930503 - Disclosure - TAX BENEFIT (Tables)",
     "shortName": "TAX BENEFIT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationTables",
     "longName": "99930603 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "99930703 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "99940401 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails",
     "longName": "99940501 - Disclosure - TAX BENEFIT (Summary of Taxes on Income) (Details)",
     "shortName": "TAX BENEFIT (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:DeferredIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails",
     "longName": "99940502 - Disclosure - TAX BENEFIT (Additional Information) (Details)",
     "shortName": "TAX BENEFIT (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "99940601 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:LaborAndRelatedExpense",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
     "longName": "99940602 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4ybsI5_mqUqIV1P-uoYRHA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "99940701 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99940801 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "unitRef": "Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250331x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "AccountsPayableAndAccruedLiabilitiesOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).",
        "label": "Accounts Payable and Accrued Liabilities, Other, Current",
        "terseLabel": "Other",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r35"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable - Trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r525"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r37"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r621"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r682",
      "r683",
      "r684",
      "r685",
      "r704",
      "r746"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r127",
      "r128",
      "r129",
      "r130",
      "r140",
      "r177",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r346",
      "r347",
      "r356",
      "r357",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r375",
      "r376",
      "r377",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r240"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r603",
      "r613",
      "r645"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r596",
      "r606",
      "r616",
      "r648"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r641",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings (loss) per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r84",
      "r98",
      "r120",
      "r151",
      "r158",
      "r166",
      "r169",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r308",
      "r312",
      "r348",
      "r412",
      "r473",
      "r535",
      "r536",
      "r557",
      "r584",
      "r699",
      "r700",
      "r711"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r104",
      "r120",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r308",
      "r312",
      "r348",
      "r557",
      "r699",
      "r700",
      "r711"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r656"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r657"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r14"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r97",
      "r523"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r59",
      "r118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r59"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r153",
      "r221",
      "r222",
      "r223",
      "r225",
      "r228",
      "r233",
      "r235",
      "r442",
      "r443",
      "r444",
      "r445",
      "r545",
      "r671",
      "r678"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r76",
      "r413",
      "r460"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain for sale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in gross sales price of shares available for future issuance.",
        "label": "Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance",
        "terseLabel": "Increase in aggregate gross sales price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r578",
      "r579",
      "r580",
      "r581",
      "r682",
      "r683",
      "r685",
      "r704",
      "r744",
      "r746"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r461"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "CommonStockValueOfCapitalSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of common shares reserved for future issuance.",
        "label": "Common Stock, Value of Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain available, total gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r120",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r348",
      "r535",
      "r699"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r126",
      "r133",
      "r140",
      "r184",
      "r190",
      "r193",
      "r278",
      "r279",
      "r292",
      "r294",
      "r317",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r329",
      "r332",
      "r334",
      "r335",
      "r367"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r126",
      "r133",
      "r140",
      "r184",
      "r190",
      "r193",
      "r278",
      "r279",
      "r292",
      "r294",
      "r317",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r329",
      "r332",
      "r334",
      "r335",
      "r367"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r126",
      "r133",
      "r140",
      "r184",
      "r190",
      "r193",
      "r278",
      "r279",
      "r292",
      "r294",
      "r317",
      "r319",
      "r320",
      "r322",
      "r323",
      "r324",
      "r329",
      "r332",
      "r334",
      "r335",
      "r367"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerAdvancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerAdvancesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Advances, Current",
        "terseLabel": "Advances from customer",
        "documentation": "The current portion of prepayments received from customers for goods or services to be provided in the future."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r37",
      "r74",
      "r75",
      "r122",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r555",
      "r679",
      "r694",
      "r695",
      "r696",
      "r709",
      "r710"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r205"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r122",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r555",
      "r679",
      "r694",
      "r695",
      "r696",
      "r709",
      "r710"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred income tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r86",
      "r681"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r237",
      "r238",
      "r239",
      "r472",
      "r549",
      "r714"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r23"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r620"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r631"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - BASIC (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r141",
      "r143",
      "r145",
      "r146",
      "r147",
      "r150",
      "r296",
      "r305",
      "r335",
      "r336",
      "r409",
      "r420",
      "r529"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "LOSS PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r143",
      "r145",
      "r146",
      "r147",
      "r150",
      "r296",
      "r305",
      "r335",
      "r336",
      "r409",
      "r420",
      "r529"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r149"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r708"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r550"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r272",
      "r283",
      "r550"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r586"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r90",
      "r107",
      "r108",
      "r109",
      "r123",
      "r124",
      "r125",
      "r128",
      "r135",
      "r137",
      "r139",
      "r152",
      "r184",
      "r190",
      "r193",
      "r236",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r334",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r359",
      "r369",
      "r419",
      "r431",
      "r432",
      "r433",
      "r448",
      "r499"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r593",
      "r603",
      "r613",
      "r645"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r600",
      "r610",
      "r642"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r408",
      "r553",
      "r554"
     ]
    },
    "plx_FiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "FiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Financial income, net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r481",
      "r582",
      "r706",
      "r707",
      "r745"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r649"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r649"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "plx_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the additional capital contribution to the entity.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross stock issuance proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r78",
      "r83",
      "r410",
      "r416",
      "r531",
      "r535",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAX BENEFIT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxBenefit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAX BENEFIT",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r268",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r284",
      "r286",
      "r287",
      "r288",
      "r446",
      "r550"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "TAX BENEFIT",
        "totalLabel": "Total tax benefit",
        "verboseLabel": "Tax benefit",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r138",
      "r139",
      "r151",
      "r161",
      "r169",
      "r271",
      "r272",
      "r285",
      "r421",
      "r550"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (increase) in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Increase in contracts liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r677"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r641",
      "r649",
      "r653",
      "r661"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r665"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r665"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r589",
      "r665"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r117"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r191"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r526"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r524",
      "r557"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r528"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r527"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Employee salaries and related expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r36",
      "r37",
      "r38",
      "r40",
      "r41",
      "r42",
      "r43",
      "r120",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r309",
      "r312",
      "r313",
      "r348",
      "r459",
      "r530",
      "r584",
      "r699",
      "r711",
      "r712"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r77",
      "r414",
      "r557",
      "r680",
      "r693",
      "r705"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r96",
      "r120",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r309",
      "r312",
      "r313",
      "r348",
      "r557",
      "r699",
      "r711",
      "r712"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r40",
      "r41",
      "r42",
      "r43",
      "r120",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r309",
      "r312",
      "r313",
      "r348",
      "r699",
      "r711",
      "r712"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "LICENSE AND R&amp;D SERVICES",
        "verboseLabel": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r702"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r548",
      "r567",
      "r571",
      "r701",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r176",
      "r548",
      "r567",
      "r571",
      "r701",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r60",
      "r62"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r62",
      "r79",
      "r94",
      "r105",
      "r106",
      "r109",
      "r120",
      "r127",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r138",
      "r139",
      "r144",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r296",
      "r305",
      "r336",
      "r348",
      "r418",
      "r482",
      "r497",
      "r498",
      "r582",
      "r699"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "New accounting pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r597",
      "r607",
      "r617",
      "r641",
      "r649"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME, NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r687"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING LOSS",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r531",
      "r686",
      "r688",
      "r689",
      "r690",
      "r691"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r361"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r557"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Expense",
        "negatedLabel": "FINANCIAL EXPENSES",
        "verboseLabel": "Interest expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "negatedTerseLabel": "Interest income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r595",
      "r605",
      "r615",
      "r647"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r608",
      "r618",
      "r650"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r598",
      "r608",
      "r618",
      "r650"
     ]
    },
    "plx_OutstandingStockOptionsAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "OutstandingStockOptionsAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding stock options and warrants.",
        "label": "Outstanding Stock Options And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "plx_PayableToCustomerCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "PayableToCustomerCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payable To Customer, Current",
        "terseLabel": "Payable to customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r675"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r41",
      "r71"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "plx_PfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "PfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "verboseLabel": "Stock issuance proceeds",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "plx_ProceedsFromWarrantsAndStockOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ProceedsFromWarrantsAndStockOptionExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.",
        "label": "Proceeds from Warrants and Stock Option Exercises",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "GOODS",
        "verboseLabel": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r374",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r521",
      "r546",
      "r566",
      "r568",
      "r569",
      "r572",
      "r573",
      "r697",
      "r698",
      "r701",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r172",
      "r374",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r521",
      "r546",
      "r566",
      "r568",
      "r569",
      "r572",
      "r573",
      "r697",
      "r698",
      "r701",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Sub-contractors expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r105",
      "r106",
      "r114",
      "r120",
      "r127",
      "r135",
      "r138",
      "r139",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r296",
      "r305",
      "r307",
      "r310",
      "r311",
      "r336",
      "r348",
      "r410",
      "r417",
      "r447",
      "r482",
      "r497",
      "r498",
      "r551",
      "r552",
      "r583",
      "r673",
      "r699"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r363",
      "r411",
      "r415",
      "r557"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r622"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r590",
      "r600",
      "r610",
      "r642"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r520",
      "r535",
      "r713"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r591",
      "r601",
      "r611",
      "r643"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r592",
      "r602",
      "r612",
      "r644"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r599",
      "r609",
      "r619",
      "r651"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r123",
      "r124",
      "r125",
      "r128",
      "r135",
      "r137",
      "r139",
      "r184",
      "r190",
      "r193",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305",
      "r317",
      "r320",
      "r321",
      "r324",
      "r334",
      "r357",
      "r359",
      "r431",
      "r433",
      "r448",
      "r746"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues from customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r110",
      "r120",
      "r151",
      "r159",
      "r160",
      "r165",
      "r169",
      "r172",
      "r174",
      "r176",
      "r180",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r348",
      "r410",
      "r535",
      "r699"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r556"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r660"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxBenefitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Taxes on Income",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r703"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenues",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r49",
      "r50",
      "r51"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r19"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r66",
      "r68",
      "r69",
      "r70",
      "r99",
      "r100",
      "r101",
      "r153",
      "r221",
      "r222",
      "r223",
      "r225",
      "r228",
      "r233",
      "r235",
      "r442",
      "r443",
      "r444",
      "r445",
      "r545",
      "r671",
      "r678"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r585"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r587"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r450",
      "r451",
      "r452",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r547",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r570",
      "r576",
      "r701",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r151",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r162",
      "r163",
      "r164",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r176",
      "r532",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r163",
      "r164",
      "r169",
      "r535"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "terseLabel": "Segment reporting description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r163",
      "r164",
      "r169",
      "r535"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r45",
      "r46",
      "r47",
      "r90",
      "r107",
      "r108",
      "r109",
      "r123",
      "r124",
      "r125",
      "r128",
      "r135",
      "r137",
      "r139",
      "r152",
      "r184",
      "r190",
      "r193",
      "r236",
      "r278",
      "r279",
      "r292",
      "r293",
      "r294",
      "r297",
      "r304",
      "r305",
      "r317",
      "r319",
      "r320",
      "r321",
      "r322",
      "r324",
      "r334",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r357",
      "r359",
      "r369",
      "r419",
      "r431",
      "r432",
      "r433",
      "r448",
      "r499"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r174",
      "r175",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r450",
      "r451",
      "r452",
      "r504",
      "r505",
      "r506",
      "r507",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r522",
      "r547",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r570",
      "r576",
      "r701",
      "r715",
      "r716",
      "r717",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r152",
      "r359",
      "r374",
      "r441",
      "r449",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r577"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r124",
      "r125",
      "r152",
      "r179",
      "r359",
      "r374",
      "r441",
      "r449",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r480",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r499",
      "r577"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r594",
      "r604",
      "r614",
      "r646"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under the Sales Agreement, net (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r70",
      "r442",
      "r499",
      "r508"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued as a result of exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Shares, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock under the Sales Agreement, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r44",
      "r45",
      "r70",
      "r448",
      "r499",
      "r508",
      "r583"
     ]
    },
    "plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Value, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r64",
      "r462",
      "r479",
      "r500",
      "r501",
      "r557",
      "r584",
      "r680",
      "r693",
      "r705",
      "r746"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r119",
      "r220",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r236",
      "r325",
      "r502",
      "r503",
      "r509"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r371"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r371"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r371"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r371"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r371"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r372"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Information of Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250331",
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r640"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r632"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r659"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r663"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r661"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r664"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r127",
      "r128",
      "r129",
      "r130",
      "r140",
      "r177",
      "r178",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r192",
      "r193",
      "r194",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r346",
      "r347",
      "r356",
      "r357",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r375",
      "r376",
      "r377",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r658"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - DILUTED (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r147"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE - BASIC (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r147"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r626"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>57
<FILENAME>0001558370-25-007063-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-25-007063-xbrl.zip
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M5>.@6Z"MK51+GD2)"P)$@44".A02S>OGMM5Z0XX&,HV%Z>:EG[FVW\X]H&U
MO N?O4*$3L=LAH-P\-+!D&*R?DH<45B]?BZZWW)9*VKKO.%]L]^[;?5&K5OQ
M;M3O=FX;8_APT^@V>LV6-OJKU1J/9%?E0S*IL5&@*?IARL(-*(TW1?Q!6G#!
MBX\(V<*2M1(V'>X_$;Y<D[;T'OQL<!Z 9J(';,)@:NO+4EYZ-1>,@?UBU?-D
M?EY4KZXJU4JEK%?+5]5R_:*\I7C 1QIL$P/XKU^&Y\K[>?J4T?FN^;R2:!;-
M*9M@!J/<@K;@H RU15G(+&C/F#S.'/E-#K2(G@Y:#_&O]?>"/"%3]( -IXD8
M6\% _!LR%SB"KE1IE:4QCJQ=@O?'^CK$[_1C\.#G:$:9,\9L?H.L7[?8IISL
M- 61<IO*U_2J7GU/1&7#Y9%2B2/%9@1&5,Y*BN718GI]_! ;&!P.NOD>=A(:
MT)@D[YS?O2%Z5%<5:WCE."U-I[@K>"),I@3F\5=3C+_U[ K<+X*YH,B)<)8(
MR6/K7#&V;F$V:<'PWYU6#F 2X*)O4R8^>,]YCUI&;&7,G(^RO(>Q>QQTV?K6
M6B[^,&#4QLQ9"5@.C.O$F,X6,[OHVAR7Y%VQG!E(FAXT;T+!=3&XY,1=(1JC
MI8L_FL[H!.^*S(PP%.U,O45DZ[&+$<=#H4I_>L^Q!!,U+HI+LPG^7*_4%>8P
M.Y(TO>Q+C;S(A=,N00_$) [!'!J9D4.-7S-J@MY<-#C.*H+6I&1@C\MR3:]5
M*O6+R]KE9:6VO9[PYO"2D2CHCGO9>==WDT JNNP54#MQS!<JJS:CH=K%DI>
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MCG@FV_L9%>KK%]T21XF>$%F98::.!XI:Z_">BY<'Q/&7_P-02P,$%     @
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M_/&86!45^+61D[.<?:RV ,*U?0IB!#?D?TE'W0<A6/0S^OZSA_VO%]@(P6>
M3H30:1VRC]"N/M)@+_L#R^C\A][Y>>]=*J5J6Q3)JYNS';@V<@>!.XS#"*X'
M+UYX#=>V%UR#A1W[4:C@9-)UE>5SA 41>&$^/"_L\#$19!SVEK:](=..#WV
MVR/?D"I#PO.'A%\ W/6A-1U4D2H#T_9'+Q'ND+U''XP"/+E*QYA;+XQ4;&FG
M:R^(^JZWWNG;]OWCC*8P'R$SAHL$7%);?:;P9P(9!CTW55R#+%+J;I3AQ-[:
MX3>KN@%VDYIZ:[!^/+;/H/-:KK<^HRO,$W+B1]#;B:%!=JFU%YC&!N(%7NIN
MP>]9&X2ONFY;1  (G0O<W;=>1!K8%[<*Y:VT.\-+*2+A4)';!CMC+N]X37-V
M9O6L?<WXC[QR"]=NI=5;I/X<TJX%@BC'Y$.GU*!/5CL0'=T7DV_V77'VQ;?]
MY->W0SS%3>98A+>\'=]^!#Y>\(KHOYU7)"%5HM\]XB(;UZ4>JP+UD)")D4Y:
M K<WT0$JP\0.GU>[0'"M)FLH8B(.<1-P0QJV=\-=UL?4&8U2 >Q174IP;<VA
MQ><6(CS-^GS2H&6$*"I8!?YK;Q'XCV]3!-W8B29H!M"3YP"*Z;/(#JR!1]@M
MG!!W-!D#(=7&N;0\8'3J8RU=0K10HOG.;)S-+S%M(9_-6[="OS<.\+ '=MZ9
M!\\X?3VG!+,G%)0Q!S>WZ^>64<7>W( @IQ"HP%'GHP,70G%\$+*NU9EV?*71
MOR%<;V! 0ATR4R=:&?'TB55* _H**UQ7HM(RT3*I&YM+"80/)7C1-Z6B,U]T
M&R;36MUE\(Q7/W/< ,<]2C1, SF@TN'\*QN!9+^.R!DK,^W"$"*[ \E6P=5V
M3S.UM^2[A/$]]X$[]>W@WEX#KO>TT12[JVFIL;J^R[(,V#[KG;MZ!6O1M=O"
MJ+5GN :/T3@((Y3LG7.ZAT-"IAW32;6#$SH[BUP2:+-.QY4WE..A<^^A,5UT
M(1ZS6MV ..=D4?!ECB=0:9DVPJ36,0TH]%6X*[J'9#\M_Z:XL7M7BLY7)PIJ
MM;"G$NKUU'4JD>I@+>XZ=S<&G*+''0&C,4<,@7.ZA$]]%WBI=>(/>Z/$?WR[
M!4O;'P48X9;B<!2* V-BT+3.>=H<=3BI_DSEN4IPK&7S903IC75FJ%3NB'G2
MN.H\]KQ;UMT N$3V9N4YML\(0#-IJ<%:+G57Z-+$EB('S% TDY:.CD==)Q0M
M(V0HP4.G\6@.TWE0FLMLYV;_0+I_AIGO?J,JOO1KE]Q2YR.57]D<UY\_L$0#
MJ:UT:GX%MG)SJ["C-U ;/X:>Z]EH.[-)2IUP?YM%SXZ:\$KH0+SG@BQP)HO"
M+(L?:Q(69,M JFCM&*Z$;J J4]T'<]DH2M$>*>ZU^U8AS5,0WV50<_V*06\&
M5KXSL>A5\#;K.GSA0TE.M/@+E?62M_!8[GR&,R29]0!M;!1MB?,R)CLT,NHL
M@D78U10(;&+DK.P0#)8(9$<ERAPQ9_;29>G3)Y72=297 E7 (]CI=!9&YW\W
M(5/A6]\R>.: P$8>%"V!BW3\Y6^5LBM$6;-?@W #G.18'GOIRZ*E(^-1-[+T
M90@72K2O9]E;9GBWY.4QJG?6M((HF@.T)IL1HCD3C9:S?\N@-@&E8)N;2BV/
MM,&9DD#D4(J+[F=)=+;+^\=,=K4ZQ!?;0[_8?@RNMKN//WL 86FLMK?@"=!B
MHFJ%F88D7URG8.Z 34X2))LHAVQR/4NI#K&89&NIZX7*:H4UF.W<6671%;U7
M&956GRXP.0XVL6B<8Y$S#9)7P!"X7+=D%U""W)S#26@ RO+2N3^QF2]Z$)]I
M@[*@'H +UHGXI@!/85WIK"A:0<GD(591XX2AD$%%+WJD0-K*K!+HC)EIQ>9/
M<]85'1 ["XL-1*M+IG=]C(/]/1FC,/+6>-%YM16,9C)%V4<))0L;)1+A>"=3
M] B1-#L&*NH-JG/8N6O*02J=RY2$TGF8<$Y 3A;CP/6>/#=F9LI0Z:C!-":E
M+D2_>M'J ?CI34HK;S.'G#2O(VJ0DX*XCCJ!1I%ZX-%<=1I^9,#(PX]'L*]U
MM+M!=A"!Y+A=S#O#=D#'[+2IE+J1<<<H"J4<NN9&()YXH;#USD<7"KO%H83!
MIE9#SX^_<&R\2,(T@"J11BA<HY8\^M7\H2V&%"&OS<X-N,QDT78-.R8U17 #
M4+0E;$6#P"7'/#=D]21<C$B49%N%7%F3Y"%<B4B45)='L^L0-95!9?ZZ=S,9
M0"7ODP.B]TRS^UL<1FD8'J)[\%RX41/! ']TLF,OG#//*G6P#S*IUJ+O@)N;
MFAWW?!>-5'2\[8"X]IGC(S4#Q:QU?Z98#4O1$5D8M'K> XB\-(Y/^@?!^$<G
M9MH3F]P(H-RAC46N +:Y04PH=RC'1^?>PF*\Z!8\AK6ZQBT,EI%<;A&-E&DI
M+&(#(')=@DXL#;,Y=Q!(&\KPT+DKT)DN.@*;6<TC1 A(.@2>.EZ3= J83!X+
M9Y&',(B0[41S. 6(W+R-!\9)M (H%"ZH&JF;TR4W5/OKDKK$V-9 W6U(O>E1
MLUGC@BU@U# B-R*4\@#>D# TIQ+3;@1*O@T'<;2"R/L3N%\#S&)RD&R2;K/C
M*0L6S.@%(,<+P11Y#F"=R6VQ)4YR;RMMO2[]'.(XXIZP6BVUH1]>6_43M]LT
M4>%=8[7Q:T@9;T%@X@O+:@M*;UI0>FWUK\DM-M$$/7C+%>^R)B8].]N%5\(4
MQ#(7I]-*J*%N,+5'0@V'5ZFSN.D^C8?-/N5.=1;;FI=D/GE.:TH.'!;O?;K:
M%G_AKKMD*^!,\U6JT"PDP7*H2B@%NLF%RA':@"*N-"PMY&&4UP\T]@VXWWUN
MOV1#*]>9Z,1,&V*3&P%4XB[W0W(%L$W?X,Z1^\'E[70^--W;?LCXX97M=(8U
MW,&P?\,Q2;7S &TGED=*39?D$6N$QDP191-+PVOJB@6AE*$,#QW?J\!B.L_T
MY#.K=42XLGWRS.QL!8#,<Q\L<F9'R2M@"%SNR, NH 2YN=%!0@-0EI?.1P@V
M\\4Q@L]TYZ/$G?T;1.F+; "QQH=#(FK722?K"$AZ1UB)!>:0P*2EPN)2UQD0
MN&*%$HUW.A+0N,W' "Z7>I/4\(CD>GX<>4]@!IP8)>/3Z,7Q8Q>X7[ N2&@N
MCK('AD<V"KQ@&4X!2H-W6WH%O)2V]EID)\"UVZ8Q>A-F>XN**4JPX6<\.K$,
MJ :J^V2\-J50NGE= KW6OND7$)(41$Y?4J!@6FZ%1A\.KF.6:$18FG,YN@ A
MI\7._:'$8M%^#U@S,7RM'J\^)D!M2$1:]B)A;AE5[*V'K.5BU&;<'<R%P(I/
M=W1QL"AH%:]C<OSU"8P6"^!$Z64/^]QR5FQ.HA@]D"59T!#X[/B=5,&C1-!0
M7$]-0U"5MV[C?5)@=K$_:1#=/[* 1\_L@DR&9U4HJ!9$H>F>?\[=PA4:$89F
M#)XM.,AIL=M'&:HL[F\"IK!FQDNZ5W'H!2 ,L\=*I%[2I95AYZV)2NE G[+
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M^87=RTF5?5UY]Y*@7H<:4],[4H\'A5]9_KTD*L,T60@7S"$C&)I@>*R^0?,
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M:\I8)30TCE+,ZL9>]Z$%UN.G"EW9VVD% [JWM],*;Z<5:@TFPM IDUQSN%0
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MMC,Y/U8I?F2'A9V_4I5<&GK9TTV4O&;VE;$D* Z4'-*(HJB#U8+'+G^E8.C
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MU/*T<R]J"&2'X40H)A?&N-%J1G/-/O0;KR8<AS35N!&K4+>3;\A.-WF6>W'
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M'#*G,+AA%'+\BS(9!]D0>Q0X% +G3&#G<G+D8C8_R2"_H0&3-H(,I T<3#6
M.PU@1\JN6?-! V,V\TYD';+_ _@^PC%X.2E>0*HW[".Y[3[Z&*^=Z'M^Q9GC
M7M&Z:D[720K5?\:[PJY7V^*AY3&P/24GCH>["JXX-K8E@WV<W(W/MB(7E/A&
MCP G%3%2HW9!'K85A!/'T!K1[PSG<W:HB.K<0;2&_EK@X2BL-6-M#=5II4M'
M?<?(.+K]-)HLR7AR,YU_&L#9'ZYME46?B@ [?BR$4QF4!A[/BHQ"U$U'"8QB
M+P9N-#6V*HS262/OX=U!=9Q!',QI!#<GBOHZ"K%5P'@ZI&>_KD!R2!3MT;'2
M;AX/P'S+J@ O:S<AN]-.0HR>UU&RI12*"GAI6%1=2@N!RNI+Z.<]*YIE_-"=
MR06[&*GGYPN:OH1^57E*O9]OA8QZ!M1!O+W3( M,K',A:]9D)T05,M?'$IV4
M^(Z8VE%2+C8/EWZ!D:19:6QNK0VF^1--(0+3WFTW8KFS(E (I%L,[*$XL0Z0
M\F1> EP0CEBM1X&"(S?$#Y-0B),5XK@Q7RDE@2ON2<;3QZYIYJ?A6I+ =C 5
M!VU,+["5S<E)N&6#.AX/M<D:S0M2H^JJE1XT!FFU-1%82'BX\69I7C-<]MO.
M:-DOOWWR_CM)AYLL3YZ9_)+N2BJ@\YN<GEVP*#G$60U&QT([L:& .5UK(,/7
M%ZW^&OQ*^P 98'%TP<A\J1)*P+-KAH$3C8*<K(W/;!7^3E-EJY[F8YQ$?1F+
M93I^_1E:TGV;B7;:M2AC3]] 4%[T["KU?@\CG"QY"X8%2/_Z=A,F?KKY7:EP
M>\]Q-$[*9*ERC8=G[T4C>;OD-C&'04Y0*;;7BKVXN]![""->G6JX25.J7%!;
MX"$FE]@*U4@=,2'A)(;8<:7<-KTL=TIKF"QV%[C821P'RC;SMNP%D8,;P0.?
M630-/GL^GX3T)J0"1BR@J&6_41%1"HE3XE##2KL2GP F);0KIM!)B%F:O(2P
MI\LCE)<"QPG-MYX_-/#H^F\W7RB!,:W VH>6AN#@M'"H*$Y- ?-DZT769M"&
M1C<"E0 2$]@'Q30 .2]*G:G '5-^2S$J,++VMI"XAZO[2^^-9C/!B5[OI9!X
M.J]AO*[O$C 475?RT:X5 )"D '5%Q^W9'^]2L)U0\'*G;Q"\P%UC@W-70B->
M4M0+T+B;* ?%N9*HXT6]'UN"NZ+XW<0HH8KJX 7N"?:6A64MDY(]N5;K09'V
MG VL5_O/"CB\O6@M0VV-]M)T"Z>0HE^)Q^_90A67!R_B10^R)TIS$L"UGN))
M\A"%C^(&'=QD ?(!>Y FF\<G]J]70,,>2N%:H3),J679-^0^ X2$,,6)J)]S
MHK[@DO!#45&F'OX<[4)U\BY@#+Z&^5/('L>4;*F7PE7@XD^\%3 D3T<DJ?)9
M_:W/7A^N2)3$CS3]&JDJ3<>/4H"394)*!&Q'<X04M8_?OXLI>I67D_XLA6^?
M;P=Q,/KG)ER#I?"6PR$33.U]#J*"XYB.$+CT60>00'-G!_-ZK*>3>KD]G[8N
MN!'M6DM^1'?J\/]35]??!RLI[189)3'>[[PB1RIZ+CC)_N2?&;0+.=-O\Y Q
MIAA'HQ?3O5 I*&+.GH;U1F*>! XG^T[)B"RSN@ E'-:1:Y=[ K!725+-C-#N
MJ,R> #JM*4"=4)P&+V;= ?C3Y:8=IS_2/#4+>*=TJ)VO9@1V18^T>6L*3>HC
MB:UO7=(6(E? .J-#ZC+D4D 7=$>;N-2>O=RH07Z,#*=*V1P\IE1=2E\#AYG$
MJ6"ZF<VY!X2<UBGE1I$N22I@S+S.PSC&MK7#^._?NOCJ#-9K2^H_Q4F4/&Z7
MJ1=GJQIC/[-UN"F1]4 Z.-9YE-"E]1Y$!,VZC^"V?5I.U]#8&S8KPEJA$5B^
MLX '=F?R1"S<Q6H^KUY)\N*=Q*L,$79Y2/%:I%V</@=')+K7'$U=/D1GT[^,
M3@6V=Z9Z1DIP9\+;E@B:"/<.MU:1EAF+./?.G9)$'46YOUJ,_G8/E8A&G]E_
MC^L_TFN!].H*GD)2!:P;)=%;S*MJH5> Z$70]S@Q5#^OH-$[-W>189E VY-U
M0Y+,$[7PV%^#C=\NGE3_G9G3/_[RA_(O[#\/7D;_\O\ 4$L#!!0    ( ($X
MJ5H2_($FJB8  )ID @ 4    <&QX+3(P,C4P,S,Q7W!R92YX;6SM75MSXS:6
M?I^J_0_:WH?-/'1;%U^[)IF29;FC&K>D6.KT9%^Z:!*2.:%(!23=5G[] KQ(
MI B   F*()W:V8YM 1#.^3X<  <'./_XY^O&ZKP Z)J._>.[WH?NNPZP=<<P
M[?6/[WQO]?[ZW3]_^J^__>._W[__]^WC0\=P='\#;*^C0Z!YP.A\-[WGSM+9
M;C6[\QE :%I6YQ::QAIT.KWN!_0_]$_G_?N?@C9N-1?5<>Q.T%C_0R_^8!0U
MY]@?.Q=GUV?];O^B<_&Q?_GQXKPS_QP7^XQZMC)SREFF_?M'_,\3^K8.$M!V
M?WSW['G;CV=GW[]___#Z!*T/#ERCRMW!65SP75CRXZMKIDI_'\1E>V?__ORP
MT)_!1GMOVJZGV?JA%FZ&5*]W<W-S%GR*BKKF1S>H_^#HFA>H/+=?'6H)_-O[
MN-A[_*?WO?[[0>_#JVO$_<IT*T=X]*G)*+\7^Z>_=3JAHJ%C@4>PZ@0R?O1V
M6_#C.]?<;"W<:/"W9PA6/[[;6J_O,5K=0=C#_[F+J!3_=V@;8]LSO=W$7CEP
M$^CG70<W_^5QDNK3%CJ>9IFO'W1G<X8+G/&U=2:AUPL/\11_Q<BQ#6 C.J,?
M7,<R#<S?6\W"ZED\ ^"YO)T7:K)Z&?:?NK/5; M@H#Q)PM#:/JU4HV?-7@-W
M8B\\1__]V;$,9 #'?_B(+_+%9'Z9,G+/-8C*/ //U#7KI$HX^N83:T1SG^\M
MYWL%]$XT+4.F.]/5+<?U(5B8:QM-@KJ&S)RN.SZR<_9ZCKJ@FX!;#N[FY/9]
M8K\@[3BP4$]3E>7VZUXSX:^:Y8//0,._8PS%.TAN13+Z>  MH6:[FBYDF)E-
MR.WC4GN]!398F05TF*PK67-@C0$ILKI@MB&YE_X6%<=?HL'=O6FCN=_4K+UA
M*==[@;9E2_7D@C]\]"5C/(:+D#;3P@FM:D76]016=JD]625M;=Q$53:B:!>S
M+51M+XKVE-Y27;:CL"3"WW#"47H'/,VT9 _2?:N5C5'L4C!\"\Q6\1]WA47A
M;+;B-4EQ)*@M565]%OYF@[@\6Z$_ 7=F3VS4+5!8 .Z&JY)G:!@FUIQF)0:C
M!''8[59M>0]<SGY6G&S%ON9TLJ)2VGH-P3KX^VSU"- X]LL8NC)?5M=<%9ED
M=Z[M\)PRM WT%^AKECOSG@$LK@SI/:AVS5Q"4$I#!?J+O])%WQFXA5V@?U@[
M+V= -[ C_AS_@*4Y#R29V*YI (BL.3Y-&$*(74 ;\NH_TUP@ JN%1-^W$+@8
M10S5 _I#U&'<A!2W<5(GX-4#M@&,_5]-#W_+S<U%O]OMWG0[[SMQ8\D?-=OH
MA"UWDDUC&6(I+$=/?9.%CP@<R*%^ YBA^M$/!_6C7[Z-G!< AT^N!]%T&K=D
M:4_ ^O$=X?.SJOL3ZV.)6B1T)_GQM\O!]75_T.]W>X->[ZK7[5T<=3 )^Q"F
M.ZM!/6X?_9AA0OI0(RIQM@T\D>_U9]/:X[N"SH:HJ^C;',Z>.Q 1^<=WO7<=
MWT5]<;;A7/JN@Z18 0B!\1#J@=K+H(N!LDX(U"^^!CT K=TCV#J01"%*R;02
MKGOGO<L&P,<C1(1DGX"DB=;=WB[X[&0(S0'Z6F2UC#LT;S'P295K)CKY(D38
M#!HVRH(-3["ZSAUFQT6;B227%!&8YS4/M'#:OC<M,/4W3P 2P#DNTBQ0N'H?
M@7&A!!B/8&UB66QOJFU(1H]4K(F@<$@0 7/9$),7+Z]U!Z*!'VY!\8YKA#=8
M<#=R##J>S%I-A%=<H CM*R6&X5)[G1A( X'K%'<DQT!2RC<1.1%1(LRNE<!L
M:!A(F6[T'[1;!CTJ7H2R3<2*5XP(IQM%<>H+X-1/"WC3&URJO'L6$R/>2G=5
M FJ$?IS!I?/=SH/I4++!(.4($4-$<G?4!E$PP<[@'#HO9ABYR\3IJ'B#P>*1
M)$:L;K=&JN-SQ_4TZ__,+7-92"K<8+3RY8BQ(KDY3HD5-@)#"#0*.LF/FX5'
M;L]C!.KV3>!K!-;\V;'IOHGC(LU"@JOW,1IU.R<60/?QM_7Z3TM\+$1 X[A(
ML]#@ZGV,!LDC<4HTHE/#Q6[SY%@$*%*?IR0)_ADHC$-^UV,02(X"%=U",;/&
MKWIP4X#BUR,5:Q9TW!+$"*KA-ACY$(L<>NLQ]9 V?9>Z)",7;Q92PI+$B*GA
M0)C8'L!BF2_@3O.T2 Z&;Y54O(F("4@2'^6JX4G )S!PA+9J:P?NF*=,^U)-
MQ"=?@!B6I@1+A'(M-IIEW?JN::--'!6^5*DFPI<O0 P?R96@+GSC#8!K9. _
M0>>[]SQR-EO-IH]"8NDFPLDO2 QK4X(K(KH^ \O*0S-9*"7[H-\;7/64!S&W
M_S%V=?LKHC65L]DXX4W@Q3.2W9WY'GY6 .]IZ$M*1J6TS .\&54>,V%Y8@Q)
M7@YUQ]\(:0GB.P,&>/T7H _!HW*-1)1#A!C$IH1K1*OG>]/5->LWH$%ZH"&M
M:+.@%)(B1K,I7I8X_.X@W3WZ"VFQ2BG9+"Q%A(BA)+E;U(<RC(SE S-1MLEP
MYHD1 TKRQJ@(Z!")9@3B61II%93ZO%G Y7<]CMLF.6**@O6/LXPB'M ?9%P;
M$GJP*:EYYNVA7A??'MJWC7X>S:9WX^EB?(=_6LP>)G?#)?KE=O@PG([&G<7/
MX_%R4?(2T4ISGP(M^N[[M:9MHXM<EN?&?SGP-/K#MWT?9ZO]O;FY$P9T4VX;
MB51%%+GJGO?.^_V;RZM!OWMUTRT] (N(.71=A&".0.E":7:?]P;=XVW5"0=F
M:9T?AK& M))N.GD NN!!BO$MCGVT&N2BP%%9)9G  1\-<Q[QV@$]?KAK:!OX
M/_B%LA?-0G*[0V^D0;A#N_/@A2<*%;CJ*DP-'I2S#"DNM1*,R=S!1G_XMGAV
MH+<$<'.KV;_?@2VVE\>+:VJYUB L)B'C:F11- _^R6-?^HGF@>CJ_R/0 2+V
MDP6FP",?IO)4:0TQ"@LKZ8IFS7-$\.Y#2F\4,F0+MHX"G"(RKG,V"/C]4TJ(
MYA3(DT5:!W:N<(R+H@V"F6=H,RA_T1OT:PSDE&+8<Z63=//4P]Z5NI&>.K8N
ML-?+%E<8_T+ <TI8P8JO!@[<@95I R-ZZ6QN:7:HA'L'XE^BOR=T0B&'<#L*
MLX:3 %G^R%&"$AO#TL2:0V<+H+?#@@>/2Z'=\19[XNBK!U:5-M)%6-[6F)R@
MK^&KD$OM-5(CE1?T"FUDA:"T%6PJ#XZ'XZ.U$^TPP^P8]OH!:"YX--?/WFSU
MQ06!(FB;35:=-M)$7&!)N] 7 )\<9;@2:I&Y8E48_4+KTTK-0+T[D@=3>S(M
MTS.!B^;#;,*4G!T*;W4E&2'QJ+*4'B0M,M)FHEXN\9UETBLHR9=2(#,YPR.]
MI$T*;3(I'Y%=YL3CZ+%C)(LHEPJTE%;S96\PJ/%]H8*LH!^2E%5$.S;%1]K
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M4X#3K3IP!4S/AQE[6+*U=E"N"B54\%9S_>0)IPJY% K;5(I(5?!!&ML8^JK
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MJQ. .K<&XFI"NP)%%1=*Y4&UBL2XU/;&+$<Y]RR4FN2^1/FUJR:@U0(@6ZG
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M)^G9V N\]2T#&K'+(?R=<!955BQEL$)26G=5WW6AKP!%&&\IYM+57;N?^6S
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MBWAR\ ,+,LX7JU_QKESMRS0ZJ8!2#N1"SAP/Z G>$:JQ^[I(+:S[K#C_@6E
MU<>*Z?[] Z=_8*N2-W__T!?>G>6/<<WV\'6+'YBEC"$\?!<?*,KD#G$.;VGH
M'^&);7@OI3C.$@*RI9@^^(&Y$"?P5[#OS0&<A#II\%71)4#F05@V<NDZ$-!A
M.?K'/V3BAF'C?_W:!47DT(77H8MX\=V\2%)K9F1DP\T.](E.C@ANP;,].\::
M7)P_ S,28KIAB4V/-BB2MW*42C?T,CIER@7,&..(5YCQ KW5Y^I?'-J.AWO
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M;H@/*HG\H"0M"VVG:EC5["S'HSE" X6^B9,G-%&^I12X@#W>2 I<M('T.V(
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M-5H0ZHB5N8"5&3+VEMWQRT/7OIR>_;8:3MZ=]/1UDV(>VSV:T=17SW.+N%4
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M(.&!(J_T2:Y]^H:1U^NI'UD1FM$9[S D;M%0E&JVWS-!&#;J3GKA[+D7'JX
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MRM(3CFU7!L80,98H9"P!0PD82L!0;H^A',\I&C"]ZCC2GS]U6H;.#;/\O)X
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MFA=33"H=#H\8Q CPB-1H_%CT^>O[XE),F:FF6>2,>U5A(I@VD6)SA6H55:;
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MWVO>C4Y.1!\3B7\3FQ_1^?> -^$7(1^(7(;O=.ASON5]A'FU]YEFRHC3_#:
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MY#8<QQ5\J*$C#'"YA/D(;YY &HR%"=/_$E>AU&P3R6O-&)N>:)-L ^/2+K4
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M? U.M&LK,GO@]SO)8(H'&4Q!!E.0P11D,%T_@PER4-=D=27QL?P?+ZOD UE
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M+4:H0\.5Z2*#?Z3^^>6U0D4' 2H\EU.)G0$"KG'$7S[<M\_)]D<9ZEQ\JP"
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MG6ZM==?JXXWX:(-X"ZI?U>7?*G7C7:"&_E GRKLWH'T;/)%W7^8<<+BW49Z
ML4WGWA\@]MXC22!W[3 ^O3S?:%]7Q^5&ZVRC?/.E02SYKW]**[GZ(@WDA36E
M][X.;P-/\N[+G(-;_T9ZS8]<^\/>[4&[5OU\UEP_//QZ?'HFOK:&U"@/,U)7
M<]65)RMO5%/+EZ;*F=YMW7Z GTMUS/[1#MFOW/@[NXX?G_DK]RQLQ9U07,=
M*,T;[-X\W5&N$7[NKUUMU;>;D\W._=&9L-?BZ'8.>Q.N:,C95GNMU3QJ8T/!
MYE=NFRS19U]GEM@H6?82;#G8+!#NGR6\'K;%QC^O8SN(1( ?B9ZUEVH 8.%A
MY>BQ=7\$QSY!>&57=!&9SQZ/ _\.6$ DW(GU[Q=F5)J E@T"JEZL\M^20BXR
M%'(R&8O&G1,^]/T>X=3K;_'Q@WXC"&QO0"T-Z;? R"X.^["?06,0"/I<_N[K
M_6W_]F[YKM:^/EON;F_7MZOVX"C%*ZO?E6$"AA_8VKUP,_!'RMT>:J988S+?
MMX/@HGM2F\0'K2^-9GE[+;YJ=DN;(G\+9EYAFAWR\0'UN 2(A*EG(0P88I"9
M%\9@R+_Q^9'UC/;TB>@./=_U!Y,3>"KL&X=ZZD3#3<<'^70OQ_6_V:L[[O[R
M?M,I7@5?5_QPY^"T\2;G6[H\K,1^Z*P5:^7/HEGV;D<.:-__E K39>./G:]<
MD+6T%MCWCOOA)1O)OS)G"8%=YKA5@K#L 1S3 $CSN0I0.+0#$5ZLY>V+D]5&
MSR]>7QQO'1_<=99WO'<@3?S6Z3EV,&G!T1ST6Q&(K80\\;BRW&5R=7]S<7\8
MKA?+XX/6G7TN#I<W4]2WL[_Y7>1'+]T)0U# 8,V@R!["N?J]%FT5G#M]E=!C
MT:#'C:N5ZI>;@WO@-[7R5OO^2_^\43["FJ#E:C%7K$S;7A:? !X^G.@(3HI>
M#^<%ZC:=*:W:TLO.60/A"3P*;V - C\,K;&\+QA*LUVDYU^?2;T*)3R3#Z%.
MOH4[:S(B/'7,9SSH\SG1A&8RI9V=PWUO??OS73%_<#:Q)ROAU?WFX*]_E@O3
M(#MII@2W&/;9$WQ*M\!IK3#N#IE/O21/2K7&)69$YI4#1.=%'_/TR2-\:Y8>
MK+OL_J#ZKA?6<\*Q:T_P2]D(^-FK=!U/Z.[%CZN>LRT2_')*%_V!#FE&'[BN
M*^P C>QAQM:IX,M>HQ'<8RTPX"VE<G:Z_R?5MTZ'-+ OLQ]\5 :^L1"YQ66B
MI('(<UL\NP_O^FB[M_8D5)V55PKE9>4\^*B=!+ATJUI86?F/E?R)&S"U>]CR
MV=BC%-WRK])-G>5G3_3FDP<1^>/7.X4,[54,VK.M88!\]%\G!^LS21'_!OH'
M1N6FR%%^]-<_U"F<90:UPPXU(=HF,3Y*AK2'^9+9Y5MN8O)A>O.G=I6_! [8
M7<(GK/\+^@G^\D-FOU/'EF) _$+^Z('AU;'8Q&$O^J5^L5RRZQ>B(FH7R\7.
MZL7*JJA>]'LUT2VN]#KV2O$OW@C^Q4XD1N4]V[-9V0TWG+ ;AXAZ"F*OX=GN
M)'1"O[\I?_2N1B_.U6@#]O"CIK=N' CJ3OD)[1K+2I9*MG/]4V@E2R831BT:
M"6C3@6WH.J V "GUZ #HF6,1QFY$CQR,!<O[\(5M[B=[]3QWV]8;[9.=@_W&
M\9G5.FF<-/?037#<W&H<;^SL;UF;!\>G\&=^]^#@"_Y;/]-Z8I?QM<'?_SSY
M5&-_PSK>:7VQ-AOK)P?'+:O5WMN#V;RRC\+8G4>[JIWY,:B9?NQB?P"[1UIE
MWW==_Q9UR%Z:.&R#./PXL/J:0+HI @D2 O$U@8#N.1#HJ63E)?W[, )UE*X@
M#8"S@"$I.DX]"QY]4C4V\/Q(8&>XKANC>23<4-S"^P1;0##M3>"1V"M.7J-'
M-Z94S!_1&^#'.->&YZ$"?2S&?A!9L-#O'.P+X2CC="? ;:4%I_K\/7<<:>8M
M%ZP65MU+J]#Q6''%[4==W 95IZ<7_< 9YJRQC;[^V+4#L /H3.#<QJ!@HI6
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MB<*@ .?N3KI^*,5CCLR-/&;CP949C6+/A^UQNDXT>=76!FE-=I;^HPB 79/
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MFW\I Y:,8J0][])?S%^R&@HF/.G]5@\WH&]'T80:T,D&8^PMBD.=C4&>4)@
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M)O70L30#,4!IZ*AAP:SB4']%NZ;1CXTT#'\L&\WC"Q1V"[5#=G27#"STP%6
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MC$$ L XYNL54-*FI&OEF;V0<1=*/CC+!H;9$J9!GPOFEJUWZG8G-(S9 Q!V
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MR@6LC"BL?DCY#O$KY%SPNIP!PHPX\6C*6T55$!1V28RU]781O'2>L-G7 D>
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MU@+,@YY_*'J.C2WPK,W=LS<.*?&-H6Z]? VII17'7F,TF%P@;5^V=P)3"@S
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M(I2OB6&NLQ/_O5Q-C<7"&/0+4Z,<8:XCI;;]NZ3>W4G>G8@\& 24,4;^D/,
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M):S8EQN--)VHX# '/Z2"$3CI-PI]*.BBVC*"^"(L'EX O:AT:SN)QT?.:]H
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M2[@Q[;;.U]P*,1>?*=V!(G8NU0O(]L\0HMPE?3'D'A+?U&54;L3CN8PY,K0
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M%HX.V+#', /B&D0N/'VST-2G!O_#8K0"R 7#HYS.V@^"8XX\QN-%%;WRT.D
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M_<5?C]*Y,#>CUOHZ'6L$#GDJ][;*WOL^'9NG7CN%XJ=H/3A#G%^1)^%UF+%
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M<SH\B\:$QIPV\\LP7\KB+%&V?_@DC"R=J[:G1P ?NEYW/@1;7_%CCK6BUGN
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M,UUU#O\?:NJ&#_8:;%K&9<L#90] ? N24][()=N0K)U4+9#;[F+NM3+XZA;
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M;9C.5N?<Q)$+30^2*.)*]A;P8#DJTSZ4N?GE@M.H9QFES%7QQ)$:$501&0H
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M./D^256)D4W8C+OBJ%?=E136?L$[UC9N6F]&1MH="Q<;"6\ZJQ*"W@):YP]
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M;S\5[2^5-$:9A6 U9+7!5QE2B]6N3+ F(6*_?1%-.]\R^Z+:)GOKD&=,:_'
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MEX.6![>KU'@>2"!]KK0]ZI5$YH=[Y &NR"MK)$3EGTR/F!EC-.8UPE*"\XO
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M;XA8Z X3UQ??ONSAU5F64SULZ99FH+;8RVML3G2PCBWF>(@'O U1K43[)7O
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M(61![-191+#&U1O' IY;QNX@FE'40,S2'ZR968$2\DDP$N/Y:SLH]H(&3HI
MXVA[_]%2*63V!@3=\T>\F@=,SQ'P@J%V<9Y@,\RE3.SK&(P]-"1SM]>0@/@C
M/&#A_1\Y@60W$/U1 P[4A!D5<#D11F UC* [[Q]HQP,4/$C^J )PKKJ)G0
MH?(^1XL'1&O^P;%PX2BJLRI VNU]9']!/(H[SX,'L)YQWE/ZV3\I\2<8_L#*
ML4#+G[0XB\/?T[Z]!_+_DQ+_-XFH6S-#$WQ;$[M^M<%M]V $XRM[.8*A,CZZ
MFF!-)\+]7['XGQ"+_P=9$58%Q1PX'L;LT._"SZP<.>&8T)C;;[AI*F1]L[(S
M&W(6XJQ_1>]_T^B%V<VL#YW.K.N .PELO]P..;PCP&78!>B6*/Q%O-F_SM[_
M5^,=NLJQSG5,=G1X!JOU'TV46$?4=J>]JF;5 ,V^55685?SFT[=,/$1,%BJ#
M:;I(Z5M'/XW"BPI^0)E5-N)',@H5Z/24:O[^_G'G)E&41.Q"JK+]_MT/#4)-
MS-GV%8K316#@ XSU'!Y 90M'H$E?G#P_ C$RTB3%=G]: #4\_9:D%^<0^T#B
M?M1G3Q )Z@06='.D=W79)XY$..\I5>.:E[.ID,W<B+663GPF)&DOQNMMN?!;
M6\7BIYM#D-6D[29:#S="\R#A19?X74CP*]@==$,Y5>J+8U>\$D;UH\WQBZP7
MY?VO7"]%,HI./C8%/;@=U9U'8^<>U_S5F=?B.E,7X-QK&7>Y^A'5*(VGM%5.
M)FH[V&:IUGYFGJ6%%6 I[ZE6E#(BB"N/A6L0I(><#DP:%=!*(!UQN%-O"[?V
MW5[[+C _VE9_*C/;@N)Y4U4/CF!):YD_7N0+HE3?YRDD8=7# P*:+MFD2+:6
M\K1X=8!=R10I6J-Z$M/BOK7$*/+0#]K%]PIAE?M$N>S*.JFDB J8/I%^2NR2
MBJSHZA4XCZ[VIL0L?URFWU:5*IO; *DXFQ7[3NS(OV:F9-8YV"[Q%,I[[WUS
M>;@+I;1Q.$=U'ARH7Q6\=JBE<[O;J<!8K(\FXY+Q7DFZQH$VBC*_I-_O /[J
MH9-(NMQ;1L'$P2;GN,#PS4\9^^:?N3TCQ)YLN45K//,H6=F".@K^--CZ]'"G
M0E ISOVU:,R]!N^3X89U>N9:OM[D,CS@3N+]P'1Q$G79PH.UO>:Y0[:R3'/'
MO/'[UK9DK?;G+RV$73Q?L$*L7V:A7%/G/3(E.WCMV26'9,[8(9C+?I1TTX@4
MRW#.AF&HI@)]X;M_^%4YW1!X,S9(E@4/,'9H3M,]N.GC?N*-!WS1;FW>[UH_
MZC31=YS/F??HQSURQ0,V9TZ%>7IXHSB)=06[/Q)Q#>4%*%^B443'#[V.-1EM
M?X;T"YEOM$/((3]EVG.,Y\U^D"RGN+%< WAVT =F$S5$Y[_E3,0#.AA23A,:
M-YM3>7>WQ%D<Q3;&ZG\XD$CQ,^WDT&](&63VZZ#D!U/B_';5\JS W(A#DXRO
M8SL] A-<&(&<J8?TPRH%JY^%ECIS8XW-)B8?SUVSI<8#W )[I8SI7F9Z_905
M0"VK(60%+M:ZRPVV,R)?U$<SF/2QJM3P6ZDS[7W]PN:DBE1R5K&Z^^&K0EY9
M\TWP]IHGLO@6U_E7=UY)DSW>C[G8/6=N.P_^(+3_P>6KK!P/LG0I3O+=W09X
M2[3]&V4@]^M,80W#'Q&S30GR@8QAYD9?72(B;'(C-.*UX &O-E[=SWA$^F9T
M:W$O!WFS]FE/T4AX A^?K3MXI7X3OC#8'3$<:]0K):_CR"V]H>5D"IWG",8Q
MH.!!KG+/Y[U/%8(F&1#OQDU;]$2YA!<?S['>?O#6IZ:_&DS4>K7Q(&(6R#RY
M.@IG8#Q7\E[-7D!QEIF#\_4[F^6ZNMN)9ORZNOQ;2)75X@JU(T>'9<H?CZ,U
M<UQ?B585DK##V+SEDQUYHAOHS8OLZM)'#SINK:%+AU_;9W@\+_=\(+,@6)]D
MVW_3TCS#KA':1L%C"A^Z/F!55Q\W:W24$F?ZD(O?Q/F:Q_FP&ZT7SJN2R64;
MI>(!5KH%\1^/XB>:"N5@VZO+A8MTH#([#C(QJXP+85N;C^U(P4)U:PRC0Y.*
M*A>5!Z^1Q<;4C:^/AAO@&#U\;_[8$K:L&R@5<1 NM0Q8T(;7/$<KL13LYJB5
M;^T"CMXOL,_'V-*8:H>!&JO@?J7"2+OCB9[E6$W31L;6$S[NYB9O54S5NI'-
MHI&*N(RN;?J$XU?7&,&/Z^FUF^%SN&L8N_ZVXTF] \8;\]/>-EL2+*'+-LP5
M5R4\<'K7 K]T7WC%5U@HPYG19&9&H8'4,?3!G8*2H+'?!A3HK5/^LY\.XN=4
M;M55O;T"^"KV]HHRYP4W\95FXKV3#S![I0Z&KR]W;0YP5G53ZI^S:IQ#N_3?
M_+C=*E><-RK/9BN*B>GPJBX3)@Y8Y=0/%[KCT>*IRM_@]X+-#RT;N?!J_<?/
MG_'E&P.]_'KM756FF]NPA/WF(KOI]'[Z[,: _CEHD#4J:B9\YL38]GFKL'D%
MHZ;GM'4FEW 43T* _)/ SZY=?%88JSEOX"5CCPRG8A7SFU6TA@;=[C0];)/7
M0<[4%\Y[!7$\ELL6..&DMA(H-DJ%5);5V^=#8Q>&046JLR+D"F7&&!\\ $RA
M-Z'!V._"$]FV<<, >2U#[]Z8,J51 8D#)3\B%J75JX78VDPYUJE,\5@8>D%9
MF\SLGL@5R1$_Z:Q4%2; U_'=^'.E>_6).*%0T1O;N:H522<Q5(6BO LUY2"M
M$L@+1UMG:E0';MXQ&4M71^[,*^<$Y5*Q/+I5RZL3K!T9&#]8(6N#U,DD]Y$X
M?L3HANCS=?X Y39(U^#H*O /'-V*=/D9)#;U+C]1)X_T>\[CGO5^W57'B+(F
MI;2*.Q:O$[Y\^=*E(%GJ+9^/(I1#E:C&[[4ED^M>F6-[$\P6;T2HU:UBAS^^
MB*HNZ+I'-(JH =*LNN&NH'V3AVYX%[L'##VM#M@]C K+5DG@L#'I<"3R%XU.
M+RPL?*G(*5(8_%CW:B6\# ["<FA_B$/J^XO0?I23Y&/.-O)\UIW,TIV1.APY
M6F+7Q(40\R6^,6IV8M3A+CE@,KXZRM5_(*Z=1B<U4?]F*7K*+C-LOWQ>(^C*
M=U>COM?',UIZC:G:6EQP6\XC+=K:9K<GCAE*_/*:*FH'8AD7TW1*);\E; QJ
M#*PWP@8/C,9VC@7&9$50_6UU>9E!'QOMS4Z4#.$I;HFD\_I98QY'3RRK(=/T
M6D-SHR'[^F)RZM\IGHV934S+Z$>$9IC=(6)B_M!5>)7C%LVW?!:G[PKL R0'
MNN[T7(CJ]9FDWI.!D[TU3UT^K9HOG)R<<NOC^QQO_=A_;,#8M+!V+[[+"9-C
M!#>WLSR)ZNDM;=]:Z5N^TK5UQ+&/KS=1H+;*=GJZP'?%)ECNWC3YT2OTK?5F
MC7T^=72:L#XZ(6_SANUI3"@H C;8V!!/Z!5ZH;'SPR"8L8_ #S$Y"\OLEZO'
M;V])JQ4;?CW8%X&%=Q09RK]RJ]ZBE%O+@[Z1%9H74@*!]:$9BW8:+^LLI:,:
MM-I20Z>SE5N2>++YM"?D5@Y"-7C+,@7 J=5P;'/IP? .&=^@XH#RES7-X00K
M\X!+:Y<^(?*#Z?<Y-@B%+J=U.&2]2^24";S4<QQS0*AD8RL[@?L+C+A(\?Y0
M'%U,Z1SPB&WNU P7UU_%FQV.BEF[]7>_TD44CX:';6.![OEYT2'<T&6N?@$>
M;(4.&<08EQ"-!]!LYJ7P*87 ^-B8NFL4@K33(/OK [QE0=+&A8_39[PK$Y^6
M?ELB2]3(2PPA<D<KLLD?'R-]*;&PJBYQCZS)"HJ@-R2H[@4M(ZQJ\*Y>5:4:
MP[%XBEM8?@I;T4<(XX+)"+WQGCT6V)%I;4JH:;%4,GA 4):KK6]!M^]<ZB(\
M&!0][6$QLTQL'!^SI(GT,875WCFZ>C'[>51;CT]F70=?%Y =/,@71J-0_YS?
M029Z(#)36W>3US4/4^&;>-,>I/'H50JTH]R\P'A<XZ/=G4=%/K59$:]>7=20
M*^3$%+ZX0CP@+L@WWED[&_ 1#UAYN%.&"\_PDC;-:,KSEE6L+L[/^H)1[3PT
M%4C/C5#U)A=S5V)\^#*-_1+[_JBF@H64HE:#;FSCW9[;54ONDP1DOPW_PQN6
M%IHG9G /,BCP@#))L^_\)S0-) >I&$@>9ED+=31L6:M1J71+H[+&>(LO;9'C
MOM% RMOAY%T?)?_2Y*6$5Q^\G5431P=LN?  +A\90L5-/>/Q'#.E_YAZ_/)K
MSK+%6"I=*UGJ32.+^>#*\T8WX\978^\[LXV%=XT_!R50:GZ@:@Q<-YVR.I'$
MJ,_ZCU[]<*R>B55P83"KB G8 @@Y%T<>&ROA 5WK QXI(L[H8Q^63*T80:XX
M0M.!)5K^A&F&"E*WGA\;;TL"@G<V2^GI<Y$ZB=W&A=>.AQW1UL9XP -]K2X$
MN?9U56]O7>74;TRO>NX^4WH*7AV#6/03*4O5(R H;B!.4ANZ83^KC0>(>(WB
M+G03-ESU?1YCX;BO$9HY888A[+6XOAWJ!=N@G7@#MK<52BZ70/P0="I1U'V_
MJ?DC28%K)-4QW'#QJFMU!J$6J/L<,&DD5-I7]Y7YZ>L[5%I47L?%.*:AELS=
M0T)G_ 2"=8C!6&B<A_1/$^+SS6U""U@G7_XHJ(WU7N:=E*891O6)ESZQI1Z'
M>J-[O5'RJW,,\<;=+A;AU]Z8<-XN,'8YIQ^I(\^&]ET.+H5N?@SXOH;<NY;"
M,N&:K-[V.(W]+0UX?>:L>.!<E"PI'@#\_ZP[?9%0HG2<FBE5%*WY<[MO9NEG
M?WR9'R>8=DJ!/]7;8ZZJIB(<.4VL;!%M@Y1R^SA+4^9Y[*4;@S%$[AAM!&V6
MYM^X?G.282V^A_.D?O+UE,!:YE]N20#T^>@EI_.-GV"XPUZXO1Q5(DFGKX/,
M!+C8I;PRA>6-BQHLFR>5^U+OPK:KG*^M)::\M,KM5JZA#T.UO6@WF#Y%4*F/
MC&NR<1?F=0P:GD%U95S  S(;P7C >0L\8('01E_UH,7Y[4.QI#%X0-3 ?KA<
M.!Z@4Q/A\.NG";P\/45JCG2P6H@4!ZTO2,_S$QL7Q_WZ/K.^6=I;[WNV?GPZ
M&B9.!9LZLIMCX(IF:KMQ(Y)8E_6<F>59L7C 9=M9C:,31/-OSU%[;BL46?3*
MP5=/%L:5\MLOY^T$-O\:CU.'Y#Y<MC5;#F$%I$6>.[MIG-#HBZ%XL*?K9AA:
M#CR )>>,UY0.4>W3WMWDP)+CSJ'%Z0_ZL;?SWP"7MW]]BO2!T.U/<?P)%%^'
M#Y""Y&X;/&#6#$455@"MAIQ19.5/NZZ[M)\^^BY#B#M"D^_OHZ;@VVYQPN!!
M]O,YU+W4GU'6Y%=$KAUB;Q&:X.TC["@$Q2^"$U="K(8<AZ6YQ>"(\0  YD'X
M23.."3)WB,6!FS'TC'C U9RS[\]L=%W!=X: +A!U@H.(SV#)(@AP:_YI8+_.
M_.]@NY+=M$TP@ /C2S I91M'K$#0K>#/(\=3!&TU1:,)]+4TSW)<TC1S)VA/
MA94GH-5'>'D^FX"6#N1/(W_$[RTOM!X/F O!<4#Z?Q)>O=&$H(N 9][+PY\
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M9T=]Z_^[CW__/@3*B<$$]^??#?6Q^/-/DD+) 'S'?4J_IW [Q*,$>0J7)!E
M87-6(P.@\63 ,S) W*@/8F,NCZ@ %5^NA8WYL%.T8I]>VSN!/S@R^(0,F):"
M-%+C]TD!)$Z*&N\.1/I^5P9B[D<MK=(M1X@]V8%1DP&_-P%BZ^N4**JB0B#8
MBQ"2)-A31^6'KP7N\YP8)L[5HWYKH$*X[ A%S8M-CA-H811T!L?T=(A9KU;K
M)DB?&[8AGEC'WQIT_TU1Z9VX<_]MRY]L.=*Y3XO?'I-8R??P>+'@!*+X6-[?
MIX%!78HSJ.Q!Y^[_U1-4?O?/#!(+% W<9.P"8;D=*3 X_!6&)LCOHD&3KPA.
M9,!UT\,4E2\>6+7]_=Q_]_&OZB.?B0SXB("*WBU>'.,"<#C_&& $4LA8G3*@
M5F2 !QEPX2^]-H+_@SKJ?Z6;[G^++2+H9>GI:JOCF/*05AX%$VW* F\K]MMJ
MX=N?#T%H[T#@.O\)5J[_[N/_0Q^#%7YM0 #A.A8"'A233NJ0FQ5JLPP3M^"-
MN$X7F_*YQK!,G\A#M(1=?Z"'-LBGH7W:D?.]PHM!_WS*X+M<RN8CU>O%P=\2
M=]FE>%,ZR0!?O<V[1R%%V3LPTE[&L@UQC@RHRVL^1P7^]3UGGPWB20:LY14I
M PS_^*[4 AN#["\6Z%QC)/W\"OTI(?_<?U)A>;5?HX\LLP:*<[:Q=65>7;O&
MFI^&@4XZ[L_WMH3;$P<H32+!YTJI5/:Y1O;A%-C80$4KJ*KQG>[\OKM'@<O>
MCJOEQ$UK$KJ,M 09OXW0N78.\JM!QC]8:I4!.G^T@/YBL=TZ]W]:*.L@T[:<
M?NF.<[N(_61D9KR-)>:5_^-WH1, :C6EN#9$,RRDL-X0S79"?((J_V8L9;W1
M)P,H&]=U#1\+,N"A72?QS!:6#%@F8IT;R0"&&MIIH0X=,\6;6C>VRS6$!*"T
MU4>= V%>FY?Q7JZ7OF3=[D\<:=\0OY_X)J\E[NH'C".89VU$'UE7'C6%@2C1
M4L_$7Y(1HKNK8I3P:VSR)QT#(%RNX&#081\=8;7M5C@"OK*Y!>/C]C2X@>;R
M5TGV&DCTZ^<2PT[-R\4-1KC &)1] [TSZ\V+U"Q/7Q4]9^D/$1\KC0<;OLO9
M)'B]14MEM+*J.2 6X*A\H)UO)*B&#-CI!UIHKX&(6V !O./V&QPH9&N-?8$D
MW,<$*;;I,;-Y4!9)^Y1:>5?OB:#WGJ&,S(HB[L1UO&_:-UNY")K[@W.>YVLJ
M2B,MRI &9X,Q>1(:-+RO/0XSGJ#2KQ:"&"4J? DP=%_"R[LK]5R)SN&M]I?E
M15K,U_%CYT)%5^U=4MS0>I5E4QY/U^@-PY-]ZM5X7JM(;P #R ";2+?.*0/8
M9(=QTYYC1&GD+6&P8TDI$TGCXR; 1;K-K[-.$AQ2-7[P+T$-R&;_$"N3\+0S
M>[ ^S0BOON]M6XGGXQJ>HR.Y0,SE-^D99>7KQ:B;*^-_O0OR9R[B>W'/0<&A
M..$E.9MNH[56-M!0K+R,A3RN.F<KM\9T7\UC6A\?.)%$=V)T9,C((Z!AF-3J
MY!"5+Q73RD[?Y/!)\+0D)GM1FKW8#C$!WH[D+>Q=Z'796_5UW)8B;9 !XWI_
M8.P#SR1XXP:#:^RGR  :CP2=LC['93A?? _IA![4(N?S[K7Z(UR[A<?1VQ'X
MMAR"(@HGQ1;YKK>T[4W8XCSFYBS#A>-YS%;BJ43/#Q\9P?J]N"'=]GET1EWM
ME3*B=F7=7VYX1+@T%&,Q51=M-ZG-8 9Y@L%#[LN;(Z...,JW"1;3JWZKY%?@
MVNKQV-].&EQ3XD,%;W:>L1FC[;6_ZXF)7,FI^/;]IL41H,E)\X0^P?%L\"<(
M1D]XK!;$"<W_Z\2">%T#VM?WR-#%>T[//ZY%)C6Q<=A(QR/L#RTG@DIYG[J=
M+<^P=.JNS4^J)F8J75ZH.]6M8.CD;4&,=)8W#MX7-IY[O#\2//[&5URO> ^.
M6?+V8^:;?4.O>7&S;LQMU1<!<<VVN<'@[<OY/E$YF$>A7J::0S B58T7(-^/
M^*5!@)_\8IT8CJZEDV9<I/VLR:*XS: 7A\]3_\]W"W%1/:L*<Q&^0BNU''8&
MJ8!RTEBJK#1^&=0S6_[IWF7M=PD @.3\40OC4\MIM,[@MV/!8B-?G;X70^\Y
M_C[/$M9*\&GP;WB+%N9RRGWNHV*!>&!RN\HLA2M#M"U.]!8E_'&QJ"#8S:\P
M;T?V^8A,.!X96MR37GOE8U]@''HTXM:-U7</"YL" V[,L<!M)VSO#8^3V&:E
MG 7UQ=KA^*URK>PNL>QF[A7S&2^''-2O20O!6D+,VVR#'L7'&B3=J"KMWZ36
MK^[^\):F_F$E782K DY?&HAA;O)::QBU:&9C#G18AO,@U41<60LM7*UD3]<?
M7S_[)C"UQFL J)_OJX\LOYF]],8^HRYA>-D;NJU8OF-,VI."6(Q 7%%K&6 @
M&="PA=L@=0Q6Q3Y8O+%J%WL6QU*I@[R_?O>T(=#%@J63L=M'!O_=$[OT2>Z<
M5RWJE8_^%.JLB4/I1Q2*OAH=1-7]>??LV^1+K9^?)@[<%PR5J:Z-X'FK&ZOV
M(0[AO+#V^^1;PV!*3-..5&(AW"@K*ZG#PL)*-61L1#"0L29G_R]+47YQS2HX
MP;WQ>M"1V;XM%+V:;UXG=YMT5/;W$P&B^BH8&2%6ZF,LGZ=Y:N\\B^/:DQ_!
M5CY'W],>[3<B R*A!:"_+18X, .I#[M@=F'0992A(8'$6]X50KCC^##%0E55
M7OL(1T3@9X0!EB:J=/P5B;%XL/2#A=USE%,+*XOKO54AVNY<+4%=(\[+3;JY
M_,?D2VW_P$WE%Y#27F&?Y@7(@+^3 1E$Z*]5%#BT/3Y*65?[%P4._6T$#'/>
M'P?]:M#]#Q:S=/]_2M55R5:FG]3(6=K)Z__/$%G\69A>[)T W1.KYB",5.=_
MG/7_7R;4ULZ.!<[RMOY(!$=R_S]_I:9\_).2DX_AUA(!J6&()(0JRDC2=8%Y
MZ1J30-YNU6;X5H:,6;1?*97Y?_#*2Q'/;(5'O93W!AS2<DV,3(Z(MPS?=8Z]
MQC;1^Z+C86$YB+ .I;B[P( #:"X"LM/]_E2>$'#??)KD@?X!69GH'_2P_YKT
M([C44+%0'V#A/%8U6C/GOK9UC%I*7L_M+[3HAYH^&6DD-(Q>0?&#V4(\UY7>
MIZ5+RR=R'DJ\$-C9%5HR-MX/SSW^:MKDY):TW0'ZR'X-!MTPI^#V:<3+K%<Q
M;]9<YRSJGY(!EIK<XQ/$\9? NU9]A?S&C3E!$W?>!^U"J@,:24?LY!MA);"H
M%=CMCWTUFNGUZ0N?;D-*"IA7&-[/<Z9<UJ*6!"O/+O6(#40<#&._KT-AN7LE
M4"<M*P[^(6)W9WI\N<0=I]V$<8.G+QHDVJDXB!0&?7YHJ3^IBE&4'"CS$_%K
M'ZB[BMT)MB\U_KQ9>[,1Q\M4?"<IP\7DX67654E\XG;R@>#N'UZCP:@OD$GB
M#/,0I'=V #'-A7KP3T##5WSTN?*G?+W5X@<8=X6EPAFC9!Y>/L%T!WHO\ 'H
M-!GP. E./8U^O;07F366,G6_W;;,>Z=YO^69U@3U=9YUQ/N- U^\[5#+3;3>
MZS=]N@+ITJ!1T<C'$+UAER&-0OA)@F#J<0CS AF #88/8HZ8,^^KF$Q_ )T<
M3/&QPC[ #JZ<H@3KC5Y'NXMB!KZTG-#(9B]3FVL-X2%.QPBMWOGAWLH[+Z5J
MM0T#]6NZ-I-J=4_5Z6]NYVR@2[^[5;('T_(^Q!GWHK4D:K;&UWRU;"M=957B
M4Z%:^Z*OL*,TV^#!QSCF4(+&E+T;6F?05=[FH?_([25ZR0@'6586]/7$W#2_
M+U6D.*Q&T]CQV/N]9OOZ5>6I0D$;"IEG/[,$[SK'T#P"JUO]8XP&P";P\?+)
M(E2?@-O:8-U<QY@D,5YZC9X@C64.GNC?G"^L4;"2[.!_5VSZ774XJ!.[TVR,
MDUEN+FB>SB$83IH::@205/5%[;?LG*6$]P_%'Z8I%)I_^L]!8I+(ZR&2 9SU
M$]:*]B,(^[,3^?MR'F%KDPEA4J;WF@S<,:L?H]'G\AVXR\KUXTQ>( ]SK)#T
MPPM)7Q))^5CC:UA+KY;$!(SK3+F$B<R[[Y<=_'TJ.R?_;$'/_:K<4:7RD1F9
M%QDB; OV>V9SG2AZB)6]8]/.V-'^35.KELX'V.\IR&KV4F>&&G;UCY]:V5],
M3(?MB"@UZD*.-S_),[GIE(=$Q#DIG'^%N5$A3#7'"C_Y3Q.^N&;K"DK,VVO3
M:;W)$MCZA@/[HTI*".*.]#*O0,7(DEQMCH^,(9 WU(3 6H^OD[T]"!\S_(4\
MC_(6+[H(!:$\S +7A9XWMP+6);JJ?$;=9N9F>1B7WOUC&D1J,^CT;4<NJC?T
MZ,7QEI+>;10 B^O@_($*Y@F8T93.,,+MMMEO>54CM],:'YYTF.-*R>\NI7LY
MR 0\E(%E')VY.'^_-M_T!JUF<_@A"2HT=^VA*>\DC_"XR**1B[EDP%,32"<+
M97W,T/)(C.VN*S]W^4UN=;-+^:*'2,CR]VDIO%B>QZ$UX^[,%]_5A+,B>=DO
MCR1YCGSU#3+#B2WWYYO9^!VNZT8F:8@QXLV/^&O*21K?>3_WL?-(ZK=517&S
M86*1$QF@8/$C\AAA!FZT@"BAAZ\#?,VO?*3NI>_M2+A#_'A)E0)(@_@.&=)%
M\'0M6#)PKQ/&W:*C3>5]7!8BDAPEN:=OMS8<8E+=Y<<T) K/#E7@DVQS0;<W
M??I:[ ,32Y].=C;;^+<ZZMZJ*J\E _*-U^ERNI%P_.[XA@*[*3'11S\;'](<
MZP%JDG,-CIYZZ#=L[\N0 !6^_U*0+K=>>AE\W(_3B"",58:&K%C915.;J;VU
M\$[-Y@RR^Q->*MO-: +N8,%)N:.L'OT]5CH[.$O=!$>)_;1OFH>A24,59$"J
M.&7_=1NZ$@[=G082-^V2%Z\(%$#^*%K_J8W_OU.%;3^\HZ/]<</MBJLMF@"S
M]/Q_SK]=1\,$ZW[,9!V#F6 XX/[_GDHAN4725'_#V^FG$5O2-'^@*$55I&SQ
M;\'[7[7"H'1_6'2T,3WG,(]-!V5@_ARPU8GCT;B2ICH@/A<'T@Z9LDQEDV,I
MMF>^P>8B<V@KLRQR5.(>1%@;,K7]88Q@C[N=A3LRY!$[Q92%700NR[/7/WZ4
M%CX^_KGRF<J;Y;J:Q,7[GE(I9 !H_>J8("W2410VZYNF[/-]"LJ%SV]&G=V$
M CS +>+S3&Y<')K.AKA;VZJ]ZIEYA3ROC]SPV[=\>'B$)5_I!'[.><+Q]"B,
M#1^BA4NI,<H;,K8SXXRG36Z9.]OJS';UK#.:=4_/F]5H-G5,IF2D<I./<<,0
M#<)PSV+L3&7J!]WC98S<PUQ6A'1K+S=AM6*IK:*N\)5\8KW*LFQ7FK"=BNU'
MA?8JQZKBJ'FK8EI.W1G**:U(H1*.+GK6E/R0LT*IM/;-<DK(RJ1;H?<IQ@WW
M1@BF64Q!!+Y8=ZE[R[J0V216JQ=N+_RFMIOWV,H4.\E&A:_XVEQNX1=M3$C#
M90^S)8.*T@$1A CR:$]F5R82O$+UO%&()4+V7O37FQ9C(;=M,)_R>VUW%/W"
ML"A_,H#)%1H*HO>!.'IN[VN*-J@:]-[I@\>PPI\K/7Y8V4H&O&#+F-0.]>/K
M\U'$8::F]6PN8E<ZEKV,WV8 K?208_Z/_)[*@*Y8NV0F:;?ACAJ)7*P:QRH%
MI-<Y8?E7-.VS/30^>5E5?\ '-M6)#DA9B\W87VR15>@8]WQU^KU%[L3)>S5\
M^ZHV=<!2W#G,UUR$1^H*X=:>:7 <5^Q)0W5\9S1]9J9J'M7NM]SM#_,=X.N"
M6+>^/8FP]5R0=2VMC]"3 I4TCQCOI/P/Q9JL4FN;DX+$";V/UVA,UM"U%J:D
M0:63Y=VEX?/+KOE)D5IVK[A[,\I#'70FT(DL"GGO"U6H0F4GV.+4'=.TD-)]
MVXM"K82;^ZIX]VNF@E(]"M?S;)FW01@5S:)>,J#'WGZ_II7G8ON9VQ+:'%:U
M- UF@KT^CI-MIYS5DE;8?)?-59,C.+S.#@6V")KP,;J%WXM(B96>3P\+:/C]
M]$8EXJS2Z'45HB2P?5 ##""-@KD(GMC.:>4/L9.(,VI9"VL9]<\>&GM84M^.
MN:ME2CN?@;(=B),Q,,EI0-[OABI 2[ACI6W8I7<U@2N!. ](^W<9$M4(!%>5
M GD*BJ#<<=%?'0F'RLB :?V1+;:4[D9BAD8) =1.-."\9+?^T6\(QD)90'@R
MQ_%'[<F EES(9)'?93*@:X$BQO@@,4_:O2KF[3C13DKT)KFE'D:@;,."F_&-
M9,#-/WAR_D;))=[(=@%B]*I!C83.?D&A]7(2._,T'?%T+&2"L?Q'5J/?RHN,
M\N])/5G#)."L7ZX.. Z%'4*Q0.9=DL@  /Q'\I_?RG=S*4'?_TNU<O:"M.9!
MI;END)!=6)Z>X7='PA6Q%N >YT4RX).0XT%ZIM_*?8+NUXE9/P'334<)_8X.
MZ-] BVY%T!0V27JR&,>X:TP&G K'A9!"U%#8XR,_4S/]1M@ZGM(%L=%=)@/H
M-D!Z.8@OX_BGX C0IIPF&>!O,'Z0P^BW<H[>:N"^>L(3/.3=7I:RGP$EK#8G
M/"(#TGI^C;0>Y'>"[Y_'@\A/4C(F-A*:[0QGGH++P"VJ+,4> X]Y+4#FR ,_
M$2-<R6Z![7'Q4U!@!_^&@GTZBA<UB522HEB- Y$ &#+@ (;?"'_&8<F><9>/
M8G8N+IL4$DK9'U /_@+B-\I?D#"V1K2*X>VU(T&;"MH4RZ^@#I#XK?QG)$:4
M_=0@C;8^-A2[IR $*N1/('XC_!F( 8S0N@:)_=ZT-I&.@0R8.(7XZ9F_$?[L
MFF7=X!@P%@-C@\Q[P"BN: \Y<,W?RG]QS;(P0@S%$?OPE&GC9A,9@#]L]\LW
M?R?]V3GAI88S";\/P[]X6+BRR  NZ!;P:U'^#!DP-+?]!J?2S#2P"69:HM'K
MNW#"R9&GF<,2W1U\5N^9*B*7NW:T;Y!372);U,#]'H*M2#?T>=A3YTM+'0^@
M7QPG"RH?("3.IQ<>LU!D@G*#5KN_H-OOI1=Z'N1E_UEN?)NM;++.0UKAN@49
MS8@+$=<*JYQ1(6(47I$!U2I"I\U3&)T_0_=+?[!$&7 TRPG.10-WK ]8. ID
MPUST.P_D'+#(WG<^M_3G$PCZ/@="=)MF&3$AUE^=*-(LU,/2MD-!M7LZ/Z^4
M[E'*=_=OP<:( C^OWQ^U@]-S?-.UU_S>_+P^_S@KUJVGU,V_@U+_>:5TQ#R?
M![2.W1_/^GFE:!*^J4]7JD9<ZX'^N!ZHNB<8@N$E[2RH_+Q2C"$RWERAAWAO
M9OR\4LSU^YM"(90[UPRV2@8891C10Q5?0-Y&"8+^/;":ST\]D'/ 0;'Q4K?A
M3SD''!04_F?#].L]%D\HS6W[7]I&[=^^FI9_M*U41UGM^A]/FB7C[TV"MIF;
MP5SXLE4[NR&?V]N:1RM#Q!QGKG'+\A>J=C*V>61/K$6B)NV7E"2PA:CT(73N
ML#%&L2S+O#=N'7WW.EIZ'%\^-1>D<,HYQWA)+GO8JG?94+?J5H":3[Y;;)NA
M_+FMI_YRR0P1Q^<(LOL:!%F<#LH4!+80B2PQTSS5'-=$?^Q:JZL:C\&C*+^[
M=FER,'HS8XX>O3JF%?C.91\;K$Q3XBPJTZ-:%<<8_VZ:Q:4DTU:;+_O=8U^'
MCHH,E;Z3<T"C#<19GU-%> UL!KK<CZ>/.CL7'_J:UTLS^//46V=@ EN4+*?=
M((%O7YMP!5=6^2C3QN^\,P0"*U9Q?^1L6S+QY%A/2QZ:\P6<%F0-I+J>OF14
M4#4?W'N[FDFF0>-!_/UL?BJ%]*2AV%[ +%R]X&DBX>0W@2\KTCN[7+(3:\/Y
M!CB:3XBC0Z;C%V&%A94TH:ZLHAG"/9=!SE'71\H1ZF_]6OUX(*^N<'%7X?2S
M\,7](SJ1A8^BLZU;0=7\5UEH#C-N]L?-& 7%U?;Q14BV%*>Y"(S<MWRL>H2#
MZZ6E 7,PB1OOWHR9169:[R6[[^Q)!0C-3QF,,$2G5!<AH86T:"^8_3V#L.US
M<;&D @\NY#[WDMQ $"2C8TJ(5IC!S!>B&:5A('_1CY-O;E:7ED-O#[(<[IZ-
MO];H6+ P8'8QW!!J4%:-+!YQ9#]_GD=LS"FP+WFP8GZ<04%RBM/=I'MSQ4 H
MGWCFL-\K>-G)B'4\1IN3ZFHAJ &%%&MT9%=<M*X:[5@H*8W9,Z\RQ;PX;N%]
MJ/O4T.<)2Y*^>M:3\AGMXO>I"(BX$IT/[R#AU-0XHT=(D]'W#T40A)0#&6!9
M?KG@\>W3-%G/S2X14Q1,7!'LD :^:793X'5<H&-?P2I<8?ALV-/7+:/EHLY;
M"*\>:3M-]SO(OJ?\QDE";YL^MJ=PJGZ6?EZ\7:Q;65X4&!8ZK72."$MJ #$H
M2$^Q:VK)]+J8TNUSVIO2)<ZQC%=G3YIX$-](A[./P"TT<2+P0A1SZ./!S=W4
M;S6JQ9<,PI05/125?464N3"^]5T?]KBHIE#^2M(XQY>;^?)D  ??6.[I-)&5
MN:03(@6+1.[CF6?RAPPOHHK&BH O7(A4R,C3.\OE@X;&#LNL&4*73>QEOT5D
M>7.<L5NLNI2W8<1MQI7D_N2+$7I9VUDZ(403]DH$X<H)ND/JJ$PP?/%![?;V
MPWFJSSQN (6'Q_<8)A,">/"N$Y%BC;A6#I0%U$[MY T^J]4;44==I?2^%LS"
M+YH(-"35W-519HS^^+?W@GS?(9Q+*]J_<9^R.E!38A45;7".]*XK&7!4^*E?
MUP!P&T")+;I[!]WH\-FP*!)=^^[^+>PWN81 !66XPM=8FQA,IE,..[CC"0U(
M,W #7DT7[(Y9"R9(NJ9?=\Y=K"H=G'\Z==<MJ[BE.81P= BV8YO=N&*H%MN8
MRH<EP7-/<;J*.PHS%S>L-T%/B!^?NMQ.-=YW:<%T-7P:<1JO-*C:\Q39ZTV$
M92SE85)*&518JVI*K:>B%+\@&@5/-5]CKZ6V&WH>,[+72^@\>EO$CFA'4J&1
M:10[AUG<KC*I$ODR;M)B%7R>:LS_]?TS3O[7.6V6L-7-]@57XJ7D$>4%W!/-
M+YH@8U^=H#Z#'_#&4]I!@Y.G$R;E:^_:8"(&$@9*QI(\[QLY5CS@^::O]OCA
M:3?+* DA.;01%HD(1D)I(0T/OSH^?:0\D%5><25G0<#Y.")A]M5GFI3 9">]
M;*6&F1!(LR^:P0X;WB)3GAA4H 2L]BQ00"!% 6=IKXO'J+6P"#W<-X@L_[3&
M^,W#^VX?&5"2I2:,8&I='J*3JMQD+42@(6<WY6'!"68LO=+OD.Q)'B[AUUW,
M8Z1K[_N-K4=77C\6/,M[=X+^#(<3&IQ#,,":Y>:V2MBUVD:;+@R&]1AI[Z\)
M7BX6&&%MM(0P46WE.N<.96G!(.@^G*?2:?Q73EU[68*B6\)']&P;@SVU]&BY
ML/.+3HY!)^S&MB^8WL9PW2[6;($M,FLY'FI[UN/$L=<,,&=HUCU8LQ=S&+HI
M4F*I"3RT +>+MBWS"FIGJ)%$LW^#BEYGDPJ/EJOX$OT6^\S)[-U['WNL69P=
M7W+5\B#PB;AQ5E]9B=6,BN7'W0J,ZLE%#P=?Y4M?LDIOOKPTMK*PZ+-&!AS?
M:((-T1B3T)6DMK.['Z8/LTM&#GUU2L7#.W@FMBME0K8BG]SK72V0VM<4'F\4
M/Q%Z>N;8L46JT]I:_0M&Y<V0D^ %'CUD9;>]&#K$6/V*L\U.#%CRK=%%Z+/'
M_K?K2ZIEV4,QJJSM..:(&O'\,?Q<4Q$>P;"TIS(\T87!3'^-,K"&OFGG62^[
MV'+\)A=@0;]3I@OVY.@ &0!:6E58JU<Z6=1?:@]N8AMMW\8PQ9_E9?)GS7[W
ME5YJ]-.JFB) J@H15&IOIGBA!NCLZ>ONS?M:*=;MW.BMI0 61BIUB50Z<WAJ
MG/NGU O=5EB_VDE%AZ7]2V+?P]9[]:Q3[T^F"OL7"QX:>? @6$_\2)10GQ0P
MW(P5.QMJD67KU1]<G=.A,(F$BZE=F6J@*1<7: V6Y5B5O7JO7B%62S?&X;-.
M!)OADXA1@@C.-'+&H&3>4$VA2$U"X*X[]\G*(QS/Y/K7#A/.XYBAC%G%I=8K
MFO#F/N=6_^)7U[[E=YH40UMJ>>J5E+ (_P*IT>/:#*>L+CVNL=DZ)O*$:=M.
M6(1^TDSZ]4S9+"8[FS6KN^;1Q!K=?!U[ETH8?$T!+F^(K.KC+JD\<YVO(3NN
M\19GPDS]!5J:,MG,.<48 G5NHQL9P#CC<3CC]G+$Y2_/5-(RLU73.-]<?D9+
M%?S,=_?#H-J7_Y7' +W RTO3)=B=J8&0G-(@$<NWQM^<T?%DP*7.7EE$'\6U
MEM:K)V0".J-(EZP3G=.\]=]J.[6HQ,/$.P=9$+T5#AMF6N*BC[]M?Q19EU]6
MP9UH<4^EPY961;Z\J^W"%\6K$;'<=IGUZERMLQDWOK4 3[_GS6EU2L*SP<B$
M=SMH@#=,8\A^9HPEYAB# TU:_6:NWR5K=S\1K$O5X^2+4P\NAH;1'GEB_4R[
M717-M443KL0^5!ZT*N(B(OZXIK*N-_-MIWCTF #B0G2]YWWL69.53L47%VM:
MH/I27HJPIO%3WVS*97!+3+,]PPT:%U4QZ/?G(S8,#*? P5I15=G;-<!'-G7M
M%^?>B<>\;7&.<HJ*FR&)8,=?C3<;U65E+9 !-N5OAY>'NMY=AOFT%,OE/)-C
M^E2P JSWXX?N:U&"4=7^.4]D40ZF]72V;3D6DL%2\\GC)6Q24'O4 =_,':M8
MM3,%#-[</R$_$FDV)F_</'KD';_'%N!DO_8K/QDE!KQWKD>LEJHCJ9,&=L9*
MGI>SDO&[N(=DB\'.MEP-=C'VRP"=Y?:>?O,;2?ZU&1>)75@U;WZ.>4B.XFVA
M0AS_"U=YE/^@&>O'TB?]7-W1(IF5*O+#X6<L+YS;VCS<$ZUB,0D[IUF(AS;O
M/7V-YO 2(1@XR3&\8UPYGQR_T][D-'0\8&0J(0C)#BL>MC,HE[GS@%Z:?]8)
MEG"UY;G</07.]V ;)1'<]Y4^)=.RW+SKSM;[?;O1\,C2.\].JW2R1W!P278%
MFH$F3(%&.,/&D5-,G3=B,*/2&1Z83ZEG6?1@3@VK&S+)%JO38_Z*\HTP%JE0
MPH7,10SQ>V&LLU],Q4NF\X*JK:ES'*<UG]J"&0A"F6!V^=KG ^RO0R]$Q*@:
ML!I<Y3@D/_B:WU_!/AMOUJD>KEJIZ^()9S.5F^JV?)!J$]5J9D@&Z",S0-Q%
MWTLPR!H^;&>3G%O"E')-;[_#FI2&G<#]#G;)S]&3">=Q@=\F= _WB-8)X'4[
M[_G*V3_O%^-QB9SZIF;P[/BA:Y\^/XK8ZS?$9T\2!6<]I$V]M:(<2]M.ZC2B
MW,Y,Y)]^WEAW%7&UMX[9(WY\<A#Z%*BEWX\T-KZZH@+C>NRQ8GXS?O1%B,&B
M2LZ2 8$.VV;6X\>/+AA?R(F_Y)SSA5^BI8GV/LMGJM 9;R<*%!(;4V+!!<+"
M:T\&1'H&L$P!=V)GJ?K\J9\)VB$8[W=,J@P*2[-?*1(/Y:E]$TLM&1$CB^ZI
M@=;7<>%H_!5N.8B6/BK0<'+TRGUT:J6X\\CMF:NO:7GO6L@'+W,$&/(D]F"#
M WT1?NWQ;*YQ>>QMM;(G+]^NOQM0']PSQ(*^X=0,<(]'G:L147I?Y;Z]DK3(
M93M2HZIU)/-P^=5I69;6-2,S;EQ4^.2%IZZ1M]GI2F,^AJJUOWQ^[7"AI)F>
M$NL2CB"/4X)Q)8?G@>UL/(^'6AR= O.?-':COB)S9 [J-81'23<CH$H<WXP6
M(O,[&$=[1?+D>&"C5'&B-V:>5'+N?J!Y(-.L33M2_T0J<24/[=$>3TC^W+;C
MS_)5^3X2'SI9/6KJ\EDZW%/L7;O=,?[XPWS76R3]/3IM-QQ/$V0'P5.:":%B
M+JB/F#9GSV?;:U): TG3@N\P34S\A=^F![**L9!7J*+2SA-J[X]EE R>3L<L
MF=PP%P\/@3W/<>9_^^GE^4(EJSF63)KWY4V(DQ<_N&P/P(/FWLWL/E! [5QO
MH9W8S'F(AT\*P96,YUU''MAS1YO;Z,7()$^J<,#BJKS8UFDM^AYU*9R:;,RX
M*5[:]U)\$6MZ7=B0[^:A[I7G$\F$$7\TW [4*';6AL2$/3%B/*;LGE:+QA24
MYH=[S!'GGW&R@4?I94[.! 8_Y<!JO%AD!M$K2-ID8\8U"D9$X -K%Z^IC4?5
M4*7*SV8F3=&$/.R#%P -RIG=J4[JS*2,D-:N?NJL]50A"-4ZM#2,K7+2/6![
M$S.J.6=L6Q:\RA1=$GI3L$&_ZJ/ND.S20&9LO9]8P"*M_>:[B7XKXT>*_?#^
M$IOUY:<P)>;&@ R2Y^'.F]>XYI3/W0/\Y2^%_X5//A/$LR[.K. !<79/U_N4
M@W%ZF)#DM3^>?9RF"Y7H\,SVZS-D?DC,/9WBD%3URN#J%X"BDA5(URYC0.DX
MWM_C^0XZ50C'5PAW?33I6; L4O TJ$J%(]H9%5LQ53L%"MH^2[@YX*/%2Z]2
M,-1HDV-3W( XM\(@DW"I\QF\G&5940@1,\ *CZQYW8)E'#)_?%1]S^*#$'P
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M6BSAHALJRWDDN.Z)I%F*/R! #8()=TSQ'"NH=EG6+58*L.,QGDI=RC 1BO*
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M_)/ST^BV'Z?(OT?,+[M>:GGYLVQ-EIRQ/Z-<PB8P]U26Y=]H1;3@/W>=A*W
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MLZ^'2@SS91?X=Y0\#X!O_F'K7,A/G?_=-UFZ"JA7'P#]QI_F&X-,97L.>1F
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M#&+DM 8-_0JT,1-A',6[^#'M?79>PINLU710KO.Z[D<KO4'$ \"!QY*6D&%
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MVD5*A>#0Y0$PLUCX]S<+O0&T X38V%C*H^Q;D(@8=GN?N6D4^E[^61->:-;
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M0WD/T.C;6D?"R;JI5U<)*FFKS5;P+_+-1 [RL?W)/\A(*7BKXT=/ER5K-[=
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MKH:F"3BF_@:U?5SDA98N/EBA,FPUJCF!_7=!T^MB_"#;2(8-06K%*1/*Y5)
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M>G.&8H?C6#$7%2(YWC!NY@OH4^PO%'E[$P<X7=%H 4*"(7=56-%!M)3DBQ9
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M-6G6:!%+D^0A:B%A*-'@E0!87!KJ',!C%^QEWOYS9G%SZ@Z=I!B7DRP)7@@
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MZL3EW*+[*ZD5CZ:EZALEB](N.^;U<>8* G/)&55D9A_!@FWS (X%3Q$A4:7
M"EV94O'B\I<28C-B,@3LT;;P<)"%Q1AE\R:<IH[1(NF9B%29/EDYDCH<][E9
M/.P_&[=8\*^^SY+XX.U?Y];@V=;,'N<O+^M'^<C'<KOL\WJ#0WZ*C:!3^W3K
M!?Y?5R_Y_"Q^A#-PMQ5^LPD>0,P]E=:.WA@GCL-$-)^OX:(15TTA0FNCF\>2
MTQ#FDMR*W_8IO.G>R<:T]7(^])CPF'G)?D]:'?^?2%CK_R3AR?\FX2..>R:&
M!/'V)^'--0/]#]#1V[3"4?*D9BE,%]6ZZ]KH5\P_?N517QN6/X0927USZ$ '
MPF?#)7U^^7P?#CN7OL_?69U[EK5=A5A,@)I8>(;3-=)$DL,?5PEVSG\;[)1&
M%'&4W/NL@:3H-Z9^TY5J\RD>FY.V[QECS.W->929Q9LR[>^5GQO=IL04HA/E
MZM]\O[?;^3/'?+S-] 8H27CELZ9Z]Z?E[[=&B!A\Z_WR1WIV;=\A[*LYK7O3
MW<X;6'IZ*>W:&X!*8D\="_UXL+CW531XI!)"X]88;KE'7,IL >GLO9>[?@,\
MW+T!1I/NY]\ *)NY;P!1B8N]5U[WO ,;="+D6GQH5RST#;!#OO@&. I] _3\
M5\.#J&?8OUX)JMSF^S983:ZQ*+N=2??RO/]&V_FG3U*)_Z/#5'A*-E[\4>*R
MNNZ]Z(5Q8@!?*=6#]__^ZJ+! ,3!LU7B[O<;@-1P+"#^DN57 R9RM]LKS5QD
MON,@E8"%\>LKV@+]TTK1&Z#O?['WUD%Q=LN^\! \6""XRV!!@KN&X &"NQ/<
MW0<))#@,08,&=V=P=W<([NZNP^4]^[RG]MG[?N\^7]6Y]7WWUOV#*KJ>7K_5
MW:O[M[JIAYF%1TON4YHP\D[-3="LQ,L2YM>,C\^ LX3 6>G90^:6WNT/$)C*
M9H-887<OPK-6O%L[J9FKD,W&QKJT2[VF\7:;-QY4UM$L721-KJ2YK<I7PH&^
M6#.8\0>R6 @'(3H@*HUX4)5"9Q%RLH8 7P@#5O?C'C(P)25UZD?RG#=$F/O8
MFZ3 /7F")U:T-H*J33M"GM.,!W\'-NV=-!3'2IV+'?G*KEJ^(BY@GL7(CXL'
M[CU/V43L*4;;X6\^+H7FKO1'55F\MBBX-L=D%D1HHS24XR[A\Y;9MGZ@ +U'
M26^N>1KMZ=;0[!N3?@<LDMH)LV"U0XQ\P:*%2P44+7??#GY^%9M06;P8"/O;
M*;!G\@,[%+OWJT/486GZY4OP>I)]D6]Y&_:$[T@5H.]B+4+$4W8.I_%B5\.F
M>Q];N:%^-?O<(?48$X7N=AT-=E^+TR9E(0^<C:V)RAYV/P%F8!\&&95%-.E?
M]+M]2@2BSX"TX/12\YD6RO$3Y\%-"\83"G<:<<>@&']4&#C,]OUW+";5KG2P
ML%.$QONQ!>L $"&"<&<::>5IKK]AED5%M1HN"W43TK%N'+;!JR%I 3?.=JM6
MI)QIEP@KM2C%).92NZ,3 PBWL@]8/)1#F?@TL*+3AI9?&M'B*/18N*94>,?O
M<9CVNO@9<''<FI2-&'6;MX;WG5!]RO"!Y+&?RM\:Z%.%_-[@)XT G,@OKA$V
M!9W8;HL5;[SI]S511W:0^7;^3[;#*5Y-?L\ B]I$\123'O%Z5'MTG137,CGH
M5#K49_:" V0Y(KRU!&)707QK<[JA%MAV8:'G$J W6-1?P"96)UY1BKJL8903
M5^[0Q.S(QJI!J- V+#/ZJ0F2!IV0W@J0,O;NVV:;_YH@<FSW,\B^?L2QODP5
M.OTG].@S0.C@+EETVV$9]]8I?S>-LW*:F;K"BY\!I9%N6;!GW8FSRS$XEAS]
M%>;4N=-R_6"9?W+8LI:N>($HT7PUF-&A2H+:V(.I#;6-&*T2)H489P2I3.6?
MX&',/6*]<:?0,[.62[; _7F2?"BN6'PR9A:H04F5CFFFQN0 9%]L(003$ RG
M_UK1$\Z)\Z9T6YR=,<;V"2ZR57E$JWT<4\H.L5%SX(,:Z.Y&?VC\J4CX\:%L
MVQSVV^FWCL85-/=D_CT[\/8\0TAI3'BEW1(E/'U5T'QS"*U?*QT5I[+2+;L#
M"&V]Y*@)PR'?$L^&,K-?]OM 8;H.23W!+L^1WK<_\?ZT':9-YY%NBE/.Z$"E
M/E:A-GE]>1NC2KN(PZ%J(5NF+8Y F%D!-APFQ;3P]R/];%I_B=V*;-):):2B
MND':9$BQB\JH1?.3[]G&W<BQ.FR*43/M/]K="#O$J1"@%5_FL$[4SWQH4#]]
M6):A88PZ/M_/I_WK!Q#6_]IGR!Z9:>+G>E0@X4@533,Q7BV]70%1\]>F&&F"
M-)X$!Q.=6E2SS3Y$\K3$,L5_BCE@XW(T. $W#6NFNB@>TI)\\YE[''HO%9"2
MJ9\JL66@S NX/A@6>^' ;_/749ZVMG8<3S+:W[&0@?4*R7- <(.' 3FZZP ,
MK:W,L:"#+N3/',_Z=T?&$"-!G<)6W%%AJ6KSO[48-))*-F.^LXJY$?$5P"@+
M6RCAB,!:D%XMW/*O;6=E(NO9J,G2I_=)X#)38V7+B&!L]X@@"KY! /A<+!3_
ML^EG/F)KM"'.15$8PW!:KOD-SLDN*0ZV!JCV<@S5$U]\]>-Z41KAW$IGM6_U
M/0IN&3Z-@\_AZB M7OW$P><]&U38\NQ^)FW76H<O+;/9,R#=Y7&8;/[E'AUM
M@)H&Y:TX<#A"D6X]7-;X/8RYN>Y\" ?E254\%(&L#55'@J*+PN\VJ^T"[K>3
M"G.S;^*5Y6P97;4(LLU-S7&WB%S5D9!2-=Z58F<<S#2K_^.9'CBDJ.6<KBA-
M49W!UQ[Q4LP8?9C ,9HI+6?4T[&*-.9WNOF&VDD\A7;ZZ^'S&?%]\^9UO.DZ
M2ETR"GF7R)=@_+BQ:%Y21>"J"VRM5=,_!85KCEM@6 CKH*0@;-;GG6"%9OOF
M0E-,$B[^SH=MD9\_TGGE\<JI7'D+Y\W:K!Z$,30UI L64!*9G>_DID0#CP+(
MF#IB1Q2 )C?MG/NM?P8CZNBEI]AYX1818KATU!H/#KG7LSY?G?9>4^K3J(LZ
MITF'>7\S0QMQ"%PT2PE+?FGD/3A!*.YV'R./Z=;+@ZSM" ++TZ9^A5#I@'V-
M0FY"-@1B==/_*5&H^B]7_ EK(G-R++'VXQ,2:L\6. <;RB^V9!/B%GB KTJQ
M?1B*;GU.9S;:$[2<P3K:#=J[]A:.C*_5O;\?=D._N<TTK/QII^2?Z+FX/-ID
M03>[WNQVSLY[3-7\SX#JNP=9.=<TE5V4+1&T)/]]3]91SO!6^)HXN==DD-\_
M)N?;!XO!%,\ 2<>A1I'.8[C5BHT,DH.IO\^1V+^%)7J4.FP--V=-D+]SLFLO
M7S;[]]Y,S\QOC 2!>*BYJ4/XH9"M*"!Z !V=[E2RO5F-Q%AFYHKBBW5%'%A.
M@)Z?Q:X.%O\9D%!];V-Y5?9/EF=@$ >NY39F2:_YX#)H7"$=,5?7'[L0P'1]
M^"UB1Y?6:R<6&"_PQI&/1&$-6K9.AG,;ZZPVP^<\'U&SJ#Z<7BV]-?_K2 >C
M0?N=-&_/6F#*;.9_9(APC9GP^<L.OUZ*&M7C*J&#?TFH4Z$BTNLMUMQ>;>QP
M36#73%E=M1CQ\0@O%8G'GF;O:D^E;5;"D1;H'B<GI[DZ"<2VEM&D[3=)TH2+
M$A@Q!TRSFFJMH?V'"O+C>8_\R#KCS5M,(N'AO+!3SU[2A87W&^#5;PLK?KY9
M2SWO%*DH[][]>:P%8W\>YSC)LVH/HK0W)@KG.F&'^8DJTOV&=>$\Y5,Q"SI+
M9QWG7OH_9R.I1[8W4>/$!@3A>EZ:<JJXS'OL*U>?\>L^038G_TD<XVX0DJVW
M=(&E.N9*3L(")W7C11:<+#'(T,H(!GJ]4>?:[0;ZGX":V9W:J03/C"C4BC ?
MT0;-4-<E#"89!V@$:Y0-@+RB7Q'; .)7@V)71[((]VHKAO,6-<7=+-S8=9((
M)OO#!EDE4U*_E3&UFUYM3/Q/>,6/58C87>*F U<=-W;P316IUOQ\-\,G<E7=
MN@L2L7(! RZ'R-Q&OMX_R[IU?I;LHLW7U(]SMSCJR"KJ;E7X)45J>A]/R9(R
MT#P9J!ZT-J#N&"_<4N+PTNDBOEQT>J%]T)FZEWX']H45K'1 HS O3#G[J_+/
M-H3LOPNR4*OPI%81.I?_5B6UH0UQ0^$]];CN/HXD#S:,[9C1$CSV;8*U@:((
MQJ]8REC[#$1%N46Z13J8*66WU]RO 2[82QT1'7XDXMSV6?\O'U(09/^;7(8O
M6*7XTT507*Y.L>XS'-D7Y?FHRO<Y"G^33/1EA/I:XH36)-9$WOC$^- ]4-ZK
M/ 01!0%$K\4OLP[#]I2/L6VQ81!_XTW\MRTSBO=C^/=%J@$B+V:^PGC1^>-I
M^A^>(+WH_'AY_L[G#_?(7[047T +;OYP*_ %6O(%-.\/W_Z/7H9IBV@98[P@
MOTCO!BL"6 _5HGN5,]P7\AWX.O?^U_LSC)&FSHV=L"LR#*:<TG1^K9I.K/,>
M^SF /89MS3KH].?!3FF-MV]5#<#'[JDP?9GL9<+3BSI2@9Z^C$WW5^>2CS3S
MSX GA/>@DPO%9P!R;?,S0#1LY>%Q"N:J];H0Y.X+>O(4KE%^Z+QX!AS,]I.=
M_K1:N<1_T6KMB;J5JSFY1]5[!JQLB)!I/P,L\VZ^[3P#9K,>5(6;A(6AS=XQ
M?P]I_@SXNO"BG=%]\@3E^-?XT;>S^L(7?_O=3Z@..JUP@O%"RF62?ZZ[HX*^
MM7$'#1G=0%]&0>$UKMG675:O9P HXB^\O7EQUND9H!OQ]UOY"4'^'^"]H(%X
MK3=_#+U_YPCL >A/T$O0GUZ7@?_> K+3Y(/_E>C_:VW_O^C_/T GK#3[&[J2
M9'X1Z:\_/M#X[^HGJU>(7,=8JX7L^O<?VGVA]D][)W2O/<I8;]G7!T^PW"VR
M6Z.'!=[B-TU.][ AWVPW+C2F%B0#XJVNY#?."G=411_%+LKB'V7/B+KPYJ<W
M2O.<;-[$Q5$$?R@LQ" 13OV23G3P=/5SY0$*^C=79_XW"B3MO]<YZ.0L Z/T
M/^AE_#\XH47J/\42U&%3!AK[&XT [E?^I"^R^8*GM;MGP-7!YM]SW1]?VEK:
M''7W)_/I@/Z9^*+^WF0+T(MMWQY[_K#GO[2#Y-_;7_+2%_WW.O!_X?]/@.__
ME_"E"(7?ZO[MYC-%F8X-#[U]>*DI$#20N_7FKLBJ@PSSZN']F]\>R7'=4U@R
M!4#V>OL!>0R]8#^A6HG%C'%%C98'C859X9%0P.G[>67H!RV[1XR7C)8YT[I.
M_T-._E.V!.P+P%@9.^4O1WS@65[4XF$B'XV75L6X-1,.LI)=PS]\Y$5/=;+;
MVA\%X<>KR$U0<B=FBIS<</M2UGEY]9? =>#148L1^3_*>$:-J6Z?"17>T+@V
MQ^2^)TK@ ?[0+5HH[WN4 U@ONG\8F/A=FMN4*,+4U4ZEXMJ?V NAJ%@0SM&P
M@]5X*H2RYBML:4IS.-9__=)4-[@E<7Q+%:MS=/+]BN2#,+-7ZK@UYO=I'!4Z
MFW81 (!]!)[C]IOB\*!/P86];LZJ]Y:_VM$B%AVLS2.9!3"$I'EZ"(QOL_/.
M@,Q5"0& UD_T;7:^^A*$N-!S$()E5VVMPE8HO55>%X&\&NU(E%>/T]==MO]&
MIK+7^8#REP2^ 4F^J.*M@<K)^I'N//MU1P"CAQ7ANT) >SDV*DR]:-N)")&#
M.QISO-J#;#?E5\?BT(RB3Q6GC551B6\<(EDUM68";0S-(;BS;+)D\UO50I;P
MO')Y]NT";Y;XC7[IXQ^@H'R$9#/ HYTS:S @?-8F(,>,QE"P'$U7K*__VLG8
MO<%6O0!:,( E*VC+A)D\H(M/OL[\M6#Q1D?[0PGQ%Z.NUG<[(\L("G++7QTN
M*^Q6'YB$E9,)F#?JTQ:;[&!M**)^;):W PT3ZBXYAUM#:G@9Y;)T*[YF?#_E
MQB9YT\*-0YK4S9A&/_WEHUJ3$5[+&(IWCF,7:D4[%2T05J+-3DM#2W)#4(D*
M&]D.K?J<'$R^1X")162+;N]1.&_JCQ%J5ZKXGG+)[DUB<TU>?+C?6C" C)N*
MV&F2,P07X@7_F%#$96NBINXF;M 6_D8E (EJ/EN(JO4SG%)..7HE*$N4F/<+
MK<4=MAG!2PC1UE DWTCB;*Z8)[>M^)T!,E!3ZT=U8(<U&T\%@TJZY_C"BM_H
M_:0\+Z1@%+HP@,BGN!0/:_?<!^?8V+UJC2%V/8 -4AU<"Q'P0U*R=]TA5J7S
MEBM8&'5BT^5.<J!-I?BB-GAQL1H BYHF@<'A FL,?7/ 5E&YK^=L&"W'(4-@
M#'\-5N<OY^'M0;?L+@M06@,J"O5I (/5/L9ND1K:A!>+KO$YS.($M+R;CN<9
MM\LFU80W:5MI7X2QMB4GM9<7+"#J)BSBJVMD_?%N@%)5)$>:"D8$%JQ XC0,
M,)=<*\*=T%?F5D>QI&1^.T TB(SS^JI'R,#I"K\XPDZ>4+[(R;R20(VFS9%%
MJD="<D.^<?;D)&[&*D!Q3,)8154N$V) !T#WV&A6:6B(OU[;3AH"MRX;3XU/
M(>7_%]X3_?N?F];?+P32S>OQ#-"7?"EVG'U"_R[)Y/.3W\\ J/C@Z/V]\#U2
MF<(4:)H0</L,4'D&1,>M/+F MJU^C7$\T(P9-M3AFA_E>S!1+S^UZ+4YG%_N
M>Y1Z*?]-S16T;>DEZ+C=,Z15V,GX2I\'.,[@=]OC<0T;"M@U.WVGH[<?9GN^
MP,BVZ*$HH/FY(F!!\QQ!BJ3JY+.FN[9\E%Z@0F,+6#I>D:1+L4,"F8!?6V#U
MU"G*>AIF@TG9.7(2"*[[04!*;?I*H06FEZ!_[^33"[%6*6$! Z2^%NY1\02Y
M\2H&,3J,DE8C3;\\0>0Z[9L]Z[KX"$$"6^OT# >1@?C[[FHW2*^ +:B0!8XW
M2W=0N0-M:;[YBNC*3" =JBBQ6V_]JPK)T"L80CHPB[$^$_''QFEN6Y1&@AXO
M3X>/I Q3)=U]TC]*NJ(8"\<+T(>0K,.=V_=$^NT>&6=(R2&3>D9JSI'B,4:,
M[9IB/MVC5#QMPA%Z#:>?N# YNZ<?HQ>^@T706DP&^9DG,LN1WBGHQ<5RA]CE
M3:VUFH7KB.,'<7TLS'QUM #![UFF?^\M[>5C7CO!QO@Z##^29QKP6A:F[<H(
M1 A8J3K5+8DL026,FW.-R\7\6(%5^0Z!P#A:G9$'7Y"WV_36^%/%+'A[P UW
M%AD*3J"E9<VG$>\M72R_QUS.5""P#*.([G_;7_];=TW-A)%E09H8]NCQ@*T'
MZL/GFHR =$34)4UPIRD#V94#N.!!T4/=AQ?9NXUHPHY8%OB9X4P>BU(7PF)&
M7JW>CZU@=%1_7.%P:)1*3,8D#N_+6%--=!DE"DVW[ [L)@RJ9@4Z9I@K#T0J
M$R;AL-<Q'YH1%&2?Q>< Y3#-!>+-S*+Z/O&"FA2(=V#W(NE>]=2L/<C1BFEZ
M]\_?'$4A8XF78R,5\]"2/RZG/WG8K9>/EQ9;"U=VGR398%?V:7X%"WS'MVYO
M6ZB#:>]'%+2B? 9T<3>D-HHY4?831$L!1+A2,WWU18-@23MR(&<2F58X#=G?
M]99D1-D_E@!EO!@P8\)3/,U" 4N3W@A%0FFSZHH)($H+II3"X(C?OI_=;)F"
M$8D\S=+H(5HXX;[LXX<S *9<J62I&V)6WM%F(['U$@GXK\!\0NJ/6(D_^FO0
M566-@:\0]445N;^_SYZR*9L7L2WI^&J4!4!/<<M 0Y'#MIK/=GVC8 YA0W@3
MYNS-?_U!X5/XZLL]ON]\ZE+5W"1;:)NVO7:4H0C3R;=J I: H25!OBYVKSGX
M:4RE7:QVSL?Q93V<P4;0XR@MQ;7O1,N-E*<Y?N2W2/A2+V-E3>?'( B+8AVQ
MO:^>0IF@A;_Y+2XU6(4OQ-@.56GTN]^\R>>!0LTVX\!1^=1]FM,/Q7CR#5^=
MJAD[N?:!(AFO"/JL\\FOVF$1@6HRMZ&W<@*19X,[$C%2E1+%I?D G0!^>.*K
M@MCNAA_6(Y4]U/RU_5O,EXLL'U+L67L0UZ30<D[?,IZ+P0TZZ]%@]C-^I.+:
M!&0QO/&]49ZLR[=I0H/?G/Q>([RX(%"Q*#6&60'F!OTPBW9E&46<KR+KOL\"
M?J\"TFTE?64MW$HLU?:?W=+SR8_MOD\)%MNA] B6B#61:?P]5<1NX"@%]#+U
M8[#24MISU,;?OEBK\S>+&#CBEY= ZF^'([U*56,^V6[6P#5=)/\N1@8P% 5B
M3$U[_I<(\1TTP*%D[Z7O.B.#?GT7I#_6NLEI^ S0G7P&?,"&N<Y-&/XJ+/8X
MC&VA?X[Q;1>4],N/5QC7FV_"VZN@]3HIQ><GD4 (UQ4L[^J]&O<C.R1(N!GT
M,K'T/@/>Z@79/ ,H^%=N$<]Q//T$6J$$"QWIRZTO$]+&,R DZS^+99^SC?U%
M2%]V1CU:4SC1?^G]7D:+KO%_D*<;06'1XB667%IQ*?$6-@Y I-5C9G4+N'"'
MZ-\X7WR9+>SX)3=U_  4 ^'<-89'!25$G-?*AU^> 9W\[LH/L\^ FT?0&0?H
M[R7.27>J[LG;<OU^ZJ2:4.0/$M+]]A(>-\2^+M-J%6!P [M%GJD'Z#^[)OD/
MGJ9YJG$&5X"<UG45Y']*U-=4U$32!JIX4+'JLILY%@;6X6SP^XVX%V)V_:4A
MC6<H780MW]S6G"<H(]>UC]0/)]H9[JR (+/4LU8KFRWL'9**Y:8TC"@AX&2I
MRYS=1D6PE=0QC7I3+.[9G>/R.M- H2P.1 3#^VUXI%S;\3-@+;6)_NG@&?
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MFYZDZ GHM=#6$OFRORS!XE3^#822,G>[;C?6G-22Z<@ 3FT7R."@#15R!?;
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M(' 58!CHCKJFZ0J-N,>[U098L%!AX:AY8_JQ][<SW$5I)?Y>Z&]UQDS=Q!N
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M(M#$B<&>7S\#_/.>+@4ME^_OQEM>W39HYC9>7"[8*&G,T)5EQ@W.^]7RO-/
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MY*< B8Z "I9RPX(747)D8('[#U'XTJCW02Y(4N^+NAEMRMTT.L FB+G$=#M
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M9_">&87U VM*^$ZD]%6&)$8.=*RL$+%. ?W'Y :&_07G[@5\>1W76H?UUF"
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MML%H<NZ,_ESC'1+O8^IA5IV1A$,&JZFUQ@%M#P:\^AJ#<ORJY\3P5N6AD22
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MEL!\,X1N$6@.^1,H1[,-^P0;'TIPLK$!3QSO-) [6:\DC%*A$VY[&$GZU)I
M$1<;M4=YM,\ '7*8J?-[SJF.)CU!]K'X30'^TO%[@Y9)T9_/@+,_3Y0=+7]^
MS'R<=2TPZ R?0ZK+9U;,HMGZ5OF=F9_ADX@6OB2E/W3$X+C6[I;6]H4B%<26
MGAT/9'N9RGP6DJB6#2MUFNG(:#+D[WO;HKKV<><;O@"2[#)&IW[+8WJ'!OD@
MKJ=NW1Q::8([B%$\:-8H-G7I;1-!,2Y=LD6*ZC$K#=[R0C>0CB10[/NRE5Q
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MT-?E 1<Y)JY97D+(2]$.S8^<FC0W=-IGC<6B-M[:\[3/=&U,0C\5Q%JRUB-
M9^U6+4 V^SE%3^=!#\E?3R,7=)PVX3[WGL=:,*N)WB<CJ1GZV/,7F?I@V3[W
M-"V4P$^E\!A'_N7-/<GNIR6U;LQ%%"+<O 8\L- P'<Q3O_X,M!!;^_#6$ST&
MU><FQ#%9PX4QRI"=$.=7V(ZNC:@>)$I4C+H2?>^/&(E]!Y.TS.&UD]1NR<:Q
MM)0X]B_!6^G1X.G1/<U7OR)QO[%B [0\XU-ZRB7%[A41228MTQO/@$BIFN(6
M2&-72Y*F6<RUDN<(8),K]&>XF9_.$%*1COG-\E2+_T)T2!\"_KJA4V_#-LD@
M'-R_OVV>5?W#WIM_E"+:DY4M 8ZAE]_RNCJ$+M"VH.\)Y4^@AHVK:SGV0(9A
M[(L&]+KG*LET],AB\ )/(#TJT7!3M=,V*[G3X3YXEB-J0):3AO5-]=TS^02;
M$_89S"8?34C"1\H8&&DEC%QE6=QK^"-IT[?(9!JY$\J<Q!/305+0FKP JB5U
M$.07?5N 0[)DBN2Z*ZB?(S<17TR487&;\2U'N/L0L ^B#<,PB9-K;YV]Q Z(
M\5KRN\)5.ZY5KS*L=&=TMD&7_(5(2)R!N"^PD.#K:I*O<Y<!:YPIO8>:V<Z^
M-<]L1/&PX:15M[?3DTT8.9[/-DE_D/ T.I&QKZ9T@OB--2V(B ?E&+\6HA&F
MJH-G9;\WL$5E"#\2\>#UPT"&=@3 HPY[VQ['OU)BSE8=07Y46:X$012G^G=)
MWA);KZZQB8XDN1NWN0X_:IA$B7%VL)'DAUQ'SO=I:EL'!(AU5%AT>Y_7?VS7
MR]W>B1(3(L^RW[H.:LJ_UV^A3&C@.N=7<Q;\)CTI;:LR/F#E84B%'-57AWJ1
M[P0C/[IQ* 3'*<U--/MZ"N?0J]>K1@!!9J$DMJD_I?^X\;L1*GGXWQS+!'-Z
M=8:HG#UX@*UK:JSS@3G5S43?JIA:6<O)L4985S6\9'C>+-@$P)MV.O2> 9@G
MZ1L;(56J?VZQA/Y%B> [NU T'H%:4!S7MU/^Z-B+A!R>B+V61C]L0Z\N<S(E
M21..<CWBJ:W9!?NH@Y98XD\-83]; !&A'AVQ!]#3R+N"N [/3;%:;Y;&LSE$
MG6NC_)=QB=[6KAO]?M D]5:\IZ&D%+RS0VE+9(K^;.< -NC'7,!U4)7X-EMH
M]'0@V%AVT:)/WC/IZZMM!\3&%A4=N;.PBM*,:U6UJ[?^^><EQ2%L8]"*UBGG
M1K?_\H?M9'Z^;%]0;4=>[;E2W.FBX<+[AIFC'3C3Z)*))+^\'50E!<?M6U,1
M\?D/U+SOWBSY<U.]9V3S"T930A1"?O-;&K%]K#=]535<&08OC\NPOR/ K/$*
MGA.^$3:Z^QS]&8I]S#W-XI"'&EH5!]I+WAOA^^E![/M-:U/:W-,TNWGXOAO_
M=U%-R<:]H$@#3$G2L*TBV\S&S?TU^UL4ZO@3N^L5-2NYF\OF7S/PI)Y+N$M[
M0-!CLU0Z]'BE^FJP4+:VR\P;%BDF!@CEYYOUKAJM76Q4ZVR< ;D(:52 CBX/
M<84R/R;Q<45^I_NXZC19BL[!+ .+V9BY5)F59+]NB^H$N?J6FBF %SCHU54?
MMQB9DN.)Y(ON#0>L((296K,.(;@6IN8F*O:FJ^?*G[/*6L'B@M;AX3D1I*,<
M>&A<&2]DD/ 9D))2]H VOP5_@,6WW9=T%=B4]998QH%_T^I:##*ZTOK=LNBU
M;+%\7X^=.3L]FBI"N.K/N'[,GS\'.AZGFM1"VOWV?"(D3,4HB D97L,DW"$7
MQD]DC]^AK2\L;!9B%I#G<K2D D3K7/UKJ5;6(=<ZYB=+-IOJ4U#B3Q?3$53M
MJ+T1)Q&"I^1;!>1AIS+Q1B+QV17-5AX+HW*[=>/M'.[BT.=:S/GY@#_#TQ'D
MO5EN.L*QE/4V6[EU>KTUG3%&OB+1"'4($SM92O3-A7E>=P^N61_L)'*5&HXV
MX-/MU-8QRUU3J&:L+4AEE\S&(&VSGD[-MC],:B/W6'0J:>+K2I:V8>#5WA(U
M,7<"Y6&%3+KN):\K+AGH\RYCVX:%39)$'S,$H5?Z7_QS_/3-S-34M'CB_+%^
M)UN,]%IQ^ -OTVL%:H#[!#*T2NIDO.(98)_WRH)B?VCO&#/3)S,9^]#QA,$H
M')\%G\IM(].=(5&;8M X[3H8*I*M_\>9UVFWW]IH!E(98**\P*U#R\M'11RE
MC(,Y6<'R5L8Q2'EK@$S<HC9RC_(SO#E*0N,^"HK% %WG-"E<:23+PG!D%!7%
MB)T[6QO>V*1Q58" B.^%9_3TL;W]O/2\RL!LY"?7&E'O"#O-DN6SA8@?7Q$%
MCYF"5AI[/2M'27".5I4+/F745?!JD%TE>/S<&U]6!1 5A7)XR(2';PU4;])H
M6V0_ PPS7G]/56HV+F(]^Q**B37T!^O 0^T?+WMTW#/ L5.B5YJM9<I;BML;
MZ+=M4IKX?HF> (L^C>(9D!'?QRO3N;R RW),N,41MS_8%6WMDO)M"^ATHO&+
M63S.C-\%$YV7EZI^#Z-$=.4@^L!_H."5Z9K264)-3M6H=3G8>>UHOGD(-=.?
M(E*S%?_U&Y0C%7?SE;VCX\>238JK@&["T0!/D@7^XDP?@K&]B;!"VX^+:.@>
M!*S4'R)ZJ3"V;,E"<!_D-N,>V38*%-NS^S;[L 9^[*DI?F#\;,0^F+G[QD8R
MD2.N[;%<*"=(?4&>%N +-UN>=!7^Y@V.=/_43(X4N<3;\T/R X&*OT5(S8^9
MNW^?6(Y6/B7W$\PK:E /&3_$86X)O\C]2I0VI,__L/1:<O4SZ!HM4TK,K.1L
MI*I_CNULY'.QH[7*VQ,C,?:X)B/SQ2>*[T686T;?ZP.E&>:X'>+Z=4P1?KM3
M1=#<E:@"D=3(#X?-U($K,NTGO!DA39I'=[Y+Q8@ 3YJROPMZ_*655"&%?KOD
M:51(RU046NM7),[D"W<'WA=/8]GZ=S,''BNP5?..9LX0B&"Y2WCQ JY;KV+6
MJ][5=R)%'R)B#R39SE+QL1$C>U:QMYZ"'@,@$(AHCFEUQ/<=0]_("/FK03E
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M+XSZAD 6!F7P$)82.7$),J:M<Y(RP*I^H<Y8><&Y@&YF9= $:8\NGOG/B 4
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M[*3BA],S .;KOS*>/A>'1J1:'6BEGO$Q$;O) [&UD VTZA%NO0[V5 I4VRB
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MK*,#NUS<*?K\P,M'4)B<9+]FL.)?%E<7[?A"7A.RY \=FXO=J!M,0%%$>09
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MIC*UP5KY6]G+<3)&:53@?5(3JZ@IH_?"$R#+Z'P/3'880#>5_FDR-U:UB:?
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M..(ZRH]AO5SWL^+<!I0BK<RUQG1(WX%@Q-021_6^R7A1:3=IU&1:DFA3X@E
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MU.O\*GJJUBD9J,.)A^H-AJ8^<XU1[1"YM?$ C=0(4P8REE!HVM"/'?%01I&
MY\ULF+G +_W1LOY,ZRZ_GI"NHQ0/L?I!M90F"#V"\R]GH Q&L)(UW;Q5TQ/
M]B]-1G8(U)CB:))3G+G+L/&O^K.BU.U>J'-YTK>\0-G#M*-[(@\KZ1_5^\.<
MGE5*$YQN]?I\]U+*E.-R \5;*-\\9:ZZ+-4\PT:/-]M>7P%DU=-^I?U0X%X
M0RWB@J37N@QC2O!,H'['6KIH'H!=14J<1WD4:3!W'PUGN*M] APEYY0_ 09(
M/C\!*KUE+DCT;_^%FMG^;R%9Q<'I_];Z])7IH+'7.YC:/%6*R/[-=CM7IIM]
M3UPMW$9P_LOB6* E[O=-8$[E.T&TY T9LKVVEU./JQ4'$!]Y")(!SF.ME[?D
M0S#R;K#L%*6?170G/\* 2-PW\2BO7+2).TXXB<2W&37+HJ#=0D9VHD81LTZ1
MU*;A1Q:^VF'=1K73)\3'JLS5'^Y2^4(2%=$E=<>SB=HM6QW[>TR)8(9FQ4\
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M3G[8QCQ7"<UTDVL./E>;=E^TB9S]\(NEQXZ)_PF 9V]%A^4RIKRFI[Y0U)L
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MQ!AVAD/Q0P\2MA>0J.NJ$ZEW\)W5$:^=5;(Q,,>@A6\_G3F:E,#05SVV3<<
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MG8L_(T^]DJ4!GM?=>$]UTMSI-;$+@2T!?K/LCW%9-Z1-<U<FE6RV_P-&)D4
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MWP/#,K(;9_.;(N78"RM<TG%YQ- 81FU$S5R'*U0EX"+]P#/LCMW)"+<'I!>
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M8 ?K)_2,(X ?0C>OTA6U&/<HTG3!;GL =I6N>XKGXBFPPK?>Z>OX7485:1F
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MJON,8GT5$G2E/4L#')JU>9Z(!RXMQY_D1\6%TNXZ)G8ZK+?/MLN=_QA4V>H
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MWF/>D6NLNF-7C)C];IT0PP./=9865)XX'G7\Q_6';^N/"%8X_Q-\\2C[M+Y
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M=9D%ZP'(*Z_=T5+GB AH4U;[:W3)^RL#U\3;GDK-0'8,ZL?]>(/&M&MCM>/
M#$.Z=X0XT:50U[-,J5#FU9J33L7/02WOI2^Y,OJG">5TN94^_G"6E;%_V]=+
MGV]D;JZ0^F\V.EZ* _<D\1W@^$HNO%+,<:]<ZM?IMYI6AA9!UTQ[O(1SZO4B
MM=?TJ!/+"1A#J"Q> $4?MP6](1]9GM4FP ==(P6* P^]!IUMREP'S2(4/E:
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M]'IF6GW,IU/=ID<ZVWO# QL:G8]MP8;*$=B?O9\/MNJ7Y[%U!$\B0%,[GPB
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M<-L..CW2DQ@;,/%HU);. L^&WH%J8^<:3U5<N+2B*MW]BMN_Q$A@H%_:7_J
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MR@RJ*QNX^19M<G*97-OM6,DY*FFY@N]!V8+X\(?+>YW^ ZZ^'9MEN[P5<D0
M/09$,V)V]I':YDR<6J;HX['%T1E]32@#5 /OE(^W?+#G9\NK9 F.X;/V& O=
MK+SZ$B+ *UJX)82S;7>0QJO6!,DU@V'^7XMWWSY_1M8R-X%+8 63D)LA?91F
M,MX-COD>FV=63A-X\6%$ -5P#]*_;J3Z2^>TD_IX\492?HAS^88:V?DU2/I
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MS9;.1]"J6.8%(B#)T;0856[.<D#-V.730ZZGU8,4R+6.?#;>G$J ]9[('S[
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M-_;_&!*AE;CVB<; (P76XI([_3E[)U.8=#*2". 3.L/8F+_/@?7$$ &0R30
MBXG6WXC5P(H(>.,[CP6>73%'YI?!>A4]\?3G$<*DZ+.1_?S/H ;5M]4 $RV6
M_V/(E,M&\RY'^NP?QJ!5JZ<V+_. O/Q/2RB5U[A(PLSGN'+1_[1'=9Z<=O._
M\!WMR]S'UZJS7 529H2I7M3WJ:R2U9:!F#?D@LS3!^KO\7E>&6Y?9/#*7"2P
M*V=FQ C6?9F\,2[.O\>$MK9CS32<90PF7\O,.[UG.V>,73&!D'$\3OK^1@P
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MC YH,>C]#R7U 54$RMSZ1RFKERQ3-JCF:52O=91>G<X!)UYK,#EZDEUU2N:
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MQ0:L-2GFR]8L#3*P(]+@?=N) /;\^7G3P!I?I]'T%>>EY_$GU7.B!]E=<)H
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MPC$ML)5W_LC?.(J2?VIQ;[.JTBKZ62K%<^OW$A_\_]P\NV**3"_U1;%,6ZK
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MFSURHH#,!$7S2EADF!PM"1TL^.6)J\]B)MF^R NR6LOJ?N;>D)?YI?;__AC
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M0K5(8/V[9@GHR;V[:<4>8JE=_7% 1(771D?8W_?]@;SI'NOJLRJ#_5I)INE
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M7@B#BZ?QL=.0 =[D@S7$>==GHQ89*NKR)QF'HQ?;K]--L)"6HD.C2T 'FY3
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MD6*_M\]S'IVA532O#<EQ^MN)XFX>?R[:\G(S-C7LDKI/(?*AA2DO'\\L]Z?
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M<_$3'*F>Z@[7QLRVI%@%76Z^H4E+?-D0F=) XT>5S]"IRL"KS+,+O#CB@:5
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M76LK%]VH_YH0U&SCVP I/ 1#ESB[7OOIK0I3-!/59;J+O3HN./'V)*_W[E/
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M]$X&1^E8C^D_8?QW;="\JMS=Z3O(JO_'FO:S(P:Z_KN*!A(:YU5EN?E&*,B
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MN-DM]*[5&^(P[M91Y(.M+ECC0+R?9\&(9'U37_0GO#0*6E'>AB1C!0CU<V0
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MJ@<=?*S\2!\IMQK+?CZZN)I+F0OZ2W =1P8TA68JL3(3O8]_9(8+?ET\\YW
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M?Z%:D49Q3  MZ9>^/80!Y@[AQ)BMO=G#>]"T+P0?'2Q5!C#[7<,Y5\\WAK&
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M29<4PKSVT'V]6P3O9#YRE!!^!PD_.FOR[P#^DU!N;8_ODC3V0/M'TKM,AF1
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M4F7&2;P,9 E_'*.OIO[M*_@?OVE8&KH^^"H2JJ]?WEEOJ3XRK/-+NRL>0 ;
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M3IMWG$77K2VDTT:&@PB_AHV5MCR >ME"-P_OJ_;6!IK#=[RYK"?0?;]%:7,
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MU\HO/VFZ6]H8&YO!BK1XGRXQ<H#P>"]""VPJ:3T%L-$N4Y+;4C::"R@FOI+
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M]3Q3M/_$3>,I:;G<W!!K1;X8Z^(AMRO/RI6HVN[D*B#S1/4P2]*TP7)K!D\
M87=_VC__/B6+_V(H@OW;U1C1]7!'2/L@(\1S7Y_R4+>NZM[;IG G_P]3?5?2
M0#TSZ,]@FO14J;2EG>2-&>'GS]]__73>72XNDS;3D/%Y-ZQ)(9?*1;8/7T<9
M'_.M>-Z$_Q#PF8OU^4?K;I_]U\VC/3GBM-^\-S9CX>1LB#>_[Z:KFFP,92U
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MN1K+2,G0P<3L]QF_6[#%^[\QUAN(ZV+ED"OI8U-XM/$[2T/V1I9 W-H/[@'
M&]"@#^(ST 'L@12W,B39A&1B);7]\OF8;_;7WO!;JTY_:-0$RE_]!']C!=&C
M1)>OBB=(=!.9Z*/,Q<[SO?]H?V%GO,X1%\P][32#>[7DQ\LAT9>4@EE>&<S>
M*$>NW?!V$HWA'K+[,0&@]_8O($=!#I+-O;Y$HR=K?ILOTDBOOUH4KG2GNU@>
M!&+L/:%Z^F-4_:*9F=["ER,U&;<)32X;-*',78Y1RL-]*,5[5N"92<LP%<@/
M4BK599[KD^A=[)HR"E'L_#3#%DZ;!W+1-/TJ)G1/#D\!\R744X!PTM9FF+^
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M5]4:Z=V,<J)2#TI6:1S;JKS>+4]XY*LP'GEVZW8YXYM09X\#(06XP4G%!DT
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MGIM,<H0%S9DDO(7AG<(O3 N/5<=6F]Y?,*2-['+$JPC-V83=Z2??+SH)RE<
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M4<4H[=,W6-(0$(M2\;'6;"/>&I+'3#/)<Z?;WO?]@RK2O5R'ZW;U\&RX%"*
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M$ZJZ_# MM9W*OE"&D]*)(^KAY[&L,<L<,2S:.B8G^2';EWYSN/4?2G?JQEM
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MZ*'WW@(D+^Q][CGJO=M]SAUOO/$6,,8:K/7/?Y;O^^;\!P$S@ID&7)>6D)(
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M'=4??-FOP=8Z$YAJKK@V@ZT9,5CY&#9I@0'\['CR+VDP5I0L#-W)+Q.!RR]
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M+,BC2_M?E!QLC[7#-4?V&6XCX=3?4"Y%O>N]"_[FLA63S]WOS]Y.W$_*6A)
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M$XIDL$\7A0.=8\JOKN3-?L>NI<8 OF(?G7 J;J]OE(*9O)8!_E 7IGX&5NN
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M%Q^8+]XD,!/4MOAPQ"89;"3USL["T\!7OL*Z82_S5.SSDB=+HDO^*6$^QX)
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M)IO>:H F,S2EYP 3CRE;]=A>9BW;OC0X5*3OB:;[</:>4C]PW6;Z%@5G?W]
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M.U9/-"ML>#Q4#.)&%$.O:TU,:4B*%J_MN#BQ/0>R7A7<[0MQ&;,^L-\P-<<
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MDNA_2/W]=BS^8@Q(]\ZV@82^" 'SLL_AX8>*3@S.);CI71UIC'DOBP5 &+
MO^31YG<(WONL4"P J>).C2-^1<A4,Q8PFX$%>!K/Q!]=8D$?0S#W@BVN(4C_
M\V;9I%,S6(#W6..!??,+I?.CR3['0W5O)MSW\7/47*BO]VAB ;\:\HNA]*.W
MUYE>*_Q?-%2FLYGI\N;<TQ97VVN4)9V44B$5>X(O W0^49KW00:4C@3W.Q>?
MMI@Z7Z,3_:2 $:^8[+VK0.<\R(^B[2[T^3 ,!H@%D$N7^+A04Y&IX(2Q PEQ
ME1\;< M'N_!7_]CLZM]NIK3/[8UA\&^\R5]AVI;?5D3YA'TF/R'@>*#\5_,&
M[_R]>%U'_7WI_]!,V7=Z"J=/S?;Q#2W3=HZ<G?,=[$O>MR#D](,"92[4.@VV
M_[/F_Q,%9KMP"A3U33OR+?A&+_+=-73_M"-V@I=8ZKO60NP0#'F\%V29+/X
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M'\$T1@5L6U5L-)&=^:5&?;?K@4VZF_AA[+ +EO&Y8%K,I5C !]E,&O9[S37
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M :3;ZLK%;EY;U3;X"Q"N92.^=P.^IW$OT(F;(.=+E!%^4.<6Q!YS)O-FSU\
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M_N'QRM_[MJ$[O/%_'S!P?U[P7U!+ P04    " "!.*E:93MI*9\%  "W&0
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M\Q6Y4#DMGCG-"/RMN!;IL]"NKL1?'$2#>X9?&Y=*L03A:&O8^!_ ',&7WWY
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M"=:F?3H=C%YL&*89\^PCD>9WCZ']V>1O4$L#!!0    ( ($XJ5H%\D!;IP4
M ,T9   7    <&QX+3(P,C4P,S,Q>&5X,S)D,BYH=&WM66UOVS80_BNW%&L3
M0+)E.PY<R0V0> YJH&FR5!GZE1(IBR@EJA05Q_OU.U*2([O-MF;-$A0M:L?F
MR[T^]_ H3W]QW7F>DCQF%-Z&Y^^ RKC*6*XA5HQH'%UQG4(HBX+D<,Z4XD+
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MOUH49,G<NE,E"=Y=?'(C.6W2/IGTAH<;LJG'//MTI/XUI&]_3/D+4$L#!!0
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M.J%(1\X0?EI58=(2A0;O>-HR5K[2 8O520F]Q^7WJ?JLIL(EDO-JRTM0?';
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M6/NX)]WW)PUY6RP34F#A2QR+0UBCH='/9;/'XD'*2'2/N*JBM,5XEV.XCE6
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M%LHWFP@W;8N(=85@HO.+8/>$/.#VW2]ITWAH+FK;(DM6Y35K6A* ]0T3HIW
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MRSO)_7#&U/\$7*5==FBPU F#5/D12I%78A[WOD%O:^SU0P*$>1RVA94-S_#
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M=T4"74-?D4"&0*9:)&\XEZ+C:AN=Q37(F<"DY<%(A:!.&<#>*_#"R#TE J<
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MO3/RZM+<&X88;H9SY8L?]#!J?6P556-ZOQ)/3K,/!8VQZI 3"LRV5D%B^Q#
M>X0 'NQ# /L0P%\F!#"BQY(]*TZ>/C2,(5'.(Y%="9QMF"8;85?+S/BF*T7Q
MS*QOF2_669(OVLH9K51R@'M![;8K]+#%)O(;^]>C^!1E+0D+O?(=!:*T73CF
M>W.%%2"TR^(RJP1\<%M;%/3$?@V3&4%SFQ!5OV$.+.9KDDT)@3_:[MKEZ9:Z
M+55["]WGH6^?@B'->O4&?6C6+19DZ965:G.&HFB(ZV_,\/?;<;2F.=Z0F&='
M*# -.N2%P^@-A!B&5!1"E@=$>'[W:JLX5L+Y$VJP6^[2SCG[:-O" E9L@%]G
M#-_SS[:LVJ6J2/OT[=U.WS[>G?3M7_)WN']>,Z7F<Q"$^Z1LFY1-V\Z+I&X.
M<NC,WX)XF?5TRNE-F!1B-'.YI[A[;7S8OT8]@M-$OGW'OJRQ%DL=[7T-7'PG
M\X&F=A6$FGRY,VQYB(8:JVZDY6IM]K,XM-?T Z,3+JGC^_N4C.-3=#3R8QB1
M@@(5]LXLRF[W2,"LZUQW2#."%WOI>OMU'5U5=VWHAAHK*\P%A+4RDG[BUD;S
MVEQ\K^0B%O[SZP0OEOB]7M0-.)IBPHBR/XI.-K".>Y9>-UWO.U?.)=<]#:$2
M\<S%#SWQI3^W:P\+%B(>(E:7EV&^D;)WF;I'^ 03IMPMM\3DHTM'48(\()T=
MKEHAR?@D\KJI\DGKDA46B[*Q/Y'R2F6O\&3X0E=\R_PFU/8(NTY(7:WY56N6
MC")X=;?&@CNR^EF8G+%(KF?M0MRLNRJ\UXOH2<:^0BNB0]<3UQZG(:X3P[<4
MMK/2%,_3R;V5# TF9&#::?AU=[H\)!VOW*;\V*>\IXEM>^P#A],&<QSL6=CG
M2=T3!H,'^^3UF_/3W\ZB\_-S]4YL%"!]#X?X=TB/[?@Z)M5/S\]?GYV^>?GZ
M8F^H[+ZA\O!HA^R4%YQ>B#+J3<88SY>4X3UFK7QR*DSH%#J7?-ZCA^);]@!T
M]<#-TS8LIJ]!LCF8Q( X<K*-E=8>X@+56".G1ALZBOZAOB'.1C!/<Y[ZD"+,
M'<?(D(EE,NY'[W:GS4N20V)8'N$.]9OGH4M"^#(@BA,\"3#7(,]V"T/AA*!0
MS%I75\#%Y58@B5:+MDH()$9JLRRD*[0F@5H!Q#@$]N1&@-!)CWFBQQ6@24R4
MOT_KV^6@DDO5YDRE?KN=27>[(Z&4?R9CP"!KOF!'*4S1D"/./9%7GK703$K:
MFCB[P>IE8)/X0U1D4D]IHW]]'XKJAJ(>[D-1^U#4^X:B/O8PNG33DU"&H:$1
M.QMARL6CUUZL1$+BO.].D R0& J,08@&#9:S+ED0PB:CHJ!)S19BD1,6!1T:
M:$;F(0]+3_R"7%@XQW[2..-&(DDP3T56!5=KLZF0SIZ[]2O0J1_LCD[]"C-V
M1MW]GYU+'K5I2B(:Y [Q>I$X;U+F2;)U-K0^5.'HET 7:F[&:GQYQ6N]*KT_
M5KM_K![NSK'Z>S)%&HWQ0-IG/UFN1\S4DUV#$HWD*8&^/L]7M< 9\,XBRS.H
M.JY0_[:9EQ5T(QVT?>7"G.5ZW! C^2?\H'%I5_YA @?DA=@'8%<NL*SXY=R$
M?A*);<=BT"28'(B^NJ7D^?C,"K):T(9QP(&Z=#=WWQI1GVT+QLB*P M2YU[[
MV8BC(< B@ &/X&$JNN)DTA5.<&,LF,1PKLN;G=:QSH8YX::F-ZY^T1H7@>>8
MS][E=>.D&I$*"D18$CR2VAF-*:S['#& R_(*.: JXHZZ#,'. ?=%/J"^(&)D
M4P03V3O(H6!H2AV'C4Y AY%(VW*@:6+]^<)Y& ^/'NV2!R'Z[]=^Q6K1!&DU
MI0K!)%N4UX<^S[@9\5/1\7,.*HT/L(MJ?P]^E??@H]VY!T<WZ1Y@XA*BC:B5
M3%*<,Q6LZO 5R@,YH'DHL4?3K>(QV!T]&FN4U*?9&I)<OFM)>E1ED4^9]&Z9
M4\'"6)-N@TZ0T3N[<?P#>>,R>YDK#D.\9!YC%F8^;1=(%)IC8B:%+2D*O&H,
M2_\*R1@0N+G&R\V11L8"4@<D;1<#CIS9T/0NS* [V[[H'T3J4! BE,*@74>G
M+)TC(AVXN3OS,&L;?"G'>6^C)ODKLR%M!-F^2;^H2^D&7JQ!5H!=+ :DHL.7
M^G,86Q6%:1S@5ZC!\<2J2@*M7:DFR9N+_,*,2N*-B"DOP@QXC9WN;910W?#*
M#&;H^OD9T>6F.-KBTZMRJIA]D"YW9W$A)^NUPL#QE8WXO3A-BNFT/*XGZ8I+
MRK:'2T4C97I "*Y,D'.T)QIU#0Y:(Z,H$0_2&XYY*"DGPH>ZO3+!FZ'7C#CY
M.-BVT<FW#YWOOA[VW>[H85H:;J]VF03@ :KT3>8V\0OG2] @<L[W9?^_22FP
M9UQ8#,(T U4W\,:Y1AD7P%<57AFH0/@H-%^VQ$,HX7BKU&F"@</ OK"XU,'B
M3)M&ZM)88T]^$E8@U>D8P+VQK*07H3"N6/=WI,G*P<+0.,]ES9XCALHMB#@V
M4[AO[D"6^U#N;4*YC_:AW'TH]RO+*OR">NN9 S2)]DGBW9/2>3VTHJ(GE<K$
M>OO;@_4^P\#/]DL_WG4DE56V>@E*SF11E^X]XC^@VR-6^BRC#V,[?Q1$A4PT
M"C4Q0SBX]N ]$[Z^TD>4%4DXKB.A5D^-U_!NV4&N!L=%B +8M("=M2/?#]Z<
MHBT,KB$M'C4%)_<:G>MH=6/N@YI9FQ<2TT9<:8=**+36N(U<BWDVB\Y<O1U&
M8U8N3%/T_1AW;BLXXL-_R"$)B_ITEEA.C@H7TKRVWT+&R:5UDWCYJ#:&%C'Q
MI$(5\5C3:H+&=EDE2\IC2*9U#JN1!0X_4R) ^%5'/(.>0?71DPAV:16D;($=
M6W73=F+;$P:F<G61I028N+GC!_>W:X\*B3O=]R9(,8;)X:0HZ^D,7*W<-JK?
M3K6W^KOZ,Z45V>9N3O%O7&8F46&(4+.WU[\*>_W[W;'7_S?%NVG#_9VH=?>&
MNW,M"AA@HQPD@H7:L3B%'K_L'7$U#01$QT#W _1()DL"V]ACW-=@W'_,Q[OU
MS4_0\_PG7IKUKD]3D]#!0W#?#65^=J )K@*4;B#BF\UJ2WF$2O[Z.(S^@O1M
M3@X=V"P>Y4Y_RIX21PD!WSOVP_ANCIVVIYH#C8)&3K</^X66@CRU]^!=T[5L
M^(%4G<W^+H=/<;LB=VL<DRZFA,CLPW+.*J-K68LI<<D96VPB1W2+##DSJ@_2
M\.\[%,*P\^.N=>@H4D_Q$J28)[WWO)@&1<,<=:M&>[>++=R933.U@?AEIA?"
MV&%D,DZI:R55X!OE9$"AP)%ML.P;OC/<)IS<2-58^#W<35(.AE3OU5RBRGRV
ML>6VT"@V[H/54M1CUX+L6J13$E)*_V()[5K5=0K28HYI/70NZ#7LV#6_8JQ8
MT&%Q^R9%W4]EXTW,A75'_-!W;2^E-KH0U CLF"+K-]C([I*+3<UZ1[W$)YMB
M"5<4-UVDL4F0KJ,KN&4I;T&0E?,D#5D7*(3-G@<R>O1RFA+Y0N&(&XAMM'][
M,AMD'&4Y._3'3:A8]E]7($HF.[4FK)&$@7&N)3*WZ.AI72ALWGF<L' RZ#,N
MLF M2RYW7#'240S%O&B1Z4FF]B@Z49P#OZ>.M67F8)&?!ZF9N 0]%FY-:Z^Y
M6C$5YUA9"U5>W#%8]_;AUV ?/MX=^_"$^_0/T0Q_=_OHB^5!_\&:C*V-AT0=
M-H'XTRLO# \1+F.G0'&)39*FRMB,(*5B +L\HB6NN?35J\0MJJJ>> FTSS^]
M==#RNWW0<A^TW-7\TYQ=]&PIK//&L]#@>HXJ-6+6PB0;@T5'[+48)IJY!0C7
M03/,\_)/ZL"8C[ZL@K\Y*:.CTQA=A9B_LW1#^*&L_$"/H@OL%C09 $;05$A<
MJ8X\5(JP#YC1@X3L0F.0C)7UL"/;KJW.#_:9#%^!QO5D=S2N7S))G;-E@G8F
MN\\XM(K4RB9W(+5*%=.LJ51R(R'B0%!P8O52YJZ(=FW$3)7ERTE;U>QN)&;=
M=]B&H =<XM\[5KM"W]A6G#7[8[G[Q_*'W3F6IVY_[R-DAXYE;30.]<U/+\E%
MXZ?M*06-WHQB4N)^="-&ATB9%TU'N:F-"/ &%[NO11_P_DW]!;>TCIO5)EPP
M!R 3!)#W,JOH]J?/4Y M82>PR$653WSK5@15YJ^:<Z&=_\CK,7?-A3G9:A<A
M_YK?.2CDZ;8Q%P\[B]TZ;PK6<LZ.)VWT!%=#-%'CK<U XI?7/DM.]A=>5\\B
M'QK]A'%/%XBD-%SE1;WQ_G.NY>=2N<;XKE"#=:>#BQ@,N8L[;+2FHA49'Q/-
M @?Q\(7)V,S]L5N!:B\,A8V-8KL&$^3H#TBED7^'"=5VYQLG$>I20I$LM3XQ
M2U_+))HG;0";]DQ1FF9Z@ 8?_&ZN2WTY;Q+Y8YZONIV1X!8WYKO5/W-YQ0P!
ME.T'$K*@U%"3L\=1^'5(5#-[RLW$E3TD64MH);1N4+^76AMJE"67(A/6(:<I
MBLIJ04FSPG-@>FY(#[JT%H/+R9Y+9]:.WY3P-GY--I(CBM[,18/U.)LLV#!V
M&#%E<K*NKID?-UQ;DV *(.E=?J&;JT$_YMV]PZ9;W6&:$\7WF/BOUUY2/1SX
M. Q\4,79L=*BNRZ(.\!Y#2XWM%T=9I;/5=4%8JP)KPIFL^>9(^YKC]!5!S_6
M&:)$7V+9=S!:#Q7H-@2B>]96C:ELJ _U=@NQ5,( I6G'*/=L$/;;[W47-;YE
M9D&WJ+GQE-D]JAOE^.C!%\>W,3Q]QR!N+W_YY?STC %N$6^79Y*YYW(O!*GA
M=I&[);9B]NTL-^_>D7P+O5(<8(!\0;Q!?"I  %?&NP;YWT=WL]#)A]AU5\;1
M76'=;HZ!VSU)@]'F>?./Y$,K:.Z22[TC\J77F2U\\:,=VAI=WT65#Q \AOK(
M5G#SCP@RCTYZB+-!GJZ.YM%9NA[,9Y]V^1X1S._W$<Q]!/,K2[L<+^;H,%\J
MC VT#<6(@F)C9[4ETT'</7&M*&@L-%K6 7&](FC:_K1^NIX:L4/%.?[^R6IS
ML#ZS+\WQ-81A'NU2:8Z7RO/PW&FW.Q,;18^-XZ$8L(4\4C9ZA9ZBE*'_AA2-
M.7[>5,P05JUU E$.ML9'DC4YM$DTI?39S*7/EIH^RU_,\@)YMIP=AWFUQJ_T
M=_CHGNLPQ5_1.XBF6RT]S[/@XT8'8".Z')$)>#K@]D?@*P%!N@$7'V,9!X'@
M-ZYC,KU(N\8X6C!/R456>8H1GE N)":3!&(_#U19&JYOM@[ ($WGYWEER[2V
M76CB-IZ"]8M<$SR9ZUWYTL#$&T4U=.U"R0#\%-<V(-"=&%#C,6VZR!133\5B
MD><,;TNOQ7-S@QM:;E9L0Y*1:/R.&V_!U8_G<#40(A+M!S)%-52'(Z^3!6T@
M6G47MG-X@=ZHUATL5WR1?*[6S#/&\'J?C?5C*VI[#Q78_3MJAZCNWV0%4BWB
M?G[.4JS4 E+C#/AWQF>^'7K@;QF<VF3!+G-,FG#GOT_(N#6QYN:J/]N0+;ID
M.BS.03DL1 I(\I2=A]+7+FM@AVAU[#HXMP)/G2?:))-7UDH"'H:\A"=3PE,]
M<O0U[J:YS^1:#WSWLI8\-U7+=4H<J $[\S8O4LD]@TTU;3#L1L8WN;27JT7)
MI3=[22T,=+M;(:3M8!!>CC1K"5;,NGK4Q%:/1P<,;*TH)Y05CL)M.Q=:.N3(
M16@OKUA9H@V^Z+LX.Y7 QL*MK YLUUEYKP7E2-5641OA+1['PU^I<KDA]N:#
MJSVO^9W;G-O%-_WF=%JSWWQ=_5Q\*R,FR:"666#U%:D',:D5T[#N(,0&Q7W;
MS3GRW)"ZV/I0[G;;UL5F?*B64AJ= XK/0'?.]OO\<Z73;KG/.R:QW^T]6WG8
M9G1&9ZQ67JOQ(EEJ LH$0M]OBNY9(*Q&PNZW_M.<L<L\7:%>T6E5E0K>@^%(
M/LU&'#7A-^[,?9#H-D&BQ_L@T3Y(])4%B3[_)9#=\A)P;ELO_KTGER49!\^W
MTCLH+R8OKM!3%F\P80D6-,#;X)4>J7E/?9@V F(RN74*.5(G&26S19.R?#N@
M@6FI9C$H.]EN3,7 "71A(B!EOT5#\X) #,>OD!.^!!_&^TN-PDWYUPZ*LD&=
M&WEN9&;1?#WM3JR F-"\Y3X/#^JS:VD=79&0H?1S1G+VO/3$S+B5KA&4:=FH
M:[BG326-H;?OF YQ9P3;[):"S<6?O&!S'\GTOLVR%:7A8JT+P?:]14)C7 L4
M(XSZF4Y!EVB&C#KB_T',$/'$B'A:D<\,_?6A+*-2<W3^E\R4HJ7E-6Z5S&9@
M?@W&!G*)GKC<W@0?0UA74@?45UON+SYU;CYZ>1%!<&DPC\([&JFO+8BL]$;E
MU QT+SX)<&Y:Q'$-AEXZO>@<+0<AUI.%=T59+*B^(I\2[FVN 3EK+W_Q\[FM
M7'-AQJWEFI^P;>2:6>0!N=:,3/Y?1J[M,#+ETP%3SO[S[/2/-^<O7T0O?XE.
M7[Y^]?+UR9NSZ/S%Q9O7?_Q^]N+-11R=O'B.C_[]Y9OS%W_#YR[@-Z_/WYR?
M740O__'B['GT\W]%;WX]<[^'YO9 E]T/(GZW2T 7(3MG=^*I8_TZIZ +78/[
M2*(EP1L!4("<Q^K<\%+40G$Z'29#P-"@A+")X44K&1+T[[+RH;?2HU=B3Z&H
M/E_]%Q:K*\6QG0E06Q<O=XM'%TXYI7\SXU3)1'3VG@<3*5EFCNIID8-9(@99
MQN4CN*Q/OVJ$H_)TZ)O,;Z=*QH:A4N>3GV"*'!@XA,+?Q^1D8_6XQ@)HRS;H
MGH#PMT^U.J/S[R*E0ZI>C*N*]#FX%\'^1*A5"G8\/UN!^A@C_*>Y3"X#$$V&
M.Z$0Y X.>0+F,S'*#KW#@F_ZV[6V^[4V]G"X7>LL67!34\^VQFD;\Z22?Z&!
M'I779M:"CK@=*4<(&2:YQB0Z%XH4YG2+2A/;!C-]:1&G:#V3''\W6EOP1#NE
MF1(=+SD1]]YT3&AXA]<[)5X_9![C5WWMDB@C!59 ZV-7A<36YF5QQUTIK=<M
MH*LJJ$/%K#?DV:R3/!5@E5%D!5_EN1!855^+.-@[\=_#B?]D[\3?._'W3ORM
M2;8QN6R>3=^*E*Q@V]7XGVOD\8\F2?'67\YPH=*T,1 5OF8WC+AT0$"G^: 7
M2Z2A).B)NVL]1%4N,Z6\[JF/&SW"+M4.BQ1##]/RSNEGJ:^B9HRD45U;+S0J
M^,Q1"^<2=%S2,#$M:B^^*%$8S'"7J.4?,VF/&V^[O>F_TZ;_#N&'N1"/A!C5
M!_Q2->;3P##;C<P78C4GQ=[;$:'_.K0MF#;H6K1ZXA3HVP($;@7C/5O,J%J8
M-[FQDD!&A:WIS"=X:)H;+V.QLH5@P!@!5K[#YRFT"'KLBMSU0H$Z8&](5[34
M@#_C*G"WY1CD@G<]Y!K;(]*LTMQ\'(,F'K)H+!=%:+!P9L-=<!B??S*/\<6O
M)Z_1\?M+=/'FY>E_[*7][DO[[W?)T?N+!B9#CZ]QH.R,F+_H>G'6Z+E5)I!6
MOK6L0XC+,.J#6%/*?9>JIXBHR51Q$T^6U#W"\/(]:!@1!3=UDRTM(L71+U[F
MH/\EGFB$>NPSO"::LX=9Y7"M'$5O6-F'V6"&[*31OB#GS]KA<(:X=7G9G,%$
M8L]4VV-])L99$C;4,QN4/PS]P@.S#TT?G!SV;Y**Y/[:"KL]T&C"OPF=6P<_
M'_:]6W 3G3C'5?!-&'/M/MJ)KZ+SR=*"DS-J8) 'C$:ROJK$J^V@T!>757(E
MY1@JOA<_-R6CJPWGN1G95^^)4,PJYQBA;_'V\]9APMP',[S>+VE)&E>-;< ,
MI3S0&<4Z.,,FDW.6UW(8LDH;-H?C/=KTP9%V(.=T8+THI- _(IJ>I M7#Z[<
M471>,(>]S8)"-B%+UNH<Q-?$_.!M.-]1![TG1IYTK%>FU2DR]BEQ%7L\71(6
MU1U:=^SKNF6&Q8P3L0A_#7]1/,$],*3U^OV/AYR-5C0Y\UG8B6O<3G6#!#Z>
MXE-2X4**17K7/HGU*U!+=L@(_:VLF\^HA00>TC7Q7 4"P8&Z#F0H@M'L43R
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M_P]02P$"% ,4    " "!.*E:VC#32%,,  #&8P  $               @ $
M    <&QX+3(P,C4P,S,Q+GAS9%!+ 0(4 Q0    ( ($XJ5K6[*W&A0L  'J.
M   4              "  8$,  !P;'@M,C R-3 S,S%?8V%L+GAM;%!+ 0(4
M Q0    ( ($XJ5J%$X(_O!@  &=. 0 4              "  3@8  !P;'@M
M,C R-3 S,S%?9&5F+GAM;%!+ 0(4 Q0    ( ($XJ5I*H 6(;C@  )KE @ 4
M              "  28Q  !P;'@M,C R-3 S,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( ($XJ5H2_($FJB8  )ID @ 4              "  <9I  !P;'@M,C R
M-3 S,S%?<')E+GAM;%!+ 0(4 Q0    ( ($XJ5KO%I<",T8! *D<#  4
M          "  :*0  !P;'@M,C R-3 S,S%X,3!Q+FAT;5!+ 0(4 Q0    (
M ($XJ5J%,;P@JM\  .4H 0 7              "  0?7 0!P;'@M,C R-3 S
M,S%X,3!Q,# U+FIP9U!+ 0(4 Q0    ( ($XJ5J0XN2.+,T  %/D   7
M          "  >:V @!P;'@M,C R-3 S,S%X,3!Q,# V+FIP9U!+ 0(4 Q0
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M;'@M,C R-3 S,S%X97@S,60Q+FAT;5!+ 0(4 Q0    ( ($XJ5IY P:JC0@
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M+P8 <&QX+3(P,C4P,S,Q>&5X,V0W+FAT;5!+!08     $0 1 'P$  ##D@8
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>plx-20250331x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20250331"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20250331.xsd" xlink:type="simple"/>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ghu49akz20uatgeBd2X7xQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WKF5iW7GJEWP-U2zSvqbMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m6Piq_wnjEaeFfGE5kdjsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_prBuP7Wn10WQWwJPcpXf0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ds3ukx2XekWVsDH9lI71mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lxOjswxMb0m6s5VE-STvCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4HrirPbHHkGUdsaYl6N3qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_BmLMKInirk-W2LzHEG8PAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lSnbdXconU6DulGwTT8MFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_90621vYqvEa1pn7bmcTY_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4ybsI5_mqUqIV1P-uoYRHA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_7lP2AsW-rUWHh6Iroj0Xlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_F8q1dlZWwEuLw9hXrYpvwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZEZl7VBCOkKOl7NTRveViw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_oXa9IlN4NEi0krV8osIOWA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_Vzwfwx4x6UqY4cHH7H5agQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F4FQvuyunUGq_SflJl8NoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eW1ZtmVb80KFn9rh2Sehpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_jLrTiAYktE2BXNkVgYPROg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Lwwrp-grPUmPH5Z8rNY9-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_75AYESP9RUK-GveVvLuOfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_nmHBOM5hwEqT3t2gduL9Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7Tgj53JZECcqAlPLWNniA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-05-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OiVYUMJ14ka7WcB5y23CLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_y6-CsnHhbUiWoMezhWCoiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_Y_QC7Pagx0qp-Num1NGb4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_1_2025_AUlgaLjEa0WUZCpYvk3KDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-05-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_8DshOwwsq0-xcl9XB1lxCA">
        <measure>plx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      id="Hidden_kXUOmRnMF02g3IyaxSwPaw"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      id="Hidden_y4BLMcGH-Eq_mG7qitP-Ug"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_EOoZn2yox0qPdi7ano0h_A_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_i-mbnwOuikCCoMKpd06nsg_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_drruE08GmkeoNkNkB__yJg_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_-O580WD-90ekHFLu0xXy3A_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_jEyg01ZU8kmrkQqHK5_QKw_6_1">false</dei:AmendmentFlag>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="INF"
      id="Hidden_cSxaNzcnK0mLWtm562rZ5w"
      unitRef="Unit_Standard_segment_8DshOwwsq0-xcl9XB1lxCA">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_kjVEEPh2HUe4hZOMM69Qfw">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_wZTt4ejim0CLEVa4hDdO6w">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_0kC4NtG1TE6xbH520_w_ng">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_k3Wy6JpS50u76jHYfnTpXw">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_swxYyikyvkGfsy7bL9EuSQ">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_CImdXA9cdEGPUPAvP3WQVQ">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_IuBxkhTkukaAJmw4SGBV4Q_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_8uLDFUCUqkyF11YEnNmdbg">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_ra0JVbjJmkeIv_leOzBAMQ">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_2N5oZ9gOaUek6fmi-KDSHw">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_9DnQZfCdlkiz6Z1CLGrpTA">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_FABw_24LRkyfXaQWZhXr0A">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_TxKh7Pxod0u5lRNYJS910g_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_GX0ZQ6liFEy_dUZrxfgyQQ">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_MybInQVo7kWYJ0zaOQyfsg">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_R6BD4iAfWUiM6oWQszFE-g_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_0iXSR1xaGUajYC1iqEEyrA_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_tm0Te8iX8E29uIIIy4_FfA_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_Ov9qVew_9kyUu1mjnXaoZA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_K79iQ70NK0eXfJ4266vWUQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_SeHj-nU3EUigOMpyYUVqsQ_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_XlfLjRgufUyNshZVMcgPXA_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tc_2UNg9VEol0qgkirrseWi3g_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_2440yCXe20GY82uIV6JruQ">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_5_1_2025_AUlgaLjEa0WUZCpYvk3KDQ"
      decimals="INF"
      id="Narr_05ao0GJ0lUyXynVNdZuIRA"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">79607115</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_Y9cpRAOSs0eFzEyRHDQeEQ_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19458000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_0SDRnSTt3k21AnH2c3RiMg_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19760000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_sMbG1-7GPkG-dxhWbsrFZQ_7_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">15285000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_XOPCCnd0m0KvHXPIvWoS9w_7_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">15070000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_wRl_QXQUOkC71B3tD8U_6Q_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4675000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_yHXuI7K3UU2dTRq7nsIRzQ_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_tsvYIKnix0q5p_GvfxomqQ_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1590000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_N5Y_baO0gEyJnK9x0_T6zQ_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_8mKh-T6hbku0Fyum8V4a2w_10_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19506000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_S3dLIMeOU0GWRLrbY2jF8A_10_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">21243000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_Xuzik89rckiPDODqCu-rZg_11_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">60514000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_ESblADCv9E-n8EJxdHLtXg_11_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">60078000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_WoV-ezwUIk6tZiMnbjGBeg_14_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">459000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_RPCtLAvE20C5KDgbaBSUJg_14_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">462000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_tA1AVMPePkCLtXi0aF3vwQ_15_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4725000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_qxjuQISDjk2hgFyIxKwaeA_15_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4591000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_0XzrGHmp-kieA1YteD_nQA_16_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2969000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_Mq3FJxVEBkSEbJofjDeyVg_16_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2856000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_I6JMCYCchkuyulKolY05Ow_17_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5225000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_rko8BqloLkWKKEYJcuW5qA_17_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_BBydNfPL8kq7vhXx4nfESw_18_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73892000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_a5PHMAcvIk6XIQhLxyn7iw_18_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73417000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_B6aDeqth80qN_XI-A0h6tw_24_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4121000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_BJ_YBCO4NEKm1m1W7SyobA_24_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4533000</us-gaap:AccountsPayableTradeCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_jWd1b05QkkuChel8aRLv4Q_25_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">18776000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_d7489LY8fUmP7o0B1sNUzA_25_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_NpL2fYaCtUWL8M0VGBnvXA_26_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1425000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_B2chn85XskyaBFyPMl7XNw_26_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_-jDtqQIeNE6QmSy4gNARew_27_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">24322000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_HREHp-SYdECJOMREJ0TYDQ_27_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">25621000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_4qSrYWjqHUa6S7aZM6jcBA_30_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">551000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_bjHPVaTelkeQfxkDLynfOA_30_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">559000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_bh-gN9IgLUyJWrOknOGvHA_31_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3811000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_eqiUMkTWoUKrJpE7-NTKQQ_31_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4026000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_OaFknihgxUuoRk4yMs09nA_32_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4362000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_jU9oCQ0hb0inFNdFnmxc3Q_32_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4585000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_62bHHtloDUyOIZLkmrFiNA_33_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">28684000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_LidYRO_8ukW2Dy9F-M--Dw_33_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">30206000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_mnYHrr5SS0CU0g2FYw2_pA_37_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">45208000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_iJWOQ-zBmEWeOPAiRpJDlg_37_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_gfMpKjJZv0264jmbtU1WRg_38_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73892000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_Ux20Gjp9MUiAWFk5LP3EEQ_38_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg"
      decimals="-3"
      id="Tc_eFpIevg1gkyo4OYmTwjTpg_3_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">9995000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g"
      decimals="-3"
      id="Tc_Pg4QVXPB_E-DOnhti01I-w_3_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA"
      decimals="-3"
      id="Tc_I0P_rLjZTEG85u8TprNDPQ_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">118000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ"
      decimals="-3"
      id="Tc_8llzS4G6H0OkTZ-cYp0_Bg_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">71000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_RDBdw8TED0SQzWeqg4jw3Q_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">10113000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_vawvG6JNIUm70X77HCiJSA_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3748000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_SvluBpTFIEi3cfpkzZrvxg_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">8180000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_ixOZfNGyjEWLljo0RyjVPw_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2602000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc__dsWtLPblEi7pcennhLIqA_7_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3475000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_Dp2uxrItVkyLjn2hnR6KJQ_7_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2887000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_-1UGxZIvmUmaUqBeqNySGg_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2603000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_56r9E1OqL0-ssZzCcsdzPQ_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3115000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_9HiS5crlV0O6PJmzuqfD2g_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4145000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_tuoVy8dJqEqngiz_rYIffg_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4856000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_eqioKDVYSU-RXWnQ0wu4mQ_10_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">6000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_1JNuyZXtJka-GfRE8Ux8AA_10_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">390000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_voBBEjhlIk22uAzonA8E4A_11_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">419000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_fdXVKX3Sh0WF2hcbBFtpgg_11_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">513000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_msr2LrXjtkuzk-Kcw83Hhg_12_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">413000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_8twngDkZ40e-Pr1sGHRMqA_12_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">123000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_XHpAgl2Zak2KUxQJ8R9WLw_13_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_9IuQ4kjEEUuSQbjauS0LqQ_13_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4733000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_yM9fGBVSfEutjkL9nN1s_w_14_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_Z6ePgPXz2E6jDjedu-YMTg_14_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_j7TYlBnGyEmwhoRydxrW-g_15_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3619000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_WgAg3mvWzUW9gEt89uOIGA_15_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="2"
      id="Tc_E7ITEF5KjEmco47dTg3fXA_16_3"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="2"
      id="Tc_E7ITEF5KjEmco47dTg3fXA_16_3_2"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="2"
      id="Tc_FiMWM5Pufk2puCOg-6wccQ_16_6"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">-0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="2"
      id="Tc_FiMWM5Pufk2puCOg-6wccQ_16_6_2"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">-0.06</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="0"
      id="Tc_I9hpCZQJKkSx7cnwzNN8QQ_18_3"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">76611980</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="0"
      id="Tc_I9hpCZQJKkSx7cnwzNN8QQ_18_3_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">76611980</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="0"
      id="Tc__IkDqh97fUGro3cDU5JcIg_18_6"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">73036569</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="0"
      id="Tc__IkDqh97fUGro3cDU5JcIg_18_6_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">73036569</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw"
      decimals="INF"
      id="Tc_rmq72pKmPkelc_kfVf5utA_6_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_DcvH8kn_XEedtsrUxtKDUw"
      decimals="-3"
      id="Tc_0q10Q1vhvUGGYtui_Ld9dA_6_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_90621vYqvEa1pn7bmcTY_Q"
      decimals="-3"
      id="Tc_Ga3ZAIXMSUWrWymKXw5HPg_6_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lSnbdXconU6DulGwTT8MFQ"
      decimals="-3"
      id="Tc_qzOjhZVh50iRJINS3VuPDg_6_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ"
      decimals="-3"
      id="Tc_1Re7MFaLyEeE4aa3HeAuOQ_6_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Yredx23EEU-Bu_svAmQ3Ng"
      decimals="-3"
      id="Tc_mMR0VvF-xkubS-wPGSZOXQ_8_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4HrirPbHHkGUdsaYl6N3qw"
      decimals="-3"
      id="Tc_oIQkYAZQoky4DC0yu0i71g_8_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_BmLMKInirk-W2LzHEG8PAQ"
      decimals="-3"
      id="Tc_GNhPdNy_WEKbVi5XTfRkWw_8_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-169000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA"
      decimals="-3"
      id="Tc_pnOZAhi9rUe_WgumPUscMg_9_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_SnmF-fcwm0OJTMUFzJCudg_9_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">500000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_J7Tgj53JZECcqAlPLWNniA"
      decimals="INF"
      id="Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">100000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_mlWGfo-B-0G2GFiFJ5EcpA"
      decimals="-3"
      id="Tc_AjRDmy9tBEad27ugDaseHg_10_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">481000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_H4iIR9ZAEUSC_T-fRjiuFg_10_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">481000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eW1ZtmVb80KFn9rh2Sehpg"
      decimals="-3"
      id="Tc_C43cnB8A0kKM4ewT6xVfPg_11_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_YR4HIHROrkOx6bMK8sU5RQ_11_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q"
      decimals="INF"
      id="Tc_cLY55batqEe12Eox0KmcKQ_12_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">73052124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_p2VV8J7JEkajMFfIcn8u_Q"
      decimals="-3"
      id="Tc_pMi4htmvfka0rQRpJi5uOw_12_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lxOjswxMb0m6s5VE-STvCQ"
      decimals="-3"
      id="Tc_3mcrCn4DB0S6paMfFFjDXg_12_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">415633000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Ds3ukx2XekWVsDH9lI71mw"
      decimals="-3"
      id="Tc_Evu7j8K8uEK2C2VxnB0Kdg_12_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-385920000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA"
      decimals="-3"
      id="Tc_9tYqwtLsqEW4JGz39uxIwQ_12_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">29786000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg"
      decimals="INF"
      id="Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">75850275</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hACr-pxYAUWC1ShZV01ROg"
      decimals="-3"
      id="Tc_448eJnejT0GQZzRtwqoFEg_13_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_prBuP7Wn10WQWwJPcpXf0g"
      decimals="-3"
      id="Tc_F_LefStl0kKH-G0qP_J73A_13_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">421528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_m6Piq_wnjEaeFfGE5kdjsA"
      decimals="-3"
      id="Tc_YDvKPqPVg0aPUG8-hxS78Q_13_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-378393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_kVNKx1j8oEe2rmNQQzRYHg_13_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw"
      decimals="INF"
      id="Tc_D3oA6QxgOk6teZp4KIJaIA_15_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">1325179</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw"
      decimals="-3"
      id="Tc_IeP4rHtYZEKfF2m_ETMbrg_15_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew"
      decimals="-3"
      id="Tc_qplUGL3sl0m84fVnG-bF9Q_15_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2860000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_wNqaEuSB8U-MvZSsiNbzYg_15_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2861000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew"
      decimals="-3"
      id="Tc_svpamVYWgkWK1YkIHomWTA_16_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">336000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_bB2tEEVrH02XS_5DbsuqLg_16_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">336000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew"
      decimals="-3"
      id="Tc_02_x5qSVW0yEHxCQBZfXBw_17_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">204000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_nnkgaQdj_Eukm-0TrR4ITg_17_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">204000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw"
      decimals="INF"
      id="Tc_YtLlGAbz7060zZ-cwF33Pg_18_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">958375</plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5mWxhwoQQEeJ9GDFxWbrGw"
      decimals="-3"
      id="Tc_aXTaYk4D3Ue0ZX1RRRToJQ_18_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_bAWNk4YwXUSrp_gFawP8ew"
      decimals="-3"
      id="Tc_vvApkqWZhUG9G3fZcB-aTg_18_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2214000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_4B49NbwbRk223UbWya6-Kg_18_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2215000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_F4FQvuyunUGq_SflJl8NoQ"
      decimals="-3"
      id="Tc_ZMqV7ZADSEu_BP_CzkSzSA_19_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3619000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_1NcpxM2Orku52iIsPq9DLQ_19_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3619000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg"
      decimals="INF"
      id="Tc_Xbxl8-joqECHr07q_Wk7jA_20_2"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">78133829</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember__bQ8XmUJmU-Qs34A-kLFXg"
      decimals="-3"
      id="Tc_QxcrfEo3t0a-XOgbZmN--w_20_5"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">78000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WKF5iW7GJEWP-U2zSvqbMw"
      decimals="-3"
      id="Tc_z70Y6JriXUKbHJki9EcSOw_20_8"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">427142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_ghu49akz20uatgeBd2X7xQ"
      decimals="-3"
      id="Tc_bCn9d4bgJUCw9Mi9sKV9Jw_20_11"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-382012000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_IMsrR3ksJEKgSv4GsfnVQw_20_14"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">45208000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="INF"
      id="Narr_QlF9HKuia0Kh0wSWX7ZPMQ"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="INF"
      id="Narr_skyon_ELj0ub-2eYTUqusQ"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="INF"
      id="Narr_vRM7f8f25Uu3U95OosYpCQ"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="INF"
      id="Narr_4_n1MFNAU0yiqnDzSeC7Tw"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_KcpPO3aTzEq1E5MVAruavA_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3619000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_lDs_1pk8j0iRvJc_YrxolA_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4595000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_f0RHtBLUCU6ubrWu7h-_Jw_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">540000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_gfu3clcMUEWhWN_pUi2m2Q_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">981000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_x2dWKK6mTkid7rPMSTm5Qw_7_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">346000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_MT1wkaD36kywjxbno4hMBw_7_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">322000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_rKqUm9cmykSr4AyV2u8acA_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">375000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_HjtzN_UZAEa8KvVgP84Nng_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">471000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_eX2Bwbcg7kWOdaT2SZOmVQ_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_cXnHybNRWUiacLd_kjnnnQ_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">8000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_aAtRR44sjEGox_EDP9A1xQ_10_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-113000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_j_Ji1KzviES3WGtfsyuXAA_10_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-138000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_zxw-c6rAxE6prIB22jF0yw_11_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_qxIM1NCMYUSdB5_nT8KgzA_13_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">11039000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_mXIpSjwWBkiLtUZEj7IbBw_14_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2275000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_bk1DY0_mnUyyNuW1K3xSHw_14_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-1746000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_NCKM_5iY6k6-cLrWTpujGg_15_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">18000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_BaNckAlkckCGQb9ujMlY_g_15_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-14000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_2r3lJ35WCUacmK_1X2X8JQ_16_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-1737000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_vrVePh_UEEa6Q6pIon41Ww_16_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3301000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_RfgkaGbGjU6cAQ7-7oe78Q_17_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-1284000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_dDQKXqQ1X0iTAqh_zay6oQ_17_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-1414000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_Ml2icdSQt0WrgSBfP65Evg_18_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-5058000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_w579qvKwlEy8wgat2ANlnw_18_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4188000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_ypDA6L4s80-SCk7jc5C8gA_21_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">306000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_m3QhI8-Fb0GTfrnO4Gt8dQ_21_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">598000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_dpDcT-MLW0eGe8PvnoK7Qg_22_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">6000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_zjRzed665UWBpjPsThw5iA_22_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">8000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_PuskA3_YwUScdyJF5vnEQg_23_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-312000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_2ACUrL_XwE-YaLCO5GJ20w_23_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-606000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_2X0TEztaI0idJpF9kAQUAw_26_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2861000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:ProceedsFromWarrantsAndStockOptionExercises
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_xLqDwK-Q9UG6swDFvvlFug_27_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2215000</plx:ProceedsFromWarrantsAndStockOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_Dl9n9Dsz-0eHMqJgrDV_yg_28_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5076000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_DuiZ_Ahky0WVWzObckWS4Q_29_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-8000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_5vT_G7zo3kukdGX8nClp_A_29_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-7000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_Aq5ffg5RhUu4nNwNQQQ31w_30_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-302000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_NFgOjojJuk2SwJBABC33hA_30_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3575000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_Ij9rzwLxXUqkh6Lk1ntIWA_31_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19760000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_dfsi8WWPOUawBLcDGnWsAQ"
      decimals="-3"
      id="Tc_067AxH7vpkeu-lcQswnkWA_31_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_2UicSS9fc0Cdh8IMOcgVIQ_32_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19458000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_3_31_2024_o59zx2ND3EOBEaHyctPNAA"
      decimals="-3"
      id="Tc_RPtaq6caeEWxd4C_r6PrgA_32_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">27209000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc__1amH-tWeUCAbhnTYMgblg_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">427000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_6cncF4hx7UGGqVB71tz9rA_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">146000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_uD98oP6d5kaa3YXBdFqXLQ_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">33000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_E57N5wzMWUusww8qPsfQxg_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">186000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_piRujhfNBEGPmYpk8XCOLQ_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">766000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_BzbRpsqwXUSrv2gwhHIE_A_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">166000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_zHbQSwLnKUCHWhErtVb54Q_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">33000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_SidqCRLA-0K4DwhfO0FIYw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. Although ceasefire negotiations are on-going and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 18,216,366 and 31,839,345 shares of Common Stock underlying outstanding options, unvested shares of restricted stock, warrants and convertible notes of the Company, as applicable, for the three months ended March&#160;31, 2025 and March&#160;31, 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;New accounting &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;pronouncements&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_FAYgudVWCEeGr1xB0tm1Cw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients with Gaucher disease. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia and Singapore. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its track record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;On May&#160;5, 2023, the European Commission (&#x201c;EC&#x201d;) announced that it had approved the Marketing Authorization Application (&#x201c;MAA&#x201d;) for Elfabrio and on May&#160;9, 2023, the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) announced that it had approved the Biologics License Application (&#x201c;BLA&#x201d;) for Elfabrio (pegunigalsidase alfa), each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 54pt;"&gt;The Company has entered into two exclusive global licensing and supply agreements for Elfabrio with Chiesi. On October&#160;19, 2017, Protalix Ltd., the Company&#x2019;s wholly-owned subsidiary, entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October 2015, Protalix Ltd. and Pfizer entered into an amended exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;) remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of March&#160;31, 2025, shares of Common Stock for total gross proceeds of approximately $19.7&#160;million remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel.&#160;In October 2023, Hamas terrorists infiltrated Israel&#x2019;s southern border from the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas also launched extensive rocket attacks on Israeli population and industrial centers located along Israel&#x2019;s border with the Gaza Strip and in other areas within the State of Israel attacking a number of civilian and military targets while simultaneously launching extensive rocket attacks on the Israeli population and industrial centers. At the same time, clashes between Israel and Hezbollah in Lebanon increased. In response, Israel&#x2019;s security cabinet declared war against the Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. Moreover, the attacks by Hamas and Hezbollah, and Israel&#x2019;s defensive measures, may result in a greater regional conflict. Since the outbreak of the war, other regional actors, including Iran, have taken military action against Israel. Although ceasefire negotiations are on-going and the level of military activity has decreased in recent months compared to previous levels, it is currently not possible to predict the duration or severity of the ongoing conflict or its effects on the Company&#x2019;s business, operations and financial conditions. The situation could disrupt certain of the Company&#x2019;s business and operations, among others. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss due to the military operations. As of the issuance of these financial statements, the impact of the war has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of March&#160;31, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="INF"
      id="Narr_BqHONMmeHE-hXTSaYShZmw"
      unitRef="Unit_Standard_agreement_JIvEmtTOmEGdUQBX7yGm3w">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_Y_QC7Pagx0qp-Num1NGb4Q"
      decimals="2"
      id="Narr_JuiIWNpPZE-PR5hvhrDbfQ"
      unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ"
      decimals="INF"
      id="Narr_cwCPPKmRoE2aL8mQfof-kA"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_oX7DWbaBrUqVoezAoArJLQ"
      decimals="INF"
      id="Narr_zMFjX5YNWkK3hpIfzpi-Eg"
      unitRef="Unit_Divide_USD_shares_eyXtgwHhZ0KX8PeRG0HWaw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance
      contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_y6-CsnHhbUiWoMezhWCoiw"
      decimals="-5"
      id="Narr_4rYSn9sufkCGq3b1zJ25Xg"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">20000000</plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance>
    <plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OiVYUMJ14ka7WcB5y23CLQ"
      decimals="-5"
      id="Narr_l4IwlGo2gkS9YaK_dKDxog"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19700000</plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_SYKjAsG4b0e4IPp1ICVxxQ">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;). The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_eF39j4eRRU66JyQ0vHzJWg">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net loss per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic and diluted loss per share (&#x201c;LPS&#x201d;) is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding for each period. The calculation of diluted LPS does not include approximately 18,216,366 and 31,839,345 shares of Common Stock underlying outstanding options, unvested shares of restricted stock, warrants and convertible notes of the Company, as applicable, for the three months ended March&#160;31, 2025 and March&#160;31, 2024.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_75AYESP9RUK-GveVvLuOfA"
      decimals="INF"
      id="Narr_zwu2z07czEekGfJY2OELVQ"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">18216366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndWarrantsMember_nmHBOM5hwEqT3t2gduL9Wg"
      decimals="INF"
      id="Narr_KImh077cZEO4_8n00f7TKw"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">31839345</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_C-1qFB4GmE-0nuf5qVyPAA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the convertible notes may be settled wholly or partly in cash, at the option of the Company, when converted.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_jLrTiAYktE2BXNkVgYPROg"
      decimals="INF"
      id="Narr_oPtgTdbfrUmWsyxbQAj7HQ"
      unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_V1VhlSBie0KBVUvUxTRLwg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_wXEJf3ve7U6tF9hFXBBxuw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Group_awHWg-BHlEaehZaZrKMk5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at March&#160;31, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,484&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 19,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_Ncu1bG-ss06nt5KEFsBzsA_3_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4484000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_EaVHYkHrHkibv7zCFxCtHA_3_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4549000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_25hunJbYiEu9cosIXuxPag_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">8002000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_5fY7-5rOUEefGrKzU8auVg_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">11245000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_AlACnlOqoEe8IdVgfopbAw_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">7020000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_LyUdVx8j5k-ntnX__pwJhw_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5449000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_wm5kvcH7rkyprPbJmC46XQ_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19506000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_lhB-AOeDc0S0fWZ2KmAmnA_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">21243000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_dehfHFbqgEakH1IYr9Ssow">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_00wfl_EeJUOfUpUNgAUoyA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 4 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the three months ended March&#160;31, 2025, the Company sold, in the aggregate &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,325,179&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock under the Sales Agreement. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company generated &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;gross proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such sales (issuance costs were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the three months ended March&#160;31, 2025, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;908,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from such exercises. The remaining warrants expired on March&#160;11, 2025. Accordingly, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;as of March&#160;12, 2025, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; warrants remain outstanding&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg"
      decimals="INF"
      id="Narr_2LuDTnk0EUypn9b_YSEDUw"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">1325179</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg"
      decimals="-5"
      id="Narr_r3k46BbPzkaRFbje147amQ"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3000000</plx:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_hpfWXFmTCEGaHmtcvUk1Tg"
      decimals="-5"
      id="Narr_bbRzSq8yOkyv7UVuyVXBsg"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg"
      decimals="INF"
      id="Narr_At0lw6Ef6UCB1BntdLYMzg"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">908000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_3_31_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_edKnu5vkzkmmZx_3voqGfg"
      decimals="-5"
      id="Narr_E7TeWzOcwEiLPcxjhp8UEA"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_Lwwrp-grPUmPH5Z8rNY9-g"
      decimals="INF"
      id="Narr_R883z2tHYUK2zc_u1uDmGQ"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_Ks5J4iuFxUOwlGXCSMMncA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; TAX BENEFIT&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of (3)% for the three months ended March&#160;31, 2025 and for the three months ended March&#160;31, 2024. For the three months ended March&#160;31, 2025, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#x201c;TCJA&#x201d;), which was enacted in December 2017.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Group_Y3Da7sPgSka3hztilwsVQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_SE9yU9aWl0O-U9QAVNit7g_3_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-113000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_nLwSHsOzB0aK-tF9msHV2Q_3_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-138000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_ref7X-U8_UWEtC00Fis3Nw_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_mq6SIxmkvkC7uWhu2q59SA_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="2"
      id="Narr_ZS9WEgAIR0W7n2z1zKzfYg"
      unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="2"
      id="Narr_G61aNaAp2UaEWoCPkpmM8w"
      unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">0.03</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="2"
      id="Narr_VoeyvbTvC0GLrkWizYuMHQ"
      unitRef="Unit_Standard_pure_RcCe9yMHHECvV9i34YQCsw">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_tw3kMhuR70-RjtR-VXYsYQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company operates in Israel as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_cSxaNzcnK0mLWtm562rZ5w;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; operating segment. The Company&#x2019;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (419)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (513)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,733)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,619)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,595)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Long lived assets are located in Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_xTJHn25IhUW-XFM2yvWaYg">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,205&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,144&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,689&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,155&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 390&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (419)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (513)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 322&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 983&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,732)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,733)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Tax benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (138)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,619)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,595)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_bQEzuz-3o0SaxVkUwHdmCQ_3_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">10113000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_1AtY4L41KU69-paSvZxtJA_3_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3748000</us-gaap:Revenues>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_1Or2i9u6uEyCYwpcBvf0WQ_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5205000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_fBk3vDQToEWatZyfz3ngSg_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">5144000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_vIPO1OUbvEe3I8pbS8Up7Q_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2689000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_URBejJlP40yX-PXFChWayA_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2155000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_tJ8n4mIzhUqNX5yAYeKqfw_7_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">6000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_QMhfOmW-aUeYqTZzZSV3ig_7_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">390000</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_VRDEqwqWC0mMh37h5ychrw_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">419000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_XDb1IIpqs0yvYiN1FFzf9g_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">513000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_el5HVNy930em19L_LPN53A_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">346000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_O70bAoKls02S10_5W6QynQ_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">322000</us-gaap:Depreciation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_aMCF-J59Tk6TSIs2OOmMSg_10_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">6018000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_EyneGA37l0aS0j0q5fjJ2g_10_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">983000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_h6L5v3B_dUWFqtdOCgd7vw_11_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3732000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_ESuF0bJaCU-PtoozAuMBEA_11_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4733000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_5UMYnaXAX0SGtX75G6HuMg_12_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-113000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_yFEP28CErEWOPuVAnZUFqg_12_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-138000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      decimals="-3"
      id="Tc_h6bdgPSV3E2O-pjLZYgKUA_13_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-3619000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      decimals="-3"
      id="Tc_5a38jctklkKrRyrGMqgQYw_13_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">-4595000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_3_31_2024_AyPDZY7Z2UmI0KxuoCRV8w"
      id="Narr_CCM9Yf6ahk-krFQDUcpIyg">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_lsZJJ5CE80-NHRC85pNJUw">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_jX-u19dRv0e6L5bhoIgZMA">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,979&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;1,127&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,016&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,550&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;-&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;118&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;71&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_4ybsI5_mqUqIV1P-uoYRHA"
      decimals="-3"
      id="Tc__iY56oFBQEmI07o5UwTrHQ_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">6979000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_F8q1dlZWwEuLw9hXrYpvwQ"
      decimals="-3"
      id="Tc_bRPBq7l8h0uEGgjqdiAppA_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1127000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_7lP2AsW-rUWHh6Iroj0Xlg"
      decimals="-3"
      id="Tc_SE4fSRbLFkCj09sNcU1feA_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3016000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_ZEZl7VBCOkKOl7NTRveViw"
      decimals="-3"
      id="Tc_GPhInPem6kG3T9Z-kPWRSA_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2550000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_zG4n-BEWOUupt05DCYYoBg"
      decimals="-3"
      id="Tc_CrUJT7JZGkuj0DZWQCJSCw_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">9995000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_MabtYUMo_kyotVkTI2tN5g"
      decimals="-3"
      id="Tc_BU7fGt8U3E-qAIEUglR39A_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3677000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_3_31_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_Bp9UP1xBtUGXq2vaSVIAkA"
      decimals="-3"
      id="Tc_Pnq1f-E1_0OoHH4VNRR7Dg_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">118000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_3_31_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_gVJStbJjEEawJask-ukRBQ"
      decimals="-3"
      id="Tc_frVXyN0go0-c4VgJqtrc-w_9_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">71000</us-gaap:Revenues>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_OVoAhAYmOkmwqBf7HU5jNA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Advances from customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_uYxUY0qvDUqERdjZgUKCDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;March&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,346&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,349&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 300&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Advances from customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 427&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,776&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_dI4ZsJP7KUCEOHpqY2IPrw_4_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1346000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc__nW8r97jOUWf9lTyDu8qhg_4_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1343000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_LiAHUEavCEe0j7aSfr9UEw_5_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1878000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_An2uKAcwWUyMrwyDoIxkwA_5_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1811000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_0yWwcYdIVEiJ-4FuSGxRKg_6_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">9349000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_upMRGiHCJk6cSedElb6A-Q_6_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">9568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_dZ5iz6rYKEqa9gQRDrdXuQ_7_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">300000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_Zoeqf2RcyU20-cPhS21nmw_7_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1080000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_qfSnp1ZIrESY8LcCNY4Pwg_8_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3476000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_ptltZDLo1UCkaWciOYybeQ_8_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">3476000</us-gaap:TaxesPayableCurrent>
    <us-gaap:CustomerAdvancesCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_FWigNfAO0kC1bZZUen4qyA_9_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2000000</us-gaap:CustomerAdvancesCurrent>
    <plx:PayableToCustomerCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_l6pAzlH-2UauxGULeFB4-w_10_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2056000</plx:PayableToCustomerCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_UIcsVuPBJU6NMjZ-UZKN7A_11_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">427000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_HRWg5gkSNkWGBcB7pDuQDA_11_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">254000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_3_31_2025_JHlmg3p-XEO7ZQS2xnZGSw"
      decimals="-3"
      id="Tc_qxUsuWjZDUq5p2ASYD2vKA_12_3"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">18776000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_ksGgipi1j06xA5bo75l68A"
      decimals="-3"
      id="Tc_PdwOU65JYECPPVRWYeVShg_12_6"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Tb_AsJfBkG7HEyFbzQYeaButw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the end of the quarter ended March&#160;31, 2025, the Company collected approximately $2.8&#160;million from sales to Pfizer and approximately $1.9&#160;million from sales to Fiocruz (Brazil).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 36pt;"&gt;Since the end of the quarter ended March&#160;31, 2025, the Company sold, in the aggregate 1,450,036 shares of Common Stock under the Sales Agreement, generating gross proceeds equal to approximately $4.1&#160;million in connection with such sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_Vzwfwx4x6UqY4cHH7H5agQ"
      decimals="-5"
      id="Narr_cT6yuOSKAE2HBukEc1Fe-w"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">2800000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_oXa9IlN4NEi0krV8osIOWA"
      decimals="-5"
      id="Narr_1jP3uosiB062JeE2nwmiSw"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">1900000</us-gaap:ProceedsFromCustomers>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA"
      decimals="INF"
      id="Narr_Dk85KvOzAE262GUzKfZA2Q"
      unitRef="Unit_Standard_shares_B-a_T9Ado0q_RGROxb4Ing">1450036</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_4_1_2025_To_5_9_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_ykzv_zPsC02pOSxaZeP4FA"
      decimals="-5"
      id="Narr_IIPNnCHJx0-OYyay8skzFg"
      unitRef="Unit_Standard_USD_DEM7FWuQ8UimLtwQ71K-Bg">4100000</plx:GrossProceedsFromIssuanceOfCommonStock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_7OnY5WJhwEub5kZ9d08uGw">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_tu3x0uX5-0mbjE9BSB43cA">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_wCaVbVAQ4USBE2aBzrtOPg">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_1_1_2025_To_3_31_2025_0N-uT0DEb0ySJCEZU9ehEQ"
      id="Narr_-qWHtjj-PUyYP-t_wdl-Ng">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2"
          xlink:label="Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of March&#160;31, 2025 and December&#160;31, 2024 &#x2013; 185,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_dqrq_1q6OU-W5de6oJ5dKA_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_YtLlGAbz7060zZ-cwF33Pg_18_2"
          xlink:label="Tc_YtLlGAbz7060zZ-cwF33Pg_18_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_YtLlGAbz7060zZ-cwF33Pg_18_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rmq72pKmPkelc_kfVf5utA_6_2"
          xlink:label="Tc_rmq72pKmPkelc_kfVf5utA_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rmq72pKmPkelc_kfVf5utA_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_cLY55batqEe12Eox0KmcKQ_12_2"
          xlink:label="Tc_cLY55batqEe12Eox0KmcKQ_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_cLY55batqEe12Eox0KmcKQ_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2"
          xlink:label="Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_nb_t-n8J5EGFy4TAlaf-jw_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Xbxl8-joqECHr07q_Wk7jA_20_2"
          xlink:label="Tc_Xbxl8-joqECHr07q_Wk7jA_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Xbxl8-joqECHr07q_Wk7jA_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_D3oA6QxgOk6teZp4KIJaIA_15_2"
          xlink:label="Tc_D3oA6QxgOk6teZp4KIJaIA_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_D3oA6QxgOk6teZp4KIJaIA_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
